<SEC-DOCUMENT>0001437749-23-008658.txt : 20230330
<SEC-HEADER>0001437749-23-008658.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330170947
ACCESSION NUMBER:		0001437749-23-008658
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC.
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		23781660

	BUSINESS ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		(973) 535-2717

	MAIL ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MILESTONE SCIENTIFIC INC/NJ
		DATE OF NAME CHANGE:	19970409

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mlss20221231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:mlss="http://www.milestonescientific.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:rr="http://xbrl.sec.gov/rr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>mlss20221231_10k.htm</title>
  <!-- Created by RDG Portal -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0000855683</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">MILESTONE SCIENTIFIC INC.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
<ix:nonFraction id="c96106584" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c96106585" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c96106589" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96106590" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96106592" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000,000</ix:nonFraction>
<ix:nonFraction id="c96106593" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000,000</ix:nonFraction>
<ix:nonFraction id="c96106595" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">69,306,497</ix:nonFraction>
<ix:nonFraction id="c96106597" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">69,273,164</ix:nonFraction>
<ix:nonFraction id="c96106596" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">68,153,336</ix:nonFraction>
<ix:nonFraction id="c96106598" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">68,120,003</ix:nonFraction>
<ix:nonFraction id="c96106605" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:TreasuryStockShares" scale="0" format="ixt:numdotdecimal" decimals="INF">33,333</ix:nonFraction>
<ix:nonFraction id="c96106607" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:TreasuryStockShares" scale="0" format="ixt:numdotdecimal" decimals="INF">33,333</ix:nonFraction>
<ix:nonFraction id="c96106949" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c96106999" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96107013" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96107014" format="ixt-sec:duryear">7</ix:nonNumeric>
<ix:nonFraction id="c96107022" contextRef="d_2020-04-27_2020-04-27_DebtInstrumentAxis-PaycheckProtectionProgramCARESActMember" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">276,000</ix:nonFraction>
<ix:nonFraction id="c96107023" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">276,180</ix:nonFraction>
<ix:nonFraction id="c96107032" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c96107035" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c96107135" contextRef="i_2021-12-31_PublicUtilitiesInventoryAxis-SlowMovingDentalFinishedGoodsMember" unitRef="USD" name="us-gaap:InventoryValuationReserves" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c96107149" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="6" format="ixt:numdotdecimal" decimals="-5">1.3</ix:nonFraction>
<ix:nonFraction id="c96107150" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="6" format="ixt:numdotdecimal" decimals="-5">1.3</ix:nonFraction>
<ix:nonFraction id="c96107160" contextRef="i_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" unitRef="Pure" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">28.4</ix:nonFraction>
<ix:nonFraction id="c96107193" contextRef="i_2021-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c96107252" contextRef="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">49,663</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96107357" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c96107358" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-04-23_2021-04-23_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96107363" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-04-23_2021-04-23_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96107364" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96107384" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c96107504" contextRef="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction>
<ix:nonFraction id="c96107532" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c96107516" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">63,400,000</ix:nonFraction>
<ix:nonFraction id="c96107533" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c96107535" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" name="us-gaap:OpenTaxYear" id="c96107527">2019 2020 2021</ix:nonNumeric>
<ix:nonFraction id="c96107620" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c96107779" contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="mlss:NumberOfMajorCustomers" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c96107782" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember" unitRef="Pure" name="mlss:NumberOfMajorCustomers" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c96107785" contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" unitRef="Pure" name="mlss:NumberOfMajorCustomers" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c96107788" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember" unitRef="Pure" name="mlss:NumberOfMajorCustomers" scale="0" format="ixt:numdotdecimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c96107792" contextRef="i_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember" unitRef="Pure" name="mlss:NumberOfVendors" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c96107794" contextRef="i_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember" unitRef="Pure" name="mlss:NumberOfVendors" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c96107810" contextRef="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="6" format="ixt:numdotdecimal" decimals="-5">1.7</ix:nonFraction>
<ix:nonFraction id="c96107850" contextRef="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction>
<ix:nonNumeric contextRef="i_2021-01-08_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c96107913" format="ixt-sec:duryear">7</ix:nonNumeric>
<ix:nonFraction id="c96107924" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">443,685</ix:nonFraction>
<ix:nonNumeric contextRef="i_2022-12-31" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="c96107961" format="ixt-sec:duryear">2.04</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2021-12-31" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="c96107962" format="ixt-sec:duryear">3.04</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2022-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c96107963" format="ixt-sec:duryear">4.25</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2021-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c96107964" format="ixt-sec:duryear">5.25</ix:nonNumeric>
<ix:footnote xml:lang="en-us" id="fabee3baa-b46a-463f-af9a-7d2dd726a667">For the nine months ended September 30, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mlss-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2022-01-01_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-03-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-27_2020-04-27_DebtInstrumentAxis-PaycheckProtectionProgramCARESActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mlss:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-27</xbrli:startDate><xbrli:endDate>2020-04-27</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mlss:SlowMovingMedicalFinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mlss:SlowMovingMedicalFinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingDentalFinishedGoodsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mlss:SlowMovingDentalFinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PublicUtilitiesInventoryAxis-SlowMovingDentalFinishedGoodsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mlss:SlowMovingDentalFinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2014-06-30_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneBeijingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneBeijingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AnhuiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AnhuiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="CNY"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-10-08_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AnhuiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsReceivableFromRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsReceivableFromRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:TradeShowDisplaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:TradeShowDisplaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ComputerAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ComputerAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingSafetyWandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingSafetyWandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingEquipmentSTAAndWandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingEquipmentSTAAndWandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:EPIAndIAInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:EPIAndIAInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:STATrialsInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:STATrialsInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mlss:FoundationIntellectualPropertyPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mlss:FoundationIntellectualPropertyPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_TitleOfIndividualAxis-NonemployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:NonemployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_TitleOfIndividualAxis-NonemployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:NonemployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-04-23_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ViceChairmanOfTheBoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-23_2021-04-23_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ViceChairmanOfTheBoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-23</xbrli:startDate><xbrli:endDate>2021-04-23</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-23_2021-04-23_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ViceChairmanOfTheBoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-23</xbrli:startDate><xbrli:endDate>2021-04-23</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-TerritoryManagerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:TerritoryManagerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-TerritoryManagerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:TerritoryManagerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-02_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-25_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementGeographicalAxis-DomesticMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementGeographicalAxis-RestOfWorldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementGeographicalAxis-CN"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">mlss:VendorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">mlss:VendorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">mlss:VendorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_BalanceSheetLocationAxis-AccountsPayableRelatedPartiesCurrentMember_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsPayableRelatedPartiesCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_BalanceSheetLocationAxis-AccountsPayableRelatedPartiesCurrentMember_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsPayableRelatedPartiesCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-InterimChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mlss:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-01_RelatedPartyTransactionsByRelatedPartyAxis-DirectorClinicalAffairMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mlss:DirectorClinicalAffairMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-DirectorClinicalAffairMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mlss:DirectorClinicalAffairMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-10</xbrli:startDate><xbrli:endDate>2017-07-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-10</xbrli:startDate><xbrli:endDate>2017-07-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ManagingDirectorChinaOperationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ManagingDirectorChinaOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ManagingDirectorChinaOperationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ManagingDirectorChinaOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesBeginningIn2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesBeginningIn2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesBeginningIn2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesBeginningIn2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-01-08_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mlss:OfficeLeaseForHeadquarterInRoselandNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-08-01_2019-08-31_RangeAxis-MinimumMember_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mlss:OfficeLeaseForHeadquarterInRoselandNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-08-01_2019-08-31_RangeAxis-MaximumMember_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mlss:OfficeLeaseForHeadquarterInRoselandNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-08-01_2019-08-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mlss:OfficeLeaseForHeadquarterInRoselandNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-06_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-06</xbrli:startDate><xbrli:endDate>2023-02-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-01_2023-02-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-01_2023-08-01_StatementScenarioAxis-ScenarioPlanMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-01</xbrli:endDate></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fabee3baa-b46a-463f-af9a-7d2dd726a667" fromRefs="c96107956 c96107957"></ix:relationship></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>UNITED STATES</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>Washington, D.C. 20549 </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2022-01-01_2022-12-31">10-K</ix:nonNumeric> </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>(Mark One) </b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2612;</ix:nonNumeric></p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2022-01-01_2022-12-31">December 31, 2022</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;">Or</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;">For the transition period from <span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span> to <span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center; line-height: 1;">Commission file number <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2022-01-01_2022-12-31">001-14053</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>Milestone Scientific Inc.</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>(Exact name of registrant as specified in its charter) </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2022-01-01_2022-12-31">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2022-01-01_2022-12-31">13-3545623</ix:nonNumeric></b></p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><b>State or other jurisdiction of Incorporation or organization</b></p> </td><td style="vertical-align: bottom; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><b>(I.R.S. Employer Identification No.)</b></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2022-01-01_2022-12-31">425 Eagle Rock Avenue</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2022-01-01_2022-12-31">Roseland</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2022-01-01_2022-12-31">NJ</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2022-01-01_2022-12-31">07068</ix:nonNumeric> </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>(Address of principal executive offices) </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>Registrant</b>&#x2019;<b>s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2022-01-01_2022-12-31">973</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2022-01-01_2022-12-31">535-2717</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: center; line-height: 1;"><b>Securities registered pursuant to Section</b>&#xa0;<b>12(b) of the Act: </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: 805px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><span style="text-decoration: underline; ">Title of each class</span></p> </td><td style="vertical-align: bottom; width: 478px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;">Symbol</p> </td><td style="vertical-align: bottom; width: 1039px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><span style="text-decoration: underline; ">Name of each exchange on which registered</span></p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 805px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2022-01-01_2022-12-31">Common Stock, par value $.001 per share</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 478px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2022-01-01_2022-12-31">MLSS</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 1039px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt; line-height: 1;"><ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2022-01-01_2022-12-31">NYSE</ix:nonNumeric> American</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; line-height: 1;"><b>Securities registered pursuant to section 12(g) of the Act: </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>NONE.</b></p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#xa0;&#xa0;&#xa0;&#xa0;&#x2610;&#xa0;Yes&#xa0;&#xa0;&#xa0;&#xa0;&#x2611;&#xa0;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2022-01-01_2022-12-31">No</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#xa0;13 or Section&#xa0;15(d) of the Act.&#xa0;&#xa0;&#xa0;&#xa0;&#x2610;&#xa0;Yes&#xa0;&#xa0;&#xa0;&#xa0;&#x2611;&#xa0;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2022-01-01_2022-12-31">No</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Indicate by check mark whether the registrant (1)&#xa0;has filed all reports required to be filed by Section&#xa0;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#xa0;has been subject to such filing requirements for the past 90 days.&#xa0;&#xa0;&#xa0;&#xa0;&#x2611;&#xa0;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2022-01-01_2022-12-31">Yes</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#x2610;&#xa0;No</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#xa0;&#xa0;&#xa0;&#xa0;&#x2610;&#xa0;Yes&#xa0;&#xa0;&#xa0;&#x2611;&#xa0;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2022-01-01_2022-12-31">No</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#xa0;405 of Regulation S-K (&#xa7; 229.405 of this chapter) is not contained herein and will not be contained, to the best of registrant&#x2019;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment of this Form 10-K.&#xa0;&#xa0;&#xa0;&#xa0;&#x2611;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large, accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Large, accelerated&#xa0;filer</p> </td><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#x2610;</p> </td><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Accelerated&#xa0;filer</p> </td><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#x2610;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: middle; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: middle; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: middle; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: middle; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2022-01-01_2022-12-31">Non-accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#x2610;</p> </td><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Smaller&#xa0;reporting&#xa0;company</p> </td><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2611;</ix:nonNumeric></p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Emerging Growth Company</p> </td><td style="vertical-align: bottom; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: auto; line-height: 1; font-size: 9pt;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#xa0;&#xa0;&#xa0; &#x2610;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#xa0;&#xa0; &#x2610;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive officers during the relevant recovery period pursuant to &#xa7;240.10D-1(b).&#xa0;&#xa0; &#x2610;</p>
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric>.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#xa0;&#xa0;&#xa0;&#xa0;Yes&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;No&#xa0;&#x2611;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">As of June 30, 2022, the last business day of the registrants&#xa0;most recently completed second fiscal quarter, the aggregate market value of the common stock held by non- affiliates of the issuer was&#xa0;$<ix:nonFraction name="dei:EntityPublicFloat" scale="0" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2022-06-30">43,102,239</ix:nonFraction>&#xa0;This amount is based on the closing price of $0.92 per share of the registrant's common stock as of such date, as reported on the NYSE American. As of March 30, 2023, the registrant has a total of <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2023-03-30">69,998,525</ix:nonFraction> shares of Common Stock, par value&#xa0;$0.001 per share outstanding.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;"><b>DOCUMENTS INCORPORATED BY REFERENCE </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 8pt; line-height: 1;">None&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="text-align: center; width: 100%; line-height: 1; font-size: 10pt; font-family: Times New Roman;">
  1
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%; line-height: 1;">
  &#xa0;
 </div>
</div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1;">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: center;"><b>MILESTONE SCIENTIFIC INC.</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: center;"><b>Form 10-K Annual Report </b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: center;"><b>TABLE OF CONTENTS </b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%;">
    <tbody>
     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">PART I</p> </td>
      <td style="vertical-align: middle; width: 1546px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;1.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Business</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">4</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;1A.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Risk Factors</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">11</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;1B.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Unresolved Staff Comments</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">21</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;2.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Description of Property</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">22</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;3.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Legal Proceedings</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">22</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;4.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Mine Safety Disclosure</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">22</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">PART&#xa0;II</p> </td>
      <td style="vertical-align: middle; width: 1546px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;5.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Market for Common Equity, Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">23</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;6.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Selected Financial Data</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">23</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;7.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Management's Discussion and Analysis or Plan of Operations</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">24</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;7A.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Quantitative and Qualitative Disclosure about Market Risk</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;">29</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;8.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Financial Statements</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;">29</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;9.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">29</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;9A.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Controls and Procedures</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">30</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;9B.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Other Information</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">30</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item 9C.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Disclosure regarding Foreign Jurisdiction that Prevent inspections</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">30</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;">PART III</td>
      <td style="vertical-align: middle; width: 1546px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="padding: 0.33px; font-size: 9pt; width: 73px;">Item 10.</td>
      <td style="padding: 0.33px; font-size: 9pt; width: 1546px;">Directors, Executive Officers, Promoters and Control Persons and Corporate Governance; Compliance with Section&#xa0;16&#xa0;(a) of the Exchange Act</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">31</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="padding: 0.33px; font-size: 9pt; width: 73px;">Item 11.</td>
      <td style="padding: 0.33px; font-size: 9pt; width: 1546px;">Executive Compensation</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">31</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="padding: 0.33px; font-size: 9pt; width: 73px;">Item 12.</td>
      <td style="padding: 0.33px; font-size: 9pt; width: 1546px;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">31</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="padding: 0.33px; font-size: 9pt; width: 73px;">Item 13.</td>
      <td style="padding: 0.33px; font-size: 9pt; width: 1546px;">Certain Relationships and Related Transactions, and Director Independence&#xa0;&#xa0;&#xa0;&#xa0;</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">31</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="padding: 0.33px; font-size: 9pt; width: 73px;">Item 14.</td>
      <td style="padding: 0.33px; font-size: 9pt; width: 1546px;">Principal Accounting Fees and Services</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">31</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">PART&#xa0;IV</p> </td>
      <td style="vertical-align: middle; width: 1546px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Item&#xa0;15.</p> </td>
      <td style="vertical-align: middle; width: 1546px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">Exhibits and Financial Statement Schedules</p> </td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">32</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="vertical-align: middle; width: 73px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">SIGNATURES</p> </td>
      <td style="vertical-align: middle; width: 1546px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
      <td style="vertical-align: middle; width: 65px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">34</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td colspan="2" style="vertical-align: middle; width: 1622px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">EXHIBITS</p> </td>
      <td style="vertical-align: middle; width: 65px; line-height: 1; text-align: justify; font-size: 9pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGNUM" style="width: 100%; line-height: 1; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
      2
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="width: 100%; line-height: 1; text-align: justify; margin: 0pt;">
      &#xa0;
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><b>FORWARD-LOOKING STATEMENTS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Certain statements made in this Annual Report on Form 10-K are </i>&#x201c;<i>forward-looking statements</i>&#x201d;<i> (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of Milestone Scientific Inc. (</i>&#x201c;<i>Milestone Scientific</i>&#x201d;<i>) to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Milestone Scientific</i>&#x2019;<i>s plans and objectives are based, in part, on assumptions involving the continued expansion of its business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Milestone Scientific. Although Milestone Scientific believes that its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate. Considering the significant uncertainties inherent in the forward-looking statements included herein, particularly in view of our history of operating losses that are expected to continue, requiring additional funding which we may be unable to raise capital when needed (which may force us to delay, curtail or eliminate commercialization efforts of our CompuFlo Epidural Computer Controlled Anesthesia System), the early stage operations of and relatively lack of acceptance of our medical products, relying exclusively on two third parties to manufacture our products, changes to our distribution arrangements exposes us to risks of interruption of marketing efforts and building new marketing channels, changes in our informal manufacturing arrangements made by the manufacturer of our products and disruptions at the manufacturing facility of our manufacturers, including shortages of or delays in obtaining chips and other components, exposes us to risks that may harm our business, raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights, if physicians do not accept nor use our CompuFlo Epidural Computer Controlled Anesthesia System, our ability to generate revenue from sales will be materially impaired, exposure to the risks inherent in international sales and operations, including China, and developments by competitors may render our products or technologies obsolete or non-competitive, the inclusion of such information should not be regarded as a representation by Milestone Scientific or any other person that the objectives and plans of Milestone Scientific will be achieved. Milestone Scientific undertakes no obligation to revise or update publicly any forward-looking statements for any reason. </i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; line-height: 1; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     3
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; line-height: 1; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><b>PART I </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">All references in this report to &#x201c;Milestone Scientific,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;we,&#x201d; the &#x201c;Company&#x201d; or &#x201c;Milestone&#x201d; refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Medical, Inc.&#xa0;(all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C<i>ompuDent</i>&#xae;<i>; CompuMed</i>&#xae;<i>; CompuFlo</i>&#xae;<i>; DPS Dynamic Pressure Sensing technology</i>&#xae;<i>; Milestone Scientific </i>&#xae;<i>;</i>&#xa0;<i>CathCheck</i>&#xae;; <i>the Milestone logo </i>&#xae;<i>; SafetyWand</i>&#xae;<i>; STA Single Tooth Anesthesia System</i>&#xae;<i>; and The Wand </i>&#xae;<i>.</i>&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><b>Item</b>&#xa0;<b>1. Business</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><b>Overview</b>&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific was incorporated in the State of Delaware in August 1989. Milestone Scientific has developed a proprietary, revolutionary, computer-controlled anesthetic delivery device, our DPS Dynamic Pressure Sensing Technology&#xae; System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration &#x2013; enabling healthcare practitioners to achieve multiple unique benefits that cannot currently be accomplished with the 160-year-old manual syringe. The device, using The Wand&#xae;, a single use disposable handpiece, is marketed in dentistry under the trademark <i>CompuDent</i>&#xae;<i>, </i>and <i>STA Single Tooth Anesthesia System</i>&#xae; and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in 38 other countries.&#xa0;Milestone Scientific also has 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the<i> CompuFlo</i>&#xae; Epidural Computer Controlled Anesthesia System in the lumbar spine region. In addition, certain medical devices have obtained CE mark approval and can be marketed and sold in most European countries.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and devices for medical, and dental Since our inception, we have engaged in pioneering proprietary, innovative, computer-controlled injection technologies, and solutions for the medical and dental markets. We believe our technologies are proven and well established. Our common stock was initially listed on the NYSE American on June 1, 2015 and trades under the symbol &#x201c;MLSS&#x201d;.&#xa0;The Company is focused on building its intellectual; property portfolio across numerous indications.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The recent receipt of chronology-Specific CPT Code for the Company's technology by the American Medical Association marks an important milestone, that could increase the potential number of anesthesia pain management clinics adopting the CompuFlo instrument. A CPT code expands the potential for reimbursement of epidural procedures in pain management utilizing the CompuFlo Epidural System., which should help accelerate the commercial roll-out of CompuFlo in the U.S.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><span style="text-decoration: underline; "><b>DPS Dynamic Pressure Sensing Technology; Our Proprietary Core Technology Platform</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Given our experience and established brand awareness within the dental industry beginning with our first commercial product, the first computer-controlled local anesthesia delivery (C-CLAD) system marketed as the <i>Wand</i>&#xae; and re-branded as the <i>CompuDent</i>&#xae; System, now the market leader in dental injection technology, we elected to focus our product development efforts on improving the patient experience and making the device more versatile and precise for the practitioner.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our next significant intellectual property advancement was a improvement over our <i>CompuDent</i>&#xae; System &#x2013; the development of our proprietary <i>CompuFlo</i>&#xae; Computer-Controlled Drug Delivery System with <i>DPS</i> Dynamic Pressure Sensing Technology, an advanced and FDA-approved technology for the painless and accurate delivery of drugs, anesthetics, and other medicaments into all tissue types, as well as for the aspiration of bodily fluids or previously injected substances. Its regulation and control of the flow rate continues to provide painless delivery benefits, while its innovative dynamic pressure sensing capability provides visual and audible in-tissue pressure feedback, identifying tissue types to the healthcare provider. This pressure feedback extends the benefit of painlessness from anesthetics with known viscosities to a wide range of liquid drugs and other medicaments with varying viscosities and flow rates. Such pressure feedback, part of our <i>DPS</i> Dynamic Pressure Sensing Technology, also allows the healthcare provider to know when certain types of tissues have been penetrated and permits the healthcare provider to inject medicaments precisely at the desired location. Thus, real-time continuous pressure feedback can prevent the injection to tissue outside the intended target area, an important characteristic in the injection of chemotherapeutics and other toxic substances.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In addition to the ability to determine exit pressure <i>in-situ</i> (in the injection site tissue) at the tip of the needle, minimizing tissue damage (and eliminating the pain of the injection) because the flow rate and pressure of the injection are precisely controlled, <i>CompuFlo</i>&#xae; computer-controlled Drug Delivery Systems features a proprietary algorithm, which allow for the measurement of the exit pressure. These algorithms contain the critical components of specific drugs, parameters of needles, tubing and syringes and all other pertinent components for the safe and efficacious delivery of medications for all procedures. <i>CompuFlo</i>&#xae;<i> </i>technology also enables devices to provide a digital record of the time and volume of anesthetic or medicament injected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Each Wand/STA System also includes a disposable injection handpiece that is extremely comfortable, light, and easy to use, providing for precise tactile control during the injection, an electro-mechanical (computer-controlled) fluid delivery instrument and the ability to record data from the injection event. The pencil grip used with the handpieces provides the practitioner with enhanced tactile sense and accurate control and allows bi-directional rotation, eliminating needle deflection, resulting in a greater accuracy and success. The handpiece is vibration-free because it does not have a motor or electrical component in it and, since the handpiece does not look like a typical syringe, we believe it also reduces patient anxiety and offers the possibility of curing dental phobia of which an estimated 40&#xa0;million Americans suffer.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; line-height: 1; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; line-height: 1; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As confirmed by numerous noted medical and dental experts within academia and the clinical practice arenas, <i>CompuFlo </i>Systems using <i>DPS</i> Dynamic Pressure Sensing technology have the potential to greatly increase the safety and efficacy of many drug delivery procedures that currently rely upon the over 160-year-old hypodermic syringe technology and the tactile senses and delivery expertise of the administrator.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Devices using <i>DPS</i> Dynamic Pressure Sensing Technology such as the <i>CompuFlo</i> System can be used to inject a wide variety of liquid medicaments as well as anesthetics. We believe our <i>CompuFlo</i> System avoids the negative side effects from the use of traditional hypodermic drug delivery injection devices, which are well documented in dental and medical literature and include risk of death, transient or permanent paralysis, pain, tissue damage and post-operative complications. Pain and tissue damage often result from uncontrolled flow rates and pressure created during the administration of drug solutions into human tissue. While several technologies can control the flow rate, we believe our patented <i>DPS</i> Dynamic Pressure Sensing technology and <i>CompuFlo</i> Systems provide the&#xa0;control of pressure during&#xa0;the injection as well accurately and precisely delivery the drug.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><b><span style="text-decoration: underline; ">CompuFlo Epidural Computer Controlled Anesthesia System</span></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The<i> CompuFlo</i> Epidural Computer Controlled Anesthesia System (or the <i>CompuFlo</i> Epidural System) is one such platform extension of our <i>DPS</i> Dynamic Pressure Sensing Technology platform, providing anesthesiologists and other healthcare providers the ability, for the first time, to quantitatively determine and document the pressure at the needle tip in real-time for proper needle placement in epidural procedures used for labor/delivery and back pain management. Our proprietary <i>DPS</i> Dynamic Pressure Sensing Technology allows the <i>CompuFlo</i> Epidural System to provide objective visual and audible in-tissue pressure feedback that allows anesthesiologists to identify and confirm placement in the epidural space.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">Our <i>CompuFlo </i>Epidural System provides an objective tool that we believe consistently and accurately identifies the epidural space by detecting the difference in pressure between the ligamentum flavum and the intrafilamentary tissue. In studies, the <i>CompuFlo </i>Epidural System<i> </i>with <i>DPS</i> Dynamic Pressure Sensing Technology has been shown to be effective in correctly identifying the epidural space. Knowing the precise location of a needle tip during an epidural injection procedure provides a measure of safety not presently available to doctors using conventional syringes. In the absence of fluoroscopy, identifying the epidural space by relying on the subjective perception of loss of resistance to saline requires a very long education period and learning curve and could result in morbidity and lack of efficacy. During back pain management epidural procedures, where fluoroscopy is commonly used, the <i>CompuFlo</i> Epidural System allows the clinician to locate the epidural space, without using fluoroscopy, thereby protecting the patient and clinician from unnecessary exposure to radiation along with significantly reducing capital and operating costs.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><span style="text-decoration: underline; "><b>Wand/STA Dental Product</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Since its market introduction in early 2007, the Wand STA System and prior C-CLAD devices have been used to deliver over 80 million safe, effective, and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><span style="text-decoration: underline; "><b>Medical Market Product</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">During 2016, Milestone Scientific filed for 510(k) marketing clearance with the U.S. Food and Drug Administration (FDA) for both intra-articular and epidural injections with the CompuFlo Epidural System.&#xa0; In June 2017, the FDA approved the CompuFlo Epidural System for epidural injections.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">In addition, the recent receipt of chronology-Specific CPT Code for the Company's technology by American Medical Association marks an important milestone, that could increase the potential number of anesthesia pain management clinics adopting the CompuFlo instrument. A CPT code expands the potential for reimbursement of epidural procedures in pain management utilizing the CompuFlo Epidural System., thereby helping accelerate the commercial roll-out of CompuFlo in the U.S.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><span style="text-decoration: underline; ">Cosmetic Botulinum Product</span></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Advanced Cosmetic Systems, Inc. (&#x201c;Advanced Cosmetic Systems&#x201d;),&#xa0;was originally&#xa0;owned 50% by us and 50% by Milestone China&#xa0;Company Limited (&#x201c;Milestone China&#x201d;), a company organized under the laws of Hong Kong and initially owned 40% by Milestone Scientific. Milestone China contributed $900,000 of cash to the joint venture, and we have provided a royalty-free license to utilize our technology to the joint venture to develop a botulinum toxin injection device.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">In November 2017, we announced plans for the commercial launch of our proprietary cosmetic injection device using our <i>DPS</i> Dynamic Pressure Sensing technology platform and our <i>CompuFlo </i>Cosmetic System for delivery of botulinum toxin. Our proprietary cosmetic injection device features improved needle placement with a comfortable stylus grip, precise dosing, the same technology platform that has made dental and epidural injections painless, and a new, intuitive touch-screen interface. Although the Company received positive outcomes of multi-state human factor studies with targeted customers,&#xa0;the Company did not have the necessary&#xa0;capital to move&#xa0;forward with&#xa0;the commercial launch of our cosmetic device and apply for marketing clearance&#xa0;in Europe (CE clearance), and United States (FDA clearance).&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><b><span style="text-decoration: underline; ">Other</span></b>&#xa0;<b><span style="text-decoration: underline; ">Possible Products</span></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company is reviewing using <i>CompuFlo</i>&#x2019;s <i>DPS</i> Dynamic Pressure Sensing Technology for less painful injections for use in rhinoplasty, colorectal surgery, podiatry, and other disciplines. In the self-injectable market, there are many injectable drugs routinely self-administered in a home or office setting using spring loaded automatic injection devices by people who suffer from long-term chronic conditions such as multiple sclerosis, rheumatoid arthritis, and other diseases of the auto immune system. We believe <i>CompuFlo</i>&#x2019;s <i>DPS</i> Dynamic Pressure Sensing Technology, using pressure sensing capabilities, can serve as a less painless subcutaneous injection method for these self-administered drugs. However, there can be no assurance that we will be able to successfully develop any such products, or that if developed, that we will be able to obtain FDA approval to market any such products, or even if we do obtain such FDA approval, that any such products will generate any revenue for us or be a commercial success.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><span style="text-decoration: underline; ">Ukraine</span></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Sanctions imposed by the United States and other western democracies, because of the Ukrainian-Russian conflict, and any expansion thereof, is likely to have unpredictable and wide-ranging effects on the domestic and global economy and financial markets, which could have an adverse effect on our business and results of operations. As direct impact from the conflict, we have experienced a decrease in international sales to Ukraine and halted all sales to Russia. We will continue to monitor the situation carefully and, if necessary, take action to protect our business, operations, and financial condition.&#xa0;</p>
  <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><span style="text-decoration: underline; ">COVID-19 Pandemic</span></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The COVID-19 pandemic materially adversely affected the Company&#x2019;s financial results and business operations during 2021. During the year 2022, the&#xa0;demand increased, and recovery of the dental business was seen, however, it is unclear what the effect other possible variants might have on the business during 2023. Therefore, such increased demand may or may not continue and/or demand may or may not increase from historical levels depending on the duration and severity of the COVID-19 pandemic, the transmissibility and severity of variants, the effectiveness of the on-going vaccination process, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business and manufacturing disruption, inventory shortages, delivery delays, and reduced sales and operations, any of which could materially affect our business, financial condition, and results of operations.</p>
  <p style="text-align: left; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <div style="font-size:9pt">
   <div style="font-family:&quot;Times New Roman&quot;, Times, serif">
     However, there can be no assurance that we will be able to successfully develop any such products, or that if developed, that we will be able to obtain FDA approval to market any such products, or even if we do obtain such FDA approval, that any such products will generate any revenue for us or be a commercial success.
   </div>
  </div>
  <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <div style="font-size:9pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-variant:normal">
      The Company&#x2019;s employees have been and are being affected by the COVID-19 pandemic. The health of the Company&#x2019;s workforce is of primary concern and the Company may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the coronavirus. Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic. If these conditions worsen, the Company&#x2019;s ability to manage its business may be impaired, and operational risks, cybersecurity risks and other risks facing the Company prior to the pandemic may be elevated. The COVID-19 pandemic is affecting the Company&#x2019;s customers, suppliers, vendors, and other business partners, but the Company is not able to &#xa0;predict the ultimate consequences that will result therefrom.
    </div>
   </div>
  </div>
  <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <div style="font-size:9pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-variant:normal">
      We are experiencing supply delays and shortages due to the disruptions the ongoing COVID-19 pandemic is having on the global supply chain, especially with respect to goods from China. The ongoing COVID-19 pandemic has resulted in significant disruption to the operations of certain suppliers in China and the related transportation of their goods to the United States that are parts of our global supply chain. We have been able to make alternative delivery arrangements for limited quantities of goods, at increased&#xa0;cost. While we have not yet experienced material shortages in supply because of these disruptions and our alternative delivery arrangements, if they were to be prolonged or expanded in scope, there could be resulting supply shortages which could impact our ability to have manufactured and delivered our products to the United States and, ultimately to our customers. Accordingly, such supply shortages and delivery limitations could have a material adverse effect on our business, financial condition, results of operations, and cash flows.&#xa0; All of these factors may have far reaching&#xa0;impacts on the Company&#x2019;s business, operations, and financial results and conditions, directly and indirectly, including without limitation impacts on the health of the Company&#x2019;s management.
    </div>
   </div>
  </div>
  <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <div style="font-size:9pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-variant:normal">
     <b>Patents and Intellectual Property</b>
    </div>
   </div>
  </div>
  <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <div style="font-size:9pt">
   <div style="font-family:&quot;Times New Roman&quot;">
    <div style="font-variant:normal">
      Milestone Scientific and its subsidiaries currently hold approxi
     <span style="color: rgb(0, 0, 0); font-size: 9pt;">mately 216&#xa0;U.S. a</span>nd foreign patents, and many patent applications. The Company&#x2019;s patents and patent applications relate to drug delivery methodologies, drug flow rate measurement, pressure/force computer-controlled drug delivery with exit pressure, dynamic pressure sensing, automated rate control, automated charging, drug&#xa0;profiles, audible and visual pressure/force feedback, tissue identification, drug delivery injection unit, drug drive unit for anesthetic, handpiece, and injection device. Milestone Scientific and its subsidiaries also currently hold approximately 36&#xa0;registered U.S. and foreign trademarks, including
     <i>CompuDent</i>&#xae;
     <i>, CompuFlo</i>&#xae;
     <i>, DPS Dynamic Pressure Sensing technology</i>&#xae;
     <i>, Safety Wand</i>&#xae;
     <i>, STA Single Tooth Anesthesia System</i>&#xae;
     <i>, </i>and
     <i> The Wand</i>&#xae;
    </div>
   </div>
  </div>
  <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific relies on a combination of patent, copyright, trade secret and trademark laws and employee and third-party non-disclosure agreements to protect its intellectual property rights. Despite the precautions taken by Milestone Scientific to protect its IP rights, unauthorized parties may attempt to reverse engineer, copy, or obtain and use products and information that Milestone Scientific regards as proprietary, or may design products serving similar purposes that do not infringe on Milestone Scientific&#x2019;s patents. Milestone Scientific&#x2019;s failure to protect its proprietary information and the expenses of doing so could have a material adverse effect on our business, financial condition, and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">If Milestone Scientific&#x2019;s products infringe upon patent or proprietary rights of others, we may be required to modify processes or to obtain licenses. There can be no assurance that Milestone Scientific would be able to do so in a timely manner, upon acceptable terms and conditions, or at all. The failure to do so could have a material adverse effect on our business, financial condition, and results of operations.</p>
  <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><span style="text-decoration: underline; "><b>Manufacturing</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific has informal arrangements with an U.S. manufacturer of the <i>Wand/STA</i> System, and epidural devices. Pursuant to these informal arrangements, our third-party manufacturer manufactures the <i>Wand/STA</i> System under specific purchase orders without minimum purchase commitments, and at prices to be agreed upon in each such purchase order.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our agreement with the principal manufacturer of dental handpieces includes pricing terms. Milestone Scientific has been supplied by the manufacturer of the <i>Wand/STA</i> System and its predecessor, the <i>CompuDent </i>System<i>,</i> since the commencement of production in 1998, and by the manufacturer of its dental handpieces since 2003. The manufacturer of our dental handpieces is in the People&#x2019;s Republic of China and the manufacturer of the <i>Wand/STA</i> System is in the United States. Refer to Item 1A. Risk Factors<b>.</b>&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Changes to pricing of the <i>Wand/STA</i> System instruments by the manufacturer could have a material adverse effect on our financial condition, business, and results of operations. Termination of the manufacturing relationship with any of these third-party manufacturers could significantly and adversely affect our ability to produce and sell the products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">Though other alternate sources of supply for dental handpieces exist, Milestone Scientific would need to establish relationships with new suppliers, and with respect to the <i>Wand/STA&#xa0;</i>System recover its existing tools or have new tools produced and &#x201c;burn in&#x201d; and other manufacturing and quality control software re-produced. Establishing new manufacturing relationships could involve significant expense and delay. Any curtailment or interruptions of supply, whether as a result of the inability of a supplier to meet our product delivery needs or termination of the relationship, would have a material adverse effect on our financial condition, business, and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><span style="text-decoration: underline; ">Distribution and Marketing</span></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Dental Products</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has used a combination of exclusive and non-exclusive distributors to sell its dental products.&#xa0; In the United States and Canada the Company&#x2019;s largest distributor was Henry Schein, Inc. (&#x201c;Henry Schein&#x201d;).&#xa0; In December 2021, Henry Schein&#x2019;s exclusive distribution arrangement with respect to the Wand STA System became a non-exclusive distribution arrangement for the United States and Canada, and on December 31, 2022 such non-exclusive distribution arrangement terminated.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">In anticipation of such termination, in January 2021, the Company began a process of signing non-exclusive dental distribution arrangements with dental distributors in specific geographical locations in the United States and Canada. As of December 31, 2022, there are twelve new non-exclusive dental distributors engaged in the United States and Canada. In addition, the Company developed its own United States direct distribution channel which was launched in January of 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">On the global front, we have granted exclusive marketing and distribution rights for the Wand STA System to select dental suppliers in various international regions in Asia, Africa, South America, and Europe. Additionally, the Company is in the process of evaluating current international distributors and adding new distributors globally as required based on the economics of the region.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Medical Product</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The company, markets and sell it&#x2019;s medical products in the international markets such as Italy, Switzerland, Greece, Canada and the Middle East through exclusive distributors. In the United States the Medical products are sold by a direct sales team of 3 full time employees and CTI a medical distributor covering 22 states.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><span style="text-decoration: underline; "><b>Competition</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of this filing, there is no subcutaneous drug delivery platform or device on the market regulating the flow rate and pressure of an injection capable of delivering a painless injection at the desired location like Milestone Scientific&#x2019;s proprietary, patented devices having our <i>DPS</i> Dynamic Pressure Sensing technology.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific&#x2019;s devices compete based on their performance characteristics and the benefits provided to the patient, practitioner, and their business operations. Clinical studies have shown that our devices reduce fear, pain and anxiety for many patients, and Milestone Scientific believes that they can reduce practitioner stress levels, as well. Other computer-controlled local anesthesia delivery (C-CLAD) options are the Quicksleeper and SleeperOne, from Dental Hi Tec, Dentapen from Septodant, the Calajet from Aseptico, and the Comfort Control Syringe by Dentsply. In the medical segment, for needle verification and placement the EpiFaith Syringe made its market entry in 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Quicksleeper was invented in France by Dr. Alain Villette in 1991. It is marketed as the only local anesthetic delivery device in France that allows the ability to perform all intraoral local anesthetic injection techniques, including osteocentral anesthesia, quickly and without failure. The extra feature that gives the Quicksleeper this ability is a built-in motor in the syringe/handpiece that renders the syringe both an injector and a perforator of bone. That is, the handpiece of the Quicksleeper can perform an intraosseous injection via a motor driven perforation of the cortical plate of bone. A standard dental needle that attaches to the syringe spins as the motor rotates the handpiece thus acting as a perforator. However, the handpiece is relatively heavy, weighing 240 g. as compared to a standard syringe that weighs 80 g. Injection speed increases during the injection, but the operator cannot control when the injection speed increases.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Calajet instrument,&#xa0;manufactured in Europe, has been very slow to grow market acceptance. It recently began marketing in the United States with similar slow acceptance. The instrument is a higher price than the Wand STA and does not provide dynamic pressure sensing technology. Although a competitor, we believe that without a substantial distribution network&#xa0;this instrument will have a difficult time to be successful in the United States.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Dentapen from Septodent is&#xa0;the newest competitor in the market. This device is manufactured in Europe and began marketing in the United States in 2018. This device&#xa0;is priced similar to the&#xa0;Wand/STA device, but at this time, to our knowledge, it has been slow to attract viable distribution in the United States.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The EpiFaith Syringe claims to assist the physicians in entering the epidural space. The instrument is introduced at a lower price. Although a potential competitor, we believe that our technology is well documented and is the only pressure sensor guidance system for epidural analgesia assisting the physician over the entire trajectory of epidural needle placement and catheter verification.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific&#x2019;s proprietary, patented devices with its <i>DPS</i> Dynamic Pressure Sensing Technology platform also compete with disposable and reusable syringes that generally sell at lower prices and that use established and well-understood methodologies in both the dental and medical marketplaces.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Rapid technological change and research may affect our products. Current or new competitors could, at any time, introduce new or enhanced products with features that render our products less marketable or even obsolete. Therefore, Milestone Scientific must devote substantial efforts and financial resources to improve existing products, bring products to market quickly, and develop new products for related markets. In addition, the ability to compete successfully requires that Milestone Scientific maintain&#xa0;an effective distribution network with a strong marketing plan. Any new products must comply with applicable regulatory authorities before they may be marketed. Milestone Scientific cannot assure that it can compete successfully, that competitors will not develop technologies or products that render our products less marketable or obsolete, or, that Milestone Scientific will succeed in improving its existing products, effectively develop new products, or obtain required regulatory approval for those products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><span style="text-decoration: underline; "><b>Government Regulation</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The manufacture and sale of medical devices and other medical products are subject to extensive regulation by the Food and Drug Administration&#xa0;&#xa0;("FDA") pursuant to the U.S. Food, Drug and Cosmetic Act (&#x201c;FD&amp;C Act&#x201d;), and by other federal, state, and foreign authorities. Under the FD&amp;C Act, medical devices must receive FDA clearance before they can be marketed commercially in the United States. Some medical products must undergo rigorous pre-clinical and clinical testing and an extensive FDA approval process before they can be marketed.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">These processes can take many years and require the expenditure of substantial resources. The time required for completing such testing and obtaining such approvals is uncertain, and FDA clearance may never be obtained. Delays or rejections may be encountered based upon changes in FDA policy during the period of product development and FDA regulatory review of each product submitted. Similar delays also may be encountered in other countries. Following the enactment of the Medical Device Amendments to the U.S. Food, Drug and Cosmetic Act in May 1976, the FDA classified medical devices in commercial distribution into one of three classes. This classification is based on the controls necessary to&#xa0;reasonably ensure the safety and effectiveness of the medical devices. Class I devices are those devices whose safety and effectiveness can reasonably be ensured through general controls, such as adequate labeling, pre-market notification, and adherence to the&#xa0;FDA&#x2019;s&#xa0;Quality&#xa0;System&#xa0;Regulation (&#x201c;QSR&#x201d;), also referred to as &#x201c;Good Manufacturing Practices&#x201d; (&#x201c;GMP&#x201d;) regulations. Some Class I devices are further exempted from some of the general controls. Class II devices are those devices whose safety and effectiveness reasonably can be ensured using special controls, such as performance standards, post-market surveillance, patient registries, and FDA guidelines. Class III devices are those which must receive pre-market approval by the FDA to ensure their safety and effectiveness. Generally, Class III devices are limited to life-sustaining, life-supporting&#xa0;or implantable devices.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Prior to Pre-market Notification clearance, the manufacturer or distributor may not place the device into commercial distribution until an order is issued by the FDA. By regulation, the FDA has no specific time limit by which it must respond to a 510(k) Pre-market Notification. Currently, the FDA typically responds to the submission of a 510(k) Pre-market Notification within 180 days. The FDA response may declare that the device is substantially equivalent to another legally marketed device and allow the proposed device to be marketed in the United States.&#xa0;However, the FDA may determine that the proposed device is not substantially equivalent or may require further information, such as additional test data, before the FDA is able to decide regarding substantial equivalence. Such determination or request for additional information could delay market introduction of products. If a device that has obtained 510(k) Pre-market Notification clearance is changed or modified in design, components, method of manufacture, or intended use, such that the safety or effectiveness of the device could be significantly affected, separate 510(k) Pre-market notification clearance must be obtained before the modified device can be marketed in the United States. If a manufacturer or distributor cannot establish that a proposed device is substantially equivalent to a legally marketed device, the manufacturer or distributor will have to seek pre-market approval of the proposed device, a more difficult procedure requiring extensive data, including pre-clinical and human clinical trial data, as well as extensive literature to prove the safety and efficacy of the device.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The FDA cleared the Wand, our <i>CompuDent </i>System, and its disposable handpieces, for marketing in the United States for dental applications in July 1996; the <i>CompuMed</i>&#xae; System for marketing in the United States for medical applications in May 2001; the <i>Safety Wand</i>&#xae; for marketing in the United States for dental applications in September 2003; the <i>Wand/STA </i>System for dental applications in August 2006; and our <i>CompuFlo </i>Epidural System in June 2017.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">For us to commercialize other products in the United States, Milestone Scientific would have to submit and have cleared additional 510(k) applications to the FDA. In 2017, the FDA reduced the barrier to marketing clearance for certain dental devices. As&#xa0;a result, other manufacturers of injection devices could more easily enter the dental market.&#xa0;However, we believe that any new device will be very limited in sales volume without a significant distributor in the dental market.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Though certain dental&#xa0;and medical devices have received FDA marketing clearance, there can be no assurance that any of the other medical devices&#xa0;under development will obtain the required regulatory clearance in a timely manner, or at all. If regulatory clearance of a product is granted, such clearance may entail limitations on the indicated uses for which the product may be marketed. In addition, modifications may be made to the products to incorporate and enhance their functionality and performance based upon new data and design review. There can be no assurance that the FDA will not request additional information relating to product improvements; that any such improvements would not require further regulatory review, thereby delaying the testing, approval, and commercialization of product improvements; or&#xa0;that ultimately any such improvements will receive FDA clearance.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Compliance with applicable regulatory requirements is subject to continual review and is monitored through periodic inspections by the FDA. Later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions on such product or manufacturer, including fines, delays or suspensions of regulatory clearances, seizures or recalls of products, operating restrictions, and criminal prosecution.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific is subject to pervasive and continuing regulation by the FDA, whose regulations require manufacturers of medical devices to adhere to certain QSR requirements as defined by the FD&amp;C Act. QSR compliance requires testing, quality control and documentation procedures. Failure to comply with QSR requirements can result in the suspension or termination of production, product recall or fines and penalties. Products also must be manufactured in registered establishments. In addition, labeling and promotional activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission. The export of devices is also subject to regulation in certain instances.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Medical Device Reporting (&#x201c;MDR&#x201d;) regulation obligates us to provide information to the FDA on product malfunctions or injuries alleged to have been associated with the use of the product or in connection with certain product failures that could cause serious injury. If, because of FDA inspections, MDR reports or other information, the FDA believes that Milestone Scientific is not in compliance with the law, the FDA can institute proceedings to detain or seize products, enjoin future violations, or assess civil and/or criminal penalties against us, our officers, or employees. Any action by the FDA could result in disruption of operations for an undetermined amount of time.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 8pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">In May 2022, the Company initiated a Corrective Action Preventative Action (CAPA) investigation of the Epidural Disposable Kit, Part # 6100-01, lot HC 51, the scope of the voluntary market withdrawal needed to be expanded to include Part # 6100-03, lot HC 50. A new non-conformance was initiated, and Lot HC 50 was added to the scope of the CAPA initiated above. The investigation via the CAPA identified that there is an issue with the id adaptors used in both lot&#x2019;s HC 51 and HC 50. However, the Health Hazard Evaluation shows that there is no risk to the patient or the user, thus management has determined there are no potential impacts to patients or users. Lot&#x2019;s HC 51 and HC 50 are worth approximately $22,000 and $10,000 respectively.&#xa0;Management has determined that no other lots were affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">In May 2022, the Company was notified that Wand STA handpieces, reference # STA&#x2014;5050-2725, lot B210113 were packaged incorrectly. The Company initiated a Corrective Action Preventative Action (CAPA) investigation to determine the root cause and implement corrective actions. The Health Hazard Evaluation was completed and showed that there is no risk to the patient or the user due to this discrepancy, thus management has determined there are no potential impacts to patients or users. However, to provide the highest quality products to the market, Milestone Scientific decided to initiate a voluntary market withdrawal on May 13, 2022. Lot B210113 is worth approximately $25,000.&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Human Capital</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">The Company has a total 20&#xa0;full-time employees, including two&#xa0;executive officers. Milestone Scientific also has a consultant who serves as a Director of Clinical Affairs.&#xa0;None of our employees are subject to a collective bargaining agreement and we believe our employee relations are</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">good.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><b>Corporate Information</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">We were organized in August 1989 under the laws of the State of Delaware. Our principal executive office is located at 425 Eagle Rock Avenue, Roseland, New Jersey 07068. Our telephone number is (973) 535-2717.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; line-height: 1; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     10
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; line-height: 1; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 1A. Risk Factors</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><i>You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and/or prospects.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Our Financial Position and Need for Additional Capital</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>We have incurred significant losses since our inception.</i></b>&#xa0;<b><i> These operating losses are expected to continue, and we are unable to predict the extent of future losses, whether we will generate significant revenues or whether we will achieve or sustain profitability.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We are a small, non-diversified medical device company with a history of limited revenue and significant operating losses and our prospects must be evaluated considering the uncertainties, risks, expenses, and difficulties frequently encountered by similarly situated companies. The Company&#xa0;has&#xa0;generated net losses in all periods since the commencement of our operations. The operating losses were&#xa0;$8.8 million and $7.4&#xa0;million, for the years ended December 31, 2022, and 2021, respectively.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We expect to make substantial expenditures and incur increasing operating costs in the future and our accumulated deficit will increase significantly as we undertake to commercialize our <i>CompuFlo</i> Epidural System.&#xa0;Our losses have had, and are expected to continue to have, an adverse impact on our working capital, total assets, and stockholders' equity.&#xa0; Because of the risks and uncertainties associated with product acceptance, we are unable to predict the extent of any future losses, whether we will ever generate significant revenues or if we will ever achieve or sustain profitability. &#xa0;Even if we do generate profits from operations, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to generate profits from operations, and to become and remain profitable, could impair our ability to raise capital, expand our business, and maintain our commercial efforts or continue our operations. A decline in the value of our company could also cause our shareholders to lose all or part of their investment</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>We may require additional funding and may be unable to raise capital when needed, which may force us to delay, curtail or eliminate commercialization efforts of our CompuFlo Epidural Computer Controlled Anesthesia System.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our operations have consumed substantial amounts of cash since inception.&#xa0; During the years ended December 31, 2022&#xa0;and 2021, net cash flow used in operations was approximately $6.0&#xa0;million and approximately $4.0 million,&#xa0;respectively.&#xa0; We expect to continue to spend substantial amounts on commercialization and marketing activities, including the continued commercialization and marketing of our FDA-approved <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System.&#xa0; Until such time, if ever, as we can generate a sufficient amount of product revenue and achieve positive cash flow, we expect to seek to finance future cash needs through equity financings or corporate collaboration and licensing arrangements&#xa0;and may seek the sale of non-medical assets.&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely impact the price of our common stock.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Almost all our 69,306,497 outstanding shares of common stock on&#xa0;December 31, 2022, as well as a substantial number of shares of our common stock underlying outstanding warrants, are available for sale in the public market, either freely or pursuant to Rule 144 under the Securities Act of 1933, as amended.&#xa0;Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely impact the price of our common stock.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In February 2019, we issued 6,282,400 shares and 1,570,600 warrants to purchase common shares under our S-3 registration statement. During 2019 the Company issued 639,375 shares associated the warrants issued in February 2019. Since&#xa0;the year&#xa0;ended December 31, 2019, the Company issued 675,000&#xa0;shares of common stock for warrants exercised at&#xa0;&#xa0;$0.50 &#xa0;for proceeds of $337,500.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In February 2019,&#xa0;in&#xa0;a private placement we issued 714,286 restricted common shares and&#xa0;178,571 warrants to purchase common stock.&#xa0;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In April 2020, we completed a Common Stock offering generating gross proceeds of approximately $5.1 million (5,420,000 common shares and 2,710,000 warrants). The combined price of the shares and warrants was $0.95 per share. The warrants are exercisable at a price of $1.20 per share and have an expiration of three (3) years from the issue date.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In June 2020, we completed a second Common Stock offering generating gross proceeds of approximately $14.6 million (6,770,000 common shares and 3,749,000 warrants). The combined price of the shares and warrants was $2.15 per share. The warrants are exercisable at $2.60 and expire three (3) years from the issue date.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b><i>Raising additional capital by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish proprietary rights.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted.&#xa0; Any future debt financing may involve covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, redeem our stock, make certain investments, and engage in certain merger, consolidation, or asset sale transactions, among other restrictions.&#xa0; In addition, if we raise additional funds through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Recent developments in financial institutions could adversely affect our current and projected business operations, financial condition and results of operations.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Recent events involving limited liquidity, defaults, non-performance and other adverse developments that affect financial institutions have led to market-wide liquidity concerns. For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or FDIC, as receiver. On March 12, 2023, Signature Bank and Silvergate Capital Corp. were also placed into receivership. Future increases of the borrowing rate by the Federal Reserve Board, to slow inflation or for other reasons, may expose other financial institutions to greater interest rate risk and exacerbate liquidity and other adverse developments affecting such institutions.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Company currently keeps more than $250,000, the maximum amount insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;), in its current bank depositary.&#xa0; The Company may experience delayed access or a loss of its uninsured deposits or other financial assets should its existing financial institution experience financial distress.&#xa0; While the U.S. Department of Treasury, FDIC and Federal Reserve Board have provided access to uninsured funds in connection with the Silicon Valley Bank crisis, there is no guarantee that these institutions will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.&#xa0; The Company is currently evaluating its banking relationships with the intent of increasing the amount of deposits that are fully insured or invested in risk free instruments.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The results of events or concerns that involve non-performance by financial institutions could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations.&#xa0; In addition, any further deterioration in the macroeconomic economy or financial services industry, or delayed access or loss of uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution by our customers or vendors, could lead to losses or defaults by companies with whom we do business, which in turn could have a material adverse effect on our current and/or projected business operations, results of operations and financial condition. In addition, other companies could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on us, including but not limited to delayed access or loss of uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Sales and Distribution of Milestone Scientific Products </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Changes in our distribution arrangements exposes us to risks of interruption of marketing efforts and building new marketing channels.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Effective December 31, 2022, the Company's&#xa0; termination of its U.S. distribution agreement with Henry Schein became effective. The goal of changing our marketing plan from a sole exclusive distributor in the United States and Canada, to a large number of non-exclusive distributors and an e-commerce platform, may not be seamless or uninterrupted&#xa0;.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Returns under our Distribution and Supply Agreement with Henry Schein, Inc. could have a material adverse effect on our business, financial condition, and results of operations. </i></b>&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Under our Distribution and Supply Agreement with Henry Schein, Henry Schein has a right to return our products for full credit against the purchase price paid by them in accordance with such agreement, including but not limited to, returns due to shipment error by us or factory defect.&#xa0;On December 31, 2022, such non-exclusive distribution arrangement terminated, subject to certain post-termination rights and obligations of the parties, all in accordance with such agreement.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b><i>Milestone Scientific</i></b>&#x2019;<b><i>s International Operations Subject it to Certain Business Risks.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">A substantial amount of Milestone Scientific&#x2019;s sales come from its operations outside the United States and we intend to continue to pursue growth opportunities outside of the United States. Milestone Scientific&#x2019;s international operations subject it to certain risks relating to, among other things, fluctuations in foreign currency exchange, local economic and political conditions, competition from local companies, increases in trade protectionism, United States relations with the governments of the foreign countries in which Milestone Scientific operates, foreign regulatory requirements or changes in such requirements, changes in local healthcare payment systems and healthcare delivery systems, local product preferences and requirements, longer payment terms for account receivables than we experience in the United States, difficulty in establishing and managing foreign operations, weakening or loss of the protection of intellectual property rights in some countries and import or export licensing requirements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>We are exposed to the risks inherent in international sales.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In 2022, export sales outside of the United States made up approximately 63% of our total sales, and we sell our products to customers in approximately 30 countries and U.S. territories.&#xa0; We have exposure&#xa0;to risks of operating in many foreign countries, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">fluctuations in foreign currency exchange rates, could increase the end user cost for instruments;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">restrictions on, or difficulties and costs associated with, the currency exchange from foreign&#xa0;countries to obtain U.S. dollars;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">difficulties and costs associated with complying with a wide variety of complex laws, treaties, and regulations;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">unexpected changes in political or regulatory environments;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">political and economic instability;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">import and export restrictions and other trade barriers; and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">difficulties in obtaining approval for significant transactions.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>If physicians do not accept nor use our CompuFlo Epidural System, our ability to generate revenue from sales will be materially impaired.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Although the FDA has cleared our application to begin marketing the <i>CompuFlo</i> Epidural System, this is no assurance that physicians, hospitals, clinics, and other health care providers will accept and use it.&#xa0; Acceptance and use of the <i>CompuFlo</i> Epidural System will depend on many factors including:</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">perceptions by members of the health care community, including physicians, about the safety and effectiveness of our product;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">cost-effectiveness of our product relative to competing products and systems;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">convenience, ease of use and reliability of our product relative to competing products and systems;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">patient satisfaction;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">product availability as well as, manufacturer warranty, maintenance, and customer and technical support;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">availability of reimbursement for our product from government or other healthcare payers; and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">effectiveness of marketing and distribution efforts by us and our licensees and distributors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Because we expect sales of the <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System to generate substantially all our medical product revenues in the near-term, the failure of this product to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable terms, if at all.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Milestone Scientific</i></b>&#x2019;<b><i>s sales and marketing efforts rely upon independent distributors that are free to market products that compete with Milestone Scientific</i></b>&#x2019;<b><i>s products, and if Milestone Scientific is unable to maintain or expand its network of independent distributors, its business could be materially adversely affected.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Scientific believes that a significant portion of its sales will continue to be to independent distributors for the foreseeable future, and it is possible that the percentage of its sales to independent distributors could increase. None of Milestone Scientific&#x2019;s independent distributors in the United States have been required to sell Milestone Scientific products exclusively, and each of them may freely sell the products of Milestone Scientific&#x2019;s competitors. If Milestone Scientific is unable to maintain or expand its network of independent distributors, its sales may be negatively affected.&#xa0; If any of its key independent distributors were to cease to distribute Milestone Scientific&#x2019;s products or reduce their promotion of such products as compared to the products of Milestone Scientific&#x2019;s competitors, Milestone Scientific may need to seek alternative independent distributors or increase its reliance on other independent distributors which alternative arrangements may not be sufficient to prevent a material reduction in sales of its products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Developments by competitors may render our products or technologies obsolete or non-competitive.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The medical device industry is intensely competitive and subject to rapid and significant technological change.&#xa0; We expect that other companies (or individuals), whether located in the United States or abroad, will pursue the development of alternative injection-based or imaging-based systems that will compete with our products.&#xa0; Many of these potential competitors have substantially greater capital resources, larger research and development staffs and facilities, longer product development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do.&#xa0; These companies also compete with us to attract qualified personnel and parties for acquisitions, joint ventures, or other collaborations.&#xa0; As a result, we may not be able to compete effectively against these companies or their products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Our ability to commercialize our products will depend in part on the extent to which reimbursement will be available from governmental agencies, health administration authorities, private health maintenance organizations and health insurers and other healthcare payers.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our ability to generate revenues from our products will be diminished if the products sell for inadequate prices or hospitals or physicians are unable to obtain adequate levels of reimbursement for the cost they incur in connection with the use of the product.&#xa0; Significant uncertainty exists as to the reimbursement status of newly approved healthcare products.&#xa0; Healthcare payers, including Medicare, are challenging the prices charged for medical products and services.&#xa0; Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for products.&#xa0; Insurance coverage may not be available, or reimbursement levels may be inadequate, to cover the charges for the use of such product.&#xa0; If government and other healthcare payers do not provide adequate coverage and reimbursement for any of our products, market acceptance of such product could be reduced.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">Prices in many countries, including many in Europe, are subject to local regulation and price controls.&#xa0; In the United States, where pricing levels for medical products, procedures and services are substantially established by third-party payors, including Medicare, if payors reduce the amount of reimbursement for a product, it may cause groups or individuals dispensing the product to discontinue use of the product, to substitute lower cost products even if the alternatives are less effective or to seek additional price-related concessions.&#xa0; These actions could have a negative effect on our financial results.&#xa0; The existence of direct and indirect price controls and pressures on our products could materially adversely affect our financial prospects and performance.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>We could lose our market advantage earlier than expected.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We believe that our products represent a significant improvement over any existing drug delivery injection system in use today.&#xa0; However, this competitive advantage can evaporate quickly if we are not able to commercialize our products quickly.&#xa0; In the medical device industry, the majority of an innovative product&#x2019;s commercial value is realized during the early stages of commercialization, before competing products are developed.&#xa0; Our market advantage is based, in part, on patent rights and the need for new competing products and systems to obtain regulatory approval before they can be commercialized.&#xa0; The scope of our patent rights may be limited and may also depend on the availability of meaningful legal remedies.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our failure to adequately protect our intellectual property rights, through patents or otherwise, or limitations on the use or loss of such rights, could have a material adverse effect on our ability to prevent the commercialization of competing anesthetic delivery systems.&#xa0; In some countries, basic patent protections for our products may not exist because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file in those markets.&#xa0; In addition, the patent environment can be unpredictable, and the validity and enforceability of patents cannot be predicted with certainty.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Risks Related to the Covid-19 Pandemic</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>The COVID-19 pandemic has and may continue to adversely affect the Company</i></b>&#x2019;<b><i>s business. Additional factors could exacerbate such negative consequences and/or cause other materially adverse effects.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Certain COVID-19 pandemic-related impacts were experienced by our businesses during 2022 and may continue for an indeterminable period. These included supply chain delays for some of our products which are manufactured in China and supply shortages in key components in our dental products. Future resurgences in COVID-19 infections or other new viral outbreaks may affect the prioritization of non-acute versus acute healthcare utilization, which may temporarily weaken future demand for certain of our products and increase the demand for other of our products. Also, adverse macroeconomic conditions may worsen if governments impose future restrictions, such as lockdowns or quarantine requirements, in order to control infection rates associated with COVID-19 or other viruses.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">Additionally, the pandemic escalated challenges that existed for global healthcare systems prior to the pandemic, including budget constraints and staffing shortages, particularly shortages of nursing staff. Changes in the ways healthcare services are delivered, including the transition of more care from acute to non-acute settings and increased focus on chronic disease management, may place additional financial pressure on hospitals and the broader healthcare system. Healthcare institutions may take actions to mitigate any persistent pressures on their budgets and such actions could impact the future demand for our products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>We are experiencing supply delays and shortages due to the disruptions the ongoing COVID-19 pandemic is having on the global supply chain, especially with respect to goods from China</i></b><b><i><span style="text-decoration: underline; ">.</span></i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We are experiencing supply delays and shortages due to the disruptions the ongoing COVID-19 pandemic is having on the global supply chain, especially with respect to goods from China. The ongoing COVID-19 pandemic has resulted in significant disruption to the operations of certain suppliers in China and the related transportation of their goods to the United States that are parts of our global supply chain. We have been able to make alternative delivery arrangements for limited quantities of goods, at an increased cost. While we have not yet experienced material shortages in supply as a result of these disruptions and our alternative delivery arrangements, if they were to be prolonged or expanded in scope, there could be resulting supply shortages which could impact our ability to have manufactured and delivered our products to the United States and, ultimately to our customers. Accordingly, such supply shortages and delivery limitations could have a material adverse effect on our business, financial condition, results of operations, and cash flows.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b>Risks Related to Employee Matters&#xa0;</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt;"><b><i>We may not be able to attract and retain qualified employees.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our future success depends upon the continued service of our executive officer and other key management and technical personnel, and on our ability to continue to identify, attract, retain, and motivate them. Implementing our business strategy requires specialized territory managers and other talent, as our revenues are highly dependent on technological and product innovations. The market for employees in our industry is extremely competitive, a number of such competitors are significantly larger than us and are able to offer compensation in excess of what we are able to offer.&#xa0;If we are unable to attract and retain qualified employees, our business may be harmed.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt;"><b>Risk Related to Our Dependence on Third Parties </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt;"><b><i>Relying exclusively on third parties to manufacture our products, changes in our informal manufacturing arrangements made by the manufacturer of our products and disruptions at the manufacturing facility of our manufacturers and failure to maintain existing supply relationships exposes us to risks that may harm our business.</i></b>&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt;">We have limited&#xa0;internal experience in manufacturing operations and have not historically established our own manufacturing facilities.&#xa0;We currently lack the internal resources to manufacture any of our products, including our <i>CompuFlo</i>&#xae; Epidural Computer Controlled Anesthesia System.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: -9pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific&#xa0;has been supplied by the manufacturer of the Wand/STA System and its predecessor, the CompuDent System, since the commencement of production in 1998, and by the manufacturer of its handpieces since 2003. The manufacturer of our handpieces is in the People&#x2019;s Republic of China and the manufacturer of the Wand/STA System is in the United States. At present, we have an informal arrangement with the manufacturers of our products.&#xa0;Our current arrangement with our manufacturers&#xa0;is on a purchase order-by-purchase order basis.&#xa0;As a result, we do not have price protection or a supply commitment for our devices or handpieces.&#xa0;If either manufacturer insists on a material change in terms or determines to discontinue manufacture of our products, it could have an adverse effect on our financial condition and results of operation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">An operational disruption in the facility of the manufacturer of, or their ability to ship, our handpieces or devices could negatively impact our financial results.&#xa0;The occurrence of a natural disaster, such as a hurricane, tropical storm, earthquake, tornado, severe weather, flood, fire, or epidemic, pandemic, or other health emergency, or other unanticipated problems such as labor difficulties, equipment failure or unscheduled maintenance, in each case could cause operational disruptions of varied duration.&#xa0;&#xa0;&#xa0;</p>
  <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">These types of disruptions could materially adversely affect our financial condition and results of operations to varying degrees dependent upon the facility, the duration of the disruption, our ability to shift business to another facility or find alternative sources of supply.&#xa0; Any losses due to these events may not be covered by our existing insurance policies or may be subject to certain deductibles.&#xa0; Given our current manufacturing relationships, it is possible that our manufacturing requirements may exceed the available supply allotments under our existing agreements.&#xa0;Our anticipated future reliance on third-party manufacturers exposes us to the following additional risks:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 9pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited, and the FDA must approve any replacement contractor.&#xa0;&#xa0;This approval would require new testing and compliance inspections. In addition, a new manufacturer would have to develop substantially equivalent processes for production of our products.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store, and distribute our products.</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Contract manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state agencies to ensure strict compliance with current good manufacturing practice and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers' compliance with these regulations and standards and our manufacturers may be found to be in noncompliance with certain regulations, which may impact their ability to manufacture our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 9pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">If any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to the innovation.&#xa0;&#xa0;We may be required to pay fees or other costs for access to such improvements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Though other alternate sources of supply for dental handpieces exist, Milestone Scientific&#xa0;would need to establish relationships with new suppliers, and with respect to the Wand/STA System recover its existing tools or have new tools produced and &#x201c;burned in&#x201d; and other manufacturing and quality control software re-produced. Establishing new manufacturing relationships could involve significant expense and delay.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Each of these risks could delay the commercialization of our <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System, limit our available supply of The Wand/&#xa0;STA for dental applications, cause damage to our reputation, result in higher costs and/or deprive us of potential product revenues.&#xa0; Any curtailment or interruptions of the supply, whether as a result of termination of the relationship or otherwise, would have a material adverse effect on our financial condition, business, and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Our business is exposed to risks associated with the economic, environmental, and political conditions in China because the sole manufacturer of our handpieces is located in China.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Because the sole manufacturer of our dental handpieces is located in China, our business is disproportionately exposed to the economic, environmental, and political conditions of the region. China&#x2019;s political and economic systems are very different from most developed countries in many respects, including, the amount of government involvement, the level of development, the control of foreign exchange and the allocation of resources. Uncertainties may arise with changing governmental policies and measures. China also faces many social, economic, and political challenges that may produce instabilities in both its domestic arena and in its relationship with other countries.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">These instabilities may significantly and adversely affect our supply of dental handpieces which would in turn adversely affect our financial performance. In addition, as the Chinese legal system develops, there can be no assurance that changes in laws and regulations and their interpretation or their enforcement will not have a material adverse effect on our business relationship with the sole manufacturer of our dental handpieces. Any adverse change in the economic, environmental, and political conditions in China could have a material adverse effect on economic growth and the level of investments and availability of capital in China, which in turn could lead to a reduction in the supply of our dental handpieces and consequently have a material adverse effect on our businesses.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In general, our success depends upon the quality of our products.&#xa0; Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services, and assuring the safety and efficacy of our products.&#xa0; Our future success depends on our ability to maintain and continuously improve our quality management program.&#xa0; A quality or safety issue may result in adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses.&#xa0; An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.&#xa0;See Item 1; &#x201c;Government Regulation.&#x201d;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Use of third parties to manufacture our products may increase the risk that we will not have sufficient quantities of our products or such quantities at acceptable levels of cost and quality, which could impair our commercialization efforts.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific relies on a number of third parties to supply and manufacture the components and raw materials for its products and its does not have long-term supply agreements with suppliers of these component parts and raw materials, and its arrangements with these suppliers are on a purchase-order basis. These products we obtain from suppliers are subject to fluctuations in price and availability attributable to a number of factors, including general economic conditions, commodity price fluctuations, the demand by other companies for the same raw materials and the availability of complementary and substitute materials.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">While Milestone Scientific works with suppliers to ensure continuity of supply, no assurance can be given that these efforts will be successful. In the event that any of its existing supply arrangements are terminated or there is a reduction or interruption of supply under these existing arrangements, Milestone Scientific expects that it will be able to enter into new arrangements with alternative suppliers, but these new arrangements may be on terms that are less favorable, including with respect to price and volume, and it may be costly or cause delays in our manufacturing process to transition to a new supplier, particularly in cases in which we must comply with regulatory requirements relating to qualification of new suppliers. The termination, reduction or interruption in supply of these raw materials and components could adversely impact Milestone Scientific Scientific&#x2019;s ability to manufacture and sell certain of its products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Third-party suppliers may encounter problems during manufacturing for a variety of reasons, including failure to follow specific protocols and procedures, failure to comply with applicable regulations, equipment malfunction, component part supply constraints, and environmental factors, any of which could delay or impede their ability to supply the components and raw materials for Milestone Scientific&#x2019;s products. Any such failure to perform or a reduction or interruption in supply could have a material adverse effect on Milestone Scientific&#x2019;s business and operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Regulatory Compliance and Other Legal Matters </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>We are subject to substantial domestic and international government regulation, including regulatory quality standards applicable to our manufacturing and quality processes. Failure by us to comply with these standards could have an adverse effect on our business, financial condition, or results of operations.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The FDA regulates the approval, manufacturing and sales and marketing of many of our products in the United States. Significant government regulation also exists in other countries in which we conduct business. As a device manufacturer, we are required to register with the FDA and are subject to periodic inspection by the FDA for compliance with the FDA&#x2019;s Quality System Regulation requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. In addition, the federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is rigorously monitored through periodic inspections by the FDA.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">In the European community, we are required to maintain certain ISO certifications to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications. Failure to comply with current governmental regulations and quality assurance guidelines could lead to temporary manufacturing shutdowns, product recalls or related field actions, product shortages or delays in product manufacturing. Efficacy or safety concerns, an increase in trends of adverse events in the marketplace, and/or manufacturing quality issues with respect to our products could lead to product recalls or related field actions, withdrawals, and/or declining sales.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>We may be subject, directly, or indirectly, to U.S. federal and state health care fraud and abuse and false claims laws and regulations. Prosecutions under such laws have increased in recent years and we may become subject to such litigation. If we are unable to comply or have not fully complied with such laws, we could face substantial penalties.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our operations are and will continue to be directly, or indirectly through our distributors, customers, and health care professionals, subject to various U.S. federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, federal False Claims Act, and the Foreign Corrupt Practice Act of 1977 (&#x201c;FCPA&#x201d;). These laws may impact, among other things, our proposed sales, and marketing and education programs. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program such as Medicare or Medicaid. Several courts have interpreted the statute&#x2019;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, the statute has been violated. The Anti-Kickback Statute is broad and, despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment, and possible exclusion from Medicare, Medicaid, and other federal health care programs. An alleged violation of the Anti-Kickback Statute may be used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act. Many states have also adopted laws like the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only the Medicare and Medicaid programs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government. Suits filed under the False Claims Act, known as &#x201c;qui tam&#x201d; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#x201c;relators&#x201d; or &#x201c;whistleblowers,&#x201d; may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of medical device, pharmaceutical and health care companies to have to defend False Claim Act actions. The Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been previously dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims act to be at least as effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws with qui tam provisions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Affordable Care Act includes provisions known as the Physician Payments Sunshine Act (section 6002), which require manufacturers of drugs, biologics, devices, and medical supplies covered under Medicare and Medicaid to disclose to the Centers for Medicare and Medicaid Services any transfers of value to physicians and teaching hospitals.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Manufacturers must also disclose investment interests held by physicians and their family members. Failure to submit the required information may result in civil monetary penalties of up to $1 million per year for knowing violations and may result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the United States, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states, such as Massachusetts and Vermont, impose an outright ban on certain gifts to physicians. These laws could affect our promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our products. Both the disclosure laws and gift bans will impose administrative, cost and compliance burdens on us. If we are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, or an administrative action of suspension or exclusion from government health care reimbursement programs and the curtailment or restructuring of our operations</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In addition, we are subject to the Foreign Corrupt Practices Act (&#x201c;FCPA&#x201d;) and other countries&#x2019; anti-corruption/anti-bribery regimes, such as the U.K. Bribery Act. The FCPA prohibits improper payments or offers of payments to foreign governments and their officials for obtaining or retaining business. Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, sales agents, or distributors may be ineffective, and violations of the FCPA and similar laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, results of operations and financial condition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, sales agents, or distributors may be ineffective, and violations of the FCPA and similar laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, results of operations and financial condition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Changes in United States policy regarding international trade, including import and export regulation and international trade agreements, could also negatively impact Milestone Scientific&#x2019;s business. The United States has imposed tariffs and export controls on certain goods and products imported from China and certain other countries, which has resulted in retaliatory tariffs by China and other countries. Additional tariffs imposed by the United States on a broader range of imports, or further retaliatory trade measures taken by China or other countries in response, could result in an increase in supply chain costs that Milestone Scientific may not be able to offset or that otherwise adversely impact its results of operations. In addition, political tensions between the United States and China have escalated in recent years. Rising political tensions could reduce trade, investment and other economic activities between the two major economies. Any of these factors could have a material adverse effect on Milestone Scientific&#x2019;s business, prospects, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Certain modifications to Milestone Scientific</i></b>&#x2019;<b><i>s products may require new 510(k) clearances or other marketing authorizations and may require Milestone Scientific to recall or cease marketing its products.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Once a medical device is permitted to be legally marketed in the United States pursuant to a 510(k) clearance, a manufacturer may be required to notify the FDA of certain modifications to the device.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Manufacturers determine in the first instance whether a change to a product requires a new 510(k) clearance or premarket submission, but the FDA may review any manufacturer&#x2019;s decision. The FDA may not agree with Milestone&#xa0;Scientific&#x2019;s decisions regarding whether new clearances are necessary. Milestone Scientific has made modifications to its products in the past and has determined based on its review of the applicable FDA regulations and guidance that in certain instances new 510(k) clearances or other premarket submissions were not required. Milestone Scientific may make similar modifications or add additional features in the future that it believes does not require a new 510(k) clearance. If the FDA disagrees with Milestone&#xa0; Scientific&#x2019;s determinations and requires it to submit new 510(k) notifications, Milestone Scientific may be required to cease marketing or to recall the modified product until it obtains clearance, and it may be subject to significant regulatory fines or penalties.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Milestone Scientific may be subject to enforcement actions if it engages in improper marketing or promotion of its products.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Scientific&#x2019;s promotional materials and training methods must comply with applicable laws, regulations and regulatory authority&#x2019;s rules and guidelines, including the FDA and the Federal Trade Commission (the &#x201c;FTC&#x201d;). If the FDA, the FTC or another regulatory agency determines that Milestone Scientific&#x2019;s promotional or training material constitutes off-label, false or misleading, unfair or deceptive promotion of its products, it could request that Milestone Scientific modify its training or promotional materials or subject Milestone Scientific to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider Milestone Scientific&#x2019;s promotional or training materials to constitute off-label, false or misleading, unfair or deceptive promotion of its products, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement, and reputational harm.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Changes in laws and regulations over which we have no control can significantly affect our business and results of operations.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Any governmental entity that regulates our operations in the country in which they are located may enact new legislation or adopt new laws and regulations or policies at any time, and new judicial decisions may change the interpretation of existing legislation or regulations at any time in any of the countries in which our operations or projects are located. We have no control over any such changes. Any new laws or regulations governing our operations could have an adverse impact on our business, results of operations and prospects.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Milestone Scientific Common Stock </b>&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Milestone Scientific is effectively controlled by a limited number of stockholders. </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific Scientific&#x2019;s principal stockholders, Leonard Osser and Gian Domenico Trombetta control approximately 25% of the issued and outstanding shares of common stock. As a result, they can exercise substantial control over our affairs and corporate actions requiring stockholder approval, including electing directors, selling all or substantially all our assets, merging with another entity, or amending our certificate of incorporation. This&#xa0;control could delay, deter, or prevent a change in control and could adversely affect the price that investors might be willing to pay in the future for Milestone Scientific&#x2019;s securities.&#xa0; In addition, because of the concentration of ownership of our shares of common stock, our stockholders may from time to time, observe instances where there may be less liquidity in the public markets for our securities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Failure to implement effective internal controls required by the Sarbanes-Oxley Act of 2002 could result in material misstatements in our financial statements, cause investors to lose confidence in the Company</i></b>&#x2019;<b><i>s reported financial information and have a negative effect on the trading price of our common stock.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Section 404 of the Sarbanes-Oxley Act of 2002 requires management of public companies to develop and implement internal controls over financial reporting and evaluate the effectiveness thereof. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company&#x2019;s annual and interim financial statements will not be prevented or detected on a timely basis. Any failure to complete the Company&#x2019;s assessment of its internal controls over financial reporting or to remediate any material weaknesses that management may identify could harm the Company&#x2019;s operating results, cause the Company to fail to meet its reporting obligations or result in material misstatements in the Company&#x2019;s financial statements. Inadequate disclosure controls and procedures and internal controls over financial reporting could also cause investors to lose confidence in the Company&#x2019;s public disclosures and reported financial information, which could have a negative effect on the trading price of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>The market price of our common stock may be volatile and may fluctuate significantly, and stockholders could lose all or part of their investment in Milestone Scientific</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our stock price may experience substantial volatility because of many factors, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">our failure to meet analysts&#x2019;&#xa0;expectations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">sales or potential sales of substantial amounts of our common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">delay or failure in initiating our strategy to commercialize our CompuFlo&#xa0;Epidural System;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">the success of our strategy to commercialize our CompuFlo&#xa0;Epidural System;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions that could adversely impact the market acceptance or competitive advantages of our&#xa0;CompuFlo&#xa0;Epidural System;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">developments concerning our licensors or product manufacturers;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">litigation and other developments relating to our patents or other proprietary rights or those of our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">our ability to successfully develop and commercialize products and services for the healthcare industry;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">conditions in the medical device industry;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">governmental regulation and legislation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">variations in our anticipated or actual operating results; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 8.6%; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">change in securities analysts&#x2019;&#xa0;estimates of our performance, or our failure to meet analysts&#x2019;&#xa0;expectations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Many of these factors are beyond our control.&#xa0;The stock markets in general, and the market for small, medical device companies, in particular, have historically experienced extreme price and volume fluctuations.&#xa0;These fluctuations often have been unrelated or disproportionate to the operating performance of these companies.&#xa0;These broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>We have never paid and do not intend to pay cash dividends in the foreseeable future.</i></b>&#xa0;<b><i> As a result, capital appreciation, if any, will be your sole source of gain.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We have never paid cash dividends on any of our capital stock, and we currently intend to retain future earnings, if any, to fund the development and growth of our business.&#xa0;In addition, the terms of existing and future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Provisions in our certificate of incorporation, our by-laws and Delaware law might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Provisions of our certificate of incorporation, our by-laws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests.&#xa0; These provisions include:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">the inability of stockholders to call special meetings;</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">the ability of our Board of Directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right&#xa0;to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely&#xa0;preventing acquisitions that have not been approved by our Board of Directors; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 4%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">limitations on filling of vacancies.&#xa0;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">All of which could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years, has owned 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.&#xa0; The existence of the forgoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock.&#xa0; They could also deter potential acquirers of our Company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>If we fail to adhere to the strict listing requirements of NYSE American, we may be subject to delisting.</i></b>&#xa0;<b><i> As a result, our stock price may decline, and our common stock may be de-listed.</i></b>&#xa0;<b><i> If our stock were no longer listed on NYSE American, the liquidity of our securities likely would be impaired.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our common stock currently trades on the NYSE American under the symbol &#x201c;MLSS&#x201d;. If we fail to adhere to NYSE American's strict listing criteria, including with respect to stock price, our market capitalization and stockholders&#x2019; equity, our stock may be de-listed.&#xa0;This could potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price, which may be depressed by the relative illiquidity, but also through delays in the timing of transactions and the potential reduction in media coverage.&#xa0; As a result, an investor might find it more difficult to dispose of our common stock.&#xa0; Any failure at any time to meet the continuing NYSE American listing requirements could have an adverse impact on the value of and trading activity in our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Your percentage of ownership in Milestone Scientific</i></b>&#xa0;<b><i>may be diluted in the future</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In the future, your percentage ownership in Milestone Scientific&#xa0;may be diluted because of equity issuances for acquisitions, capital market transactions or otherwise, including any equity awards that Milestone Scientific will grant to its directors, officers, employees and consultants. Such awards will have a dilutive effect on outstanding share count which could adversely affect the market price of Milestone Scientific&#x2019;s common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Risks Related to Our Intellectual Property</b>&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>If we are unable to adequately protect our patents, trade secrets and other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be materially damaged.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">Intellectual property rights, including patents, trade secrets, confidential information, trademarks, trade names and trade address, are important to our business.&#xa0;We will endeavor to protect our intellectual property rights in key jurisdictions in which our products are produced or used and in jurisdictions into which our products are imported.&#xa0;Our success will depend to a significant degree upon our ability to protect and preserve our intellectual property rights.&#xa0;However, we may be unable to obtain or maintain protection for our intellectual property in key jurisdictions.&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Although&#xa0;we own and have applied for patents and trademarks throughout the world, we may have to rely on judicial enforcement of our patents and other proprietary rights.&#xa0;Our patents and other intellectual property rights may be challenged, invalidated, circumvented, and rendered unenforceable or otherwise compromised.&#xa0;A failure to protect, defend or enforce our intellectual property could have an adverse effect on our financial condition and results of operations.&#xa0;Similarly, third parties may assert claims against us and our customers and distributors alleging our products infringe upon third party intellectual property rights.</p>
  <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We believe that the intellectual property underlying our products is a competitive advantage.&#xa0;We rely on a combination of patent rights, trade secrets and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so.&#xa0;There can be no assurance that our patents, trade secret policies and practices or other agreements will adequately protect our intellectual property.&#xa0; Our issued patents may be challenged, found to be over-broad or otherwise invalidated in subsequent proceedings before courts or the U.S. Patent and Trademark Office.&#xa0;Even if enforceable, we cannot provide any assurances that they will provide significant protection from competition.&#xa0;The processes, systems, and/or security measures we use to preserve the integrity and confidentiality of our data and trade secrets may be breached, and we may not have adequate remedies resulting from such breaches.&#xa0; In addition, our trade secrets may otherwise become known or be independently discovered by competitors.&#xa0;There can be no assurance that the confidentiality, nondisclosure and non-competition agreements with employees, consultants and other parties with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary rights, or any other security measures relating to such trade secrets, proprietary technology, processes and proprietary rights, will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge.&#xa0; To the extent that our consultants, contractors, or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">If we must take legal action to protect, defend or enforce our intellectual property rights, any suits or proceedings could result in significant costs and diversion of our resources and our management&#x2019;s attention, and we may not prevail in any such suits or proceedings.&#xa0; A failure to protect, defend or enforce our intellectual property rights could have an adverse effect on our results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Third parties could obtain patents that may require us to negotiate licenses to commercialize our technologies, and we cannot assure you that the required licenses would be available on reasonable terms or at all.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Third parties may claim that one or more aspects of our technologies or products may infringe on their intellectual property rights.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Our computer-controlled anesthesia systems are complex systems and numerous U.S. and foreign patents and pending patent applications owned by third parties exist in fields that relate to the development and commercialization of drug delivery systems.&#xa0; In addition, many companies have employed intellectual property litigation as a strategy to gain a competitive advantage.&#xa0; It is possible that infringement claims may occur as the number of products and competitors in our market increases.&#xa0; In addition, to the extent that we gain greater visibility and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement claims.&#xa0; We cannot be certain that the conduct of our business does not and will not infringe intellectual property or other proprietary rights of others in the U.S. and in foreign jurisdictions.&#xa0; If any of our computer-controlled anesthesia systems are found to infringe third party patent rights, we could be prohibited from manufacturing and commercializing the infringing technology unless we obtain a license under the applicable third-party patent and pay royalties or are able to design around such patent.&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We may be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign the system to avoid infringement.&#xa0; Even if we can redesign our products or processes to avoid an infringement claim, our efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an inferior or costlier product.&#xa0; Any claim of infringement by a third party, even those without merit, could cause us to incur substantial costs defending against the claim and could distract our management from our business.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Furthermore, if any such claim is successful, a court could order us to pay substantial damages, including compensatory damages for any infringement, plus prejudgment interest and could, in certain circumstances, treble the compensatory damages and award attorney fees.&#xa0; These damages could be substantial and could harm our reputation, business, financial condition, and operating results.&#xa0; A court also could enter orders that temporarily, preliminary, or permanently prohibit us, our licensees, if any, and our customers from making, using, selling, offering to sell, or importing one or more of our products or using our proprietary technologies or processes, or could enter an order mandating that we undertake certain remedial activities.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Any of these events could seriously harm our business, operating results, and financial condition.</p>
  <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>General Business Risks</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Continued instability in the credit and financial markets may negatively impact our ability to commercialize our products.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Financial markets in the United States, Canada, Europe, and Asia continue to experience disruption, including, among other things, significant volatility in security prices, declining valuations of certain investments, as well as severely diminished liquidity and credit availability.&#xa0; Business activity across a wide range of industries and regions continues to be reduced.&#xa0; As a small medical device company, we rely on third parties for several important aspects of our business, including contract manufacturing of products, distribution of our products and sales and marketing.&#xa0; These third parties may be unable to satisfy their commitments to us due to tightening of global credit from time to time, which would adversely affect our business.&#xa0; The continued volatility&#xa0;in the credit and financial market conditions may also negatively impact our ability to access capital and credit markets and our ability to manage our cash balance.&#xa0; While we are unable to predict the continued duration and severity of any adverse conditions in the United States and other countries, any of the circumstances mentioned above could adversely affect our business, financial condition, operating results and cash flow or cash position.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Our business and operations would suffer in the event of cybersecurity or other system failures.</i></b>&#xa0;<b><i> </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Despite the implementation of security measures, our internal computer systems, and those of any third parties with which we partner are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any cybersecurity or system failure, accident or breach to date, if an event were to occur, it could result in a material disruption of our operations, substantial costs to rectify or correct the failure, if possible, and potentially violation of HIPAA and other privacy laws applicable to our operations. If any disruption or security breach resulted in a loss of or damage to our data or applications or inappropriate disclosure of confidential or protected information, we could incur liability, further development of our products could be delayed, and our operations could be disrupted, any of which could severely harm our business and financial condition. Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In general, our success depends upon the quality of our products.&#xa0; Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services, and assuring the safety and efficacy of our products.&#xa0; Our future success depends on our ability to maintain and continuously improve our quality management program.&#xa0; A quality or safety issue may result in adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses.&#xa0; An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><i>Insurance coverage may be inadequate or unavailable to cover any product liability losses we incur.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Our business exposes us to potential product liability claims that are inherent in the design, manufacture, testing, inspection, and sale of dental and medical devices. We are subject to product liability lawsuits alleging that component failures, manufacturing flaws, manufacturing defects, negligence in manufacturing, design defects, negligence in design, or inadequate disclosure of product-related risks, warnings, or product-related information resulted in an unsafe condition, injury, or death to customers. The risk of one or more product liability claims or lawsuits may be even greater after we launch new products with new features or enter new markets where we have no prior experience selling our products and rely on newly-hired staff or new independent distributors or contractors to provide new customer training and customer support. In addition, the misuse of our products or the failure of customers to adhere to operating guidelines could cause significant harm to customers, including death, which could result in product liability claims. Product liability lawsuits and claims, safety alerts or product recalls, with or without merit, regardless of any available insurance coverage, could cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business, harm our reputation and adversely affect our ability to attract and retain customers, any of which could have a material adverse effect on our business, financial condition and operating results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item</b><b>1B. Unresolved Staff Comments </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">None.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 2. Description of Property</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The headquarters for Milestone Scientific is&#xa0;located at 425 Eagle Rock Avenue, Roseland, New Jersey 07068, and our telephone number is (973) 535-2717. In August 2019, the Company signed a seven year lease for a facility in Roseland, New Jersey (the &#x201c;Roseland Facility&#x201d;). The Roseland Facility&#xa0;carries monthly lease payments of&#xa0;$9,275, commencing April 1, 2021. The Company is also responsible&#xa0;for electric charges equal to $2.00 per square foot, which is equal to $11,130 annually, payable in equal monthly installments of $928.&#xa0;The Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises in excess of new base year amounts.&#xa0;A third-party distribution and logistics center in Pennsylvania handles shipping and order fulfillment on a month-to-month basis.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific does not own or intend to invest in any real property. Milestone Scientific currently has no policy with respect to investments or interests in real estate, real estate mortgages or securities of, or interests in, persons primarily engaged in real estate activities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item</b>&#xa0;<b>3. Legal Proceedings </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific is not involved in any material litigation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item</b>&#xa0;<b>4. Mine Safety Disclosure </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Not applicable.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     22
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>PART II </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item</b>&#xa0;<b>5. Market for Common Equity, and Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Market Information </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">On June 1, 2015, our common stock was listed on the NYSE American under the symbol &#x201c;MLSS&#x201d;. The following table sets forth the high and low sales prices of Milestone&#x2019;s common stock for the periods presented.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 20%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">High</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Low</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; width: 20%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">High</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Low</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">First Quarter</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.20</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.13</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">First Quarter</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4.85</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.11</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Second Quarter</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.60</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.75</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Second Quarter</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3.83</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.88</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Third Quarter</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.27</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.71</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Third Quarter</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.51</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.47</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Fourth Quarter</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.87</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.45</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Fourth Quarter</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3.00</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.79</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Holders </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">As of March 31, 2023, we had approximat<span style="color: rgb(0, 0, 0); font-size: 9pt;">ely 99&#xa0;stockholders </span>of record of our common stock. We believe that we have approxima<span style="color:#000000;">tely 3,911&#xa0;<span style="font-size: 9pt;">beneficial owners</span> of</span> our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Dividends</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The holders of common stock are entitled to receive such dividends as may be declared by Milestone Scientific&#x2019;s Board of Directors. Milestone Scientific has not paid and does not expect to declare or pay any dividends in the foreseeable future.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Sales of Unregistered Securities</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Not applicable.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 8pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>ITEM 6. Selected Financial Data</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific is a &#x201c;smaller reporting company&#x201d; as defined by Regulations S-K and as such, is not required to provide the information contained in this item pursuant to Regulation S-K.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     23
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>ITEM 7. Management</b>&#x2019;<b>s Discussion and Analysis of Financial Condition and Results of Operations</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this annual report. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements. See "Risk Factors" elsewhere in this Form 10-K.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>OVERVIEW</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and devices for medical, dental and cosmetic use. Since our inception, we have engaged in pioneering proprietary, innovative, computer-controlled injection technologies, and solutions for the medical and dental markets. We believe our technologies are proven and well established. Our common stock was initially listed on the NYSE American on June 1, 2015, and trades under the symbol &#x201c;MLSS&#x201d;.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">We have focused our resources on redefining the worldwide standard of care for injection techniques by making the experience more comfortable for the patient by reducing the anxiety and stress of receiving injections from the healthcare provider. Our computer-controlled injection devices make injections precise, efficient, and virtually painless.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using The Wand&#xae;, a single use disposable handpiece. The device is marketed in dentistry under the trademark <i>CompuDent</i>&#xae;, and <i>STA Single Tooth Anesthesia System</i>&#xae; and is suitable for all dental procedures that require local anesthetic. Our proprietary <i>DPS</i> Dynamic Pressure Sensing technology&#xae; is our technology platform that advances the development of next-generation devices. It regulates flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, used in various dental and medical injections. It has specific medical applications for&#xa0;epidural space identification in regional anesthesia procedures and intra-articular joint injections.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific remains focused on advancing efforts to achieve the following three&#xa0;primary objectives:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 9pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Establishing Milestone&#x2019;s&#xa0;<i>DPS</i>&#xa0;Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first time, objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 9pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Following obtaining successful FDA clearance of our first medical device, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 9pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Expanding our global footprint of our <i>CompuFlo </i>Epidural and CathCheck System by utilizing a targeted&#xa0;field sales force and partnering with distribution companies worldwide.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Because of combining the ability to regulate the flow rate and monitor pressure at the tip of the needle, Milestone Scientific developed the industry&#x2019;s first solution for painlessly administering an intra-ligamentary&#xa0;injection, i.e., &#x201c;<i>single-tooth anesthesia</i>&#x201d; which could be used as the only injection necessary for achieving dental anesthesia, foregoing the need to administer traditional injections such as a nerve branch block.&#xa0;In addition to <i>single-tooth anesthesia</i>,<i> </i>the STA System can effectively perform all the traditional injections that dentists routinely give but can provide them virtually pain free and with numerous clinical advantages. This device, which also utilizes a disposable handpiece, is currently marketed by Milestone Scientific as the <i>Wand</i>&#xa0;<i>STA</i>&#xae; System.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Our dental devices have been used to administer tens of millions of injections worldwide. Each of our devices has a related single use disposable handpiece, leading to a continuing revenue stream following sale of the device. At present, we sell disposable handpieces unique to our legacy product (the <i>Wand</i> and <i>CompuDent</i>) to users who have not upgraded to our current dental product, the <i>Wand</i>&#xa0;<i>STA </i>System.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Building on the success of our proprietary, core technology platform for dental injections, and desiring to pursue other growth opportunities, we have recently begun to expand the uses and applications of our proprietary, patented technologies to achieve greater operational efficiencies, enhanced patient safety and therapeutic adherence, patient satisfaction, and improved quality of care across a broad range of medical specialties. In June 2017, we received FDA regulatory clearance to sell the <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System in the United States for certain medical applications. We intend to continue to expand the uses and applications of our <i>DPS</i> Dynamic Pressure Sensing technology.&#xa0;We believe that we and our technology solutions are widely recognized by key opinion leaders (i.e., academics, anesthesiologists and practicing dentists whose opinions are widely respected), industry experts and medical and dental practitioners as a leader in the emerging, computer-controlled injection industry.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><span style="text-decoration: underline; "><b>Wand/STA Dental Product</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Since its market introduction in early 2007, the Wand STA System and prior C-CLAD devices have been used to deliver over 80 million safe, effective, and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;"><span style="text-decoration: underline; "><b>Medical Market Product</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; line-height: 1; text-align: justify;">During 2016, Milestone Scientific filed for 510(k) marketing clearance with the U.S. Food and Drug Administration (FDA) for both intra-articular and epidural injections with the CompuFlo Epidural System.&#xa0; In June 2017, the FDA approved the CompuFlo Epidural System for epidural injections.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The following table shows a breakdown of Milestone Scientific&#x2019;s product sales (net), domestically and internationally, by business segment product category:&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 13px;">&#xa0;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; width: 769px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">For the Year Ended December 31, 2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 46%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Domestic: US</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 13px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; width: 234px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Dental</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Medical</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grand Total</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">524,715</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">532,215</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,653,914</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">25,250</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,679,164</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">78,493</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">78,493</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,257,122</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,289,872</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="width: 13px; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: Rest of World</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 13px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; width: 234px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Dental</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Medical</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grand Total</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,413,525</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,413,525</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,391,748</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">20,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,411,748</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,797</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,797</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,866,070</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,886,070</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="width: 13px; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: China</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 13px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; width: 234px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Dental</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Medical</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grand Total</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">270,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">270,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">359,964</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">359,964</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">629,964</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">629,964</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="width: 13px; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Total Product Sales</b></p> </td>
     <td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>8,753,156</b></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>52,750</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,805,906</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">For the Year&#xa0; Ended December 31, 2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 46%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Domestic: US</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Dental</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Medical</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grand Total</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">560,424</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">560,424</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,905,354</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">35,200</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,940,554</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">69,271</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,300</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70,571</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,535,049</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,571,549</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: Rest of World</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Dental</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Medical</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grand Total</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,226,486</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">70,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,296,486</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,246,302</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">44,900</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,291,202</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,546</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">800</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,346</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,519,334</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">115,700</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,635,034</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: China</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Dental</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Medical</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grand Total</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">303,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">303,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,795,128</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,795,128</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,098,128</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,098,128</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Total Product Sales</b></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>10,152,511</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>152,200</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>10,304,711</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>Current Product Platform</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">See Item 1. Description of Business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>Summary of Critical Accounting Policies and Significant Judgments and</b> <b>Estimates</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, Milestone Scientific evaluates its estimates, including those related to accounts receivable, inventories, stock-based compensation, and contingencies. Milestone Scientific bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not clear from other sources. Actual results may differ from those estimates under different assumptions or conditions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">While significant accounting policies are more fully described in Note C to the consolidated financial statements included elsewhere in this report, Milestone Scientific believes that the following accounting policies and significant judgment and estimates are most critical in understanding and evaluating the reported financial results.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>Principles of Consolidation</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific's discussion and analysis of the financial condition and results of operations is based upon its consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of&#xa0;Milestone Scientific and its wholly-owned and majority-owned subsidiaries including, Wand Dental, and Milestone Medical. All significant, intra-entity transactions and balances are eliminated in the consolidation.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&#x2019;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific has&#xa0;completed the VIE analysis relating to Milestone China and&#xa0;Anhui Maishida Medical Technology, Co. Ltd. (&#x201c;Anhui&#x201d;).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has determined that due to the loss of equity investment in Anhui, the company no longer has significant influence of Anhui and therefore Anhui is not a variable interest. Milestone Scientific&#xa0;has a variable interest in Milestone China, it considered the guidance in ASC 810, &#x201c;Consolidation&#x201d; as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary.&#xa0;Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 9pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Power Criterion: The power to direct the activities that most significantly impact the entity&#x2019;s economic performance; and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-size: 9pt;">
     <td style="width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific does not have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has not been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO of Milestone China who have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is not the primary beneficiary under ASC 810. Accordingly, Milestone China has not been consolidated into the financial statements of Milestone Scientific and is accounted for under the equity method. See Note F.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>Assessment of our Ability to Continue as a Going </b><b>Concern</b></span>&#xa0;&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In accordance with&#xa0; (&#x201c;ASC&#x201d;) 205-40, &#x201c;Presentation of Financial Statements &#x2013; Going Concern&#x201d;, the Company continually &#xa0;evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year since its inception.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Total operating losses since inception of $116.4 million.&#xa0; The operating losses were&#xa0;$8.8&#xa0;million and $7.4&#xa0;million, for the years ended December 31, 2022, and 2021, respectively. Management has prepared cashflow forecasts covering a period of 12 months from the date of issuance of these financial statements. These forecasts include several revenue and operating expense assumptions which indicate that the Company&#x2019;s current cash and liquidity is sufficient to finance the operating requirements for at least the next 12 months. Management believes that the Company&#xa0;will have sufficient cash reserves to meet its anticipated obligations for at least the next twelve months from the filing date of this report.&#xa0;Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company&#x2019;s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>Inventories</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirement and regulations.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>Revenue Recognition</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition &#xa0;the Company performs the following five steps:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 4%; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 5.9%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">identification of the promised goods or services in the contract;</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 4%; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 5.9%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 4%; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 5.9%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">iii.</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">measurement of the transaction price, including the constraint on variable consideration;</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 4%; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 5.9%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">iv.</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">allocation of the transaction price to the performance obligations based on estimated selling prices; and</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 4%; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 5.9%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">v.</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third parties.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b>Results of Operations.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The following table sets forth the consolidated results of operations for the year ended&#xa0;December 31, 2022 compared to the year ended December 31,&#xa0;2021.</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2021</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Operating results:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Product sales, net</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">8,805,906</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,304,711</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cost of products sold</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,905,092</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,992,811</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Gross profit</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,900,814</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">6,311,900</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">12,514,323</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">12,738,362</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,150,209</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">878,210</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Depreciation and amortization expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,755</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,836</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">13,728,287</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">13,690,408</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(8,827,473)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(7,378,508</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Other income, and interest expense net</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">54,607</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">502,076</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(8,772,866</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(6,876,432</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss attributable to noncontrolling interests</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66,735</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58,115</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss attributable to Milestone Scientific Inc.</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,706,131</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,818,317</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash flow:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2021</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 64%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Net cash used in operating activities</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px; text-align: right;">(6,031,996)</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px; text-align: right;">(4,033,664)</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 64%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Net cash used in investing activities</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px; text-align: right;">(8,527)</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px; text-align: right;">(15,189)</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 64%; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Net cash (used in) provided by financing activities</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px; text-align: right;">(8,544)</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px; text-align: right;">4,589,282</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><b>Year ended</b>&#xa0;<b>December 31, 2022, compared to year ended December 31, 2021.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Net sales for years ended December 31,</b>&#xa0;<b>2022, and&#xa0;</b>&#xa0;<b>2021were as follows:</b>&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Change</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 46%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">8,753,156</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,152,511</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(1,399,355</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">52,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">152,200</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(99,450</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total sales, net</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,805,906</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,304,711</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,498,805</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Consolidated revenue for the years ended December 31, 2022, and 2021&#xa0;was approximately $8.8 million and $10.3 million, respectively. Dental revenue for the years ended December 31, 2022 and 2021 was approximately $8.8&#xa0;million and $10.1&#xa0;million, respectively.&#xa0; The decrease in Dental revenue of &#xa0;approximately $1.4&#xa0;million for the year ended December 31, 2022, as compared to 2021 was driven by lower revenue from China of approximately $1.5&#xa0;million and a decrease in domestic revenue of approximately $278,000 of which $179,000 related to an allowance for sales returns from Henry Schein due to the termination of the distribution agreement. Dental international revenue increased approximately $347,000 compared to December 31, 2021.&#xa0;Medical revenue decreased approximately $100,000 for the year ended December 31, 2022 , as compared to December 31, 2021, which was primarily the result of changes to the Company&#x2019;s near term commercial strategy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Gross Profit for years ended December 31,</b>&#xa0;<b> 2022 and 2021 were as follows:</b></p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Change</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 46%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">5,446,175</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">6,223,051</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(776,876</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(545,361</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">88,849</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(634,210</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total gross profit</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,900,814</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,311,900</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,411,086</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Consolidated gross profit for the years&#xa0;ended December 31, 2022 and 2021&#xa0;decreased approximately $1.4 million or 22%.&#xa0;The&#xa0;decrease&#xa0;was driven by an allowance of approximately $550,000&#xa0;on slow moving Medical finished goods.&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Selling, general and administrative expenses for years ended December 31,</b>&#xa0;&#xa0;<b>2022 and</b>&#xa0;<b>2021 were as follows:</b>&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Change</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 46%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,225,032</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,946,108</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">278,924</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,183,983</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,106,689</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">77,294</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,105,308</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,685,565</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(580,257</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total selling, general and administrative expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,514,323</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,738,362</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(224,039</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Consolidated selling, general and administrative expenses for the years ended December 31, 2022 and 2021 were approximately $12.5&#xa0;million and $12.7&#xa0;million, respectively.&#xa0;The decrease of approximately $224,000 is categorized in several&#xa0;areas. Employee&#xa0;salaries, and&#xa0;benefits expenses decreased approximately $886,000 during the year ended December 31, 2022&#xa0;compared to the same period in 2021.&#xa0;The Company reduced director fees, bonuses, employee recruiting fees, and medical insurance for year ended&#xa0;December 31, 2022. The Company reduced&#xa0;marketing expense for the year ended December 31, 2022 by approximately $86,000 due to decreased trade show participation and decrease royalties expenses by approximately $4,000. The Company increased employee travel&#xa0;and&#xa0;professional fees by approximately $322,000 for the years ended December 31, 2022 compared to December 31, 2021 due to international commercial efforts.&#xa0;During year ended December 31, 2022 warehousing, and quality control expenses associated with quality assurance in connection with ISO certification and digitizing parts of our quality control increased approximately $379,000, and other&#xa0;selling, general and administrative expenses&#xa0;increased approximately $51,000 due to the additional professional services&#xa0;quality control required in the compliance&#xa0;and regulations</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Research and Development</b>&#xa0;<b>for years ended December 31,</b>&#xa0;<b> 2022 and 2021 were as follows:</b></p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Change</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 46%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,095,523</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">797,509</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">298,014</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">54,686</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">80,701</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(26,015</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total research and development</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,150,209</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">878,210</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">271,999</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Consolidated research and development expenses for the years ended December 31, 2022, and 2021,&#xa0;were approximately $1.2&#xa0;million and $878,000, respectively.&#xa0;The increase of approximately $272,000 is&#xa0;related to the Company developing the next generation to the STA Single Tooth Anesthesia System product line.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Profit (Loss) from Operations</b>&#xa0;<b>for years ended December 31,</b>&#xa0;<b> 2022 and 2021 were as follows:</b>&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Change</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 46%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,121,815</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,475,059</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(1,353,244</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,788,105</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,105,854</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(682,251</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,161,183</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,747,713</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">586,530</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total loss from operations</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,827,473</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,378,508</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,448,965</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The loss from operations was approximately $8.8&#xa0;million and $7.4 million&#xa0;for the years ended December 31, 2022&#xa0;and 2021, respectively.&#xa0; The increase in the loss from operations was primarily driven the decrease in gross profit.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business and the medical business worldwide, and a reduction in operating expenses. On December 31, 2022,&#xa0;Milestone Scientific had cash and cash equivalents of approximately $8.7 million and working capital of approximately $9.7&#xa0;million. Forthe years ended December 31, 2022 and 2021, we had cash flows used in operating activities of approximately $6.0 million and $4.0 million,&#xa0;respectively</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Management believes that the Company has sufficient cash, along with the current cash flow and support from the dental business to &#xa0;mitigate the expected selling expenditures for commercialization of the Epidural&#xa0;medical device, as well as other operating expenditures and planned&#xa0;new product development programs, over the next twelve months&#xa0;from the filing date of this report.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Contractual Obligations</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The impact of the consolidated contractual obligations at December 31, 2022, expected on the liquidity and cash flows in future periods, is as follows:&#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Payments Due by Period</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Total</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">Less than 1 Year</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">1-3 Years</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">3-5 Years</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Operating lease obligations</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">597,196</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">141,518</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">420,201</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">35,477</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Purchase obligations (1)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,233,838</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,233,838</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,831,034</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,375,356</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">420,201</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,477</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">(1)&#xa0;&#xa0;&#xa0; Purchase obligations include agreements for the purchase of dental&#xa0;devices, including purchase obligations entered into post year end, which will require payment in during the year ended 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Recent Accounting Pronouncements</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">See &#x201c;Note C&#xa0;- Summary of Significant Accounting Policies&#x201d; to the consolidated financial statements for explanation of recent accounting pronouncements impacting Milestone Scientific.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 7A. Quantitative and Qualitative Disclosures about Market Risk</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific is a &#x201c;smaller reporting company&#x201d; as defined by Regulation S-K and, as such, is not required to provide the information required by this item.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 8. Financial Statements</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The financial statements of Milestone Scientific required by this Item are set forth beginning on page F-1.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 9. Change in and Disagreements with Accountants on Accounting and</b> <b>Financial Disclosure</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">None.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 9A. Controls and Procedures</b>&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Evaluation of Disclosure Controls and Procedure</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">We maintain disclosure controls and procedures designed to ensure that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified under the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer, and Chief Financial Officer as appropriate to allow timely decisions regarding required disclosures. As required by paragraph (b) of Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer,&#xa0;and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2022. Based on this evaluation, our Chief Executive Officer, and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in paragraph (e) of Rules 13a-15 and 15d-15 under the Exchange Act) were effective at December 31, 2022.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Management</b>&#x2019;<b>s Annual Report on Internal Control over Financial Reporting</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#x201c;Internal Control-Integrated Framework (2013)&#x201d; issued by the Committee of Sponsoring Organization of the Treadway Commission. Based on this assessment, management concluded that, as of December 31, 2022, our internal control over financial reporting was effective.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Changes in Internal Control over Financial Reporting</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">During the year ended&#xa0;December 31, 2022, the Company remediated&#xa0;the identified material weakness from December 31, 2021.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 9B. Other Information</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">None.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 9C. Disclosure regarding Foreign Jurisdiction that Prevent inspections</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">None.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>PART III<br /> &#xa0;</b><br /> The information required by Part III is omitted from this Annual Report because it will be included in our definitive proxy statement to be filed pursuant to Regulation 14A for our 2023 Annual Meeting of Stockholders, or the 2023 Proxy Statement, and such information is incorporated herein by reference.<br /> &#xa0;<br /> <b>Item 10.&#xa0;&#xa0; &#xa0;Directors, Executive Officers, Promoters and Control Persons and Corporate Governance; Compliance with Section 16 (a) of the Exchange Act</b><br /> &#xa0;<br /> The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by reference.<br /> &#xa0;<br /> <b>Item 11.&#xa0;&#xa0; &#xa0;Executive Compensation</b><br /> &#xa0;<br /> The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by reference.<br /> &#xa0;<br /> <b>Item 12.&#xa0;&#xa0; &#xa0;Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters</b><br /> &#xa0;<br /> The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by reference.<br /> &#xa0;<br /> <b>Item 13.&#xa0;&#xa0;</b> &#xa0;Certain Relationships and Related Transactions, and Director Independence<br /> &#xa0;<br /> The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by reference.<br /> &#xa0;<br /> <b>Item 14.&#xa0;</b>&#xa0; &#xa0;Principal Accountant Fees and Services<br /> &#xa0;<br /> The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by reference.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>PART IV </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Item 15. Exhibits and Financial Statement Schedules</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The following documents are filed as part of this Report:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 41px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">1</p> </td>
     <td style="vertical-align: top; width: 1324px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Financial Statements. See Index to Financial Statements on page F-1.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 41px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">2</p> </td>
     <td style="vertical-align: top; width: 1324px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Financial Statement Schedule</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 41px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">3</p> </td>
     <td style="vertical-align: top; width: 1324px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Exhibits</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 41px; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1324px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Certain of the following exhibits were filed as Exhibits to previous filings filed by Milestone Scientific under the Securities Act of 1933, as amended, or reports filed under the Securities and Exchange Act of 1934, as amended, and are hereby incorporated by reference.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Exhibit No</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Description</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">3.1</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000156459014000701/mlss-ex3i_20131231313.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Restated Certificate of Incorporation of Milestone filed on September 6, 2013 (11)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">3.2</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000119312514148592/d715661dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Certificate of Designation filed on April 18, 2014 (12)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">3.3</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000156459016015942/mlss-ex33_204.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Correction to the Certificate of Designation filed on May 12, 2014 (13)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">3.4</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774919006239/ex_138885.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended&#xa0;</span><span style="text-decoration: underline; ">and Restated</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">By-laws of Milestone</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">filed April 1, 2019</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">(23)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">3.5</p> </td>
     <td style="vertical-align: middle; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774920006936/ex_179957.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to Restated Certificate of Incorporation (24)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">4.1</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Specimen stock certificate (2)</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">4.3</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774916043456/ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant issued in the 2016 Public Offering (16)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">4.4</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774919001648/ex_133840.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant issued in the Feb. 2019 Public Offering (21)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">4.5</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774919002539/ex_134772.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant issued in the Feb. 2019 Private Placement (22)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">4.6</p> </td>
     <td style="vertical-align: middle; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774922007873/ex_350759.htm" style="-sec-extract:exhibit;">Description of Registrant<span style="text-decoration: underline; ">&#x2019;</span><span style="text-decoration: underline; ">s Securities (30)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">4.7</p> </td>
     <td style="vertical-align: middle; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774920007375/ex_180668.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant issued in the Apr. 2021 &#xa0;</span><span style="text-decoration: underline; ">Public offering</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;(25)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">4.8</p> </td>
     <td style="vertical-align: middle; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774920013930/ex_191740.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant issued in the Jun. 2021 </span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">Public Offering</span><span style="text-decoration: underline; ">&#xa0;(26)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.1</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/0001005477-97-000955.txt" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lease dated November 25, 1996 between Livingston Corporate Park Associates, L.L.C. and Milestone (3)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.2</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000116923205001982/d63211_ex10-37.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lease amendment dated April 28, 2004 between Livingston Corporate Park Associates, L.L.C. And Milestone (4)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.3</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000095012311042788/c16276def14a.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2011 Equity Compensation Plan (7)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.4</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000119312513286158/d566198dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Master Supply and Distribution Agreement, dated July 3, 2013, between Milestone Scientific Inc and Tri-anim Health Services, Inc (9)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.5</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000156459016015942/mlss-ex1011_235.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement with Mark Hochman, dated July 2015 (13)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.6</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000119312514148592/d715661dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Investment Agreement, dated April 15, 2014, between Milestone Scientific Inc. and BP4 S.p.A. (12)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.7</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774916034685/ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Exclusive Distribution and Supply Agreement, dated as of June 20, 2016, among Milestone Scientific Inc., Wand Dental, Inc. and Henry Schein, Inc. (14)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.8</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774916042880/ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Employment Agreement, dated December 1, 2016, between Wand Dental Inc. and Gian Domenico Trombetta (15)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.9</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774917010542/ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Final Form of Asset Purchase Agreement, dated June 2, 2017, among APAD Octrooi B.V., APAD B.V., and Milestone Scientific Inc. (17)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.10</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774917010872/ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Final form of the Memorandum of Agreement, dated June 6, 2017, between Solee Science &amp; Technology U.S.A. Ltd. and Milestone Scientific Inc. (18)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.11</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774917010872/ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Final form of the Promissory Note, dated June 6, 2017, in the principal amount of $1,275,000 made by Solee Science &amp; Technology U.S.A. Ltd. to Milestone Scientific Ltd. (18)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.12</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774917010872/ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Final form of the Stock Option Agreement, dated June 6, 2017, Solee Science &amp; Technology U.S.A. Ltd. and Milestone Scientific Inc. (18)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.13</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774917012470/ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">New Employment Agreement between Milestone Scientific Inc. and Leonard Osser dated as of July 11, 2017. (19)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.14</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774917012470/ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement between Milestone Scientific Inc. and Daniel Goldberger dated as of July 11, 2017. (19)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.15</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774917012470/ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Covenant Agreement between Milestone Scientific Inc. and Daniel Goldberger dated and effective as of July 11, 2017. (19)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.16</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774917014710/ex10-8.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consultant Agreement between Milestone Medical Inc. and U.S. Asian Consulting Group, LLC dated as of July 10, 2017. (20)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.17</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774919001648/ex_133839.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Underwriting Agreement, dated as of February 1, 2019 between Milestone Scientific Inc. and Maxim Group LLC, as underwriter (21)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.18</p> </td>
     <td style="vertical-align: top; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774919002539/ex_134773.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Stock Purchase Agreement, dated as of February 8, 2019 between Milestone Scientific Inc. and BP4 S.p.A. (22)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 43px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.19</p> </td>
     <td style="vertical-align: middle; width: 1701px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774920007375/ex_180666.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Underwriting Agreement, dated as of April 9, 2021 </span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">between the Company and Maxim Group LLC (25)</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     32
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 39px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.20</p> </td>
     <td style="vertical-align: middle; width: 1326px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774920013930/ex_191738.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Underwriting Agreement, dated as of June 25, 2021 </span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">between the Company and Maxim Group</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;LLC (26)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 39px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.21</p> </td>
     <td style="vertical-align: middle; width: 1326px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774922007873/ex_348600.htm" style="-sec-extract:exhibit;">Buy Sell Agreement, dated as of November 22, 2021, by and between Wand Dental, Inc. and Michelle Zhang dba Solee Science &amp; Technology USA (31)</a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 39px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.22</p> </td>
     <td style="vertical-align: middle; width: 1326px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774921008454/ex_239478.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Succession Agreement between Leonard Osser and Milestone Scientific Inc. (27)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 39px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">10.23</p> </td>
     <td style="vertical-align: middle; width: 1326px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774921010433/mlss20210417_def14a.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated 2021 </span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">Equity Incentive Plan (28)</span></a></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 39px; font-size: 9pt;">10.24</td>
     <td style="vertical-align: top; width: 1326px; font-size: 9pt;"><a href="http://www.sec.gov/Archives/edgar/data/855683/000143774922020528/ex_411356.htm" style="-sec-extract:exhibit;">Employment Agreement, dated and effective as of January 1, 2022, between Arjan Haverhals and Milestone Scientific Inc.** (29)</a></td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 39px; font-size: 9pt;">10.25</td>
     <td style="vertical-align: top; width: 1326px; font-size: 9pt;"><a href="ex_492742.htm" style="-sec-extract:exhibit;">Offer Letter, dated as of February 1, 2023, between Peter Milligan and Milestone Scientific Inc.* **&#xa0;</a></td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 39px; font-size: 9pt;">21.1</td>
     <td style="vertical-align: top; width: 1326px; font-size: 9pt;"><a href="ex_490434.htm" style="-sec-extract:exhibit;">List of Subsidiaries*</a></td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 39px; font-size: 9pt;">23.1</td>
     <td style="vertical-align: top; width: 1326px; font-size: 9pt;"><a href="ex_490435.htm" style="-sec-extract:exhibit;">Consent of Marcum LLP*</a></td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 39px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">23.2</p> </td>
     <td style="vertical-align: top; width: 1326px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_492741.htm" style="-sec-extract:exhibit;">Consent of Friedman, LLP*</a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">31.1</p> </td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_490441.htm" style="-sec-extract:exhibit;">Rule 13a-14(a) Certification-Chief Executive Officer*</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 53px; font-size: 9pt;">31.2</td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"><a href="ex_490442.htm" style="-sec-extract:exhibit;">Rule 13a-14(a) Certification-Financial Officer*</a></td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">32.1</p> </td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><a href="ex_490443.htm" style="-sec-extract:exhibit;">Section 1350 Certifications-Chief Executive Officer***</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 53px; font-size: 9pt;">32.2</td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"><a href="ex_490444.htm" style="-sec-extract:exhibit;">Section 1350 Certifications-Chief Financial Officer***</a></td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">101.INS</p> </td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Instance Document*</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">101.SCH</p> </td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Extension Schema Document*</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">101.CAL</p> </td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Extension Calculation Linkbase Document*</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">101.LAB</p> </td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Extension Label Linkbase Document*</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">101.PRE</p> </td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Extension Presentation Linkbase Document*</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">101.DEF</p> </td>
     <td style="vertical-align: top; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inline XBRL Taxonomy Extension Definition Linkbase Document*</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 53px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">104</p> </td>
     <td style="vertical-align: middle; width: 1691px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">*</p> </td>
     <td colspan="1" style="vertical-align: middle; width: 1702px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Filed herewith.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">**</p> </td>
     <td colspan="1" style="vertical-align: middle; width: 1702px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Indicates management contract or compensatory plan or arrangement.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">***</p> </td>
     <td colspan="1" style="vertical-align: middle; width: 1702px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Furnished, not filed, in accordance with item 601(32) (ii) of Regulations-S-K.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td colspan="1" style="vertical-align: middle; width: 1702px; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">2)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Amendment No. 1 to Milestone Scientific&#x2019;s Registration Statement on Form 10-KSB&#xa0;for the year ended May 15, 1995</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">3)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-KSB for the year ended December 31, 1996.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">4)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-KSB for the year ended December 31, 2004.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">7)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Filed as Appendix A to Milestone Scientific&#x2019;s Proxy Statement filed with the SEC on May 2, 2011 and incorporated herein by reference.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">9)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on July 9, 2013.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">11)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-K for the year ended December 31, 2013.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">12)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on April 18, 2014.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">13)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-K for the year ended December 31, 2015.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">14)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on June 30, 2016.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">15)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on December 2, 2016.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">16)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on December 16, 2016.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">17)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on June 2, 2017.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">18)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on June 7, 2017.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">19)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on July 10, 2017.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">20)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-Q filed with the SEC on August 14, 2017.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">21)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on February 1, 2019.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: 42px; text-align: justify; font-size: 9pt;">22)</td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on February 14, 2019.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">23)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-K filed with the SEC on April 1, 2019.</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">24)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-K/A filed with the SEC on April 2, 2021 .</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">25)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K filed with the SEC on April 9, 2021 .</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">26)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K&#xa0;&#xa0;filed with the SEC on June 25, 2021</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">27)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Form 8-K&#xa0;&#xa0;filed with the SEC on April 7, 2021</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">28)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Incorporated by reference to Milestone Scientific&#x2019;s Proxy Statement on Schedule 14A filed with the SEC on April 30, 2021</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">29)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-Q filed with the SEC on August 15, 2022.</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">30)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-K filed with the SEC on March 31, 2022</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 42px; text-align: justify; font-size: 9pt;">31)</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;">Incorporated by reference to Milestone Scientific&#x2019;s Form 10-K filed with the SEC on March 31, 2022</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     33
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SIGNATURES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In accordance with Section&#xa0;13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td colspan="2" style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific Inc.</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">By:</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/Arjan Haverhals</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Chief Executive Officer</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td colspan="2" style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific Inc.</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">By:</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/ Peter Milligan</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Chief Financial Officer</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Date: March 30, 2023</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 90%; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Signature</b></p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Date</b></p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Title</b></p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/ Neal Goldman</p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">March 30, 2023</p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Chairman and Director</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Neal Goldman</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/ Leonard Osser</p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">March 30, 2023</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">Vice Chairman and Director</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Leonard Osser</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/ Gian Domenico Trombetta</p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">March 30, 2023</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">Director</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Gian Domenico Trombetta</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/ Benedetta Casamento</p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">March 30, 2023</p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Director</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Benedetta Casamento</p> </td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/ Michael McGeehan</p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">March 30, 2023</p> </td>
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Director</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Michael McGeehan</p> </td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; border-bottom: 1px solid rgb(0, 0, 0); font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">/s/ Arjan J. Haverhals</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">March 30, 2023</p> </td>
     <td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Director</p> </td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Arjan J. Haverhals</p> </td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

    <tr style="font-size: 9pt;">
     <td style="vertical-align: middle; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
     <td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     34
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>REPORT</b>&#xa0;<b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b><span style="text-decoration: underline; ">For the Years Ended December 31, 2022</span></b><span style="text-decoration: underline; ">&#xa0;</span><b><span style="text-decoration: underline; ">and 2021</span></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; font-size: 9pt;">Reports of&#xa0;Independent Registered Public Accounting Firms (Marcum LLP PCAOB ID Number <ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2022-01-01_2022-12-31">688</ix:nonNumeric>&#xa0;and Friedman LLP PCAOB ID Number <ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2021-01-01_2021-12-31">711</ix:nonNumeric>)</td><td style="vertical-align: top; width: 113px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">F-2</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 113px; text-align: justify; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Consolidated Financial Statements:</p> </td><td style="vertical-align: top; width: 113px; text-align: justify; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 113px; text-align: justify; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Consolidated Balance Sheets</p> </td><td style="vertical-align: top; width: 113px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">F-4</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 113px; text-align: justify; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Consolidated Statements of Operations</p> </td><td style="vertical-align: top; width: 113px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">F-5</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 113px; text-align: justify; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Consolidated Statements of Changes in Stockholders&#x2019;&#xa0;Equity</p> </td><td style="vertical-align: top; width: 113px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">F-6</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 113px; text-align: justify; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Consolidated Statements of Cash Flows</p> </td><td style="vertical-align: top; width: 113px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">F-7</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 113px; text-align: justify; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 10px; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 1619px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Notes to Consolidated Financial Statements</p> </td><td style="vertical-align: top; width: 113px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">F-8- F-24</p> </td></tr>
</tbody></table>
<div>
 &#xa0;
</div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-1
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">To the Shareholders and Board of Directors of</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Scientific, Inc. and Subsidiaries<b> </b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Opinion on the Consolidated Financial Statements</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">We have audited the accompanying consolidated balance sheet of Milestone Scientific, Inc. and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2022 and the related consolidated statement of operations, stockholders&#x2019; equity and cash flows for year ended December 31, 2022, and the related notes<b> </b>(collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of<b> </b>December 31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Basis for Opinion</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Critical Audit Matters</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="d_2022-01-01_2022-12-31">Marcum LLP</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We have served as the Company&#x2019;s auditor since 2016 (such date takes into account the acquisition of certain assets of Friedman LLP by Marcum LLP effective September 1, 2022)</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2022-01-01_2022-12-31">East Hanover, New Jersey</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">March 30, 2023</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
  F-2
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
  &#xa0;
 </div>
</div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">To the Board of Directors and Stockholders of Milestone Scientific, Inc.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Opinion on the Consolidated Financial Statements</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">We have audited the accompanying consolidated balance sheet of Milestone Scientific, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2021, the related consolidated statement of operations, stockholders&#x2019; equity and cash flows for the year ended December 31, 2021, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021<b>,</b> and the results of its operations and its cash flows for year ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Basis for Opinion</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Critical Audit Matters</b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The valuation of inventories requires management to make significant assumptions and complex judgments about the future salability of the inventory and its net realizable value. These assumptions include the assessment of net realizable value by inventory category considering future usage and forecast product demand for the Company&#x2019;s products. Changes in such assumptions could have a significant impact on the valuation of the Company&#x2019;s inventories. Additionally, management makes qualitative judgments related to slow moving and obsolete inventories. This leads to a high degree of auditor judgment and an increased extent of effort is required when performing audit procedures to evaluate the methodology and reasonableness of the estimates and assumptions.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><i>How We Addressed the Matter in Our Audit</i></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The following are the most relevant procedures we performed to address this critical audit matter:</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><tbody><tr style="font-size: 9pt;"><td style="width: 40pt; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td><td style="vertical-align: top; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Testing of whether the data used to assess obsolescence associated with inventory on hand &#xa0;was complete and&#xa0;&#xa0;sufficiently precise.</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><tbody><tr style="font-size: 9pt;"><td style="width: 40pt; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td><td style="vertical-align: top; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Evaluating whether the expected customer demand used was reasonable, considering the Company&#x2019;s current and past marketing efforts and their market studies in developing the estimate of future demand, the estimated useful life of the inventory, current economic and competitive conditions that could impact the forecasts, and the timing of the introduction and development of new or enhanced products.</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><tbody><tr style="font-size: 9pt;"><td style="width: 40pt; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 18pt; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td><td style="vertical-align: top; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Evaluating the reasonableness of management&#x2019;s assumption related to the risk of technological or competitive obsolescence for products considering the technological or competitive obsolescence experiences during the product life cycle of existing products used in other business lines.</p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="d_2021-01-01_2021-12-31">Friedman LLP</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We have served as the Company&#x2019;s auditor from 2016 to 2022.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2021-01-01_2021-12-31">East Hanover, New Jersey</ix:nonNumeric><br /> March 31, 2022</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-3
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">MILESTONE SCIENTIFIC AND SUBSIDIARIES</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">CONSOLIDATED BALANCE SHEETS</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">ASSETS</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106537" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">8,715,279</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106538" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">14,764,346</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accounts receivable, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106539" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">693,717</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106540" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">943,272</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106541" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">443,872</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106542" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">375,360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106543" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="0" format="ixt:numdotdecimal" decimals="INF">1,792,335</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106544" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="0" format="ixt:numdotdecimal" decimals="INF">1,541,513</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Advances on contracts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106545" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="0" format="ixt:numdotdecimal" decimals="INF">1,325,301</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106546" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="0" format="ixt:numdotdecimal" decimals="INF">1,309,260</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106547" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">12,970,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106548" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">18,933,751</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Furniture, fixtures and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106549" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">18,146</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106550" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">23,713</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Intangibles, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106551" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:numdotdecimal" decimals="INF">227,956</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106552" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:numdotdecimal" decimals="INF">277,619</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Right of use assets finance lease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106553" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">17,645</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106554" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">26,294</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-size: 9pt;">Right of use assets operating lease</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="text-align: right; font-size: 9pt;"><ix:nonFraction id="c96106555" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">443,685</ix:nonFraction></td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="text-align: right; font-size: 9pt;"><ix:nonFraction id="c96106556" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">524,217</ix:nonFraction></td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106557" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">24,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106558" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">24,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106559" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">13,702,086</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106560" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">19,809,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106563" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,102,729</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106564" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">780,428</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accounts payable, related party</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106565" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableRelatedPartiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">803,492</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106566" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableRelatedPartiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">395,857</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accrued expenses and other payables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106567" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,124,839</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106568" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,417,248</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accrued expenses, related party</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106569" contextRef="i_2022-12-31" unitRef="USD" name="mlss:AccruedExpensesRelatedParty" scale="0" format="ixt:numdotdecimal" decimals="INF">167,549</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106570" contextRef="i_2021-12-31" unitRef="USD" name="mlss:AccruedExpensesRelatedParty" scale="0" format="ixt:numdotdecimal" decimals="INF">414,241</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Current portion of finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106571" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">9,365</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106572" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">8,545</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Current portion of operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106573" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">91,701</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106574" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">81,001</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106575" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">3,299,675</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106576" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">3,097,320</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-current portion of finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106577" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">10,698</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106578" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">20,062</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-current portion of operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106579" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">385,279</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106580" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">476,980</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106581" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">3,695,652</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106583" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">3,594,362</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Commitments</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;<span style="-sec-ix-hidden:c96106584">&#xa0;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;<span style="-sec-ix-hidden:c96106585">&#xa0;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Stockholders&#x2019; equity</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock, par value $<span style="-sec-ix-hidden:c96106589"><span style="-sec-ix-hidden:c96106590">.001</span></span>;authorized <span style="-sec-ix-hidden:c96106592"><span style="-sec-ix-hidden:c96106593">100,000,000</span></span> shares; <span style="-sec-ix-hidden:c96106595">69,306,497</span> shares issued and <span style="-sec-ix-hidden:c96106597">69,273,164</span> shares outstanding as of December 31, 2022; <span style="-sec-ix-hidden:c96106596">68,153,336</span> shares issued and <span style="-sec-ix-hidden:c96106598">68,120,003</span> shares outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106587" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">69,306</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106588" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">68,153</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Additional paid in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106599" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">127,478,325</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106600" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">124,915,560</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106601" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">116,410,405</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106602" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">107,704,274</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Treasury stock, at cost, <span style="-sec-ix-hidden:c96106605"><span style="-sec-ix-hidden:c96106607">33,333</span></span> shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106603" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">911,516</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106604" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:TreasuryStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">911,516</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total Milestone Scientific, Inc. stockholders' equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106608" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">10,225,710</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106609" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">16,367,923</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Noncontrolling interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106611" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:MinorityInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">219,276</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106612" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:MinorityInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">152,541</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106613" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">10,006,434</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106615" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">16,215,382</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total liabilities and stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106616" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">13,702,086</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106617" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">19,809,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">See notes to Consolidated Financial Statements</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">MILESTONE SCIENTIFIC AND SUBSIDIARIES</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF OPERATIONS</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">YEARS ENDED DECEMBER 31,</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
    <tbody>
     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><em style="font: inherit;">2022</em></b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><em style="font: inherit;">2021</em></b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Product sales, net</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106623" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">8,805,906</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106624" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">10,304,711</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cost of products sold</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106625" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:numdotdecimal" decimals="INF">3,905,092</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106626" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" format="ixt:numdotdecimal" decimals="INF">3,992,811</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Gross profit</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106627" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GrossProfit" scale="0" format="ixt:numdotdecimal" decimals="INF">4,900,814</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106628" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GrossProfit" scale="0" format="ixt:numdotdecimal" decimals="INF">6,311,900</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106629" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">12,514,323</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106630" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">12,738,362</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106631" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,150,209</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106632" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">878,210</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Depreciation and amortization expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106633" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">63,755</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106634" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">73,836</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106635" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">13,728,287</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106636" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">13,690,408</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106637" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,827,473</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106638" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">7,378,508</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Interest income (expense)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106639" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNet" scale="0" format="ixt:numdotdecimal" decimals="INF">54,607</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106640" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNet" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">16,360</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Gain on debt extinguishment-PPP</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106641" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106642" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">276,180</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Loss before provision for income taxes and equity investments</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106643" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,772,866</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106644" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">7,118,688</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Provision for income taxes</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106645" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106646" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF">333</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Loss before equity investment</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106647" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,772,866</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106648" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">7,119,021</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Deferred profit and divesture-equity investment (See Note F)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106649" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106650" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF">242,589</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106651" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,772,866</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106652" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,876,432</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss attributable to noncontrolling interests</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106653" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">66,735</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106654" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">58,115</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss attributable to Milestone Scientific Inc.</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106655" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,706,131</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106656" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,818,317</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss per share applicable to common stockholders&#x2014;</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Basic and Diluted</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106658" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.12</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106659" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.10</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding and to be issued&#x2014;</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Basic and Diluted</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106663" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">70,607,338</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106664" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">68,829,860</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">See notes to Consolidated Financial Statements</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     F-5
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">MILESTONE SCIENTIFIC AND SUBSIDIARIES</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">CONSOLIDATED STATEMENTS&#xa0;OF CHANGES IN STOCKHOLDERS' EQUITY</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">YEARS ENDED DECEMBER 31 2022 AND&#xa0;&#xa0;2021</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
    <tbody>
     <tr style="font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 23%;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Common Stock Shares</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; text-align: center;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Common Stock Amount</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; text-align: center;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Additional Paid in Capital</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; text-align: center;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Accumulated Deficit</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; text-align: center;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Noncontrolling Interest</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; text-align: center;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Treasury Stock</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; text-align: center;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Total</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 23%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Balance January 1, 2021</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106667" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">64,171,435</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106668" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">64,171</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106669" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">117,934,696</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106670" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">100,885,957</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106671" contextRef="i_2020-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">94,426</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106672" contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">911,516</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106673" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">16,106,968</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106675" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106676" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">790,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106677" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106678" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106680" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">790,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to employee for compensation expensed in prior periods</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106681" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="mlss:StockToBeIssuedDuringPeriodSharesSharebasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">7,075</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106682" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">7</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106683" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">7</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106684" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106685" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106686" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106687" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock to be issued for payment of consulting services expensed in prior periods</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106688" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="mlss:StockToBeIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">40,010</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106689" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">40</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106690" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">40</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106691" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106692" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106693" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106694" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to board of directors for services expensed in prior periods</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106695" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="mlss:StockToBeIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">18,879</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106696" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">19</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106697" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">19</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106698" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106699" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106700" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106701" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock to be issued to employees for bonuses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106704" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106708" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to employee for stock options exercised</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106709" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">826,499</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106710" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">826</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106711" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">1,381,060</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106712" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106713" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106714" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106715" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">1,381,886</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to employee for compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106716" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">18,345</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106717" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">18</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106718" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">107,482</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106719" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106722" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">107,500</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock to be issued for payment of consulting services</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106723" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">289,661</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106724" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">290</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106725" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">770,044</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106726" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106729" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">770,334</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to board of directors for services</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106730" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">277,767</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106731" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">278</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106732" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">617,889</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106733" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106736" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">618,167</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to employee for bonus expensed in prior periods</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106737" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="mlss:StockToBeIssuedDuringPeriodSharesEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF">402,490</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106738" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF">402</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106739" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">402</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106740" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106741" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106742" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106743" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued for warrants exercised</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106744" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="mlss:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">2,101,175</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106745" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">2,102</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106746" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">3,213,942</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106747" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106748" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106749" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106750" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">3,216,044</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106754" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,818,317</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106755" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">58,115</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106757" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,876,432</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106758" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">68,153,336</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106759" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">68,153</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106760" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">124,915,560</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106761" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">107,704,274</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106762" contextRef="i_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">152,541</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106763" contextRef="i_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">911,516</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106764" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">16,215,382</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106767" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,499,302</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106771" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,499,302</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock to be issued to employees for bonuses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106773" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106774" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF">264,385</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106778" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF">264,385</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to employee for compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106779" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">30,196</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106780" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">30</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106781" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">39,973</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106782" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106783" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106784" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106785" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">40,003</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued for payment of consulting services</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106786" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">577,074</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106787" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">577</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106788" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">746,774</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106789" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106790" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106791" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106792" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">747,351</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Common stock issued to employees for bonuses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;"><ix:nonFraction id="c96106793" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="mlss:StockToBeIssuedDuringPeriodSharesEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF">147,338</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;"><ix:nonFraction id="c96106794" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF">147</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">(<ix:nonFraction id="c96106795" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">147</ix:nonFraction></td>
      <td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><ix:nonFraction id="c96106796" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><ix:nonFraction id="c96106797" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><ix:nonFraction id="c96106798" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" xsi:nil="true"></ix:nonFraction></td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;"><ix:nonFraction id="c96106799" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:StockIssuedDuringPeriodValueEmployeeBonuses" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to board of directors for services</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106800" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">398,553</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106801" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">399</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106802" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">12,478</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106803" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106804" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106805" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106806" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">12,877</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106810" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,706,131</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106811" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">66,735</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106813" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,772,866</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Balance December 31, 2022</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106814" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">69,306,497</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106815" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">69,306</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106816" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">127,478,325</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106817" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">116,410,405</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106818" contextRef="i_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">219,276</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96106819" contextRef="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">911,516</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106820" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">10,006,434</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
   <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">See notes to Consolidated Financial Statements</p>
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     F-6
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">MILESTONE SCIENTIFIC AND SUBSIDIARIES</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">YEARS ENDED DECEMBER 31,</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2022</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2021</em></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash flows from operating activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106824" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,772,866</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106825" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProfitLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,876,432</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Depreciation expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106827" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">14,180</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106828" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">22,205</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Amortization of intangibles</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106829" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">49,663</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106830" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">51,630</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106831" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">1,499,302</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106832" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">790,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Employees paid in stock</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106833" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:SharebasedCompensationBonusPaidInStock" scale="0" format="ixt:numdotdecimal" decimals="INF">317,265</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106834" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:SharebasedCompensationBonusPaidInStock" scale="0" format="ixt:numdotdecimal" decimals="INF">793,110</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Expense paid in stock</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106835" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:ExpensesPaidStock" scale="0" format="ixt:numdotdecimal" decimals="INF">747,351</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106836" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:ExpensesPaidStock" scale="0" format="ixt:numdotdecimal" decimals="INF">707,861</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Inventory Reserve</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106837" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:InventoryLIFOReserveEffectOnIncomeNet" scale="0" format="ixt:numdotdecimal" decimals="INF">582,299</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106838" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InventoryLIFOReserveEffectOnIncomeNet" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Amortization of right-of-use asset</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;"><ix:nonFraction id="c96106839" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">80,533</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;"><ix:nonFraction id="c96106840" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">73,552</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Gain on debt extinguishment-PPP</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106842" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">276,180</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Deferred profit and divesture-equity investment (See Note F)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;"><ix:nonFraction id="c96106843" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">(<ix:nonFraction id="c96106844" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF">242,589</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding: 0px; margin: 0px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Decrease in accounts receivable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106846" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">249,555</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106847" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">137,384</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">(Increase) decrease in inventories</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106848" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="0" format="ixt:numdotdecimal" decimals="INF">833,121</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106849" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">878,666</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">(Increase) in advances on contracts</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106850" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:IncreaseDecreaseToAdvancesToContractManufacturer" scale="0" format="ixt:numdotdecimal" decimals="INF">16,041</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106851" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:IncreaseDecreaseToAdvancesToContractManufacturer" scale="0" format="ixt:numdotdecimal" decimals="INF">895,058</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">(Increase) decrease in prepaid expenses and other current assets</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106852" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">68,512</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106853" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">40,555</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Increase in accounts payable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106854" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" format="ixt:numdotdecimal" decimals="INF">322,300</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106855" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" format="ixt:numdotdecimal" decimals="INF">297,456</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Increase in accounts payable, related party</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106856" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" format="ixt:numdotdecimal" decimals="INF">407,636</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106857" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" format="ixt:numdotdecimal" decimals="INF">10,719</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">(Decrease) increase in accrued expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106858" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">292,495</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106859" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">562,824</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">(Decrease) in accrued expenses, related party</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106860" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:IncreaseDecreaseInAccruedLiabilitiesRelatedParties" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">246,692</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106861" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:IncreaseDecreaseInAccruedLiabilitiesRelatedParties" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">47,493</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Decrease operating lease liability</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106862" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">72,353</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106863" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">62,789</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106864" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,031,996</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106865" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,033,664</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash flows from investing activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Purchase of furniture, fixtures, and equipment</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106867" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">8,527</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96106868" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">15,189</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net cash used in&#xa0;investing activities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106869" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,527</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106870" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">15,189</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash flows from financing activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Payments finance lease obligations</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106872" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" format="ixt:numdotdecimal" decimals="INF">8,544</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106873" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" format="ixt:numdotdecimal" decimals="INF">8,648</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Proceeds from exercise of warrants</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106874" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106875" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">3,216,044</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Common stock issued to employee for option exercised</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106876" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106877" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">1,381,886</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net cash used in (provided by) financing activities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106878" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,544</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106879" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">4,589,282</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
      <td style="font-size: 9pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net (decrease) increase in cash and cash equivalents</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96106880" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,049,067</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96106881" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">540,429</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of period</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106882" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">14,764,346</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96106883" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">14,223,917</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of period</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106884" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">8,715,279</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96106885" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">14,764,346</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">See notes to Consolidated Financial Statements</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; margin: 0pt; font-size: 10pt; font-family: Times New Roman;">
     F-7
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="width: 100%; text-align: justify; margin: 0pt;">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>MILESTONE SCIENTIFIC INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: center;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2340311" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE A </b>&#x2014;<b> ORGANIZATION AND BUSINESS </b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">All references in this report to &#x201c;Milestone Scientific,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;we,&#x201d; the &#x201c;Company&#x201d; or &#x201c;Milestone&#x201d; refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C<i>ompuDent</i>&#xae;<i>; CompuMed</i>&#xae;<i>; CompuFlo</i>&#xae;<i>; DPS Dynamic Pressure Sensing technology</i>&#xae;<i>; Milestone Scientific </i>&#xae;<i>;</i>&#xa0;<i>the Milestone logo </i>&#xae;<i>; SafetyWand</i>&#xae;<i>; STA Single Tooth Anesthesia System</i>&#xae;<i>; and The Wand </i>&#xae;<i>.</i>&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific was incorporated in the State of Delaware in <em style="font: inherit;"> August 1989. </em>Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using <i>The Wand</i>&#xae;, a single use disposable handpiece. The device is marketed in dentistry under the trademark <i>CompuDent</i>&#xae;<i>, </i>and <i>STA Single Tooth Anesthesia System</i>&#xae; and in medicine under the trademark <i>CompuMed</i>&#xae;<i>. CompuDent</i>&#xae; is suitable for all dental procedures that require local anesthetic. <i>CompuMed</i>&#xae; is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics, and many other disciplines. The dental devices are sold in the United States, Canada and in <ix:nonFraction id="c96106888" contextRef="i_2022-12-31" unitRef="Pure" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" format="ixt:numdotdecimal" decimals="INF">60</ix:nonFraction> other countries. Certain medical devices have obtained CE mark approval and&#xa0;can be marketed and sold in most European countries.&#xa0;In <em style="font: inherit;"> June 2017,&#xa0;</em>Milestone Scientific received <em style="font: inherit;">510</em>(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the<i> CompuFlo</i>&#xae; Epidural Computer Controlled Anesthesia System (&#x201c;Epidural&#x201d;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">We are in the process of&#xa0;meeting&#xa0;with medical facilities and device distributors within the United States, Middle East and Europe.&#xa0; Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;">2020,</em> the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its new CompuPulse System,&#xa0;which combines the benefits of our CompuWave technology with a manual syringe.&#xa0;The new CompuPulse System allows <em style="font: inherit;">one</em> to identify a pulsatile pressure waveform in a variety of applications, thereby improving the reliability and safety of a drug delivery procedure. Importantly, <em style="font: inherit;">not</em> all procedures require the sophistication of our CompuFlo system, which precisely controls the administration and flow rate of medication as it is being administered. This new technology provides an efficient and low-cost alternative for procedures where a manual syringe <em style="font: inherit;"> may </em>suffice, while still providing the ability to verify needle and subsequent catheter placement.</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="c2340312" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>NOTE B-</b>&#xa0;<b> LIQUIDITY</b>&#xa0;<b>AND UNCERTAINTIES</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the consolidated financial statements are issued. Total operating losses since inception of $<ix:nonFraction id="c96106894" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">116.4</ix:nonFraction> million.&#xa0; The operating losses were&#xa0;$<ix:nonFraction id="c96106895" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">8.8</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96106896" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">7.4</ix:nonFraction>&#xa0;million, for the years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively. Management has prepared cashflow forecasts covering a period of <em style="font: inherit;">12</em> months from the date of issuance of these financial statements. These forecasts include several revenue and operating expense assumptions which indicate that the Company&#x2019;s current cash and liquidity is sufficient to finance the operating requirements for at least the next <em style="font: inherit;">12</em> months Management believes that the Company&#xa0;will have sufficient cash reserves to meet its anticipated obligations for at least the next <em style="font: inherit;">twelve</em> months from the filing date of this report.&#xa0;Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company&#x2019;s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.</p>
   <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In addition to its employees, the Company relies on (i) distributors, agents, and <em style="font: inherit;">third</em>-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If the Company, or any of these entities encounter any disruptions to its or their respective operations or facilities, or if the Company or any of these <em style="font: inherit;">third</em>-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then the Company or they <em style="font: inherit;"> may </em>be prevented or delayed from effectively operating its or their business, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The coronavirus (COVID-<em style="font: inherit;">19</em>) adversely impacted the Company's operations, our distributors and suppliers in recent years. Notwithstanding the reopening of dental offices, hospitals, and pain clinics throughout the country and the rest of the world, revenues for years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> were adversely affected. Any business interruptions, resulting from COVID-<em style="font: inherit;">19,</em> or new variant, could significantly disrupt our operations further and could have a material adverse impact on our business in the future.</p>
   <p style="font-size: 9pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="font-size: 10pt; font-family: Times New Roman; text-align: center; margin: 0pt;">
        F-
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="margin: 0pt;">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Sanctions imposed by the United States and other western democracies, against Russia because of Ukraine conflict, and any expansion of the conflict, is likely to have unpredictable and wide-ranging effects on the domestic and global economy and financial markets, which could have an adverse effect on our business and results of operations. The conflict has caused market volatility, a sharp increase in certain commodity prices, and an increasing number and frequency of cybersecurity threats. As direct impact from the conflict, we have experienced a decrease in international sales to Ukraine and halted all sales to Russia. We will continue to monitor the situation carefully and, if necessary, take action to protect our business, operations, and financial condition.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2340313" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE C</b>&#xa0;&#x2014;<b> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ConsolidationPolicyTextBlock" id="c96109271" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">1.</em></b>&#xa0;<b> Principles of Consolidation</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The accompanying&#xa0;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&#xa0;("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC)&#xa0;include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Medical (majority owned).&#xa0; All significant, intra-entity transactions and balances have been eliminated in the consolidation.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:UseOfEstimates" id="c96109273" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">2.</em> Use of Estimates</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The preparation of consolidated&#xa0;financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, stock compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c96109283" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">3.</em></b>&#xa0;<b> Revenue Recognition</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following <em style="font: inherit;">five</em> steps:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">identification of the promised goods or services in the contract;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">iii.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">measurement of the transaction price, including the constraint on variable consideration;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">iv.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">allocation of the transaction price to the performance obligations based on estimated selling prices; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">v.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC <em style="font: inherit;">606.</em></p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and <em style="font: inherit;">third</em> parties.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has <em style="font: inherit;">no</em> obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Sales Returns</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers&#x2019; return rights and the Company&#x2019;s historical experience with returns and the amount of product in the distribution channel <em style="font: inherit;">not</em> consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, adjustments to the allowance for product returns <em style="font: inherit;"> may </em>be required.&#xa0;The Company recorded allowance of approximately $<ix:nonFraction id="c96106939" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:AllowanceForSalesReturns" scale="0" format="ixt:numdotdecimal" decimals="INF">179,000</ix:nonFraction> for sales&#xa0;returns from Henry Schein due to the termination of&#xa0; the&#xa0;contract on <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">9</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Financing and Payment</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company's payment terms differ by geography and customer, but payment is required within <em style="font: inherit;">90</em> days from the date of shipment or delivery.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Disaggregation of Revenue</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#xa0;operates in <span style="-sec-ix-hidden:c96106949">two</span> operating segments: dental and medical. Therefore, results of the Company operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note M&#xa0;for revenues by geographical market, based on the customer&#x2019;s location, and product category for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2022, </em>and&#xa0;<em style="font: inherit;">2021.</em></p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><em style="font: inherit;"></em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="c96109288" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b><em style="font: inherit;">4.</em></b>&#xa0;<b> Variable Interest Entities</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&#x2019;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific has&#xa0;completed the VIE analysis relating to Milestone China and&#xa0;Anhui Maishida Medical Technology, Co. Ltd. (&#x201c;Anhui&#x201d;).</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has determined that due to the loss of equity investment in Anhui, the company <em style="font: inherit;">no</em> longer has significant influence of Anhui and therefore Anhui is <em style="font: inherit;">not</em> a variable interest. Milestone Scientific&#xa0;has a variable interest in Milestone China, it considered the guidance in ASC <em style="font: inherit;">810,</em> &#x201c;Consolidation&#x201d; as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary.&#xa0;Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Power Criterion: The power to direct the activities that most significantly impact the entity&#x2019;s economic performance; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific does <em style="font: inherit;">not</em> have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has <em style="font: inherit;">not</em> been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO of Milestone China who have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is <em style="font: inherit;">not</em> the primary beneficiary under ASC <em style="font: inherit;">810.</em> Accordingly, Milestone China has <em style="font: inherit;">not</em> been consolidated into the financial statements of Milestone Scientific and is accounted for under the equity method. See Note F.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c96109294" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">5.</em></b>&#xa0;<b> Cash and Cash Equivalents</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific considers all highly liquid investments purchased with an original maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> Milestone Scientific has approximately $<ix:nonFraction id="c96106985" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="6" format="ixt:numdotdecimal" decimals="-5">8.7</ix:nonFraction> million and $<ix:nonFraction id="c96106986" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="6" format="ixt:numdotdecimal" decimals="-5">14.8</ix:nonFraction> million, respectively, invested in cash. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> Milestone Scientific had approximately $<ix:nonFraction id="c96106989" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashUninsuredAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">8.3</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96106990" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashUninsuredAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">13.9</ix:nonFraction>&#xa0;million, respectively, invested in cash that exceeded the Federal Deposit Insurance Corporation insurance limit of <em style="font: inherit;">$250,000.</em></p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"></em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="c96109296" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">6.</em></b>&#xa0;<b> Accounts Receivable</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the ability or inability of its customers to make payments on amounts billed. Most credit sales are due within <em style="font: inherit;">90</em> days from invoicing. There have <em style="font: inherit;">not</em> been any significant credit losses incurred to date.&#xa0;As of <em style="font: inherit;"> December 31, 2022&#xa0;</em>and&#xa0;<em style="font: inherit;">2021,</em>&#xa0;accounts receivable was recorded, net of allowance for doubtful accounts of <span style="-sec-ix-hidden:c96106999">$<ix:nonFraction id="c96107000" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000</ix:nonFraction>.</span></p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:InventoryPolicyTextBlock" id="c96109301" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">7.</em></b>&#xa0;<b> Inventories</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inventories principally consist of finished goods and component parts stated at the lower of cost (<em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method) or net realizable value. Inventory quantities&#xa0;on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected&#xa0;future sales, potential technological obsolescence, and product expiration requirements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">10</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The valuation allowance creates a new cost basis for the inventory, and it is <em style="font: inherit;">not</em>&#xa0;subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation&#xa0;allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the&#xa0;underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:EquityMethodInvestmentsPolicy" id="c96109308" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">8.</em></b>&#xa0;&#xa0;<b>Equity Method Investments</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Investments in which Milestone Scientific can exercise significant influence, but do <em style="font: inherit;">not</em> control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the provision for income tax on the Consolidated Statements of&#xa0; Operations.&#xa0;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments <em style="font: inherit;"> may </em>be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c96109310" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">9.</em></b>&#xa0;<b> Furniture, Fixture and Equipment</b>&#xa0;&#xa0;<b> </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:c96107013">three</span>&#xa0;to <span style="-sec-ix-hidden:c96107014">seven</span> years. The costs of maintenance and repairs are charged to operations as incurred.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c96109312" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">10.</em></b>&#xa0;<b> Intangible Assets </b>&#x2013;<b> Patents and Developed Technology</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are recorded at acquisition cost and be amortized at the estimated useful life.&#xa0; Patent defense costs, to the extent applicable, are expensed as incurred.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0; &#xa0; &#xa0;&#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c96109313" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">11.</em>&#xa0;</b><b>Impairment of Long-Lived Assets</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company&#x2019;s impairment review process is based upon an estimate of future undiscounted cash flow. Factors the Company considers that could trigger an impairment review include the following:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant under performance relative to expected historical or projected future operating results;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant changes in the manner of our use of the acquired assets or the strategy for our overall business;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant negative industry or economic trends; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant technological changes, which would render the technology obsolete.</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:DebtPolicyTextBlock" id="c96109315" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">12.</em> Note Payable</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> April 27, 2020, </em>the Company received a loan (the &#x201c;Loan&#x201d;) from Savoy Bank. in the aggregate amount of approximately&#xa0;<span style="-sec-ix-hidden:c96107022">$276,000,</span> pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under Division A, Title I of the CARES Act, which was enacted <em style="font: inherit;"> March 27, 2020. </em>The Company received forgiveness for the Loan during the year ended <em style="font: inherit;"> December 31, 2021 </em>and recorded a gain on debt extinguishment of <span style="-sec-ix-hidden:c96107023">$276,180.</span></p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c96109316" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">13.</em></b>&#xa0;<b> Research and Development</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development costs, which consist principally of new product development costs payable to <em style="font: inherit;">third</em> parties, are expensed as incurred.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c96109318" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">14.</em></b>&#xa0;<b> Income Taxes</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> we had <ix:nonFraction id="c96107031" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Consolidated Statements of Operations. <ix:nonFraction id="c96107034" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> interest and penalties are present for periods open. Tax returns for the <em style="font: inherit;">2019,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2021</em> years are subject to audit by federal and state jurisdictions.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c96109322" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">15.</em></b>&#xa0;<b> Basic and Diluted Net Loss Per Common Share</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific presents &#x201c;basic&#x201d; earnings (loss) per common share applicable to common stockholders and, if applicable, &#x201c;diluted&#x201d; earnings (loss) per common&#xa0;share applicable to common stockholders pursuant to the provisions of ASC <em style="font: inherit;">260,</em> &#x201c;Earnings per Share&#x201d;. Basic earnings (loss) per common share is calculated by&#xa0;dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares of&#xa0;<ix:nonFraction id="c96107042" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">70,607,338</ix:nonFraction> and <ix:nonFraction id="c96107044" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">68,829,860</ix:nonFraction> during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of&#xa0;additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and&#xa0;warrants were issued during the period.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Since Milestone Scientific had net losses in the years ended <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em> the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (&#x201c;RSA&#x201d;) and warrants, were <em style="font: inherit;">not</em> included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA and warrants&#xa0;totaled <ix:nonFraction id="c96107049" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">7,855,160</ix:nonFraction> and <ix:nonFraction id="c96107050" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">7,291,800</ix:nonFraction> on <em style="font: inherit;"> December 31,&#xa0;</em><em style="font: inherit;">2022</em>&#xa0;and <em style="font: inherit;">2021,</em> respectively.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c96109323" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">16.</em></b>&#xa0;<b> Fair Value of Financial Instruments</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required to classify fair value measurements in <em style="font: inherit;">one</em> of the following categories</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">1</em> inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company&#xa0;can access at the measurement date.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">2</em> inputs which are defined as inputs other than quoted prices included within Level <em style="font: inherit;">1</em> that are observable for the assets or liabilities, either directly or indirectly.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">3</em> inputs are defined as unobservable inputs for the assets or liabilities.</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and <em style="font: inherit;"> may </em>affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&#xa0;As of <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em>&#xa0;the Company does <em style="font: inherit;">not</em> have any assets or liabilities that were measured at fair value on a recurring basis.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c96109324" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">17.</em> Stock-Based Compensation</b>&#xa0;<br /> &#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific accounts for stock-based compensation under ASC Topic <em style="font: inherit;">718,</em> Share-Based Payment. ASC Topic <em style="font: inherit;">718</em> requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="c96109325" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">18.</em></b>&#xa0;&#xa0;<b>Reclassifications</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Certain reclassification has&#xa0;been made to the <em style="font: inherit;">2021</em> consolidated&#xa0;financial statements to conform to the <em style="font: inherit;">2022</em> consolidated&#xa0;financial statement presentation. These reclassifications had <em style="font: inherit;">no</em> effect on net loss or cash flows as previously reported.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"></em></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c96109326" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">19.</em></b>&#xa0;<b> Recent Accounting Pronouncements</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> August 2020, </em>FASB issued&#xa0;ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em>&#xa0;&#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;, which, generally, provides guidance for accounting regarding derivatives relating to entities common stock and earnings per share. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em>&#xa0;is effective for all entities with fiscal years beginning after <em style="font: inherit;"> December 15, 2021, </em>including interim periods therein. The adoption of this standard did <em style="font: inherit;">not</em> have an impact on the Company's consolidated financial statement.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Measurement of Credit Losses on Financial Instruments</i> (&#x201c;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#x201d;</em>), which amends the guidance on measuring credit losses for certain financial assets measured at amortized cost, including trade receivables. The FASB has subsequently issued several updates to the standard, providing additional guidance on certain topics covered by the standard. This update requires entities to recognize an allowance for credit losses using a forward-looking expected loss impairment model, taking into consideration historical experience, current conditions, and supportable forecasts that impact collectability.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em> <i>Financial Instruments - Credit Losses (Topic, <em style="font: inherit;">326</em>), Derivatives and hedging (Topic <em style="font: inherit;">815</em>), and Leases (Topic <em style="font: inherit;">842</em>): Effective</i>&#xa0;<i>dates</i>, which deferred the effective&#xa0;date of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> for the Company. As&#xa0;a result of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em>&#xa0;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for all entities with fiscal years beginning&#xa0;after <em style="font: inherit;"> December 15, 2022, </em>including interim periods.&#xa0;The adoption of this update is <em style="font: inherit;">not</em> expected to have a material impact on the Company's&#xa0;consolidated financial statement.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:InventoryDisclosureTextBlock" id="c2340314" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE D</b>&#xa0;&#x2014;<b> INVENTORIES </b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="c2340315" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107139" contextRef="i_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">1,315,263</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107140" contextRef="i_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">342,465</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107141" contextRef="i_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">334,124</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107142" contextRef="i_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">1,119,709</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Component parts and other materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107143" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">142,948</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107144" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">79,339</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107145" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="0" format="ixt:numdotdecimal" decimals="INF">1,792,335</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107146" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="0" format="ixt:numdotdecimal" decimals="INF">1,541,513</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Company recorded an allowance on slow moving Medical finished goods of approximately $<ix:nonFraction id="c96107130" contextRef="i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember" unitRef="USD" name="us-gaap:InventoryValuationReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">582,000</ix:nonFraction>,&#xa0;and $<ix:nonFraction id="c96107131" contextRef="i_2021-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember" unitRef="USD" name="us-gaap:InventoryValuationReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">450,000</ix:nonFraction> as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively due to the slow adoption of the epidural instruments and handpieces. The Company recorded an allowance on slow moving Dental finished goods of approximately $<ix:nonFraction id="c96107133" contextRef="i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingDentalFinishedGoodsMember" unitRef="USD" name="us-gaap:InventoryValuationReserves" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction> as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="mlss:AdvancesToContractManufacturerTextBlock" id="c2340316" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>NOTE E</b>&#xa0;&#x2014;<b> ADVANCES ON CONTRACTS </b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The advances on contracts represent funding of future dental STA "Single Tooth Anesthesia System" and epidural inventory purchases&#xa0;and epidural replacements parts. The balance of the advances as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was approximately <span style="-sec-ix-hidden:c96107149"><span style="-sec-ix-hidden:c96107150">$1.3</span></span> million.&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="c2340317" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE F</b>&#xa0;&#x2013;&#xa0;<b>INVESTMENT IN AND TRANSACTIONS WITH EQUITY INVESTEES</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Milestone China Ltd.</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Ownership </i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> June 2014, </em>Milestone Scientific invested $<ix:nonFraction id="c96107151" contextRef="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="us-gaap:EquityMethodInvestments" scale="6" format="ixt:numdotdecimal" decimals="-6">1</ix:nonFraction> million in Milestone China Ltd. (&#x201c;Milestone China&#x201d;) by contributing dental instruments to Milestone China for a <ix:nonFraction id="c96107152" contextRef="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="Pure" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">40</ix:nonFraction>% ownership interest. Milestone China owns approximately <ix:nonFraction id="c96107153" contextRef="i_2014-06-30_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneBeijingMember" unitRef="Pure" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">75</ix:nonFraction>% of Milestone Beijing Medical Equipment Company, Ltd (&#x201c;Milestone Beijing&#x201d;). At the time, Milestone Beijing had primary responsibility for the sales, marketing, and distribution of the Company&#x2019;s dental products in China. Milestone Scientific recorded its investment in Milestone China under the equity method of accounting.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020,</em> Milestone China and certain manufacturing/marketing affiliates entered into a reorganization agreement (the &#x201c;Transaction&#x201d;) pursuant to which Milestone China was to merge into an affiliated manufacturing company, Anhui Maishida Medical Technology, Co. Ltd. (&#x201c;Anhui&#x201d;), with Anhui as the surviving entity and to have complete responsibility for sales, marketing, and distribution for the Company&#x2019;s dental products in China. After completion of the Transaction, Milestone Scientific was expected to have an approximate <ix:nonFraction id="c96107156" contextRef="i_2021-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember" unitRef="Pure" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">28.4</ix:nonFraction>% direct ownership in Anhui. Due to the COVID-<em style="font: inherit;">19</em> pandemic, the regulatory approval of the planned Transaction was delayed while applicable government offices were closed in China and Hong Kong. Until the completion of the transaction Milestone Scientific's <em style="font: inherit;">28.4%</em> in Anhui was held by Milestone China.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">On <em style="font: inherit;"> November 23, 2021, </em>management of Milestone Scientific became aware that on <em style="font: inherit;"> October 8, 2021, </em>without approval from Milestone Scientific, (i) Milestone China entered into an Equity Transfer Agreement whereby Milestone China&#x2019;s <span style="-sec-ix-hidden:c96107160">28.4%</span> equity stake in Anhui was transferred to Lidong Zhang, the CEO of Milestone China and Anhui, in exchange for RMB <ix:nonFraction id="c96107161" contextRef="d_2021-10-08_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" unitRef="CNY" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" format="ixt:numdotdecimal" decimals="-7">2,840</ix:nonFraction> million (approximately $<ix:nonFraction id="c96107162" contextRef="d_2021-10-08_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF">440,351</ix:nonFraction>) of which <em style="font: inherit;">no</em> amounts have been or are expected to be received, see below, and (ii) Anhui held a shareholders&#x2019; meeting at which the Equity Transfer Agreement was approved by the shareholders of Anhui, eliminating Milestone China&#x2019;s equity interest in Anhui and Milestone Scientific&#x2019;s indirect equity interest in Anhui. Based on a review of the minutes of the Anhui shareholders&#x2019; meeting, Milestone China was <em style="font: inherit;">not</em> listed as a shareholder in such meeting due to the executed Equity Transfer Agreement between Lidong Zhang and Milestone China.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Though management believes that this conveyance by Milestone China to Lidong Zhang is outside of the laws of Hong Kong and/or China, as <em style="font: inherit;"> may </em>be applicable, at this juncture Milestone Scientific has <em style="font: inherit;">no</em> ownership in Anhui and Milestone China has <em style="font: inherit;">no</em> assets or operations. After considering taking action to assert our rights in the matter, and based on the acknowledgement that such course of action is <em style="font: inherit;">not</em> without its procedural and substantive challenges in Hong Kong and/or China and, importantly, in view of Michelle Zhang dba Solee Science &amp; Technology USA (&#x201c;Solee&#x201d;) (see below), a company located in New Jersey, then becoming the&#xa0;independent distributor for Milestone China and its subsidiaries, and due to the good working relationship then developing between Milestone Scientific and Solee and to the reduction of Milestone Scientific&#x2019;s credit exposure to a Chinese entity, management is <em style="font: inherit;">not</em> pursuing any legal action at this time to recover our equity interest. The Company does <em style="font: inherit;">not</em> believe it is prudent at this time to continue to pursue its investigation of any options it <em style="font: inherit;"> may </em>have regarding its Chinese distributor, and therefore, in order to preserve cash the Company is for the time being suspending its investigation.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">At this time, Milestone Scientific has <em style="font: inherit;">not</em> received any consideration, does <em style="font: inherit;">not</em> know if any of such consideration promised to Milestone China for its interest in Anhui has been paid and, if paid, whether it can recover its share of such consideration. Unless circumstances change, Milestone Scientific does <em style="font: inherit;">not</em> expect it will receive any of the consideration received by Milestone China for its assets without pursuing legal action. As a result, Milestone Scientific has <em style="font: inherit;">not</em> recorded a gain or receivable related to the transfer of Anhui.&#xa0;As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>the investment in Milestone China was zero.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Related Party Transactions</i>&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Milestone China Distribution Agreement</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone China had been Milestone Scientific&#x2019;s exclusive distributor in China. During <em style="font: inherit;">2017</em> and prior to the payment default during <em style="font: inherit;">2018,</em> Milestone Scientific agreed to sell inventory to Milestone China and its agent. During <em style="font: inherit;">2018,</em> Milestone Scientific entered into a payment arrangement with Milestone China to satisfy past due receivables from Milestone China and its agents which amounted to $<ix:nonFraction id="c96107177" contextRef="i_2018-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="us-gaap:NotesReceivableNet" scale="6" format="ixt:numdotdecimal" decimals="-5">2.8</ix:nonFraction> million at the time of the payment arrangement. Milestone Scientific collected $<ix:nonFraction id="c96107178" contextRef="d_2018-01-01_2018-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="us-gaap:ProceedsFromCollectionOfFinanceReceivables" scale="0" format="ixt:numdotdecimal" decimals="INF">950,000</ix:nonFraction> under this arrangement, until Milestone China defaulted on the payment arrangements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Beginning in mid-<em style="font: inherit;"> November 2021, </em>Milestone Scientific entered into discussions with Michelle Zhang dba Solee Science &amp; Technology USA (&#x201c;Solee&#x201d;), a company located in New Jersey, to become Milestone Scientific&#x2019;s independent distributor for China, replacing its former distributor Milestone China and its subsidiaries. On <em style="font: inherit;"> November 22, 2021, </em>Wand Dental, Inc., a United States subsidiary of Milestone Scientific, entered into a Buy and Sell Agreement with Solee, pursuant to which Milestone Scientific granted Solee the right to sell Milestone Scientific&#x2019;s STA instruments, associated handpieces, and spare parts in China to Anhui.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2022, </em>Milestone Scientific shipped instruments or handpieces to Solee for sale to Anhui and recognized&#xa0;revenue of approximately $<ix:nonFraction id="c96107180" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="us-gaap:RevenueFromRelatedParties" scale="0" format="ixt:numdotdecimal" decimals="INF">630,000</ix:nonFraction>.&#xa0;For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2021, </em>Milestone Scientific shipped instruments or handpieces to Solee for sale to Anhui and recognized&#xa0;revenue of approximately $<ix:nonFraction id="c96107182" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="us-gaap:RevenueFromRelatedParties" scale="6" format="ixt:numdotdecimal" decimals="-5">2.1</ix:nonFraction> million. As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> the Company had <ix:nonFraction id="c96107185" contextRef="i_2022-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> deposits from Solee for future shipment of goods included in accrued expenses on the accompanying&#xa0;consolidated balance sheet.&#xa0;&#xa0;As of <em style="font: inherit;"> December 31, 2021, </em>the Company had approximately $<ix:nonFraction id="c96107186" contextRef="i_2021-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">89,000</ix:nonFraction> of deposits from Solee for future shipment of goods included in accrued expenses on the accompanying consolidated balance sheet.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Gross Profit Deferral</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Due to timing differences of when the inventory sold to Milestone China, Anhui or their agent is recognized and when Milestone China and Anhui sells the acquired inventory to <em style="font: inherit;">third</em> parties, an elimination of the recorded profit is required as of the balance sheet date. In accordance with ASC <em style="font: inherit;">323</em>&#xa0;<i>Investment </i>Equity Method and Joint Ventures, Milestone Scientific has deferred its ownership percentage of the gross profit associated with recognized revenue from sales to Milestone China, Solee as an agent, and Anhui until that product is sold to <em style="font: inherit;">third</em> parties.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">As of <em style="font: inherit;"> December 31, 2022&#xa0;</em>and&#xa0;<em style="font: inherit;">2021,</em> the Company&#xa0;had <ix:nonFraction id="c96107192" contextRef="i_2022-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#xa0;deferred profit&#xa0;in the consolidated balance sheets. For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2021&#xa0;</em>Milestone Scientific recorded loss on equity investment of approximately $<ix:nonFraction id="c96107195" contextRef="d_2021-01-01_2021-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" unitRef="USD" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">242,000</ix:nonFraction> in relation to gross profit previously deferred on product sold to Milestone China, Anhui, and Solee, recorded as deferred profit and divesture-equity investment on the accompanying consolidated statement of operations.&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2340318" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE G</b>&#x2014;<b> FURNITURE, FIXTURES AND EQUIPMENT </b>&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2340319" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107226" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">24,734</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107227" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">24,734</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107228" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">178,058</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107229" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">174,147</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Molds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107230" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">7,200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107231" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">7,200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Trade show displays</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107232" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">151,462</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107233" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">151,462</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Computers and software</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107234" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">280,066</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107235" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">275,364</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tooling Safety Wand</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107236" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">125,022</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107237" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">125,022</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tooling equipment-STA &amp; Wand</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107238" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">11,100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107239" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">11,100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">EPI and IA Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107240" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">82,363</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107241" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">82,363</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">STA Trials Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107242" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">63,752</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107243" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">63,752</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107244" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">923,757</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107245" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">915,144</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107246" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">905,611</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107247" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">891,431</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107248" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">18,146</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107249" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">23,713</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Depreciation expense was&#xa0;$<ix:nonFraction id="c96107221" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">14,180</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c96107222" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">22,205</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em>&#xa0;respectively.</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="c2340320" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE H</b>&#xa0;&#x2014;<b> PATENTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="c98E01A96-4ED6-4F24-B2A6-47C9B3D5DAC9" escape="true" continuedAt="c2EF4546E-7642-4EFF-BDAE-BF3939CA1D19">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2022</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Patents-foundation intellectual property</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107268" contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,377,863</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107269" contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">1,149,907</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107270" contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:numdotdecimal" decimals="INF">227,956</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107271" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,377,863</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96107272" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">1,149,907</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107273" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:numdotdecimal" decimals="INF">227,956</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:continuation id="c2EF4546E-7642-4EFF-BDAE-BF3939CA1D19">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Patents-foundation intellectual property</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107280" contextRef="i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,377,863</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107281" contextRef="i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">1,100,244</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107282" contextRef="i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:numdotdecimal" decimals="INF">277,619</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107283" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,377,863</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96107284" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">1,100,244</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107285" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:numdotdecimal" decimals="INF">277,619</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Patents are amortized utilizing the straight-line method over estimated useful lives ranging from <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c96107250" format="ixt-sec:duryear">3</ix:nonNumeric> to <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MaximumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c96107251" format="ixt-sec:duryear">20</ix:nonNumeric> years. Amortization expense was <span style="-sec-ix-hidden:c96107252">$49,663</span> and&#xa0;$<ix:nonFraction id="c96107253" contextRef="d_2021-01-01_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">53,011</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021</em> , respectively.&#xa0;The annual amortization expense expected to be recorded for existing intangibles assets for the years <em style="font: inherit;">2023</em>&#xa0;through <em style="font: inherit;">2027</em>&#xa0;is&#xa0;approximately $<ix:nonFraction id="c96107257" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" format="ixt:numdotdecimal" decimals="INF">52,000</ix:nonFraction>, $<ix:nonFraction id="c96107258" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" format="ixt:numdotdecimal" decimals="INF">34,000</ix:nonFraction>, $<ix:nonFraction id="c96107259" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" format="ixt:numdotdecimal" decimals="INF">28,000</ix:nonFraction>, $<ix:nonFraction id="c96107260" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" format="ixt:numdotdecimal" decimals="INF">28,000</ix:nonFraction> and $<ix:nonFraction id="c96107261" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" format="ixt:numdotdecimal" decimals="INF">86,000</ix:nonFraction>, respectively.</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2340323" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE I</b>&#xa0;&#x2014;<b> STOCKHOLDERS</b>&#x2019;<b> EQUITY</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">At the annual shareholders meeting in <em style="font: inherit;">2021,</em> the Company received approval to&#xa0;increase its authorized shares of common stock from <ix:nonFraction id="c96107287" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">85,000,000</ix:nonFraction> to&#xa0;<ix:nonFraction id="c96107288" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000,000</ix:nonFraction> shares.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>WARRANTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The following table summarizes information about shares issuable under warrants outstanding at <em style="font: inherit;"> December 31, 2022:</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2340324" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Warrant shares outstanding</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Weighted Average exercise price</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Weighted Average remaining life</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Intrinsic value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Outstanding at January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107327" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">4,268,221</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107328" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">2.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="mlss:WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" id="c96107329" format="ixt-sec:duryear">1.50</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107330" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,187,546</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107331" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="mlss:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107332" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="mlss:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107335" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="mlss:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107336" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="mlss:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107339" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">4,268,221</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107340" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">2.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="mlss:WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" id="c96107341" format="ixt-sec:duryear">.50</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>SHARES TO BE ISSUED</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021</em>&#xa0;, there were <ix:nonFraction id="c96107291" contextRef="i_2022-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">2,057,976</ix:nonFraction> and <ix:nonFraction id="c96107292" contextRef="i_2021-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">1,891,979</ix:nonFraction>, respectively&#xa0;shares to be issued whose issuance has been deferred under the terms of an employment agreements with the former Interim Chief Executive Officer,&#xa0;former Chief Financial Officer, and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em> there were <ix:nonFraction id="c96107294" contextRef="i_2022-12-31_TitleOfIndividualAxis-NonemployeesMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">382,697</ix:nonFraction>&#xa0;and <ix:nonFraction id="c96107295" contextRef="i_2021-12-31_TitleOfIndividualAxis-NonemployeesMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">174,364</ix:nonFraction>, respectively&#xa0;shares to be issued to non-employees, that will be issued to non-employees for services rendered. The number of shares was fixed at the date of grant and were fully vested upon grant date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The following table summarizes information about shares to be issue at <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="mlss:DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" id="c2340325" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Shares-to-be-issued, outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107345" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">2,066,343</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107346" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">2,428,329</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted in current period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107347" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="mlss:DeferredCompensationArrangementWithIndividualSharesGranted" scale="0" format="ixt:numdotdecimal" decimals="INF">524,814</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107348" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="mlss:DeferredCompensationArrangementWithIndividualSharesGranted" scale="0" format="ixt:numdotdecimal" decimals="INF">93,918</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Issued in current period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107349" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">150,484</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107350" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">455,904</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Shares-to be issued outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107351" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">2,440,673</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107352" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">2,066,343</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2340326" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE J</b>&#xa0;&#x2014;<b> STOCK OPTION PLANS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Milestone Scientific Inc. <em style="font: inherit;">2020</em> Equity Compensation Plan, as amended and restated (the <em style="font: inherit;">"2020</em> Plan"), provides for awards of restricted common, stock restricted stock units, options to purchase and other awards, up to a maximum <ix:nonFraction id="c96107355" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">4,000,000</ix:nonFraction> shares of common stock and expires in <em style="font: inherit;"> June 2031. </em>Options <em style="font: inherit;"> may </em>be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price <em style="font: inherit;">not</em> less than the fair market value of common stock on the date of grant. Generally, options become exercisable over a <span style="-sec-ix-hidden:c96107357">three</span>-year period from the grant date and expire <span style="-sec-ix-hidden:c96107358">five</span> years after the date of grant.&#xa0;As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em>&#xa0;the Company had&#xa0;<ix:nonFraction id="c96107360" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">323,190</ix:nonFraction>&#xa0;and <ix:nonFraction id="c96107361" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">811,597</ix:nonFraction>, respectively, remaining options available for grants under the&#xa0;Plan.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 8, 2021, </em>as part of its Succession Plan going into effect on <em style="font: inherit;"> April 23, 2021, </em>the Company announced that Leonard Osser, the Interim Chief Executive Officer, would be accepting the role of Vice Chairman of the Board of Directors. As part of accepting this role, he would be granted options to purchase <ix:nonFraction id="c96107362" contextRef="i_2021-04-23_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000,000</ix:nonFraction> shares of common stock, exercisable at the fair market value of the common stock on the date of grant, vesting over the <span style="-sec-ix-hidden:c96107363">five</span>-year period after he steps down as&#xa0;Interim Chief Executive Officer of the Company or <span style="-sec-ix-hidden:c96107364">ten</span> years from the date of grant, whichever shall end first. The options were issued pursuant to the <em style="font: inherit;">2020</em> Plan.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific recognizes compensation expense over the requisite service period and in the case of performance-based options over the period of the expected performance. For the years ended <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em> Milestone Scientific recognized approximately $<ix:nonFraction id="c96107368" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">961,000</ix:nonFraction> and $<ix:nonFraction id="c96107369" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">763,000</ix:nonFraction> of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> there was $<ix:nonFraction id="c96107371" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:numdotdecimal" decimals="INF">2.5</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96107372" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">3.2</ix:nonFraction> million of total unrecognized compensation cost related to non-vested options, respectively.&#xa0;Milestone Scientific expects to recognize these costs over a weighted average period of <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c96107373" format="ixt-sec:duryear">3.09</ix:nonNumeric> and <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c96107374" format="ixt-sec:duryear">3.49</ix:nonNumeric> years as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">A summary of option activity for employees under the plans and changes the year&#xa0;ended&#xa0;<em style="font: inherit;"> December 31, 2022 </em>is presented below:</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="F1125605-D8CB-4A9B-892B-549E9EB3911D" escape="true" continuedAt="c097095CF-952C-4D2F-8CA8-0FE7C5FB04ED">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Averaged Exercise Price $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Life (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Options Value $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107415" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">2,843,693</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107416" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.39</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c96107417" format="ixt-sec:duryear">7.69</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107418" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">49,246</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107419" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">216,296</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107420" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.52</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" name="mlss:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="c96107421" format="ixt-sec:duryear">2.23</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107423" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107424" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Forfeited or expired during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107427" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107428" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107431" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">3,059,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107432" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.36</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c96107433" format="ixt-sec:duryear">6.38</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107435" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">1,026,987</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107436" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c96107437" format="ixt-sec:duryear">4.93</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The weighted-average grant date fair value per share of options granted to employees during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was $<ix:nonFraction id="c96107377" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.82</ix:nonFraction> and $<ix:nonFraction id="c96107378" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.56</ix:nonFraction>, respectively. The aggregate intrinsic value of options granted to employees exercised was $<ix:nonFraction id="c96107379" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction> and $<ix:nonFraction id="c96107380" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">290,688</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended <em style="font: inherit;"> December 31, 2022, </em>risk free interest rate of <ix:nonFraction id="c96107382" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">2.45</ix:nonFraction>%, Volatility of <ix:nonFraction id="c96107383" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">89.60</ix:nonFraction>% (which is based on the Company&#x2019;s historical volatility over the expected term), expected term of <span style="-sec-ix-hidden:c96107384">3</span>&#xa0;years, <ix:nonFraction id="c96107385" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>% dividend rate and closing price of the stock of $<ix:nonFraction id="c96107386" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.52</ix:nonFraction>.&#xa0; &#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">A summary of option activity for non-employees under the plans and changes during the year&#xa0;ended&#xa0;<em style="font: inherit;"> December 31, 2022 </em>is presented below:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:continuation id="c097095CF-952C-4D2F-8CA8-0FE7C5FB04ED">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Averaged Exercise Price $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Life (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Options Value $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107443" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">83,330</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107444" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c96107445" format="ixt-sec:duryear">3.33</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107446" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">49,748</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107447" contextRef="d_2022-01-01_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">8,333</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107448" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.73</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" name="mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="c96107449" format="ixt-sec:duryear">4.80</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107451" contextRef="d_2022-01-01_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107452" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107455" contextRef="i_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">91,663</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107456" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.75</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c96107457" format="ixt-sec:duryear">2.55</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107458" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,083</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107459" contextRef="i_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">77,776</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107460" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.66</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c96107461" format="ixt-sec:duryear">2.30</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107462" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" format="ixt:numdotdecimal" decimals="INF">1,083</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. For the years ended <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em> Milestone Scientific recognized approximately $<ix:nonFraction id="c96107388" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">22,900</ix:nonFraction> and $<ix:nonFraction id="c96107389" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">27,600</ix:nonFraction> expense related to non-employee options, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended <em style="font: inherit;"> December 31, 2022, </em>risk free interest rate of <ix:nonFraction id="c96107390" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">4.12</ix:nonFraction>%, Volatility of <ix:nonFraction id="c96107391" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="4">91.46</ix:nonFraction>%&#xa0;expected term of <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96107392" format="ixt-sec:duryear">5</ix:nonNumeric> years, <ix:nonFraction id="c96107393" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>% dividend rate and closing price of the stock of $<ix:nonFraction id="c96107394" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.73</ix:nonFraction>.&#xa0;&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The information below summarizes the restricted stock award activity for year ended <em style="font: inherit;"> December 31, 2022:</em></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="c2340329" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Grant-Date Fair Value per Award</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-vested as January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107465" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">96,557</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107466" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.33</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107467" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">975,148</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107468" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.86</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96107469" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">449,695</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107471" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="0" format="ixt:numdotdecimal" decimals="INF">186,717</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-vested as December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107473" contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">435,293</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107474" contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022, </em>there were <ix:nonFraction id="c96107396" contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-TerritoryManagerMember" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">49,615</ix:nonFraction> restricted shares granted and deferred under the terms of an employment agreements with the Territory Manager of Milestone Scientific. Such shares will be issued to each party upon completion of <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-TerritoryManagerMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96107397" format="ixt-sec:duryear">2</ix:nonNumeric> years of employment. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company recognized negative stock compensation expense and stock compensation expense of approximately ($<ix:nonFraction id="c96107399" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">20,000</ix:nonFraction>) and $<ix:nonFraction id="c96107400" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">70,000</ix:nonFraction>, respectively. As of <em style="font: inherit;"> December 31, 2022, </em>the total unrecognized compensation expense was $<ix:nonFraction id="c96107401" contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:numdotdecimal" decimals="INF">37,500</ix:nonFraction> related to unvested restricted stock awards for Territory Managers, which the Company expects to recognize over an estimated weighted-average period of <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c96107402" format="ixt-sec:duryear">1.03</ix:nonNumeric>&#xa0;years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of&#xa0;<em style="font: inherit;"> December 31, 2022,&#xa0;</em>the Company entered into&#xa0;restricted stock agreements with&#xa0;members of the Board of Directors of the Company. The Company granted&#xa0;<ix:nonFraction id="c96107403" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">899,390</ix:nonFraction>&#xa0;restricted stock awards with a fair market value of $<ix:nonFraction id="c96107404" contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.82</ix:nonFraction>&#xa0;per share. Such&#xa0;restricted stock vests as follows:&#xa0;<ix:nonFraction id="c96107405" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>%&#xa0;on the grant date in <em style="font: inherit;"> June 2022, </em>and&#xa0;<ix:nonFraction id="c96107406" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>%&#xa0;quarterly, on the&#xa0;<em style="font: inherit;">first</em>&#xa0;day of the following months:&#xa0;&#xa0;<em style="font: inherit;"> October 2022,&#xa0;</em><em style="font: inherit;"> January 2023,&#xa0;</em>and&#xa0;<em style="font: inherit;"> April 2023.&#xa0;</em>These awards&#xa0;vest immediately upon a change of control as defined in the agreements. For the&#xa0;year ended&#xa0;<em style="font: inherit;"> December 31, 2022,&#xa0;</em>the Company recognized approximately $<ix:nonFraction id="c96107408" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">549,000</ix:nonFraction> for restricted stock expenses recorded in general and administrative expenses on the statement of operation.&#xa0;As of&#xa0;<em style="font: inherit;"> December 31, 2022,&#xa0;</em>the total unrecognized stock compensation expense was approximately $<ix:nonFraction id="c96107409" contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:numdotdecimal" decimals="INF">160,000</ix:nonFraction>&#xa0;related to non-vested restricted stock awards with the members of the Board of Directors, which the Company expects to recognize over an estimated weighted average period of&#xa0;<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c96107410" format="ixt-sec:duryear">0.25</ix:nonNumeric>&#xa0;years.</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="mlss:EmploymentAndConsultingAgreementsTextBlock" id="c2340330" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE K</b>&#x2013;<b>EMPLOYMENT CONTRACT AND CONSULTING AGREEMENTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Employment Contracts</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with&#xa0;Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $<ix:nonFraction id="c96107475" contextRef="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction> for&#xa0;years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em>&#xa0;and&#xa0;<em style="font: inherit;">2021,</em> respectively.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Director of Clinical Affairs&#x2019; royalty fee was approximately $<ix:nonFraction id="c96107479" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">442,000</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c96107480" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">446,000</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em> respectively.&#xa0;Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of&#xa0; $<ix:nonFraction id="c96107482" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:ProfessionalFees" scale="0" format="ixt:numdotdecimal" decimals="INF">154,000</ix:nonFraction> and $<ix:nonFraction id="c96107483" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:ProfessionalFees" scale="0" format="ixt:numdotdecimal" decimals="INF">158,000</ix:nonFraction> for the year ended <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em> respectively. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $<ix:nonFraction id="c96107487" contextRef="i_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c96107488" contextRef="i_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">123,000</ix:nonFraction>, respectively, which is included in accounts payable, related party and accrued expense, related party, in the&#xa0;consolidated balance sheet.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 2, 2021, </em>Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company&#x2019;s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning <em style="font: inherit;"> May 9, 2027, </em>half of the royalty (<ix:nonFraction id="c96107489" contextRef="i_2021-03-02_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember" unitRef="Pure" name="mlss:RoyaltyOnNetSalesPercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">2.5</ix:nonFraction>%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated <em style="font: inherit;"> February 25, 2021 </em>to reduce from <ix:nonFraction id="c96107490" contextRef="i_2021-02-25_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember" unitRef="Pure" name="mlss:RoyaltyOnNetSalesPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>% to <ix:nonFraction id="c96107491" contextRef="i_2021-03-02_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember" unitRef="Pure" name="mlss:RoyaltyOnNetSalesPercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">2.5</ix:nonFraction>% the payments due to them on <em style="font: inherit;"> May 9, 2027 </em>and thereafter, with respect to dental products.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Pursuant to a Succession Agreement dated <em style="font: inherit;"> April 6, 2021 </em>between Mr. Osser and the Company: (i) the Employment Agreement dated as of <em style="font: inherit;"> July 10, 2017 </em>between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the &#x201c;China Operations Agreement&#x201d;), and (ii) the Consulting Agreement dated as of <em style="font: inherit;"> July 10, 2017 (</em>the &#x201c;Consulting Agreement&#x201d;) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $<ix:nonFraction id="c96107493" contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">100,000</ix:nonFraction> to $<ix:nonFraction id="c96107494" contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" unitRef="USD" name="mlss:EmploymentAgreementBaseCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000</ix:nonFraction>, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $<ix:nonFraction id="c96107495" contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction> to $<ix:nonFraction id="c96107496" contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="mlss:EmploymentAgreementBaseCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000</ix:nonFraction>, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement.&#xa0; Compensation under the China Operations Agreement and the Consulting Agreement are payable for <em style="font: inherit;">9.5</em>&#xa0;years from <em style="font: inherit;"> May 19, 2021.&#xa0;</em>The Company recorded expense of $<ix:nonFraction id="c96107498" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000</ix:nonFraction> and $<ix:nonFraction id="c96107499" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">125,000</ix:nonFraction>&#xa0;related to the Managing Director, China Operations for the year ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#xa0;The Company recorded expense of $<ix:nonFraction id="c96107501" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000</ix:nonFraction> and $<ix:nonFraction id="c96107502" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">125,000</ix:nonFraction>&#xa0;related to the US Asian Consulting Group, LLC for the year ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2340331" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE L</b>&#xa0;&#x2014;<b> INCOME TAXES</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Due to Milestone Scientific's history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets. At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> <ix:nonFraction id="c96107507" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> recognition was given to the utilization of the remaining net operating loss carry forwards in each of these periods.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Deferred tax attributes resulting from differences between financial accounting amounts and tax bases of assets and liabilities at&#xa0;<em style="font: inherit;"> December 31, 2022&#xa0;</em>and&#xa0;<em style="font: inherit;">2021</em>&#xa0;are as follows: &#xa0;&#xa0;&#xa0;&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2340332" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Allowance for Doubtful Accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107576" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107577" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Warranty Reserve</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107578" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107579" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Impaired Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107580" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107581" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Capitalized Sec. 174 R&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107582" contextRef="i_2022-12-31" unitRef="USD" name="mlss:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="0" format="ixt:numdotdecimal" decimals="INF">242,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107583" contextRef="i_2021-12-31" unitRef="USD" name="mlss:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Inventory Reserve</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107584" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsInventory" scale="0" format="ixt:numdotdecimal" decimals="INF">242,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107585" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsInventory" scale="0" format="ixt:numdotdecimal" decimals="INF">108,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Deferred Officer's Compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107586" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">428,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107587" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">439,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Depreciation and Amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c96107588" contextRef="i_2022-12-31" unitRef="USD" name="mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">56,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c96107589" contextRef="i_2021-12-31" unitRef="USD" name="mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">52,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net Operating Loss Carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107590" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">19,315,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107591" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">18,895,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tax Credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107592" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">688,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107593" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">660,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96107594" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="0" format="ixt:numdotdecimal" decimals="INF">155,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96107595" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="0" format="ixt:numdotdecimal" decimals="INF">45,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Subtotal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107596" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">21,018,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96107597" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">20,100,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c96107598" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">21,018,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c96107599" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">20,100,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-current deferred tax asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96107600" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96107601" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> &#xa0;federal net operating loss carry-forwards are approximately $<ix:nonFraction id="c96107511" contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">71,700,000</ix:nonFraction> and $<ix:nonFraction id="c96107512" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">68,300,000</ix:nonFraction>, respectively. As of <em style="font: inherit;"> December 31, 2022, </em>Milestone Scientific has net operating losses generated before <em style="font: inherit;"> December 31, 2017 </em>will be available to offset future income, if any, through <em style="font: inherit;"> December 2037. </em>Net operating losses generated in <em style="font: inherit;">2018</em> or after can be carried forward indefinitely.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">State net operating losses were approximately $<ix:nonFraction id="c96107515" contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">60,500,000</ix:nonFraction> and <span style="-sec-ix-hidden:c96107516">$63,400,000</span> for the periods ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. Net operating losses will be available to offset future taxable income, if any, through <em style="font: inherit;"> December 2041.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The utilization of Milestone Scientific's net operating losses <em style="font: inherit;"> may </em>be subject to a substantial limitation due to the "change of ownership provisions" under Section <em style="font: inherit;">382</em> of the Internal Revenue Code and similar state provisions. Such limitation <em style="font: inherit;"> may </em>result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a <ix:nonFraction id="c96107520" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="mlss:PercentageOfValuationAllowance" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>% valuation allowance for all of its deferred tax assets due to uncertainty as to their future realization.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure, and transition. At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> we had <ix:nonFraction id="c96107523" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Statements of Operations. <ix:nonFraction id="c96107524" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> interest and penalties are present for periods open. Tax returns for the <em style="font: inherit;">2019,</em> <span style="-sec-ix-hidden:c96107527">2020,</span> and <em style="font: inherit;">2021</em> years are subject to audit by federal and state jurisdictions.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">A reconciliation of the statutory tax rates for the years ended <em style="font: inherit;"> December 31, </em>is as follows:&#xa0; &#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2340333" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; width: 179px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 12px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Statutory Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107604" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21.00</ix:nonFraction></td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107605" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">State income tax - all states</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-<ix:nonFraction id="c96107606" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:numdotdecimal" decimals="4" sign="-">2.74</ix:nonFraction></td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107607" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:numdotdecimal" decimals="4">7.44</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-<ix:nonFraction id="c96107608" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:numdotdecimal" decimals="4" sign="-">2.57</ix:nonFraction></td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107609" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">NOL Expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-<ix:nonFraction id="c96107610" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="mlss:EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" scale="-2" format="ixt:numdotdecimal" decimals="4" sign="-">4.69</ix:nonFraction></td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-<ix:nonFraction id="c96107611" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="mlss:EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" scale="-2" format="ixt:numdotdecimal" decimals="4" sign="-">9.13</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-<ix:nonFraction id="c96107612" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:numdotdecimal" decimals="4" sign="-">0.56</ix:nonFraction></td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-<ix:nonFraction id="c96107613" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:numdotdecimal" decimals="4" sign="-">7.79</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Subtotal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107614" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" scale="-2" format="ixt:numdotdecimal" decimals="4">10.44</ix:nonFraction></td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107615" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" scale="-2" format="ixt:numdotdecimal" decimals="4">11.52</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-<ix:nonFraction id="c96107616" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:numdotdecimal" decimals="4" sign="-">10.44</ix:nonFraction></td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-<ix:nonFraction id="c96107617" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:numdotdecimal" decimals="4" sign="-">11.52</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Effective tax Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-<ix:nonFraction id="c96107618" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:numdotdecimal" decimals="-3" sign="-">0.00</ix:nonFraction></td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107619" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" id="c2340334" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE M</b>&#xa0;&#x2014;<b> SEGMENT AND GEOGRAPHIC DATA</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company conducts its business through <span style="-sec-ix-hidden:c96107620">two</span> reportable segments: Dental and Medical. These segments offer different products and services to different customer base.&#xa0;The Company provides&#xa0;general corporate services to its segments; however, these services are <em style="font: inherit;">not</em> considered when making operating decisions and assessing segment performance. These services are reported under &#x201c;Corporate Services&#x201d; below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments,&#xa0;financing activities and public company compliance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The following tables present information about our reportable and operating segments:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="c2340335" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Sales</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Net Sales:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107629" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">8,753,156</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107630" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">10,152,511</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107631" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">52,750</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107632" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">152,200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107633" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">8,805,906</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107634" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">10,304,711</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Operating Income (Loss):</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107637" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF">1,121,815</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107638" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF">2,475,059</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96107639" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,788,105</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96107640" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,105,854</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107641" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,161,183</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107642" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,747,713</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96107643" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,827,473</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96107644" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">7,378,508</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Depreciation and Amortization:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107647" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">3,805</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107648" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">4,351</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107649" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">4,075</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107650" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">7,313</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107651" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">55,875</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107652" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">62,172</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107653" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">63,755</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107654" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">73,836</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Income (loss) before taxes and equity in earnings of affiliates:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107657" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF">1,116,598</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107658" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF">2,544,730</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96107659" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,794,089</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96107660" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,111,159</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107661" contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,095,375</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107662" contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,552,259</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total loss before taxes and equity in earnings of affiliate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96107663" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,772,866</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96107664" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">7,118,688</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Total Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107667" contextRef="i_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">3,875,978</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107668" contextRef="i_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">6,163,169</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107669" contextRef="i_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">620,373</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107670" contextRef="i_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">1,373,511</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107671" contextRef="i_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">9,205,735</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107672" contextRef="i_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">12,273,064</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107673" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">13,702,086</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107674" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">19,809,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">The following table presents information about our operations by geographic area as of <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021.</em>&#xa0;Net sales by geographic area are based on the respective locations of our subsidiaries.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="mlss:SalesByProductAndByGeographicalRegionTableTextBlock" id="c2340336" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2022</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Domestic: US</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grand Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grand Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107687" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">524,715</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107688" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">7,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107689" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">532,215</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107690" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">560,424</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107691" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107692" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">560,424</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107693" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">2,653,914</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107694" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">25,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107695" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">2,679,164</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107696" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">2,905,354</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107697" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">35,200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107698" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">2,940,554</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107699" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">78,493</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107700" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107701" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">78,493</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107702" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">69,271</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107703" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107704" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">70,571</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107705" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">3,257,122</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107706" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">32,750</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107707" contextRef="d_2022-01-01_2022-12-31_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">3,289,872</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107708" contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">3,535,049</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107709" contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">36,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107710" contextRef="d_2021-01-01_2021-12-31_StatementGeographicalAxis-DomesticMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">3,571,549</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: Rest of World</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Dental</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Medical</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107717" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,413,525</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107718" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107719" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,413,525</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107720" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,226,486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107721" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">70,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107722" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,296,486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107723" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">3,391,748</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107724" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">20,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107725" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">3,411,748</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107726" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">3,246,302</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107727" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">44,900</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107728" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">3,291,202</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107729" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">60,797</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107730" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107731" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">60,797</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107732" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">46,546</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107733" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">800</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107734" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">47,346</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107735" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">4,866,070</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107736" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">20,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107737" contextRef="d_2022-01-01_2022-12-31_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">4,886,070</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107738" contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">4,519,334</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107739" contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">115,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107740" contextRef="d_2021-01-01_2021-12-31_StatementGeographicalAxis-RestOfWorldMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">4,635,034</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: China</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Dental</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Medical</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107747" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">270,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107748" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107749" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">270,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107750" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">303,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107751" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107752" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">303,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107753" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">359,964</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107754" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107755" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">359,964</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107756" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,795,128</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107757" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107758" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,795,128</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107759" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107760" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107761" contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107762" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107763" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107764" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107765" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">629,964</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107766" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107767" contextRef="d_2022-01-01_2022-12-31_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">629,964</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107768" contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">2,098,128</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107769" contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107770" contextRef="d_2021-01-01_2021-12-31_StatementGeographicalAxis-CN" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">2,098,128</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td><td style="font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Total Product Sales</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c96107771" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">8,753,156</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c96107772" contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">52,750</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c96107773" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">8,805,906</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c96107774" contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">10,152,511</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c96107775" contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">152,200</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c96107776" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">10,304,711</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="c2340337" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE N-- CONCENTRATIONS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Scientific has informal arrangements with <em style="font: inherit;">third</em>-party U.S. manufacturers of the STA, <i>CompuDent</i> and <i>CompuMed</i> devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. Consequently, advances on contracts have been classified as current at <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021.</em>&#xa0;The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific&#x2019;s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Scientific&#x2019;s financial condition, business, and results of operations.&#xa0;&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We had <span style="-sec-ix-hidden:c96107779">two</span>&#xa0;customers that accounted for <ix:nonFraction id="c96107780" contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">32</ix:nonFraction>%, and <ix:nonFraction id="c96107781" contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">11</ix:nonFraction>%&#xa0;amount of revenue respectively for the year ended <em style="font: inherit;"> December 31, 2022.&#xa0;</em>We had <span style="-sec-ix-hidden:c96107782">two</span>&#xa0;customers that accounted for <ix:nonFraction id="c96107783" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">35</ix:nonFraction>%, and <ix:nonFraction id="c96107784" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>%&#xa0;amount of revenue respectively for the year ended <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We had <span style="-sec-ix-hidden:c96107785">two</span>&#xa0;customers that accounted for <ix:nonFraction id="c96107786" contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">33</ix:nonFraction>%, and <ix:nonFraction id="c96107787" contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% amount of accounts receivable, respectively as of <em style="font: inherit;"> December 31, 2022.&#xa0;</em>We had <span style="-sec-ix-hidden:c96107788">three</span> customers that accounted for <ix:nonFraction id="c96107789" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">29</ix:nonFraction>%, <ix:nonFraction id="c96107790" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">28</ix:nonFraction>%, and <ix:nonFraction id="c96107791" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">13</ix:nonFraction>% amount of accounts receivable, respectively as of <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We had <span style="-sec-ix-hidden:c96107792">one</span> vendor&#xa0;that accounted for <ix:nonFraction id="c96107793" contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorOneMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">42</ix:nonFraction>%,&#xa0;of accounts payable and accounts payable related party, respectively as of <em style="font: inherit;"> December 31, 2022.&#xa0;</em>We had <span style="-sec-ix-hidden:c96107794">two</span> vendor&#xa0;that accounted for <ix:nonFraction id="c96107795" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorOneMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">14</ix:nonFraction>% and <ix:nonFraction id="c96107796" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorTwoMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">34</ix:nonFraction> %,&#xa0;of accounts payable and accounts payable related party, respectively as of <em style="font: inherit;"> December 31, 2021.</em></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="c2340338" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE O</b>&#xa0;<b>-- RELATED PARTY TRANSACTIONS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>United Systems</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Scientific has a supply agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal supplier &#xa0;of its handpieces, pursuant to which it procures manufactured products under specific purchase orders, but without minimum purchase commitments.&#xa0;Purchases from this supplier were approximately $<ix:nonFraction id="c96107809" contextRef="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="6" format="ixt:numdotdecimal" decimals="-5">3.4</ix:nonFraction> million and <span style="-sec-ix-hidden:c96107810">$1.7</span>&#xa0;million for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#xa0; As <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;"> December 31, 2021, </em>Milestone Scientific owed this supplier approximately $<ix:nonFraction id="c96107813" contextRef="i_2022-12-31_BalanceSheetLocationAxis-AccountsPayableRelatedPartiesCurrentMember_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember" unitRef="USD" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">819,000</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c96107814" contextRef="i_2021-12-31_BalanceSheetLocationAxis-AccountsPayableRelatedPartiesCurrentMember_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember" unitRef="USD" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">548,000</ix:nonFraction>, respectively, which is included in accounts payable&#xa0;and accrued expenses related party on the&#xa0;consolidated balance sheets. In <em style="font: inherit;"> June 2021, </em>the Company signed a <em style="font: inherit;">ten</em>-year agreement with United Systems for supplier of the handpieces.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Milestone China</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">See Note F.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">21</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Other</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with&#xa0; Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $<ix:nonFraction id="c96107817" contextRef="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction> for&#xa0;years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em>&#xa0;and&#xa0;<em style="font: inherit;">2021,</em> respectively.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Director of Clinical Affairs&#x2019; royalty fee was approximately $<ix:nonFraction id="c96107821" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">442,000</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c96107822" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">446,000</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em> respectively.&#xa0;Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of&#xa0; $<ix:nonFraction id="c96107824" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:ProfessionalFees" scale="0" format="ixt:numdotdecimal" decimals="INF">154,000</ix:nonFraction> and $<ix:nonFraction id="c96107825" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:ProfessionalFees" scale="0" format="ixt:numdotdecimal" decimals="INF">158,000</ix:nonFraction> for the year ended <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021,</em> respectively. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $<ix:nonFraction id="c96107828" contextRef="i_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c96107829" contextRef="i_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" unitRef="USD" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">123,000</ix:nonFraction>, respectively, which is included in accounts payable, related party and accrued expense, related party, in the&#xa0;consolidated balance sheet.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 2, 2021, </em>Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company&#x2019;s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning <em style="font: inherit;"> May 9, 2027, </em>half of the royalty (<ix:nonFraction id="c96107830" contextRef="i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-InterimChiefExecutiveOfficerMember" unitRef="Pure" name="mlss:RoyaltyOnNetSalesPercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">2.5</ix:nonFraction>%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated <em style="font: inherit;"> February 25, 2021 </em>to reduce from <ix:nonFraction id="c96107832" contextRef="i_2021-03-01_RelatedPartyTransactionsByRelatedPartyAxis-DirectorClinicalAffairMember" unitRef="Pure" name="mlss:RoyaltyOnNetSalesPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>% to <ix:nonFraction id="c96107833" contextRef="i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-DirectorClinicalAffairMember" unitRef="Pure" name="mlss:RoyaltyOnNetSalesPercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">2.5</ix:nonFraction>% the payments due to them on <em style="font: inherit;"> May 9, 2027 </em>and thereafter, with respect to dental products.</p>
   <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify;">Pursuant to a Succession Agreement dated <em style="font: inherit;"> April 6, 2021 </em>between Mr. Osser and the Company: (i) the Employment Agreement dated as of <em style="font: inherit;"> July 10, 2017 </em>between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the &#x201c;China Operations Agreement&#x201d;), and (ii) the Consulting Agreement dated as of <em style="font: inherit;"> July 10, 2017 (</em>the &#x201c;Consulting Agreement&#x201d;) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $<ix:nonFraction id="c96107834" contextRef="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">100,000</ix:nonFraction> to $<ix:nonFraction id="c96107836" contextRef="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" unitRef="USD" name="mlss:EmploymentAgreementBaseCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000</ix:nonFraction>, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $<ix:nonFraction id="c96107837" contextRef="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">100,000</ix:nonFraction> to $<ix:nonFraction id="c96107838" contextRef="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="mlss:EmploymentAgreementBaseCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000</ix:nonFraction>, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement.&#xa0; Compensation under the China Operations Agreement and the Consulting Agreement are payable for <em style="font: inherit;">9.5</em>&#xa0;years from <em style="font: inherit;"> May 19, </em><em style="font: inherit;">2021.The</em> Company recorded expense of $<ix:nonFraction id="c96107842" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ManagingDirectorChinaOperationsMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000</ix:nonFraction> and $<ix:nonFraction id="c96107844" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ManagingDirectorChinaOperationsMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">125,000</ix:nonFraction>&#xa0;related to the Managing Director, China Operations for the year ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#xa0;The Company recorded expense of $<ix:nonFraction id="c96107846" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000</ix:nonFraction> and $<ix:nonFraction id="c96107848" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">125,000</ix:nonFraction>&#xa0;related to the US Asian Consulting Group, LLC for the year ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2340339" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE P</b>&#xa0;&#x2014;<b> COMMITMENTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>(<em style="font: inherit;">1</em>) </b>&#xa0;<b>Contract Manufacturing Agreement</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has informal arrangements with <em style="font: inherit;">third</em>-party manufacturers of the STA, CompuDent&#xae; and CompuMed&#xae; devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment.&#xa0;The company entered a new purchase commitment for the delivery of <ix:nonFraction id="c96107899" contextRef="d_2022-01-01_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember" unitRef="Pure" name="mlss:PurchaseCommitmentNumberOfUnits" scale="0" format="ixt:numdotdecimal" decimals="INF">2,040</ix:nonFraction> STA CompuDent&#xae; instruments. As of <em style="font: inherit;"> December 31, 2022, </em>the purchase order commitment was approximately $<ix:nonFraction id="c96107900" contextRef="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember" unitRef="USD" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" format="ixt:numdotdecimal" decimals="-5">1.7</ix:nonFraction>&#xa0;million, and&#xa0;approximately $<ix:nonFraction id="c96107902" contextRef="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="6" format="ixt:numdotdecimal" decimals="-5">1.2</ix:nonFraction>&#xa0;million was paid and reported in advances on contracts in the&#xa0;consolidated balance sheet. As of&#xa0; <em style="font: inherit;"> December&#xa0; </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em>&#xa0;the purchase order commitment was approximately $<ix:nonFraction id="c96107905" contextRef="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember" unitRef="USD" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" format="ixt:numdotdecimal" decimals="-5">2.6</ix:nonFraction> million, approximately $<ix:nonFraction id="c96107906" contextRef="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="6" format="ixt:numdotdecimal" decimals="-5">1.3</ix:nonFraction> million was paid and &#xa0;reported in advances on contracts in the consolidated balance sheet. As of <em style="font: inherit;"> December 31, 2022&#xa0;</em>and <em style="font: inherit;">2021</em>&#xa0;the company also has advances on an open purchase order for long lead items for a future purchase order for the manufacturing of Epidural instrument&#xa0;of approximately&#xa0;$<ix:nonFraction id="c96107908" contextRef="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesBeginningIn2021Member" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="0" format="ixt:numdotdecimal" decimals="INF">76,000</ix:nonFraction> and $<ix:nonFraction id="c96107909" contextRef="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesBeginningIn2021Member" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="0" format="ixt:numdotdecimal" decimals="INF">34,000</ix:nonFraction>, respectively.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">22</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>(<em style="font: inherit;">2</em>)</b>&#xa0;<b> Leases</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Operating Leases</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> August 2019, </em>the Company made the&#xa0;decision to <em style="font: inherit;">not</em> renew its&#xa0;existing office lease for its corporate headquarters located in Livingston, New Jersey and instead signed a new <span style="-sec-ix-hidden:c96107913">seven</span> year lease in a new facility located in Roseland, New Jersey (the &#x201c;Roseland Facility&#x201d;), which commenced of <em style="font: inherit;"> January 8, 2021 . </em>Under the Roseland Facility lease, rent payments commence on <em style="font: inherit;"> April 1, 2021 , </em>and the monthly lease payments escalate annually on <em style="font: inherit;"> January 1 </em>of each year, and range from $<ix:nonFraction id="c96107914" contextRef="d_2019-08-01_2019-08-31_RangeAxis-MinimumMember_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember" unitRef="USD" name="mlss:OperatingLeasesMonthlyRentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">9,275</ix:nonFraction> to $<ix:nonFraction id="c96107915" contextRef="d_2019-08-01_2019-08-31_RangeAxis-MaximumMember_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember" unitRef="USD" name="mlss:OperatingLeasesMonthlyRentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">10,898</ix:nonFraction> per month over the lease term. The Company is also required to pay a fixed electric charge equal to $<ix:nonFraction id="c96107916" contextRef="d_2019-08-01_2019-08-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember" unitRef="USD" name="mlss:LesseeOperatingLeaseElectricCharge" scale="0" format="ixt:numdotdecimal" decimals="INF">2.00</ix:nonFraction> per square foot which is &#xa0;paid in equal monthly installments over the lease term or $<ix:nonFraction id="c96107917" contextRef="d_2019-08-01_2019-08-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember" unitRef="USD" name="mlss:LesseeOperatingLeaseElectricPaymentsAnnually" scale="0" format="ixt:numdotdecimal" decimals="INF">11,130</ix:nonFraction> annually. These fixed monthly payments have been included in the measurement of the operating lease liability and related operating lease right-of-use asset as the Company has elected the practical expedient to <em style="font: inherit;">not</em> separate lease and non-lease components for all leases.&#xa0;The Company is also required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises more than new base year amounts, which are accounted for as variable lease expenses.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022, </em>total&#xa0;finance&#xa0;right-of-use assets were $<ix:nonFraction id="c96107919" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">17,645</ix:nonFraction> and total finance liabilities were $<ix:nonFraction id="c96107920" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">20,063</ix:nonFraction>&#xa0;of which $<ix:nonFraction id="c96107921" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">9,365</ix:nonFraction> and $<ix:nonFraction id="c96107922" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">10,698</ix:nonFraction> were classified as current and non-current, respectively.&#xa0;As of <em style="font: inherit;"> December 31, 2022, </em>total operating right-of use assets <span style="-sec-ix-hidden:c96107924">were$443,685</span> and total operating lease liabilities were $<ix:nonFraction id="c96107925" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">476,980</ix:nonFraction>, of which $<ix:nonFraction id="c96107926" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">91,701</ix:nonFraction> and $<ix:nonFraction id="c96107928" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">385,279</ix:nonFraction>&#xa0;were classified as current and non-current, respectively.&#xa0; As of <em style="font: inherit;"> December 31, 2021, </em>total&#xa0; finance&#xa0;right-of-use assets were $<ix:nonFraction id="c96107929" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">26,294</ix:nonFraction> and total finance liabilities were $<ix:nonFraction id="c96107930" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">28,607</ix:nonFraction> of which $<ix:nonFraction id="c96107932" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">8,545</ix:nonFraction> and $<ix:nonFraction id="c96107933" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">20,062</ix:nonFraction> were classified as current and non-current, respectively.&#xa0;As of <em style="font: inherit;"> December 31, 2021, </em>total operating right-of use assets were $<ix:nonFraction id="c96107934" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">524,217</ix:nonFraction>&#xa0;and total operating lease liabilities were $<ix:nonFraction id="c96107935" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">557,981</ix:nonFraction>, of which $<ix:nonFraction id="c96107936" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">81,001</ix:nonFraction> and <em style="font: inherit;">$476,980</em> were classified as current and non-current, respectively.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">As the Company&#x2019;s leases do <em style="font: inherit;">not</em> provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the Medical Device industry.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The expected lease terms include non-cancellable&#xa0;lease periods. Renewal option periods are <em style="font: inherit;">not</em> included in the determination of the lease terms as they were <em style="font: inherit;">not</em> reasonably certain to be exercised.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The components of lease expense were as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="mlss:LeaseCostAndOtherInformationTableTextBlock" id="c2340340" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash paid for operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107952" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:numdotdecimal" decimals="INF">127,995</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107953" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:numdotdecimal" decimals="INF">127,526</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash paid for finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107954" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="mlss:FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">10,740</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107955" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="mlss:FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">10,740</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107956" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107957" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">663,009</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Property and equipment obtained in exchange for new finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107958" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107959" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">43,242</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Weighted Average Remaining Lease Term</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Finance leases (years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107961">2.04 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107962">3.04 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Operating leases (years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107963">4.25 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107964">5.25 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Weighted-average discount rate &#x2013; operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;"><ix:nonFraction id="c96107965" contextRef="i_2022-12-31" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">9.20</ix:nonFraction></td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;"><ix:nonFraction id="c96107966" contextRef="i_2021-12-31" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">9.20</ix:nonFraction></td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Weighted-average discount rate &#x2013; finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;"><ix:nonFraction id="c96107967" contextRef="i_2022-12-31" unitRef="Pure" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">9.20</ix:nonFraction></td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;"><ix:nonFraction id="c96107968" contextRef="i_2021-12-31" unitRef="Pure" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">9.20</ix:nonFraction></td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c2340341" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Maturity of lease liabilities as of December 31, 2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><em style="font: inherit;">Operating Leases</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><em style="font: inherit;">Finance Leases</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107971" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" format="ixt:numdotdecimal" decimals="INF">130,778</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107972" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" format="ixt:numdotdecimal" decimals="INF">10,740</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107973" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" format="ixt:numdotdecimal" decimals="INF">133,560</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107974" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="0" format="ixt:numdotdecimal" decimals="INF">10,740</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107975" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" format="ixt:numdotdecimal" decimals="INF">136,343</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107976" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="0" format="ixt:numdotdecimal" decimals="INF">433</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107977" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" format="ixt:numdotdecimal" decimals="INF">139,125</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107978" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107979" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" format="ixt:numdotdecimal" decimals="INF">35,477</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96107980" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107981" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" format="ixt:numdotdecimal" decimals="INF">575,283</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96107982" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="0" format="ixt:numdotdecimal" decimals="INF">21,913</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Less: interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107983" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">98,303</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96107984" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107985" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">476,980</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96107986" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">20,063</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">23</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="c2340342" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE Q</b>&#xa0;&#x2014;<b> BENEFIT PLAN</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does <em style="font: inherit;">not</em> contribute to this plan, but does pay the administrative costs of the plan, which were <em style="font: inherit;">not</em> significant.</p>
  </ix:nonNumeric>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2340343" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE R</b>&#xa0;&#x2014;<b> SUBSEQUENT EVENTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> January 3, 2023 </em>,the Company launched an E-Commerce platform,&#xa0;selling and shipping&#xa0;STA Single Tooth Anesthesia System&#xae;&#xa0;(STA) and handpieces directly to dental office, and dental&#xa0;groups within the US.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> January 4, 2023, </em>Leslie Bernhard tendered her resignation to Milestone Scientific Inc. (the "Company&#x201d;) as a director, Chairman of the Audit Committee and Chairman of the Board of the Company. Ms. Bernhard&#x2019;s resignation comes after nearly <em style="font: inherit;">20</em> years of service as a director of the Company. Ms. Bernhard indicated that her decision to resign was <em style="font: inherit;">not</em> the result of a disagreement with the Company. The Company thanks Ms. Bernhard for her long, dedicated service on the Board and wishes her well in her future pursuits.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In connection with Ms. Bernhard&#x2019;s resignation, on <em style="font: inherit;"> January 4, 2023, </em>the Company&#x2019;s Board of Directors (the "Board&#x201d;) unanimously appointed Neal Goldman, who has been a member of the Board since <em style="font: inherit;">2019,</em> as Chairman of the Board. Mr. Goldman is the President and Founder of Goldman Capital Management, Inc., a family office since <em style="font: inherit;">2018,</em> which was previously an investment advisory firm founded in <em style="font: inherit;">1985.</em> Mr. Goldman was First Vice President of Research at Shearson Lehman Hutton. He has also held senior positions as a money manager and research analyst with a variety of firms including Neuberger Berman, Moseley Hallgarten Estabrook and Weeden, Bruns Nordeman, and Russ and Company. Mr. Goldman has served as Chairman of Charles &amp; Colvard, Ltd. since <em style="font: inherit;">2016</em> and served on the board of directors of Imageware Systems, Inc. until <em style="font: inherit;"> November 2020. </em>He also serves on the board of directors of Koil Energy Solutions Inc. Prior to their respective acquisitions, he served on the boards of Blyth Industries and IPASS Corporation. Mr. Goldman received his B.A. degree in Economics from The City University of New York (City College).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Also on <em style="font: inherit;"> January 4, 2023, </em>the Board unanimously appointed Arjan Haverhals as a director of the Company. Mr. Haverhals has been the Company&#x2019;s Chief Executive Officer since <em style="font: inherit;"> May 2021 </em>and President since <em style="font: inherit;"> September 2020. </em>Mr. Haverhals has also been the President and Chief Executive Officer of the Company&#x2019;s Dental Division (Wand Dental, Inc.) since <em style="font: inherit;"> June 2020.</em></p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> January 10, 2023, </em>the Company&#xa0;announced it has entered into a distribution agreement granting TEKMIKA Health Technologies exclusive distribution rights to market Milestone&#x2019;s STA Single Tooth Anesthesia System&#xae;&#xa0;(STA) in Brazil. TEKMIKA Health Technologies is a leading distributor in Brazil, focused on importing, promotion, marketing and distribution of high-tech medical equipment and device.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">On <em style="font: inherit;"> January 12, 2023, </em>the Company announced it has entered into a distribution agreement with&#xa0;Sweden &amp; Martina, a leading European dental distributor and manufacturer. Under the agreement, Sweden &amp; Martina has been awarded the exclusive rights to market Milestone&#x2019;s STA Single Tooth Anesthesia System&#xae;&#xa0;(STA) in the new markets of Spain, Portugal and France. In addition, Sweden &amp; Martina will replace the Company&#x2019;s current distributor in Italy and become its exclusive STA distributor in this market.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> February 6, 2023, </em>Milestone Scientific Inc. (the "Company&#x201d;) announced the appointment of Peter Milligan as the Company&#x2019;s Chief Financial Officer, on a part-time basis, effective <em style="font: inherit;">February1,</em> <em style="font: inherit;">2023.</em> In connection with serving as the Company&#x2019;s Chief Financial Officer, Mr. Milligan will be entitled to receive an annual salary of $<ix:nonFraction id="c96107998" contextRef="d_2023-02-06_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" unitRef="USD" name="us-gaap:OfficersCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction> and be eligible to receive an annual incentive bonus with a target of <ix:nonFraction id="c96107999" contextRef="d_2023-02-06_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" unitRef="Pure" name="mlss:IncentiveBonusPercentageOfAnnualCashCompensation" scale="-2" format="ixt:numdotdecimal" decimals="1">40</ix:nonFraction>% of his annual cash compensation, which shall be payable in shares of the Company&#x2019;s common stock. Mr. Milligan will also be entitled to receive $<ix:nonFraction id="c96108000" contextRef="i_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction> in shares of the Company&#x2019;s common stock on an annual basis, of which, $<ix:nonFraction id="c96108001" contextRef="d_2023-02-01_2023-02-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction> shall have a grant date of <em style="font: inherit;"> February 1 </em>and $<ix:nonFraction id="c96108003" contextRef="d_2023-08-01_2023-08-01_StatementScenarioAxis-ScenarioPlanMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction> shall have a grant date as of <em style="font: inherit;"> August 1 </em>of each year beginning in <em style="font: inherit;">2023,</em> valued at the closing price of the Company&#x2019;s common stock on the NYSE American on the grant date, and which shares are to be issued to Mr. Milligan following the expiration of <em style="font: inherit;">sixty</em> (<em style="font: inherit;">60</em>) days after the termination of his employment with the Company.&#xa0;Mr.&#xa0;Milligan holds an M.B.A. from New York University with a concentration in Finance and Economics and a B.B.A. in Accounting from Hofstra University. There are <em style="font: inherit;">no</em> family relationships between Mr.&#xa0;Milligan and any of the Company&#x2019;s directors or executive officers, and there is <em style="font: inherit;">no</em> arrangement or understanding between Mr.&#xa0;Milligan or any other person and the Company or any of its subsidiaries pursuant to which he was appointed as an officer of the Company. There are <em style="font: inherit;">no</em> transactions between Mr.&#xa0;Milligan or any of his immediate family members and the Company or any of its subsidiaries that would be required to be reported under Item <em style="font: inherit;">404</em>(a) of Regulation&#xa0;S-K.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> February&#xa0;&#xa0;</em><em style="font: inherit;">27,</em> <em style="font: inherit;">2023,</em> the Company &#xa0;announced that its CompuFlo&#xae; Epidural System has received <em style="font: inherit;">510</em>(k) FDA clearance for use in the thoracic region of the spine, including the cervical thoracic junction. This approval expands upon the Company&#x2019;s prior approval of CompuFlo for use within the lumbar region of the spine, where the focus has been on labor and delivery.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;&#xa0;&#xa0;&#xa0;</p>
  </ix:nonNumeric>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-24
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>2
<FILENAME>ex_492742.htm
<DESCRIPTION>EXHIBIT 10.25
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="text-align: right; margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Exhibit 10.25</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">As of February 1, 2023</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Peter J. Milligan 13 Crest Drive</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Randolph, New Jersey 07869</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dear Peter,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">This letter confirms our previous conversations regarding the employment opportunity available to you with Milestone Scientific Inc. (the "Company") and sets forth the terms and conditions of that employment, effective February 1, 2023 (the "Commencement Date").</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 6px;">&nbsp;</td>
			<td style="vertical-align: top; width: 14px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 1354px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Position; Duties: </b>The Company hereby offers you part-time employment as Chief Financial Officer of the Company. By acceptance of this offer, you agree to perform from time to time such services as are customary for a chief financial officer of a company such as the Company, the common stock of which is listed on the NYSE American exchange, and other duties and services as the Board of Directors of the Company (the "Board"), the Chief Executive Officer or, if a different person, the President, may reasonably request consistent with such position. During the period of your employment, you will report to the Chief Executive Officer or such other person(s) as the Board or the Chief Executive Officer or, if a different person, the President may designate from time to time.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Your position is for work in the Company's offices in New Jersey for two (2) days per week, which will include preparation of presentations for and attendance at all meetings of the Board and relevant committees. For purposes hereof, a day is considered to be a full business day from time to time for a chief financial officer of a public company; and the particular days each week you come into the office may be chosen by you but it is expected that consideration be given to the days that other executives and members of your financial team are in person in the office. In addition, depending on business exigencies, you are expected to be available for calls and attendance at electronic meetings outside of such two (2) days per week, for your guidance, suggestions and support, whenever we need your help. During such work periods, you agree to (a) to devote your entire business time, energy and skill to your employment with the Company, for the benefit of the Company and its subsidiaries, and (b) adhere to the Company's procedures and policies from time to time.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Your position is an exempt salaried position. Accordingly, you may work additional hours or days beyond the minimum number or the Company's normal business hours if required by the nature of your job duties, and you would not be eligible for overtime or additional pay for such additional work.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Your employment at the Company is "at will." This means that, just as you may resign from the Company at any time for any reason or no reason, the Company has the right to terminate this employment relationship at any time with or without cause or notice. Your "at-will'' status may not be altered in any way except by an express written agreement signed by you and the Company, and such agreement is expressly acknowledged as an employment contract. In the event of any termination, the compensation provided for herein will be paid to you for all periods up to the effective date of termination.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 1px;">&nbsp;</td>
			<td style="vertical-align: top; width: 14px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: 1359px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Compensation: </b>Your base salary will be $120,000 per year (at the rate of $10,000 per month), payable in cash, less applicable deductions and withholdings, in accordance with the Company's standard payroll practices. Cash compensation will be pro-rated for any partial calendar year during your employment.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, you will receive grants of an aggregate of $100,000 in the Company's common stock, as follows: $50,000 granted on February 1 and $50,000 granted on August 1 of each year beginning in 2023. Such shares will be valued at the closing price of the Company's common stock on the NYSE American or such other market or exchange on which its shares are then traded at the applicable grant date. The share portion of your compensation will be issued to you following the expiration of sixty (60) days after the end of your employment with the Company and its subsidiaries and in accordance with the requirements of IRC Code &#167;409A. You must be employed on such payment date in order to receive such share compensation. You acknowledge that the shares issuable under this paragraph will be acquired by you for investment purposes only and not with a view towards the distribution thereof and will not be sold or otherwise disposed of in violation of the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 1px;">&nbsp;</td>
			<td style="vertical-align: top; width: 8px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align: top; width: 1365px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Bonus: </b>You will be eligible to receive an annual incentive bonus with a target of $48,000 per year (40% of your cash compensation), payable in shares of common stock of the Company. Incentive compensation is likely to be payable on an annual basis in February or March of the following year, and you must be employed on such payment date in order to receive incentive compensation. Bonus for the period February 1, 2023 through December 31, 2023 will determined with respect to the achievement of the to be defined targets for calendar year 2023. Bonus amounts and targets for subsequent periods will be set, and satisfaction of bonus targets for 2023 and subsequent periods will be determined, by the Compensation Committee from time to time in its reasonable discretion. Amounts and targets for partial years will be pro rated.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">YOU UNDERSTAND THAT YOU MAY SUFFER ADVERSE TAX CONSEQUENCES AS A RESULT OF YOUR RECEIPT OR DISPOSITION OF THE SHARES. YOU REPRESENT (a) THAT YOU HAVE CONSULTED WITH ANY TAX ADVISER THAT YOU DEEM ADVISABLE IN CONNECTION WITH THE RECEIPT OR DISPOSITION OF THE SHARES AND (b) THAT YOU ARE NOT RELYING ON THE COMPANY FOR ANY TAX ADVICE.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 1px;">&nbsp;</td>
			<td style="vertical-align: top; width: 9px;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">4.</p>
			</td>
			<td style="vertical-align: top; width: 1364px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Benefits; Vacation: </b>During your employment with the Company, you will be entitled to participate in the employee benefit plans and programs, subject to eligibility requirements, enrollment criteria, and the other terms and conditions of such plans and programs. Currently, such plans and programs are as follows:&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#9679;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;medical insurance - covered 100% for the executive, and 70% for the executive's spouse and children, up to the amounts paid by the Company for employees generally; coverage in excess of such amounts are available at your expense;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#9679;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;dental and vision insurance - available as a voluntary payroll deduction; and</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#9679;&nbsp; &nbsp; &nbsp; &nbsp; 401K Plan - available without match</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition to public holidays on which the business of the Company is officially closed in accordance with the Company's holiday policy, you will be entitled to eight (8) days (40% of four (4) weeks) of personal time off or vacation time, which vacation time will accrue during the term of your employment in accordance with the Company's PTO policy, as set forth in the Employee Handbook, from time to time. You will only be entitled to use any such accrued personal time off or vacation time in such a manner as to ensure satisfaction of the needs and requirements of the Company, without roll-over.</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Air travel for executives and employees is generally in economy class, though from time to time based on circumstances exceptions may be made to business class. All business travel, including hotel arrangements must be made through the Company. Reasonable effort will be made by the Company to accommodate your requested airlines, date, time of travel and hotel selection. Reimbursement of ordinary and necessary business related expenses will be made upon submission of an expense report, provided by the Company, accompanied by all original receipts. The Company reserves the right to change, terminate and rescind any of its benefit plans and programs, alter employee contribution levels or replace any of such plans or programs at its discretion.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 1px;">&nbsp;</td>
			<td style="vertical-align: top; width: 9px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: 1364px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Company Materials.</b>&nbsp;<b>&nbsp;</b>All materials, computers, devices, records and documents&nbsp;{including without limitation originals and copies, and whether in print, electronic or in other media), generated by you or coming or having come into your possession in connection with your employment with the Company or any of the Company's affiliates, including trade secrets and other proprietary information (collectively, "Company Materials"), shall be the sole property of the Company or its applicable affiliate, as the case may be. Promptly following any termination of your employment, or promptly upon request of the Company at any time, you agree to deliver all Company Materials to the Company and to use your best efforts to permanently delete and erase all proprietary information of the Company from all computers and other storage media in your personal possession or under your control and not otherwise required to be, and in fact, delivered to the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 1.4px;">&nbsp;</td>
			<td style="vertical-align: top; width: 2px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6.</p>
			</td>
			<td style="vertical-align: top; width: 1371px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Confidentiality and Work for Hire. </b>In addition to this letter, if you have not already done so, on your first day of work under this letter, you will be required to sign the Company's standard form of Employee Proprietary Information, Inventions and Non-Solicitation Agreement, a copy of which will be furnished to you on or prior to such date. Your offer of employment with the Company is contingent upon you signing and delivering such agreement to the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 6px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7.</p>
			</td>
			<td style="vertical-align: top; width: 1370px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>No Conflicts. </b>You hereby represent and warrant that you are not party to any agreement, contract or understanding, whether of employment, consultancy or otherwise, including any confidentiality, non-solicitation, non-competition or a similar agreement, in conflict with this agreement or which would in any way restrict or prohibit you from undertaking or performing services for the Company or any of its affiliates. During your employment with the Company, you may not directly or indirectly render services to any other person or organization for which you receive compensation without giving prior written notice to, and receiving prior written approval from, the Chairman of the Board or CEO (which should not be unreasonable withheld), or engage in any other unpaid activities that inhibit or prohibit the performance of your duties to the Company or inhibit or conflict in any way with the business of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 9px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8.</p>
			</td>
			<td style="vertical-align: top; width: 1367px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Conditions. </b>Your employment by the Company is subject to satisfactory proof of your right to work in the United States and the completion, with results satisfactory to the Company, of any Company-required background, reference, drugs and other customary checks. If, based upon a unique circumstance, you commence work before the Company has completed its inquiry, you will be deemed a conditional employee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 10px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9.</p>
			</td>
			<td style="vertical-align: top; width: 1366px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Miscellaneous. </b>These employment terms set forth the entire understanding and agreement between you and the Company, supersede any and all prior agreements or understandings between you and the Company, including your existing employment offer letter, and may be modified, amended or supplemented only by a writing signed by the Company and you. This agreement is to be governed by the laws of the State of New Jersey, without reference to conflicts of laws principles. This agreement is not intended to conflict with or induce you to violate any existing contractual or other obligations that you have to any other person or entity. By signing below, you are certifying, among other things, that you are not subject to any non-compete clause or similar restriction that prevents you from working for the Company. This agreement may be executed electronically, by facsimile, by .pdf, and/or in wet ink, and each method, and any copies of such original execution, shall be of the same force and effect as an original executed offer.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are excited to have you become a member of the Milestone team, and welcome you as our CFO, and look forward to a successful relationship in which you will find your new status and work both challenging and rewarding. To confirm your employment with the Company on the terms set forth herein, kindly sign and date the Acknowledgement and Agreement below and scan and email the signed copy to me at your earliest convenience. This offer must be accepted on or before January 30, 2023 and will be deemed to have been withdrawn if your executed Acknowledgement and Agreement is not received by the undersigned on or before such date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Sincerely,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Arjan Haverhals</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Executive Officer and President</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>ACKNOWLEDGEMENT AND AGREEMENT</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">I have read, understand and accept the foregoing terms and conditions of employment and understand my employment with the Company is contingent on background, reference and other customary checks by the Company, as well as satisfactory proof of my right to work in the United States.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">I understand and acknowledge that my employment with the Company is for an unspecified duration and constitutes "at-will" employment. I acknowledge that this employment relationship may be terminated at any time with or without cause or for any or no cause, at the option either of the Company or myself. I further understand that no contract of employment other than "at will" has been expressed or implied, and that no circumstances arising out of my employment will alter my "at will" employment relationship. In the event of any termination, the compensation provided for herein will be paid to me for all periods up to the effective date of termination and only as stated otherwise in this agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">I represent and warrant that I am not a party to any agreement, contract or understanding, whether of employment, consultancy or otherwise, which would in any way restrict or prohibit me from undertaking or performing services for the Company. I hereby acknowledge that I have not foregone any other opportunity, financial or otherwise, in connection with commencing or rendering my services to the Company.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Sign name: &nbsp;&nbsp;/s/ Peter Milligan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Date&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; January 23, 2023&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex_490434.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>EXHIBIT 21.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>Subsidiaries</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Subsidiary</u></b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Jurisdiction of Incorporation</u></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Wand Dental , Inc.</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Delaware&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Milestone Medical Inc.</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Delaware</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex_490435.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We consent to the incorporation by reference in the Registration Statements of Milestone Scientific Inc. on Form S-3 (No. 333-209466 and No. 333-231178), and Form S-8 File (No. 333-134245, &nbsp;No. 333-40413, No.333-252100, and No. 333-257895) of our report dated March 30, 2023, with respect to our audits of the consolidated financial statements of Milestone Scientific, Inc.&nbsp; as of and for the year ended December 31, 2022, which report is included in this Annual Report on Form 10-K of Milestone Scientific, Inc. for the year ended December 31, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Marcum LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Marcum LLP</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">East Hanover, New Jersey</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">March 30, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ex_492741.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 23.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We hereby consent to the incorporation by reference in the Registration Statements of Milestone Scientific Inc. on Form S-3 (No. 333-209466 and No. 333-231178), and Form S-8 File (No. 333-134245, &nbsp;No. 333-40413, No.333-252100, and No. 333-257895) of Milestone Scientific Inc. of our report dated March 31, 2022, with respect to our audit of the consolidated financial statements as of and for the year ended December 31, 2021 which was included in the Company&#8217;s Annual Report on Form 10-K filed for the year ended December 31, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We resigned as auditors on September 12, 2022 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements for the periods after the date of our resignation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Freidman LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Friedman LLP</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">East Hanover, New Jersey</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">March 30, 2023</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex_490441.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Rule 13a-14(a)/15d-14(a) Certification</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">I, Arjan Haverhals, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this annual report on Form 10-K of Milestone Scientific Inc.&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:80pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the supervision, to ensure that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:79pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under the supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:80pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report the conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:79pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant's other certifying officer(s) and I have disclosed, based on the most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 102px;">&nbsp;</td>
			<td style="vertical-align: top; width: 20px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 1842px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 100px;">&nbsp;</td>
			<td style="vertical-align: top; width: 24px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align: top; width: 1839px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any fraud, whether material or not, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Date: March 30, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">/s/ Arjan Haverhals</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Arjan Haverhals</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Chief Executive Officer</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(Principal Executive Officer)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex_490442.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: right;">Exhibit 31.2</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">Rule 13a-14(a)/15d-14(a) Certification</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">I, Peter Milligan,&nbsp;certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this annual report on Form 10-K of Milestone Scientific Inc.&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:80pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the supervision, to ensure that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:79pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under the supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#894;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:80pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report the conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:79pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:73pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant's other certifying officer(s) and I have disclosed, based on the most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 106px;">&nbsp;</td>
			<td style="vertical-align: top; width: 25px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 1832px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 102px;">&nbsp;</td>
			<td style="vertical-align: top; width: 25px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align: top; width: 1836px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any fraud, whether material or not, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Date: March 30, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">/s/ Peter Milligan</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Peter Milligan</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Chief Financial Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex_490443.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">CERTIFICATION</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">PURSUANT TO 18</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">U.S.C. SECTION 1350,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">AS ADOPTED PURSUANT TO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">In connection with the annual report of Milestone Scientific Inc. (&#8220;Milestone&#8221;) on Form 10-K for the period ending December 31, 2022&nbsp; as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Arjan Haverhals, Chief Executive Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:7.8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 19px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 1810px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:7.8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 13px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: 1816px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Date March 30, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">/s/ Arjan Haverhals</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Arjan Haverhals</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Chief Executive&nbsp;Officer</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">(Principal&nbsp;Executive Officer)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex_490444.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>HTML Editor</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: right;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">CERTIFICATION</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">PURSUANT TO 18</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">U.S.C. SECTION 1350,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">AS ADOPTED PURSUANT TO</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In connection with the annual report of Milestone Scientific Inc. (&#8220;Milestone&#8221;) on Form 10-K for the period ending December 31, 2022&nbsp; as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Peter Milligan, Chief Financial Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:auto;">&nbsp;</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Date March 30, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">/s/ Peter Milligan</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Peter Milligan</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Chief Financial Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>mlss-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:28PM UTC 2023-03-30--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mlss="http://www.milestonescientific.com/20221231" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.milestonescientific.com/20221231">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mlss-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mlss-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mlss-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mlss-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-equity" roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-a-organization-and-business" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note A - Organization and Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-b-liquidity-and-uncertainties" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note B - Liquidity and Uncertainties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-c-summary-of-significant-accounting-policies" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note C - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-d-inventories" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note D - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-e-advances-on-contracts" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note E - Advances on Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-f-investment-in-and-transactions-with-equity-investees" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note F - Investment in and Transactions With Equity Investees</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-g-furniture-fixtures-and-equipment-" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note G - Furniture, Fixtures and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-h-patents" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note H - Patents</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-stockholders-equity" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note I - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-stock-option-plans" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note J - Stock Option Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-k-employment-contract-and-consulting-agreements" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note K - Employment Contract and Consulting Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-income-taxes" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note L - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-m-segment-and-geographic-data" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note M - Segment and Geographic Data</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-n-concentrations" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note N - Concentrations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-o-related-party-transactions" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note O - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-p-commitments" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note P - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-q-benefit-plan" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note Q - Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-r-subsequent-events" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note R - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-d-inventories-tables" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note D - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-g-furniture-fixtures-and-equipment-tables" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note G - Furniture, Fixtures and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-h-patents-tables" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note H - Patents (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-stockholders-equity-tables" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note I - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-stock-option-plans-tables" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note J - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-income-taxes-tables" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note L - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-m-segment-and-geographic-data-tables" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note M - Segment and Geographic Data (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-p-commitments-tables" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note P - Commitments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-a-organization-and-business-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note A - Organization and Business (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-b-liquidity-and-uncertainties-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note B - Liquidity and Uncertainties (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-c-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note C - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-d-inventories-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note D - Inventories (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-d-inventories-summary-of-inventories-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note D - Inventories - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-e-advances-on-contracts-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note E - Advances on Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note F - Investment in and Transactions With Equity Investees (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-g-furniture-fixtures-and-equipment-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note G - Furniture, Fixtures and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note G - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-h-patents-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note H - Patents (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-h-patents-summary-of-patents-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note H - Patents - Summary of Patents (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-stockholders-equity-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note I - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-stockholders-equity-warrants-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note I - Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note I - Stockholders' Equity - Summary of Shares to be Issued (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-stock-option-plans-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note J - Stock Option Plans (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note J - Stock Option Plans - Summary of Option Activity for Employees (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note J - Stock Option Plans - Schedule of Restricted Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-k-employment-contract-and-consulting-agreements-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note K - Employment Contract and Consulting Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-income-taxes-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note L - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-income-taxes-deferred-tax-assets-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note L - Income Taxes - Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note L - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-m-segment-and-geographic-data-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note M - Segment and Geographic Data (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note M - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note M - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-n-concentrations-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note N - Concentrations (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-o-related-party-transactions-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note O - Related Party Transactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-p-commitments-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note P - Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-p-commitments-lease-expense-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note P - Commitments - Lease Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-p-commitments-maturities-of-lease-liabilities-details" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">061 - Disclosure - Note P - Commitments - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-r-subsequent-events-details-textual" roleURI="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">062 - Disclosure - Note R - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="mlss_AccessoriesMember" name="AccessoriesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_AccountsPayableRelatedPartiesCurrentMember" name="AccountsPayableRelatedPartiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_AccountsReceivableFromRelatedPartiesMember" name="AccountsReceivableFromRelatedPartiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AccruedExpensesRelatedParty" name="AccruedExpensesRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_AdvancesToContractManufacturerTextBlock" name="AdvancesToContractManufacturerTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AllowanceForSalesReturns" name="AllowanceForSalesReturns" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_AnhuiMember" name="AnhuiMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" name="ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ComputerAndSoftwareMember" name="ComputerAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ConsultantMember" name="ConsultantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ConsultingServicesMember" name="ConsultingServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_CustomerOneMember" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_CustomerThreeMember" name="CustomerThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_CustomerTwoMember" name="CustomerTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" name="DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_DeferredCompensationArrangementWithIndividualSharesGranted" name="DeferredCompensationArrangementWithIndividualSharesGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" name="DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="mlss_DentalSegmentMember" name="DentalSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DirectorClinicalAffairMember" name="DirectorClinicalAffairMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DirectorOfClinicalAffairsMember" name="DirectorOfClinicalAffairsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DomesticMember" name="DomesticMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_EPIAndIAInstrumentsMember" name="EPIAndIAInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAgreementBaseCompensation" name="EmploymentAgreementBaseCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAndConsultingAgreementsTextBlock" name="EmploymentAndConsultingAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" name="EquityMethodInvestmentDeferredIntercompanyProfitLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_ExpensesPaidStock" name="ExpensesPaidStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" name="FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_FoundationIntellectualPropertyPatentsMember" name="FoundationIntellectualPropertyPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_HandpiecesMember" name="HandpiecesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_IncentiveBonusPercentageOfAnnualCashCompensation" name="IncentiveBonusPercentageOfAnnualCashCompensation" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" name="IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" name="IncreaseDecreaseInAccruedLiabilitiesRelatedParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" name="IncreaseDecreaseToAdvancesToContractManufacturer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_InstrumentsMember" name="InstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_InterimChiefExecutiveOfficerMember" name="InterimChiefExecutiveOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_LeaseCostAndOtherInformationTableTextBlock" name="LeaseCostAndOtherInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_LesseeOperatingLeaseElectricCharge" name="LesseeOperatingLeaseElectricCharge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_LesseeOperatingLeaseElectricPaymentsAnnually" name="LesseeOperatingLeaseElectricPaymentsAnnually" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ManagingDirectorChinaOperationsMember" name="ManagingDirectorChinaOperationsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ManufacturingAgreementForHandpiecesMember" name="ManufacturingAgreementForHandpiecesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_MedicalSegmentMember" name="MedicalSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_MilestoneBeijingMember" name="MilestoneBeijingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_MilestoneChinaMember" name="MilestoneChinaMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NonemployeesMember" name="NonemployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_NumberOfVendors" name="NumberOfVendors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="mlss_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" name="OfficeLeaseForHeadquarterInRoselandNewJerseyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_OperatingLeasesMonthlyRentExpense" name="OperatingLeasesMonthlyRentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_PaycheckProtectionProgramCARESActMember" name="PaycheckProtectionProgramCARESActMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_PercentageOfValuationAllowance" name="PercentageOfValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" name="PreviousPresidentAndChiefExecutiveOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" name="ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" name="PurchaseCommitmentForDevicesBeginningIn2021Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_PurchaseCommitmentForDevicesMember" name="PurchaseCommitmentForDevicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_PurchaseCommitmentNumberOfUnits" name="PurchaseCommitmentNumberOfUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_RestOfWorldMember" name="RestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_RoyaltyOnNetSalesPercentage" name="RoyaltyOnNetSalesPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="mlss_STATrialsInstrumentsMember" name="STATrialsInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" name="SalesByProductAndByGeographicalRegionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SharebasedCompensationBonusPaidInStock" name="SharebasedCompensationBonusPaidInStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_SlowMovingDentalFinishedGoodsMember" name="SlowMovingDentalFinishedGoodsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_SlowMovingMedicalFinishedGoodsMember" name="SlowMovingMedicalFinishedGoodsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" name="StockIssuedDuringPeriodValueEmployeeBonuses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" name="StockToBeIssuedDuringPeriodSharesEmployeeBonuses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" name="StockToBeIssuedDuringPeriodSharesIssuedForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" name="StockToBeIssuedDuringPeriodSharesSharebasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" name="StockToBeIssuedDuringPeriodValueEmployeeBonuses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" name="StockToBeIssuedDuringPeriodValueIssuedForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" name="StockToBeIssuedDuringPeriodValueSharebasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_TerritoryManagerMember" name="TerritoryManagerMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_The2020EquityIncentivePlanMember" name="The2020EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ToolingEquipmentSTAAndWandMember" name="ToolingEquipmentSTAAndWandMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ToolingSafetyWandMember" name="ToolingSafetyWandMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_TradeShowDisplaysMember" name="TradeShowDisplaysMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_VendorOneMember" name="VendorOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_VendorTwoMember" name="VendorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ViceChairmanOfTheBoardOfDirectorsMember" name="ViceChairmanOfTheBoardOfDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" name="WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" name="WeightedAverageSharesOutstandingBasicAndDilutedAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-d-inventories-summary-of-inventories-details" name="statement-statement-note-d-inventories-summary-of-inventories-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-d-inventories-tables" name="statement-statement-note-d-inventories-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" name="statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables" name="statement-statement-note-g-furniture-fixtures-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-h-patents-summary-of-patents-details" name="statement-statement-note-h-patents-summary-of-patents-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-h-patents-tables" name="statement-statement-note-h-patents-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" name="statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-i-stockholders-equity-tables" name="statement-statement-note-i-stockholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-i-stockholders-equity-warrants-details" name="statement-statement-note-i-stockholders-equity-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" name="statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" name="statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-j-stock-option-plans-tables" name="statement-statement-note-j-stock-option-plans-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details" name="statement-statement-note-l-income-taxes-deferred-tax-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" name="statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-l-income-taxes-tables" name="statement-statement-note-l-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" name="statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" name="statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-m-segment-and-geographic-data-tables" name="statement-statement-note-m-segment-and-geographic-data-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-p-commitments-lease-expense-details" name="statement-statement-note-p-commitments-lease-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details" name="statement-statement-note-p-commitments-maturities-of-lease-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-p-commitments-tables" name="statement-statement-note-p-commitments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>mlss-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:28PM UTC 2023-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:href="mlss-20221231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ExpensesPaidStock" xlink:label="mlss_ExpensesPaidStock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:label="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SharebasedCompensationBonusPaidInStock" xlink:label="mlss_SharebasedCompensationBonusPaidInStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:label="us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mlss_ExpensesPaidStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mlss_SharebasedCompensationBonusPaidInStock" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="arc"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets" xlink:href="mlss-20221231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccruedExpensesRelatedParty" xlink:label="mlss_AccruedExpensesRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="mlss_AccruedExpensesRelatedParty" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations" xlink:href="mlss-20221231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InterestIncomeExpenseNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" xlink:href="mlss-20221231.xsd#statement-note-d-inventories-summary-of-inventories-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>mlss-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:28PM UTC 2023-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan" xlink:href="mlss-20221231.xsd#statement-note-q-benefit-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information" xlink:href="mlss-20221231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business" xlink:href="mlss-20221231.xsd#statement-note-a-organization-and-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties" xlink:href="mlss-20221231.xsd#statement-note-b-liquidity-and-uncertainties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies" xlink:href="mlss-20221231.xsd#statement-note-c-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PaycheckProtectionProgramCARESActMember" xlink:label="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories" xlink:href="mlss-20221231.xsd#statement-note-d-inventories" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingDentalFinishedGoodsMember" xlink:label="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingMedicalFinishedGoodsMember" xlink:label="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts" xlink:href="mlss-20221231.xsd#statement-note-e-advances-on-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AdvancesToContractManufacturerTextBlock" xlink:label="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees" xlink:href="mlss-20221231.xsd#statement-note-f-investment-in-and-transactions-with-equity-investees" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AnhuiMember" xlink:label="mlss_AnhuiMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneBeijingMember" xlink:label="mlss_MilestoneBeijingMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneBeijingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mlss_AnhuiMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents" xlink:href="mlss-20221231.xsd#statement-note-h-patents" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-h-patents" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NonemployeesMember" xlink:label="mlss_NonemployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_NonemployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_BoardOfDirectorsMember" xlink:label="mlss_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_TerritoryManagerMember" xlink:label="mlss_TerritoryManagerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_The2020EquityIncentivePlanMember" xlink:label="mlss_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:label="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mlss_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_TerritoryManagerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements" xlink:href="mlss-20221231.xsd#statement-note-k-employment-contract-and-consulting-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations" xlink:href="mlss-20221231.xsd#statement-note-n-concentrations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerThreeMember" xlink:label="mlss_CustomerThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorOneMember" xlink:label="mlss_VendorOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorTwoMember" xlink:label="mlss_VendorTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerThreeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="mlss_VendorOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="mlss_VendorTwoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions" xlink:href="mlss-20221231.xsd#statement-note-o-related-party-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:label="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorClinicalAffairMember" xlink:label="mlss_DirectorClinicalAffairMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManagingDirectorChinaOperationsMember" xlink:label="mlss_ManagingDirectorChinaOperationsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mlss_DirectorClinicalAffairMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ManagingDirectorChinaOperationsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments" xlink:href="mlss-20221231.xsd#statement-note-p-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:label="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:label="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesMember" xlink:label="mlss_PurchaseCommitmentForDevicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="mlss_PurchaseCommitmentForDevicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events" xlink:href="mlss-20221231.xsd#statement-note-r-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies" xlink:href="mlss-20221231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables" xlink:href="mlss-20221231.xsd#statement-note-d-inventories-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables" xlink:href="mlss-20221231.xsd#statement-note-h-patents-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:label="mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual" xlink:href="mlss-20221231.xsd#statement-note-a-organization-and-business-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual" xlink:href="mlss-20221231.xsd#statement-note-b-liquidity-and-uncertainties-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:href="mlss-20221231.xsd#statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AllowanceForSalesReturns" xlink:label="mlss_AllowanceForSalesReturns" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PaycheckProtectionProgramCARESActMember" xlink:label="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AllowanceForSalesReturns" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual" xlink:href="mlss-20221231.xsd#statement-note-d-inventories-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingDentalFinishedGoodsMember" xlink:label="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingMedicalFinishedGoodsMember" xlink:label="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual" xlink:href="mlss-20221231.xsd#statement-note-e-advances-on-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual" xlink:href="mlss-20221231.xsd#statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AnhuiMember" xlink:label="mlss_AnhuiMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneBeijingMember" xlink:label="mlss_MilestoneBeijingMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfFinanceReceivables" xlink:label="us-gaap_ProceedsFromCollectionOfFinanceReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneBeijingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="mlss_AnhuiMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromCollectionOfFinanceReceivables" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual" xlink:href="mlss-20221231.xsd#statement-note-h-patents-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NonemployeesMember" xlink:label="mlss_NonemployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_NonemployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_BoardOfDirectorsMember" xlink:label="mlss_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_TerritoryManagerMember" xlink:label="mlss_TerritoryManagerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_The2020EquityIncentivePlanMember" xlink:label="mlss_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:label="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mlss_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_TerritoryManagerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual" xlink:href="mlss-20221231.xsd#statement-note-k-employment-contract-and-consulting-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EmploymentAgreementBaseCompensation" xlink:label="mlss_EmploymentAgreementBaseCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_RoyaltyOnNetSalesPercentage" xlink:label="mlss_RoyaltyOnNetSalesPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_RoyaltyOnNetSalesPercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensation" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PercentageOfValuationAllowance" xlink:label="mlss_PercentageOfValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PercentageOfValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual" xlink:href="mlss-20221231.xsd#statement-note-n-concentrations-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerThreeMember" xlink:label="mlss_CustomerThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NumberOfMajorCustomers" xlink:label="mlss_NumberOfMajorCustomers" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NumberOfVendors" xlink:label="mlss_NumberOfVendors" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorOneMember" xlink:label="mlss_VendorOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorTwoMember" xlink:label="mlss_VendorTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerThreeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="mlss_VendorOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="mlss_VendorTwoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NumberOfMajorCustomers" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NumberOfVendors" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual" xlink:href="mlss-20221231.xsd#statement-note-o-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:label="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorClinicalAffairMember" xlink:label="mlss_DirectorClinicalAffairMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EmploymentAgreementBaseCompensation" xlink:label="mlss_EmploymentAgreementBaseCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManagingDirectorChinaOperationsMember" xlink:label="mlss_ManagingDirectorChinaOperationsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_RoyaltyOnNetSalesPercentage" xlink:label="mlss_RoyaltyOnNetSalesPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mlss_DirectorClinicalAffairMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ManagingDirectorChinaOperationsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_RoyaltyOnNetSalesPercentage" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensation" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LesseeOperatingLeaseElectricCharge" xlink:label="mlss_LesseeOperatingLeaseElectricCharge" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LesseeOperatingLeaseElectricPaymentsAnnually" xlink:label="mlss_LesseeOperatingLeaseElectricPaymentsAnnually" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:label="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OperatingLeasesMonthlyRentExpense" xlink:label="mlss_OperatingLeasesMonthlyRentExpense" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:label="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesMember" xlink:label="mlss_PurchaseCommitmentForDevicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentNumberOfUnits" xlink:label="mlss_PurchaseCommitmentNumberOfUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="mlss_PurchaseCommitmentForDevicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PurchaseCommitmentNumberOfUnits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OperatingLeasesMonthlyRentExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_LesseeOperatingLeaseElectricCharge" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_LesseeOperatingLeaseElectricPaymentsAnnually" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual" xlink:href="mlss-20221231.xsd#statement-note-r-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncentiveBonusPercentageOfAnnualCashCompensation" xlink:label="mlss_IncentiveBonusPercentageOfAnnualCashCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OfficersCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_IncentiveBonusPercentageOfAnnualCashCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="mlss-20221231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:href="mlss-20221231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ExpensesPaidStock" xlink:label="mlss_ExpensesPaidStock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:label="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SharebasedCompensationBonusPaidInStock" xlink:label="mlss_SharebasedCompensationBonusPaidInStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:label="us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mlss_SharebasedCompensationBonusPaidInStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mlss_ExpensesPaidStock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="mlss-20221231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="mlss-20221231.xsd#mlss_BoardOfDirectorsMember" xlink:label="mlss_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:label="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:label="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mlss_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-lease-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" xlink:label="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets" xlink:href="mlss-20221231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccruedExpensesRelatedParty" xlink:label="mlss_AccruedExpensesRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mlss_AccruedExpensesRelatedParty" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations" xlink:href="mlss-20221231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:label="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" xlink:href="mlss-20221231.xsd#statement-note-d-inventories-summary-of-inventories-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ComputerAndSoftwareMember" xlink:label="mlss_ComputerAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EPIAndIAInstrumentsMember" xlink:label="mlss_EPIAndIAInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OfficeFurnitureAndEquipmentMember" xlink:label="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_STATrialsInstrumentsMember" xlink:label="mlss_STATrialsInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ToolingEquipmentSTAAndWandMember" xlink:label="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ToolingSafetyWandMember" xlink:label="mlss_ToolingSafetyWandMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_TradeShowDisplaysMember" xlink:label="mlss_TradeShowDisplaysMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ToolsDiesAndMoldsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_TradeShowDisplaysMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_ComputerAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_ToolingSafetyWandMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_EPIAndIAInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_STATrialsInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details" xlink:href="mlss-20221231.xsd#statement-note-h-patents-summary-of-patents-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_FoundationIntellectualPropertyPatentsMember" xlink:label="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:label="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccessoriesMember" xlink:label="mlss_AccessoriesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DomesticMember" xlink:label="mlss_DomesticMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_HandpiecesMember" xlink:label="mlss_HandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_RestOfWorldMember" xlink:label="mlss_RestOfWorldMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="mlss_DomesticMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mlss_HandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mlss_AccessoriesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="mlss_RestOfWorldMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_CorporateNonSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>mlss-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:28PM UTC 2023-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DocumentAndEntityInformation" xlink:label="mlss_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="mlss_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DocumentAndEntityInformation" xlink:to="mlss_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="mlss_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="mlss_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-significant-accounting-policies-policies" xlink:label="mlss_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-significant-accounting-policies-policies" xlink:to="mlss_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:label="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ViceChairmanOfTheBoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vice Chairman of the Board of Directors [Member]</link:label>
    <link:label xlink:label="mlss_ViceChairmanOfTheBoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the vice chairman of the board of directors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:to="mlss_ViceChairmanOfTheBoardOfDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-d-inventories-tables" xlink:label="mlss_statement-statement-note-d-inventories-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-d-inventories-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note D - Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-d-inventories-tables" xlink:to="mlss_statement-statement-note-d-inventories-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables" xlink:label="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note G - Furniture, Fixtures and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables" xlink:to="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-h-patents-tables" xlink:label="mlss_statement-statement-note-h-patents-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-h-patents-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note H - Patents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-h-patents-tables" xlink:to="mlss_statement-statement-note-h-patents-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-i-stockholders-equity-tables" xlink:label="mlss_statement-statement-note-i-stockholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-i-stockholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note I - Stockholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-i-stockholders-equity-tables" xlink:to="mlss_statement-statement-note-i-stockholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-j-stock-option-plans-tables" xlink:label="mlss_statement-statement-note-j-stock-option-plans-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-j-stock-option-plans-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note J - Stock Option Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-j-stock-option-plans-tables" xlink:to="mlss_statement-statement-note-j-stock-option-plans-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-l-income-taxes-tables" xlink:label="mlss_statement-statement-note-l-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-l-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note L - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-l-income-taxes-tables" xlink:to="mlss_statement-statement-note-l-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-m-segment-and-geographic-data-tables" xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note M - Segment and Geographic Data</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-m-segment-and-geographic-data-tables" xlink:to="mlss_statement-statement-note-m-segment-and-geographic-data-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-p-commitments-tables" xlink:label="mlss_statement-statement-note-p-commitments-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-p-commitments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note P - Commitments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-p-commitments-tables" xlink:to="mlss_statement-statement-note-p-commitments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-d-inventories-summary-of-inventories-details" xlink:label="mlss_statement-statement-note-d-inventories-summary-of-inventories-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-d-inventories-summary-of-inventories-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note D - Inventories - Summary of Inventories (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-d-inventories-summary-of-inventories-details" xlink:to="mlss_statement-statement-note-d-inventories-summary-of-inventories-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:label="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note G - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:to="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-h-patents-summary-of-patents-details" xlink:label="mlss_statement-statement-note-h-patents-summary-of-patents-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-h-patents-summary-of-patents-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note H - Patents - Summary of Patents (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-h-patents-summary-of-patents-details" xlink:to="mlss_statement-statement-note-h-patents-summary-of-patents-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfFinanceReceivables" xlink:label="us-gaap_ProceedsFromCollectionOfFinanceReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromCollectionOfFinanceReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromCollectionOfFinanceReceivables</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromCollectionOfFinanceReceivables-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Collection of Finance Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfFinanceReceivables" xlink:to="us-gaap_ProceedsFromCollectionOfFinanceReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-i-stockholders-equity-warrants-details" xlink:label="mlss_statement-statement-note-i-stockholders-equity-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-i-stockholders-equity-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note I - Stockholders' Equity - Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-i-stockholders-equity-warrants-details" xlink:to="mlss_statement-statement-note-i-stockholders-equity-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:label="mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note I - Stockholders' Equity - Summary of Shares to be Issued (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:to="mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DueToRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DueToRelatedPartiesCurrent</link:label>
    <link:label xlink:label="us-gaap_DueToRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to Related Parties, Current, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:label="mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note J - Stock Option Plans - Summary of Option Activity for Employees (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:to="mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:label="mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note J - Stock Option Plans - Schedule of Restricted Stock (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:to="mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details" xlink:label="mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note L - Income Taxes - Deferred Tax Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details" xlink:to="mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:label="mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note L - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:to="mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note M - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:to="mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note M - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:to="mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</link:label>
    <link:label xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-p-commitments-lease-expense-details" xlink:label="mlss_statement-statement-note-p-commitments-lease-expense-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-p-commitments-lease-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note P - Commitments - Lease Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-p-commitments-lease-expense-details" xlink:to="mlss_statement-statement-note-p-commitments-lease-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:label="mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note P - Commitments - Maturities of Lease Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:to="mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatements" xlink:label="mlss_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="mlss_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NotesToFinancialStatements" xlink:to="mlss_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments</link:label>
    <link:label xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before equity investment</link:label>
    <link:label xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, before income or loss from equity method investments, extraordinary items, and noncontrolling interest, but after income taxes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="mlss_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="mlss_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:label="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:label xlink:label="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding and to be issued&#8212;</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:to="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_MilestoneChinaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone China [Member]</link:label>
    <link:label xlink:label="mlss_MilestoneChinaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Milestone China, an equity method investment of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_MilestoneChinaMember" xlink:to="mlss_MilestoneChinaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, Weighted Average Grant-Date Fair Value per Award (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued to employees for bonuses</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for bonus expensed in prior periods</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued for employee bonuses during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:to="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested as January 1, 2022 (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested as January 1, 2022 (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested, Shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, Shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested, Shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life, exercisable (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life, outstanding (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, outstanding (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, forfeited or expired (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="locator"/>
    <link:label xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_IncreaseDecreaseToAdvancesToContractManufacturer</link:label>
    <link:label xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Increase) in advances on contracts</link:label>
    <link:label xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease to advances to contract manufacturer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:to="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other payables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled, Shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of options forfeited and expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:label="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_AccountsPayableRelatedPartiesCurrentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Related Parties, Current [Member]</link:label>
    <link:label xlink:label="mlss_AccountsPayableRelatedPartiesCurrentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about accounts payable, related parties, current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:to="mlss_AccountsPayableRelatedPartiesCurrentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of furniture, fixtures, and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life, granted (Year)</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for option awards granted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, number of shares (in shares)</link:label>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="mlss_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued, number of shares (in shares)</link:label>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="mlss_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_DentalSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dental Segment [Member]</link:label>
    <link:label xlink:label="mlss_DentalSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the Dental segment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DentalSegmentMember" xlink:to="mlss_DentalSegmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_MedicalSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Segment [Member]</link:label>
    <link:label xlink:label="mlss_MedicalSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the medical segment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_MedicalSegmentMember" xlink:to="mlss_MedicalSegmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:to="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:to="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ComputerAndSoftwareMember" xlink:label="mlss_ComputerAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ComputerAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer and Software [Member]</link:label>
    <link:label xlink:label="mlss_ComputerAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to computer and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ComputerAndSoftwareMember" xlink:to="mlss_ComputerAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ToolingSafetyWandMember" xlink:label="mlss_ToolingSafetyWandMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ToolingSafetyWandMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tooling Safety Wand [Member]</link:label>
    <link:label xlink:label="mlss_ToolingSafetyWandMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to tooling safety wand.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ToolingSafetyWandMember" xlink:to="mlss_ToolingSafetyWandMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OfficeFurnitureAndEquipmentMember" xlink:label="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_OfficeFurnitureAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
    <link:label xlink:label="mlss_OfficeFurnitureAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to office furniture and equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OfficeFurnitureAndEquipmentMember" xlink:to="mlss_OfficeFurnitureAndEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_TradeShowDisplaysMember" xlink:label="mlss_TradeShowDisplaysMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_TradeShowDisplaysMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Show Displays [Member]</link:label>
    <link:label xlink:label="mlss_TradeShowDisplaysMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to trade show displays.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_TradeShowDisplaysMember" xlink:to="mlss_TradeShowDisplaysMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_STATrialsInstrumentsMember" xlink:label="mlss_STATrialsInstrumentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_STATrialsInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STA Trials Instruments [Member]</link:label>
    <link:label xlink:label="mlss_STATrialsInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to STA trials instruments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_STATrialsInstrumentsMember" xlink:to="mlss_STATrialsInstrumentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ToolingEquipmentSTAAndWandMember" xlink:label="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ToolingEquipmentSTAAndWandMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tooling Equipment - STA and Wand [Member]</link:label>
    <link:label xlink:label="mlss_ToolingEquipmentSTAAndWandMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to tooling equipments for STA and wand.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ToolingEquipmentSTAAndWandMember" xlink:to="mlss_ToolingEquipmentSTAAndWandMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EPIAndIAInstrumentsMember" xlink:label="mlss_EPIAndIAInstrumentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_EPIAndIAInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EPI and IA Instruments [Member]</link:label>
    <link:label xlink:label="mlss_EPIAndIAInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to EPI and IA instruments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EPIAndIAInstrumentsMember" xlink:to="mlss_EPIAndIAInstrumentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:label="mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_LeaseCostAndOtherInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost and Other Information [Table Text Block]</link:label>
    <link:label xlink:label="mlss_LeaseCostAndOtherInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of lessee's lease cost and other information.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:to="mlss_LeaseCostAndOtherInformationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Milestone Scientific Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Patents, accumulated amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents-foundation intellectual property</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patents, cost</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsGross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer, Chief Financial Officer and Employees [Member]</link:label>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Chief Executive Officer, Chief Financial Officer and employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PublicUtilitiesInventoryAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life, granted (Year)</link:label>
    <link:label xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based payment award options grants in period weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:label="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:type="locator"/>
    <link:label xlink:label="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining life (Year)</link:label>
    <link:label xlink:label="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the weighted average remaining term of warrants and rights outstanding,</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:to="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ExpensesPaidStock" xlink:label="mlss_ExpensesPaidStock" xlink:type="locator"/>
    <link:label xlink:label="mlss_ExpensesPaidStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense paid in stock</link:label>
    <link:label xlink:label="mlss_ExpensesPaidStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of expenses paid for with stock in lieu of cash during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ExpensesPaidStock" xlink:to="mlss_ExpensesPaidStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SharebasedCompensationBonusPaidInStock" xlink:label="mlss_SharebasedCompensationBonusPaidInStock" xlink:type="locator"/>
    <link:label xlink:label="mlss_SharebasedCompensationBonusPaidInStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees paid in stock</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationBonusPaidInStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of noncash share-based compensation bonuses paid in stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SharebasedCompensationBonusPaidInStock" xlink:to="mlss_SharebasedCompensationBonusPaidInStock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneBeijingMember" xlink:label="mlss_MilestoneBeijingMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_MilestoneBeijingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Beijing [Member]</link:label>
    <link:label xlink:label="mlss_MilestoneBeijingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Milestone Beijing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_MilestoneBeijingMember" xlink:to="mlss_MilestoneBeijingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentOwnershipPercentage</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProfitLoss</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AnhuiMember" xlink:label="mlss_AnhuiMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_AnhuiMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anhui [Member]</link:label>
    <link:label xlink:label="mlss_AnhuiMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Anhui Maishida Medical Technology, Co. Ltd. (Anhui).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AnhuiMember" xlink:to="mlss_AnhuiMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PercentageOfValuationAllowance" xlink:label="mlss_PercentageOfValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="mlss_PercentageOfValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_PercentageOfValuationAllowance</link:label>
    <link:label xlink:label="mlss_PercentageOfValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Valuation Allowance</link:label>
    <link:label xlink:label="mlss_PercentageOfValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of valuation allowance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PercentageOfValuationAllowance" xlink:to="mlss_PercentageOfValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent</link:label>
    <link:label xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:to="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueFromRelatedParties</link:label>
    <link:label xlink:label="us-gaap_RevenueFromRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredCompensation</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share applicable to common stockholders&#8212;</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred profit and divesture-equity investment (See Note F)</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred profit and divesture-equity investment (See Note F)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before taxes and equity in earnings of affiliates</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes and equity investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Decrease) increase in accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN" xlink:type="locator"/>
    <link:label xlink:label="country_CN-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in accounts payable, related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingDentalFinishedGoodsMember" xlink:label="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_SlowMovingDentalFinishedGoodsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Slow Moving Dental Finished Goods [Member]</link:label>
    <link:label xlink:label="mlss_SlowMovingDentalFinishedGoodsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the slow moving dental finished goods.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SlowMovingDentalFinishedGoodsMember" xlink:to="mlss_SlowMovingDentalFinishedGoodsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingMedicalFinishedGoodsMember" xlink:label="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_SlowMovingMedicalFinishedGoodsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Slow Moving Medical Finished Goods [Member]</link:label>
    <link:label xlink:label="mlss_SlowMovingMedicalFinishedGoodsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the slow moving medical finished goods.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:to="mlss_SlowMovingMedicalFinishedGoodsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RoyaltyExpense</link:label>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesReceivableNet</link:label>
    <link:label xlink:label="us-gaap_NotesReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate &#8211; operating leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation</link:label>
    <link:label xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation at federal statutory rate and state and local income tax rate and stock-based compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment obtained in exchange for new finance lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating leases (years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for warrants exercised (in shares)</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued for warrants exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="mlss_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment-PPP</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment-PPP</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for warrants exercised</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents value of stock issued during period for warrants exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="mlss_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfCountriesInWhichEntityOperates</link:label>
    <link:label xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="us-gaap_NumberOfCountriesInWhichEntityOperates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LesseeOperatingLeaseElectricCharge" xlink:label="mlss_LesseeOperatingLeaseElectricCharge" xlink:type="locator"/>
    <link:label xlink:label="mlss_LesseeOperatingLeaseElectricCharge-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_LesseeOperatingLeaseElectricCharge</link:label>
    <link:label xlink:label="mlss_LesseeOperatingLeaseElectricCharge-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Electric Charge Per Square Foot</link:label>
    <link:label xlink:label="mlss_LesseeOperatingLeaseElectricCharge-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents electric charge for operating lease per square foot.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_LesseeOperatingLeaseElectricCharge" xlink:to="mlss_LesseeOperatingLeaseElectricCharge-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AdvancesToContractManufacturerTextBlock" xlink:label="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_AdvancesToContractManufacturerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances to Contract Manufacturer [Text Block]</link:label>
    <link:label xlink:label="mlss_AdvancesToContractManufacturerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advances to contract manufacturer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AdvancesToContractManufacturerTextBlock" xlink:to="mlss_AdvancesToContractManufacturerTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_InstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Instruments [Member]</link:label>
    <link:label xlink:label="mlss_InstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A product of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_InstrumentsMember" xlink:to="mlss_InstrumentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Sales and Significant Customers and Vendors Disclosure [Text Block]</link:label>
    <link:label xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entire disclosure of product sales and significant customers and vendors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:to="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplierConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NumberOfMajorCustomers" xlink:label="mlss_NumberOfMajorCustomers" xlink:type="locator"/>
    <link:label xlink:label="mlss_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_NumberOfMajorCustomers</link:label>
    <link:label xlink:label="mlss_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Major Customers</link:label>
    <link:label xlink:label="mlss_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of major customers of the reporting entity during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NumberOfMajorCustomers" xlink:to="mlss_NumberOfMajorCustomers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_CustomerOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label xlink:label="mlss_CustomerOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unspecified major customer one.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_CustomerOneMember" xlink:to="mlss_CustomerOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_CustomerTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label xlink:label="mlss_CustomerTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unspecified major customer two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_CustomerTwoMember" xlink:to="mlss_CustomerTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllowanceForDoubtfulAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TreasuryStockValue</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 33,333 shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales by Product and by Geographical Region [Table Text Block]</link:label>
    <link:label xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entire disclosure of sales by product and by geographical region.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:to="mlss_SalesByProductAndByGeographicalRegionTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DomesticMember" xlink:label="mlss_DomesticMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_DomesticMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic [Member]</link:label>
    <link:label xlink:label="mlss_DomesticMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The domestic country of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DomesticMember" xlink:to="mlss_DomesticMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_HandpiecesMember" xlink:label="mlss_HandpiecesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_HandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Handpieces [Member]</link:label>
    <link:label xlink:label="mlss_HandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents handpieces.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_HandpiecesMember" xlink:to="mlss_HandpiecesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProfessionalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProfessionalFees</link:label>
    <link:label xlink:label="us-gaap_ProfessionalFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional Fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for stock options exercised (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of options exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ConsultingServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label xlink:label="mlss_ConsultingServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents consulting services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ConsultingServicesMember" xlink:to="mlss_ConsultingServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OperatingLeasesMonthlyRentExpense" xlink:label="mlss_OperatingLeasesMonthlyRentExpense" xlink:type="locator"/>
    <link:label xlink:label="mlss_OperatingLeasesMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_OperatingLeasesMonthlyRentExpense</link:label>
    <link:label xlink:label="mlss_OperatingLeasesMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Monthly Rent Expense</link:label>
    <link:label xlink:label="mlss_OperatingLeasesMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the monthly rent expense of operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OperatingLeasesMonthlyRentExpense" xlink:to="mlss_OperatingLeasesMonthlyRentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LesseeOperatingLeaseElectricPaymentsAnnually" xlink:label="mlss_LesseeOperatingLeaseElectricPaymentsAnnually" xlink:type="locator"/>
    <link:label xlink:label="mlss_LesseeOperatingLeaseElectricPaymentsAnnually-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_LesseeOperatingLeaseElectricPaymentsAnnually</link:label>
    <link:label xlink:label="mlss_LesseeOperatingLeaseElectricPaymentsAnnually-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Electric Payments, Annually</link:label>
    <link:label xlink:label="mlss_LesseeOperatingLeaseElectricPaymentsAnnually-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the annual electric payments for operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_LesseeOperatingLeaseElectricPaymentsAnnually" xlink:to="mlss_LesseeOperatingLeaseElectricPaymentsAnnually-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ManufacturingAgreementForHandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Agreement for Handpieces [Member]</link:label>
    <link:label xlink:label="mlss_ManufacturingAgreementForHandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the manufacturing agreement for handpieces.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ManufacturingAgreementForHandpiecesMember" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for stock options exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentNumberOfUnits" xlink:label="mlss_PurchaseCommitmentNumberOfUnits" xlink:type="locator"/>
    <link:label xlink:label="mlss_PurchaseCommitmentNumberOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_PurchaseCommitmentNumberOfUnits</link:label>
    <link:label xlink:label="mlss_PurchaseCommitmentNumberOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment Number Of Units</link:label>
    <link:label xlink:label="mlss_PurchaseCommitmentNumberOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of units commitment to purchase.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PurchaseCommitmentNumberOfUnits" xlink:to="mlss_PurchaseCommitmentNumberOfUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for compensation (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for compensation (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for services (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashUninsuredAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashUninsuredAmount</link:label>
    <link:label xlink:label="us-gaap_CashUninsuredAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished goods, net</link:label>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Finished goods, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Component parts and other materials</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorOneMember" xlink:label="mlss_VendorOneMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_VendorOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor One [Member]</link:label>
    <link:label xlink:label="mlss_VendorOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to one vendor.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_VendorOneMember" xlink:to="mlss_VendorOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NumberOfVendors" xlink:label="mlss_NumberOfVendors" xlink:type="locator"/>
    <link:label xlink:label="mlss_NumberOfVendors-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_NumberOfVendors</link:label>
    <link:label xlink:label="mlss_NumberOfVendors-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Vendors</link:label>
    <link:label xlink:label="mlss_NumberOfVendors-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of vendors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NumberOfVendors" xlink:to="mlss_NumberOfVendors-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorTwoMember" xlink:label="mlss_VendorTwoMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_VendorTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor Two [Member]</link:label>
    <link:label xlink:label="mlss_VendorTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to vendor two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_VendorTwoMember" xlink:to="mlss_VendorTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of operating lease liabilities</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of finance lease liabilities</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets operating lease</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities, Finance Leases</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeasePrincipalPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeasePrincipalPayments</link:label>
    <link:label xlink:label="us-gaap_FinanceLeasePrincipalPayments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments finance lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025, Operating Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026, Operating Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets finance lease</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2027, Operating Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023, Operating Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OfficersCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OfficersCompensation</link:label>
    <link:label xlink:label="us-gaap_OfficersCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024, Operating Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorClinicalAffairMember" xlink:label="mlss_DirectorClinicalAffairMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_DirectorClinicalAffairMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director Clinical Affair [Member]</link:label>
    <link:label xlink:label="mlss_DirectorClinicalAffairMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Director Clinical Affair.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DirectorClinicalAffairMember" xlink:to="mlss_DirectorClinicalAffairMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares-to-be-issued, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares-to be issued outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issued in current period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_DirectorOfClinicalAffairsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director of Clinical Affairs [Member]</link:label>
    <link:label xlink:label="mlss_DirectorOfClinicalAffairsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A personnel of the company with the title "Director of Clinical Affairs."</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DirectorOfClinicalAffairsMember" xlink:to="mlss_DirectorOfClinicalAffairsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccessoriesMember" xlink:label="mlss_AccessoriesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_AccessoriesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accessories [Member]</link:label>
    <link:label xlink:label="mlss_AccessoriesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to accessories.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AccessoriesMember" xlink:to="mlss_AccessoriesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetUsefulLife</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:label="us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryLIFOReserveEffectOnIncomeNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Reserve</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:to="us-gaap_InventoryLIFOReserveEffectOnIncomeNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationDepletionAndAmortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssued</link:label>
    <link:label xlink:label="us-gaap_SharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvancesOnInventoryPurchases-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances on contracts</link:label>
    <link:label xlink:label="us-gaap_AdvancesOnInventoryPurchases-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances on Inventory Purchases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value $.001;authorized 100,000,000 shares; 69,306,497 shares issued and 69,273,164 shares outstanding as of December 31, 2022; 68,153,336 shares issued and 68,120,003 shares outstanding as of December 31, 2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_EquityMethodInvesteeNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" xlink:label="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" xlink:type="locator"/>
    <link:label xlink:label="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses</link:label>
    <link:label xlink:label="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label xlink:label="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash paid for finance lease liabilities including accrues expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" xlink:to="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOther</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryNet</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryValuationReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryValuationReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryValuationReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_MajorCustomersAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsInventory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsInventory</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsInventory-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Reserve</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_NameOfMajorCustomerDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_BoardOfDirectorsMember" xlink:label="mlss_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_BoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors [Member]</link:label>
    <link:label xlink:label="mlss_BoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the board of directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_BoardOfDirectorsMember" xlink:to="mlss_BoardOfDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinorityInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warranty Reserve</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportableSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Officer's Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefFinancialOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NonemployeesMember" xlink:label="mlss_NonemployeesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_NonemployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Employees [Member]</link:label>
    <link:label xlink:label="mlss_NonemployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to non-employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NonemployeesMember" xlink:to="mlss_NonemployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_TerritoryManagerMember" xlink:label="mlss_TerritoryManagerMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_TerritoryManagerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Territory Manager [Member]</link:label>
    <link:label xlink:label="mlss_TerritoryManagerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents territory manager.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_TerritoryManagerMember" xlink:to="mlss_TerritoryManagerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in (provided by) financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Income (Loss), Total</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GrossProfit</link:label>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidationItemsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidationItemsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable from Related Parties [Member]</link:label>
    <link:label xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Primary financial statement caption encompassing accounts receivable from related parties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:type="locator"/>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss</link:label>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Deferred Intercompany Profit (Loss)</link:label>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate amount of deferred intercompany profits and losses on transactions between the Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting,as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:label="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="locator"/>
    <link:label xlink:label="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment For Devices Beginning In 2021 [Member]</link:label>
    <link:label xlink:label="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the purchase commitment beginning in 2021.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:to="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:type="locator"/>
    <link:label xlink:label="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NOL Expiration</link:label>
    <link:label xlink:label="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from net operating loss adjustments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued to employees for bonuses</link:label>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock to be issued for employee bonuses during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:to="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:label="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued for payment of services expensed in prior periods</link:label>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock to be issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:to="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued for payment of services expensed in prior periods (in shares)</link:label>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares to be issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for bonus expensed in prior periods (in shares)</link:label>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employees for bonuses (in shares)</link:label>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock to be issued for employee bonuses during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncontrollingInterestMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for compensation expensed in prior periods (in shares)</link:label>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares (or other type of equity) to be issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:label="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for compensation expensed in prior periods</link:label>
    <link:label xlink:label="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock (or other type of equity) to be issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:to="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesMember" xlink:label="mlss_PurchaseCommitmentForDevicesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_PurchaseCommitmentForDevicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment for Devices [Member]</link:label>
    <link:label xlink:label="mlss_PurchaseCommitmentForDevicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the purchase commitment for devices.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PurchaseCommitmentForDevicesMember" xlink:to="mlss_PurchaseCommitmentForDevicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for option exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding , weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding , weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number of shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding , number of shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]</link:label>
    <link:label xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:to="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_FoundationIntellectualPropertyPatentsMember" xlink:label="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_FoundationIntellectualPropertyPatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foundation Intellectual Property Patents [Member]</link:label>
    <link:label xlink:label="mlss_FoundationIntellectualPropertyPatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to foundation intellectual property patents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_FoundationIntellectualPropertyPatentsMember" xlink:to="mlss_FoundationIntellectualPropertyPatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AllowanceForSalesReturns" xlink:label="mlss_AllowanceForSalesReturns" xlink:type="locator"/>
    <link:label xlink:label="mlss_AllowanceForSalesReturns-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_AllowanceForSalesReturns</link:label>
    <link:label xlink:label="mlss_AllowanceForSalesReturns-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Sales Returns</link:label>
    <link:label xlink:label="mlss_AllowanceForSalesReturns-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of allowance for sales returns.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AllowanceForSalesReturns" xlink:to="mlss_AllowanceForSalesReturns-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ToolsDiesAndMoldsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tools, Dies and Molds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ToolsDiesAndMoldsMember" xlink:to="us-gaap_ToolsDiesAndMoldsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharesGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted in current period (in shares)</link:label>
    <link:label xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharesGranted-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares granted pursuant to the terms of a deferred compensation arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:to="mlss_DeferredCompensationArrangementWithIndividualSharesGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManagingDirectorChinaOperationsMember" xlink:label="mlss_ManagingDirectorChinaOperationsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ManagingDirectorChinaOperationsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Managing Director, China Operations [Member]</link:label>
    <link:label xlink:label="mlss_ManagingDirectorChinaOperationsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents managing director for China Operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ManagingDirectorChinaOperationsMember" xlink:to="mlss_ManagingDirectorChinaOperationsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_RestOfWorldMember" xlink:label="mlss_RestOfWorldMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_RestOfWorldMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of World [Member]</link:label>
    <link:label xlink:label="mlss_RestOfWorldMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the rest of the world, excluding domestic sales and sales to China.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_RestOfWorldMember" xlink:to="mlss_RestOfWorldMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_InterimChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Chief Executive Officer [Member]</link:label>
    <link:label xlink:label="mlss_InterimChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Interim Chief Executive Officer of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_InterimChiefExecutiveOfficerMember" xlink:to="mlss_InterimChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Sec. 174 R&amp;D</link:label>
    <link:label xlink:label="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment and Consulting Agreements [Text Block]</link:label>
    <link:label xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for employment and consulting agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:to="mlss_EmploymentAndConsultingAgreementsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccruedExpensesRelatedParty" xlink:label="mlss_AccruedExpensesRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="mlss_AccruedExpensesRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses, related party</link:label>
    <link:label xlink:label="mlss_AccruedExpensesRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount for accrued expenses to related parties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AccruedExpensesRelatedParty" xlink:to="mlss_AccruedExpensesRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:label="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:type="locator"/>
    <link:label xlink:label="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Decrease) in accrued expenses, related party</link:label>
    <link:label xlink:label="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period of accrued liabilities to related parties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:to="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementBusinessSegmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromNotesPayable</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable, Related Parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncentiveBonusPercentageOfAnnualCashCompensation" xlink:label="mlss_IncentiveBonusPercentageOfAnnualCashCompensation" xlink:type="locator"/>
    <link:label xlink:label="mlss_IncentiveBonusPercentageOfAnnualCashCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_IncentiveBonusPercentageOfAnnualCashCompensation</link:label>
    <link:label xlink:label="mlss_IncentiveBonusPercentageOfAnnualCashCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Bonus, Percentage of Annual Cash Compensation</link:label>
    <link:label xlink:label="mlss_IncentiveBonusPercentageOfAnnualCashCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the incentive bonus as a percentage of annual cash compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_IncentiveBonusPercentageOfAnnualCashCompensation" xlink:to="mlss_IncentiveBonusPercentageOfAnnualCashCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Plan [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwardsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable, related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and Diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic, Total (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareBasic</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments, Finance Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2027, Finance Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: interest, Finance Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023, Finance Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024, Finance Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025, Finance Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026, Finance Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerThreeMember" xlink:label="mlss_CustomerThreeMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_CustomerThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label xlink:label="mlss_CustomerThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to a third customer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_CustomerThreeMember" xlink:to="mlss_CustomerThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EmploymentAgreementBaseCompensation" xlink:label="mlss_EmploymentAgreementBaseCompensation" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmploymentAgreementBaseCompensation</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement, Base Compensation</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of annual base compensation pursuant to the employment agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAgreementBaseCompensation" xlink:to="mlss_EmploymentAgreementBaseCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate &#8211; finance leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State income tax - all states</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance leases (years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:label="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Lease for Headquarter in Roseland, New Jersey [Member]</link:label>
    <link:label xlink:label="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to office lease for headquarter in Roseland, New Jersey.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:to="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statutory Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PaycheckProtectionProgramCARESActMember" xlink:label="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_PaycheckProtectionProgramCARESActMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paycheck Protection Program CARES Act [Member]</link:label>
    <link:label xlink:label="mlss_PaycheckProtectionProgramCARESActMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding the Paycheck Protection Program under the CARES Act.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PaycheckProtectionProgramCARESActMember" xlink:to="mlss_PaycheckProtectionProgramCARESActMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previous President and Chief Executive Officer [Member]</link:label>
    <link:label xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the previous president and chief executive officer of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant [Member]</link:label>
    <link:label xlink:label="mlss_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to consultant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ConsultantMember" xlink:to="mlss_ConsultantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateNonSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNonSegmentMember" xlink:to="us-gaap_CorporateNonSegmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Milestone Scientific, Inc. stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_The2020EquityIncentivePlanMember" xlink:label="mlss_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_The2020EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2020 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="mlss_The2020EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2020 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_The2020EquityIncentivePlanMember" xlink:to="mlss_The2020EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingSegmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_RoyaltyOnNetSalesPercentage" xlink:label="mlss_RoyaltyOnNetSalesPercentage" xlink:type="locator"/>
    <link:label xlink:label="mlss_RoyaltyOnNetSalesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_RoyaltyOnNetSalesPercentage</link:label>
    <link:label xlink:label="mlss_RoyaltyOnNetSalesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty on Net Sales, Percentage</link:label>
    <link:label xlink:label="mlss_RoyaltyOnNetSalesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty percentage on net sales.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_RoyaltyOnNetSalesPercentage" xlink:to="mlss_RoyaltyOnNetSalesPercentage-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>mlss-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:28PM UTC 2023-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan" xlink:href="mlss-20221231.xsd#statement-note-q-benefit-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information" xlink:href="mlss-20221231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business" xlink:href="mlss-20221231.xsd#statement-note-a-organization-and-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties" xlink:href="mlss-20221231.xsd#statement-note-b-liquidity-and-uncertainties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies" xlink:href="mlss-20221231.xsd#statement-note-c-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PaycheckProtectionProgramCARESActMember" xlink:label="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories" xlink:href="mlss-20221231.xsd#statement-note-d-inventories" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingDentalFinishedGoodsMember" xlink:label="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingMedicalFinishedGoodsMember" xlink:label="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts" xlink:href="mlss-20221231.xsd#statement-note-e-advances-on-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AdvancesToContractManufacturerTextBlock" xlink:label="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees" xlink:href="mlss-20221231.xsd#statement-note-f-investment-in-and-transactions-with-equity-investees" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AnhuiMember" xlink:label="mlss_AnhuiMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneBeijingMember" xlink:label="mlss_MilestoneBeijingMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneBeijingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_AnhuiMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents" xlink:href="mlss-20221231.xsd#statement-note-h-patents" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-h-patents" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NonemployeesMember" xlink:label="mlss_NonemployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_NonemployeesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_BoardOfDirectorsMember" xlink:label="mlss_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_TerritoryManagerMember" xlink:label="mlss_TerritoryManagerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_The2020EquityIncentivePlanMember" xlink:label="mlss_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:label="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="mlss_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_TerritoryManagerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements" xlink:href="mlss-20221231.xsd#statement-note-k-employment-contract-and-consulting-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations" xlink:href="mlss-20221231.xsd#statement-note-n-concentrations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerThreeMember" xlink:label="mlss_CustomerThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorOneMember" xlink:label="mlss_VendorOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorTwoMember" xlink:label="mlss_VendorTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="mlss_CustomerOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="mlss_CustomerTwoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="mlss_CustomerThreeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="mlss_VendorOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="mlss_VendorTwoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions" xlink:href="mlss-20221231.xsd#statement-note-o-related-party-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:label="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorClinicalAffairMember" xlink:label="mlss_DirectorClinicalAffairMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManagingDirectorChinaOperationsMember" xlink:label="mlss_ManagingDirectorChinaOperationsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="mlss_DirectorClinicalAffairMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ManagingDirectorChinaOperationsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments" xlink:href="mlss-20221231.xsd#statement-note-p-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:label="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:label="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesMember" xlink:label="mlss_PurchaseCommitmentForDevicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="mlss_PurchaseCommitmentForDevicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events" xlink:href="mlss-20221231.xsd#statement-note-r-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="us-gaap_ScenarioPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies" xlink:href="mlss-20221231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-significant-accounting-policies-policies" xlink:label="mlss_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables" xlink:href="mlss-20221231.xsd#statement-note-d-inventories-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-d-inventories-tables" xlink:label="mlss_statement-statement-note-d-inventories-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-d-inventories-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables" xlink:label="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables" xlink:href="mlss-20221231.xsd#statement-note-h-patents-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-h-patents-tables" xlink:label="mlss_statement-statement-note-h-patents-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-h-patents-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-i-stockholders-equity-tables" xlink:label="mlss_statement-statement-note-i-stockholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-i-stockholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-j-stock-option-plans-tables" xlink:label="mlss_statement-statement-note-j-stock-option-plans-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-j-stock-option-plans-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-l-income-taxes-tables" xlink:label="mlss_statement-statement-note-l-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-l-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-m-segment-and-geographic-data-tables" xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-m-segment-and-geographic-data-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:label="mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-p-commitments-tables" xlink:label="mlss_statement-statement-note-p-commitments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-p-commitments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="mlss_LeaseCostAndOtherInformationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual" xlink:href="mlss-20221231.xsd#statement-note-a-organization-and-business-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfCountriesInWhichEntityOperates-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual" xlink:href="mlss-20221231.xsd#statement-note-b-liquidity-and-uncertainties-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:href="mlss-20221231.xsd#statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AllowanceForSalesReturns" xlink:label="mlss_AllowanceForSalesReturns-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PaycheckProtectionProgramCARESActMember" xlink:label="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="mlss_PaycheckProtectionProgramCARESActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AllowanceForSalesReturns-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual" xlink:href="mlss-20221231.xsd#statement-note-d-inventories-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingDentalFinishedGoodsMember" xlink:label="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SlowMovingMedicalFinishedGoodsMember" xlink:label="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="mlss_SlowMovingMedicalFinishedGoodsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="mlss_SlowMovingDentalFinishedGoodsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual" xlink:href="mlss-20221231.xsd#statement-note-e-advances-on-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual" xlink:href="mlss-20221231.xsd#statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AnhuiMember" xlink:label="mlss_AnhuiMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneBeijingMember" xlink:label="mlss_MilestoneBeijingMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfFinanceReceivables" xlink:label="us-gaap_ProceedsFromCollectionOfFinanceReceivables-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneBeijingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_AnhuiMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesReceivableNet-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromCollectionOfFinanceReceivables-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromRelatedParties-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual" xlink:href="mlss-20221231.xsd#statement-note-h-patents-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NonemployeesMember" xlink:label="mlss_NonemployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_NonemployeesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_BoardOfDirectorsMember" xlink:label="mlss_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_TerritoryManagerMember" xlink:label="mlss_TerritoryManagerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_The2020EquityIncentivePlanMember" xlink:label="mlss_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:label="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="mlss_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ViceChairmanOfTheBoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_TerritoryManagerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual" xlink:href="mlss-20221231.xsd#statement-note-k-employment-contract-and-consulting-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EmploymentAgreementBaseCompensation" xlink:label="mlss_EmploymentAgreementBaseCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_RoyaltyOnNetSalesPercentage" xlink:label="mlss_RoyaltyOnNetSalesPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_RoyaltyOnNetSalesPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation-n2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PercentageOfValuationAllowance" xlink:label="mlss_PercentageOfValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PercentageOfValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual" xlink:href="mlss-20221231.xsd#statement-note-n-concentrations-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerThreeMember" xlink:label="mlss_CustomerThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NumberOfMajorCustomers" xlink:label="mlss_NumberOfMajorCustomers-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NumberOfVendors" xlink:label="mlss_NumberOfVendors-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorOneMember" xlink:label="mlss_VendorOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_VendorTwoMember" xlink:label="mlss_VendorTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="mlss_CustomerOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="mlss_CustomerTwoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="mlss_CustomerThreeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="mlss_VendorOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="mlss_VendorTwoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NumberOfMajorCustomers-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NumberOfVendors-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual" xlink:href="mlss-20221231.xsd#statement-note-o-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:label="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorClinicalAffairMember" xlink:label="mlss_DirectorClinicalAffairMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EmploymentAgreementBaseCompensation" xlink:label="mlss_EmploymentAgreementBaseCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManagingDirectorChinaOperationsMember" xlink:label="mlss_ManagingDirectorChinaOperationsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_RoyaltyOnNetSalesPercentage" xlink:label="mlss_RoyaltyOnNetSalesPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="mlss_AccountsPayableRelatedPartiesCurrentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="mlss_DirectorClinicalAffairMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="mlss_ManagingDirectorChinaOperationsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_RoyaltyOnNetSalesPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation-n2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LesseeOperatingLeaseElectricCharge" xlink:label="mlss_LesseeOperatingLeaseElectricCharge-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_LesseeOperatingLeaseElectricPaymentsAnnually" xlink:label="mlss_LesseeOperatingLeaseElectricPaymentsAnnually-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:label="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OperatingLeasesMonthlyRentExpense" xlink:label="mlss_OperatingLeasesMonthlyRentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:label="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentForDevicesMember" xlink:label="mlss_PurchaseCommitmentForDevicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_PurchaseCommitmentNumberOfUnits" xlink:label="mlss_PurchaseCommitmentNumberOfUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="mlss_PurchaseCommitmentForDevicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="mlss_PurchaseCommitmentForDevicesBeginningIn2021Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PurchaseCommitmentNumberOfUnits-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OperatingLeasesMonthlyRentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_LesseeOperatingLeaseElectricCharge-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_LesseeOperatingLeaseElectricPaymentsAnnually-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual" xlink:href="mlss-20221231.xsd#statement-note-r-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncentiveBonusPercentageOfAnnualCashCompensation" xlink:label="mlss_IncentiveBonusPercentageOfAnnualCashCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="us-gaap_ScenarioPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OfficersCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_IncentiveBonusPercentageOfAnnualCashCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="mlss-20221231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:href="mlss-20221231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ExpensesPaidStock" xlink:label="mlss_ExpensesPaidStock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:label="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-n8" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SharebasedCompensationBonusPaidInStock" xlink:label="mlss_SharebasedCompensationBonusPaidInStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:label="us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mlss_SharebasedCompensationBonusPaidInStock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mlss_ExpensesPaidStock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReserveEffectOnIncomeNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-n9" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="mlss-20221231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="mlss-20221231.xsd#mlss_BoardOfDirectorsMember" xlink:label="mlss_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ConsultantMember" xlink:label="mlss_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-1" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses-1" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:label="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:label="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:label="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="mlss_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="mlss_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses-1" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss-1" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-1" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued-5" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:label="mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:href="mlss-20221231.xsd#statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:label="mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details" xlink:label="mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInventory-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther-1" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:href="mlss-20221231.xsd#statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-3" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:label="mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-lease-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses" xlink:label="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-p-commitments-lease-expense-details" xlink:label="mlss_statement-statement-note-p-commitments-lease-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-p-commitments-lease-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:href="mlss-20221231.xsd#statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:label="mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n9" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount-n9" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets" xlink:href="mlss-20221231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccruedExpensesRelatedParty" xlink:label="mlss_AccruedExpensesRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mlss_AccruedExpensesRelatedParty" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations" xlink:href="mlss-20221231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:label="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNet" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss-3" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-n8" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" xlink:href="mlss-20221231.xsd#statement-note-d-inventories-summary-of-inventories-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-d-inventories-summary-of-inventories-details" xlink:label="mlss_statement-statement-note-d-inventories-summary-of-inventories-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-d-inventories-summary-of-inventories-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:href="mlss-20221231.xsd#statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ComputerAndSoftwareMember" xlink:label="mlss_ComputerAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_EPIAndIAInstrumentsMember" xlink:label="mlss_EPIAndIAInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_OfficeFurnitureAndEquipmentMember" xlink:label="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_STATrialsInstrumentsMember" xlink:label="mlss_STATrialsInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ToolingEquipmentSTAAndWandMember" xlink:label="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ToolingSafetyWandMember" xlink:label="mlss_ToolingSafetyWandMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_TradeShowDisplaysMember" xlink:label="mlss_TradeShowDisplaysMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:label="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ToolsDiesAndMoldsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_TradeShowDisplaysMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_ComputerAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_ToolingSafetyWandMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_EPIAndIAInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_STATrialsInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details" xlink:href="mlss-20221231.xsd#statement-note-h-patents-summary-of-patents-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_FoundationIntellectualPropertyPatentsMember" xlink:label="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-h-patents-summary-of-patents-details" xlink:label="mlss_statement-statement-note-h-patents-summary-of-patents-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-h-patents-summary-of-patents-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:label="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-i-stockholders-equity-warrants-details" xlink:label="mlss_statement-statement-note-i-stockholders-equity-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-i-stockholders-equity-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightExercisedDuringPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:href="mlss-20221231.xsd#statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:label="mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:label="mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredCompensationArrangementWithIndividualSharesGranted" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_AccessoriesMember" xlink:label="mlss_AccessoriesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DomesticMember" xlink:label="mlss_DomesticMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_HandpiecesMember" xlink:label="mlss_HandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_RestOfWorldMember" xlink:label="mlss_RestOfWorldMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="mlss_DomesticMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="mlss_HandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="mlss_AccessoriesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="mlss_RestOfWorldMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:href="mlss-20221231.xsd#statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20221231.xsd#mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:label="mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_CorporateNonSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets-1" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712109387600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000855683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MILESTONE SCIENTIFIC INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3545623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">425 Eagle Rock Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Roseland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-2717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MLSS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,102,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,998,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">Friedman LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East Hanover, New Jersey<span></span>
</td>
<td class="text">East Hanover, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712107314208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,715,279<span></span>
</td>
<td class="nump">$ 14,764,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">693,717<span></span>
</td>
<td class="nump">943,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">443,872<span></span>
</td>
<td class="nump">375,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,792,335<span></span>
</td>
<td class="nump">1,541,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on contracts</a></td>
<td class="nump">1,325,301<span></span>
</td>
<td class="nump">1,309,260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">12,970,504<span></span>
</td>
<td class="nump">18,933,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture, fixtures and equipment, net</a></td>
<td class="nump">18,146<span></span>
</td>
<td class="nump">23,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">227,956<span></span>
</td>
<td class="nump">277,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right of use assets finance lease</a></td>
<td class="nump">17,645<span></span>
</td>
<td class="nump">26,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets operating lease</a></td>
<td class="nump">443,685<span></span>
</td>
<td class="nump">524,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">24,150<span></span>
</td>
<td class="nump">24,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,702,086<span></span>
</td>
<td class="nump">19,809,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,102,729<span></span>
</td>
<td class="nump">780,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related party</a></td>
<td class="nump">803,492<span></span>
</td>
<td class="nump">395,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other payables</a></td>
<td class="nump">1,124,839<span></span>
</td>
<td class="nump">1,417,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_AccruedExpensesRelatedParty', window );">Accrued expenses, related party</a></td>
<td class="nump">167,549<span></span>
</td>
<td class="nump">414,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">9,365<span></span>
</td>
<td class="nump">8,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">91,701<span></span>
</td>
<td class="nump">81,001<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,299,675<span></span>
</td>
<td class="nump">3,097,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current portion of finance lease liabilities</a></td>
<td class="nump">10,698<span></span>
</td>
<td class="nump">20,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">385,279<span></span>
</td>
<td class="nump">476,980<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,695,652<span></span>
</td>
<td class="nump">3,594,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $.001;authorized 100,000,000 shares; 69,306,497 shares issued and 69,273,164 shares outstanding as of December 31, 2022; 68,153,336 shares issued and 68,120,003 shares outstanding as of December 31, 2021</a></td>
<td class="nump">69,306<span></span>
</td>
<td class="nump">68,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">127,478,325<span></span>
</td>
<td class="nump">124,915,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(116,410,405)<span></span>
</td>
<td class="num">(107,704,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 33,333 shares</a></td>
<td class="num">(911,516)<span></span>
</td>
<td class="num">(911,516)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Milestone Scientific, Inc. stockholders' equity</a></td>
<td class="nump">10,225,710<span></span>
</td>
<td class="nump">16,367,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(219,276)<span></span>
</td>
<td class="num">(152,541)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">10,006,434<span></span>
</td>
<td class="nump">16,215,382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 13,702,086<span></span>
</td>
<td class="nump">$ 19,809,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AccruedExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accrued expenses to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AccruedExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712112068816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">69,306,497<span></span>
</td>
<td class="nump">68,153,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">69,273,164<span></span>
</td>
<td class="nump">68,120,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost, shares (in shares)</a></td>
<td class="nump">33,333<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104985424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">$ 8,805,906<span></span>
</td>
<td class="nump">$ 10,304,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">3,905,092<span></span>
</td>
<td class="nump">3,992,811<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,900,814<span></span>
</td>
<td class="nump">6,311,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">12,514,323<span></span>
</td>
<td class="nump">12,738,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,150,209<span></span>
</td>
<td class="nump">878,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">63,755<span></span>
</td>
<td class="nump">73,836<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,728,287<span></span>
</td>
<td class="nump">13,690,408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,827,473)<span></span>
</td>
<td class="num">(7,378,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense)</a></td>
<td class="nump">54,607<span></span>
</td>
<td class="num">(16,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment-PPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">276,180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes and equity investments</a></td>
<td class="num">(8,772,866)<span></span>
</td>
<td class="num">(7,118,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before equity investment</a></td>
<td class="num">(8,772,866)<span></span>
</td>
<td class="num">(7,119,021)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Deferred profit and divesture-equity investment (See Note F)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">242,589<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(8,772,866)<span></span>
</td>
<td class="num">(6,876,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="nump">66,735<span></span>
</td>
<td class="nump">58,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Milestone Scientific Inc.</a></td>
<td class="num">$ (8,706,131)<span></span>
</td>
<td class="num">$ (6,818,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share applicable to common stockholders&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and Diluted (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract', window );"><strong>Weighted average shares outstanding and to be issued&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and Diluted (in shares)</a></td>
<td class="nump">70,607,338<span></span>
</td>
<td class="nump">68,829,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, before income or loss from equity method investments, extraordinary items, and noncontrolling interest, but after income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712103732144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Consultant [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Consultant [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Consultant [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Consultant [Member] </div>
<div>Noncontrolling Interest [Member]</div>
</th>
<th class="th">
<div>Consultant [Member] </div>
<div>Treasury Stock [Member]</div>
</th>
<th class="th"><div>Consultant [Member]</div></th>
<th class="th">
<div>Board of Directors [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Board of Directors [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Board of Directors [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Board of Directors [Member] </div>
<div>Noncontrolling Interest [Member]</div>
</th>
<th class="th">
<div>Board of Directors [Member] </div>
<div>Treasury Stock [Member]</div>
</th>
<th class="th"><div>Board of Directors [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,171,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,171<span></span>
</td>
<td class="nump">$ 117,934,696<span></span>
</td>
<td class="num">$ (100,885,957)<span></span>
</td>
<td class="num">$ (94,426)<span></span>
</td>
<td class="num">$ (911,516)<span></span>
</td>
<td class="nump">$ 16,106,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">790,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation', window );">Common stock issued to employee for compensation expensed in prior periods (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation', window );">Common stock issued to employee for compensation expensed in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices', window );">Common stock to be issued for payment of services expensed in prior periods (in shares)</a></td>
<td class="nump">40,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodValueIssuedForServices', window );">Common stock to be issued for payment of services expensed in prior periods</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses', window );">Common stock to be issued to employees for bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued to employee for stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued to employee for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">1,381,060<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,381,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued to employee for compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">107,482<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in shares)</a></td>
<td class="nump">289,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">770,044<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,334<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">617,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses', window );">Common stock issued to employee for bonus expensed in prior periods (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueEmployeeBonuses', window );">Common stock issued to employee for bonus expensed in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="num">(402)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued for warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,101,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueWarrantsExercised', window );">Common stock issued for warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,102<span></span>
</td>
<td class="nump">3,213,942<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,216,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,818,317)<span></span>
</td>
<td class="num">(58,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,876,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued to employee for compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses', window );">Common stock issued to employees for bonuses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueEmployeeBonuses', window );">Common stock issued to employees for bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="num">(402)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,153,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,153<span></span>
</td>
<td class="nump">124,915,560<span></span>
</td>
<td class="num">(107,704,274)<span></span>
</td>
<td class="num">(152,541)<span></span>
</td>
<td class="num">(911,516)<span></span>
</td>
<td class="nump">16,215,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses', window );">Common stock to be issued to employees for bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">264,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued to employee for compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">39,973<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in shares)</a></td>
<td class="nump">577,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="nump">$ 577<span></span>
</td>
<td class="nump">$ 746,774<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 747,351<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 12,478<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses', window );">Common stock issued to employee for bonus expensed in prior periods (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueEmployeeBonuses', window );">Common stock issued to employee for bonus expensed in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,706,131)<span></span>
</td>
<td class="num">(66,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,772,866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued to employee for compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses', window );">Common stock issued to employees for bonuses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueEmployeeBonuses', window );">Common stock issued to employees for bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,306,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,306<span></span>
</td>
<td class="nump">$ 127,478,325<span></span>
</td>
<td class="num">$ (116,410,405)<span></span>
</td>
<td class="num">$ (219,276)<span></span>
</td>
<td class="num">$ (911,516)<span></span>
</td>
<td class="nump">$ 10,006,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodValueEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for employee bonuses during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodValueEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents value of stock issued during period for warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock to be issued for employee bonuses during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares to be issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) to be issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock to be issued for employee bonuses during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockToBeIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock to be issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockToBeIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) to be issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712103697888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,772,866)<span></span>
</td>
<td class="num">$ (6,876,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">14,180<span></span>
</td>
<td class="nump">22,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">49,663<span></span>
</td>
<td class="nump">51,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,499,302<span></span>
</td>
<td class="nump">790,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_SharebasedCompensationBonusPaidInStock', window );">Employees paid in stock</a></td>
<td class="nump">317,265<span></span>
</td>
<td class="nump">793,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_ExpensesPaidStock', window );">Expense paid in stock</a></td>
<td class="nump">747,351<span></span>
</td>
<td class="nump">707,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserveEffectOnIncomeNet', window );">Inventory Reserve</a></td>
<td class="nump">582,299<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">80,533<span></span>
</td>
<td class="nump">73,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment-PPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(276,180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Deferred profit and divesture-equity investment (See Note F)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(242,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in accounts receivable</a></td>
<td class="nump">249,555<span></span>
</td>
<td class="nump">137,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) decrease in inventories</a></td>
<td class="num">(833,121)<span></span>
</td>
<td class="nump">878,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_IncreaseDecreaseToAdvancesToContractManufacturer', window );">(Increase) in advances on contracts</a></td>
<td class="num">(16,041)<span></span>
</td>
<td class="num">(895,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="num">(68,512)<span></span>
</td>
<td class="nump">40,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase in accounts payable</a></td>
<td class="nump">322,300<span></span>
</td>
<td class="nump">297,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Increase in accounts payable, related party</a></td>
<td class="nump">407,636<span></span>
</td>
<td class="nump">10,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">(Decrease) increase in accrued expenses</a></td>
<td class="num">(292,495)<span></span>
</td>
<td class="nump">562,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties', window );">(Decrease) in accrued expenses, related party</a></td>
<td class="num">(246,692)<span></span>
</td>
<td class="num">(47,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease operating lease liability</a></td>
<td class="num">(72,353)<span></span>
</td>
<td class="num">(62,789)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,031,996)<span></span>
</td>
<td class="num">(4,033,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of furniture, fixtures, and equipment</a></td>
<td class="num">(8,527)<span></span>
</td>
<td class="num">(15,189)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(8,527)<span></span>
</td>
<td class="num">(15,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments finance lease obligations</a></td>
<td class="num">(8,544)<span></span>
</td>
<td class="num">(8,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,216,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Common stock issued to employee for option exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,381,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in (provided by) financing activities</a></td>
<td class="num">(8,544)<span></span>
</td>
<td class="nump">4,589,282<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(6,049,067)<span></span>
</td>
<td class="nump">540,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">14,764,346<span></span>
</td>
<td class="nump">14,223,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 8,715,279<span></span>
</td>
<td class="nump">$ 14,764,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ExpensesPaidStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses paid for with stock in lieu of cash during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ExpensesPaidStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of accrued liabilities to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_IncreaseDecreaseToAdvancesToContractManufacturer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease to advances to contract manufacturer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_IncreaseDecreaseToAdvancesToContractManufacturer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SharebasedCompensationBonusPaidInStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of noncash share-based compensation bonuses paid in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SharebasedCompensationBonusPaidInStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserveEffectOnIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods and any LIFO decrement which have been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserveEffectOnIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712109490176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note A - Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE A </b>&#8212;<b> ORGANIZATION AND BUSINESS </b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">All references in this report to &#8220;Milestone Scientific,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;we,&#8221; the &#8220;Company&#8221; or &#8220;Milestone&#8221; refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C<i>ompuDent</i>&#174;<i>; CompuMed</i>&#174;<i>; CompuFlo</i>&#174;<i>; DPS Dynamic Pressure Sensing technology</i>&#174;<i>; Milestone Scientific </i>&#174;<i>;</i>&#160;<i>the Milestone logo </i>&#174;<i>; SafetyWand</i>&#174;<i>; STA Single Tooth Anesthesia System</i>&#174;<i>; and The Wand </i>&#174;<i>.</i>&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific was incorporated in the State of Delaware in <em style="font: inherit;"> August 1989. </em>Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using <i>The Wand</i>&#174;, a single use disposable handpiece. The device is marketed in dentistry under the trademark <i>CompuDent</i>&#174;<i>, </i>and <i>STA Single Tooth Anesthesia System</i>&#174; and in medicine under the trademark <i>CompuMed</i>&#174;<i>. CompuDent</i>&#174; is suitable for all dental procedures that require local anesthetic. <i>CompuMed</i>&#174; is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics, and many other disciplines. The dental devices are sold in the United States, Canada and in 60 other countries. Certain medical devices have obtained CE mark approval and&#160;can be marketed and sold in most European countries.&#160;In <em style="font: inherit;"> June 2017,&#160;</em>Milestone Scientific received <em style="font: inherit;">510</em>(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the<i> CompuFlo</i>&#174; Epidural Computer Controlled Anesthesia System (&#8220;Epidural&#8221;).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">We are in the process of&#160;meeting&#160;with medical facilities and device distributors within the United States, Middle East and Europe.&#160; Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;">2020,</em> the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its new CompuPulse System,&#160;which combines the benefits of our CompuWave technology with a manual syringe.&#160;The new CompuPulse System allows <em style="font: inherit;">one</em> to identify a pulsatile pressure waveform in a variety of applications, thereby improving the reliability and safety of a drug delivery procedure. Importantly, <em style="font: inherit;">not</em> all procedures require the sophistication of our CompuFlo system, which precisely controls the administration and flow rate of medication as it is being administered. This new technology provides an efficient and low-cost alternative for procedures where a manual syringe <em style="font: inherit;"> may </em>suffice, while still providing the ability to verify needle and subsequent catheter placement.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110578768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note B - Liquidity and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>NOTE B-</b>&#160;<b> LIQUIDITY</b>&#160;<b>AND UNCERTAINTIES</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the consolidated financial statements are issued. Total operating losses since inception of $116.4 million.&#160; The operating losses were&#160;$8.8&#160;million and $7.4&#160;million, for the years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively. Management has prepared cashflow forecasts covering a period of <em style="font: inherit;">12</em> months from the date of issuance of these financial statements. These forecasts include several revenue and operating expense assumptions which indicate that the Company&#8217;s current cash and liquidity is sufficient to finance the operating requirements for at least the next <em style="font: inherit;">12</em> months Management believes that the Company&#160;will have sufficient cash reserves to meet its anticipated obligations for at least the next <em style="font: inherit;">twelve</em> months from the filing date of this report.&#160;Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company&#8217;s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.</p>
   <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In addition to its employees, the Company relies on (i) distributors, agents, and <em style="font: inherit;">third</em>-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If the Company, or any of these entities encounter any disruptions to its or their respective operations or facilities, or if the Company or any of these <em style="font: inherit;">third</em>-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then the Company or they <em style="font: inherit;"> may </em>be prevented or delayed from effectively operating its or their business, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The coronavirus (COVID-<em style="font: inherit;">19</em>) adversely impacted the Company's operations, our distributors and suppliers in recent years. Notwithstanding the reopening of dental offices, hospitals, and pain clinics throughout the country and the rest of the world, revenues for years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> were adversely affected. Any business interruptions, resulting from COVID-<em style="font: inherit;">19,</em> or new variant, could significantly disrupt our operations further and could have a material adverse impact on our business in the future.</p>
   <p style="font-size: 9pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Sanctions imposed by the United States and other western democracies, against Russia because of Ukraine conflict, and any expansion of the conflict, is likely to have unpredictable and wide-ranging effects on the domestic and global economy and financial markets, which could have an adverse effect on our business and results of operations. The conflict has caused market volatility, a sharp increase in certain commodity prices, and an increasing number and frequency of cybersecurity threats. As direct impact from the conflict, we have experienced a decrease in international sales to Ukraine and halted all sales to Russia. We will continue to monitor the situation carefully and, if necessary, take action to protect our business, operations, and financial condition.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712111308160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note C - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE C</b>&#160;&#8212;<b> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">1.</em></b>&#160;<b> Principles of Consolidation</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The accompanying&#160;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&#160;("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC)&#160;include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Medical (majority owned).&#160; All significant, intra-entity transactions and balances have been eliminated in the consolidation.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">2.</em> Use of Estimates</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The preparation of consolidated&#160;financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, stock compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">3.</em></b>&#160;<b> Revenue Recognition</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following <em style="font: inherit;">five</em> steps:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">identification of the promised goods or services in the contract;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">iii.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">measurement of the transaction price, including the constraint on variable consideration;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">iv.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">allocation of the transaction price to the performance obligations based on estimated selling prices; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">v.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC <em style="font: inherit;">606.</em></p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and <em style="font: inherit;">third</em> parties.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has <em style="font: inherit;">no</em> obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Sales Returns</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers&#8217; return rights and the Company&#8217;s historical experience with returns and the amount of product in the distribution channel <em style="font: inherit;">not</em> consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, adjustments to the allowance for product returns <em style="font: inherit;"> may </em>be required.&#160;The Company recorded allowance of approximately $179,000 for sales&#160;returns from Henry Schein due to the termination of&#160; the&#160;contract on <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Financing and Payment</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company's payment terms differ by geography and customer, but payment is required within <em style="font: inherit;">90</em> days from the date of shipment or delivery.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Disaggregation of Revenue</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#160;operates in <span style="-sec-ix-hidden:c96106949">two</span> operating segments: dental and medical. Therefore, results of the Company operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note M&#160;for revenues by geographical market, based on the customer&#8217;s location, and product category for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2022, </em>and&#160;<em style="font: inherit;">2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><em style="font: inherit;"/></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b><em style="font: inherit;">4.</em></b>&#160;<b> Variable Interest Entities</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&#8217;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific has&#160;completed the VIE analysis relating to Milestone China and&#160;Anhui Maishida Medical Technology, Co. Ltd. (&#8220;Anhui&#8221;).</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has determined that due to the loss of equity investment in Anhui, the company <em style="font: inherit;">no</em> longer has significant influence of Anhui and therefore Anhui is <em style="font: inherit;">not</em> a variable interest. Milestone Scientific&#160;has a variable interest in Milestone China, it considered the guidance in ASC <em style="font: inherit;">810,</em> &#8220;Consolidation&#8221; as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary.&#160;Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Power Criterion: The power to direct the activities that most significantly impact the entity&#8217;s economic performance; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific does <em style="font: inherit;">not</em> have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has <em style="font: inherit;">not</em> been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO of Milestone China who have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is <em style="font: inherit;">not</em> the primary beneficiary under ASC <em style="font: inherit;">810.</em> Accordingly, Milestone China has <em style="font: inherit;">not</em> been consolidated into the financial statements of Milestone Scientific and is accounted for under the equity method. See Note F.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">5.</em></b>&#160;<b> Cash and Cash Equivalents</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific considers all highly liquid investments purchased with an original maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> Milestone Scientific has approximately $8.7 million and $14.8 million, respectively, invested in cash. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> Milestone Scientific had approximately $8.3&#160;million and $13.9&#160;million, respectively, invested in cash that exceeded the Federal Deposit Insurance Corporation insurance limit of <em style="font: inherit;">$250,000.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"/></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">6.</em></b>&#160;<b> Accounts Receivable</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the ability or inability of its customers to make payments on amounts billed. Most credit sales are due within <em style="font: inherit;">90</em> days from invoicing. There have <em style="font: inherit;">not</em> been any significant credit losses incurred to date.&#160;As of <em style="font: inherit;"> December 31, 2022&#160;</em>and&#160;<em style="font: inherit;">2021,</em>&#160;accounts receivable was recorded, net of allowance for doubtful accounts of <span style="-sec-ix-hidden:c96106999">$10,000.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">7.</em></b>&#160;<b> Inventories</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inventories principally consist of finished goods and component parts stated at the lower of cost (<em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method) or net realizable value. Inventory quantities&#160;on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected&#160;future sales, potential technological obsolescence, and product expiration requirements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The valuation allowance creates a new cost basis for the inventory, and it is <em style="font: inherit;">not</em>&#160;subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation&#160;allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the&#160;underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">8.</em></b>&#160;&#160;<b>Equity Method Investments</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Investments in which Milestone Scientific can exercise significant influence, but do <em style="font: inherit;">not</em> control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the provision for income tax on the Consolidated Statements of&#160; Operations.&#160;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments <em style="font: inherit;"> may </em>be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">9.</em></b>&#160;<b> Furniture, Fixture and Equipment</b>&#160;&#160;<b> </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:c96107013">three</span>&#160;to <span style="-sec-ix-hidden:c96107014">seven</span> years. The costs of maintenance and repairs are charged to operations as incurred.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">10.</em></b>&#160;<b> Intangible Assets </b>&#8211;<b> Patents and Developed Technology</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are recorded at acquisition cost and be amortized at the estimated useful life.&#160; Patent defense costs, to the extent applicable, are expensed as incurred.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">11.</em>&#160;</b><b>Impairment of Long-Lived Assets</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company&#8217;s impairment review process is based upon an estimate of future undiscounted cash flow. Factors the Company considers that could trigger an impairment review include the following:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant under performance relative to expected historical or projected future operating results;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant changes in the manner of our use of the acquired assets or the strategy for our overall business;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant negative industry or economic trends; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant technological changes, which would render the technology obsolete.</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">12.</em> Note Payable</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> April 27, 2020, </em>the Company received a loan (the &#8220;Loan&#8221;) from Savoy Bank. in the aggregate amount of approximately&#160;<span style="-sec-ix-hidden:c96107022">$276,000,</span> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the CARES Act, which was enacted <em style="font: inherit;"> March 27, 2020. </em>The Company received forgiveness for the Loan during the year ended <em style="font: inherit;"> December 31, 2021 </em>and recorded a gain on debt extinguishment of <span style="-sec-ix-hidden:c96107023">$276,180.</span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">13.</em></b>&#160;<b> Research and Development</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development costs, which consist principally of new product development costs payable to <em style="font: inherit;">third</em> parties, are expensed as incurred.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">14.</em></b>&#160;<b> Income Taxes</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> we had no uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Consolidated Statements of Operations. No interest and penalties are present for periods open. Tax returns for the <em style="font: inherit;">2019,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2021</em> years are subject to audit by federal and state jurisdictions.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"/>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">15.</em></b>&#160;<b> Basic and Diluted Net Loss Per Common Share</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific presents &#8220;basic&#8221; earnings (loss) per common share applicable to common stockholders and, if applicable, &#8220;diluted&#8221; earnings (loss) per common&#160;share applicable to common stockholders pursuant to the provisions of ASC <em style="font: inherit;">260,</em> &#8220;Earnings per Share&#8221;. Basic earnings (loss) per common share is calculated by&#160;dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares of&#160;70,607,338 and 68,829,860 during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of&#160;additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and&#160;warrants were issued during the period.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Since Milestone Scientific had net losses in the years ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (&#8220;RSA&#8221;) and warrants, were <em style="font: inherit;">not</em> included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA and warrants&#160;totaled 7,855,160 and 7,291,800 on <em style="font: inherit;"> December 31,&#160;</em><em style="font: inherit;">2022</em>&#160;and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">16.</em></b>&#160;<b> Fair Value of Financial Instruments</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required to classify fair value measurements in <em style="font: inherit;">one</em> of the following categories</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">1</em> inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company&#160;can access at the measurement date.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">2</em> inputs which are defined as inputs other than quoted prices included within Level <em style="font: inherit;">1</em> that are observable for the assets or liabilities, either directly or indirectly.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">3</em> inputs are defined as unobservable inputs for the assets or liabilities.</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and <em style="font: inherit;"> may </em>affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&#160;As of <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em>&#160;the Company does <em style="font: inherit;">not</em> have any assets or liabilities that were measured at fair value on a recurring basis.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">17.</em> Stock-Based Compensation</b>&#160;<br/> &#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific accounts for stock-based compensation under ASC Topic <em style="font: inherit;">718,</em> Share-Based Payment. ASC Topic <em style="font: inherit;">718</em> requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">18.</em></b>&#160;&#160;<b>Reclassifications</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Certain reclassification has&#160;been made to the <em style="font: inherit;">2021</em> consolidated&#160;financial statements to conform to the <em style="font: inherit;">2022</em> consolidated&#160;financial statement presentation. These reclassifications had <em style="font: inherit;">no</em> effect on net loss or cash flows as previously reported.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;"/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">19.</em></b>&#160;<b> Recent Accounting Pronouncements</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> August 2020, </em>FASB issued&#160;ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em>&#160;&#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;, which, generally, provides guidance for accounting regarding derivatives relating to entities common stock and earnings per share. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em>&#160;is effective for all entities with fiscal years beginning after <em style="font: inherit;"> December 15, 2021, </em>including interim periods therein. The adoption of this standard did <em style="font: inherit;">not</em> have an impact on the Company's consolidated financial statement.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>), which amends the guidance on measuring credit losses for certain financial assets measured at amortized cost, including trade receivables. The FASB has subsequently issued several updates to the standard, providing additional guidance on certain topics covered by the standard. This update requires entities to recognize an allowance for credit losses using a forward-looking expected loss impairment model, taking into consideration historical experience, current conditions, and supportable forecasts that impact collectability.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em> <i>Financial Instruments - Credit Losses (Topic, <em style="font: inherit;">326</em>), Derivatives and hedging (Topic <em style="font: inherit;">815</em>), and Leases (Topic <em style="font: inherit;">842</em>): Effective</i>&#160;<i>dates</i>, which deferred the effective&#160;date of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> for the Company. As&#160;a result of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em>&#160;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for all entities with fiscal years beginning&#160;after <em style="font: inherit;"> December 15, 2022, </em>including interim periods.&#160;The adoption of this update is <em style="font: inherit;">not</em> expected to have a material impact on the Company's&#160;consolidated financial statement.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110387696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note D - Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE D</b>&#160;&#8212;<b> INVENTORIES </b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,315,263</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">342,465</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">334,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,119,709</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Component parts and other materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">142,948</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,792,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,541,513</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Company recorded an allowance on slow moving Medical finished goods of approximately $582,000,&#160;and $450,000 as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively due to the slow adoption of the epidural instruments and handpieces. The Company recorded an allowance on slow moving Dental finished goods of approximately $0 as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110312384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note E - Advances on Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_AdvancesToContractManufacturerTextBlock', window );">Advances to Contract Manufacturer [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>NOTE E</b>&#160;&#8212;<b> ADVANCES ON CONTRACTS </b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The advances on contracts represent funding of future dental STA "Single Tooth Anesthesia System" and epidural inventory purchases&#160;and epidural replacements parts. The balance of the advances as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was approximately <span style="-sec-ix-hidden:c96107149"><span style="-sec-ix-hidden:c96107150">$1.3</span></span> million.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AdvancesToContractManufacturerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances to contract manufacturer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AdvancesToContractManufacturerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712103678208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note F - Investment in and Transactions With Equity Investees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments and Joint Ventures Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE F</b>&#160;&#8211;&#160;<b>INVESTMENT IN AND TRANSACTIONS WITH EQUITY INVESTEES</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Milestone China Ltd.</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Ownership </i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> June 2014, </em>Milestone Scientific invested $1 million in Milestone China Ltd. (&#8220;Milestone China&#8221;) by contributing dental instruments to Milestone China for a 40% ownership interest. Milestone China owns approximately 75% of Milestone Beijing Medical Equipment Company, Ltd (&#8220;Milestone Beijing&#8221;). At the time, Milestone Beijing had primary responsibility for the sales, marketing, and distribution of the Company&#8217;s dental products in China. Milestone Scientific recorded its investment in Milestone China under the equity method of accounting.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020,</em> Milestone China and certain manufacturing/marketing affiliates entered into a reorganization agreement (the &#8220;Transaction&#8221;) pursuant to which Milestone China was to merge into an affiliated manufacturing company, Anhui Maishida Medical Technology, Co. Ltd. (&#8220;Anhui&#8221;), with Anhui as the surviving entity and to have complete responsibility for sales, marketing, and distribution for the Company&#8217;s dental products in China. After completion of the Transaction, Milestone Scientific was expected to have an approximate 28.4% direct ownership in Anhui. Due to the COVID-<em style="font: inherit;">19</em> pandemic, the regulatory approval of the planned Transaction was delayed while applicable government offices were closed in China and Hong Kong. Until the completion of the transaction Milestone Scientific's <em style="font: inherit;">28.4%</em> in Anhui was held by Milestone China.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">On <em style="font: inherit;"> November 23, 2021, </em>management of Milestone Scientific became aware that on <em style="font: inherit;"> October 8, 2021, </em>without approval from Milestone Scientific, (i) Milestone China entered into an Equity Transfer Agreement whereby Milestone China&#8217;s <span style="-sec-ix-hidden:c96107160">28.4%</span> equity stake in Anhui was transferred to Lidong Zhang, the CEO of Milestone China and Anhui, in exchange for RMB 2,840 million (approximately $440,351) of which <em style="font: inherit;">no</em> amounts have been or are expected to be received, see below, and (ii) Anhui held a shareholders&#8217; meeting at which the Equity Transfer Agreement was approved by the shareholders of Anhui, eliminating Milestone China&#8217;s equity interest in Anhui and Milestone Scientific&#8217;s indirect equity interest in Anhui. Based on a review of the minutes of the Anhui shareholders&#8217; meeting, Milestone China was <em style="font: inherit;">not</em> listed as a shareholder in such meeting due to the executed Equity Transfer Agreement between Lidong Zhang and Milestone China.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Though management believes that this conveyance by Milestone China to Lidong Zhang is outside of the laws of Hong Kong and/or China, as <em style="font: inherit;"> may </em>be applicable, at this juncture Milestone Scientific has <em style="font: inherit;">no</em> ownership in Anhui and Milestone China has <em style="font: inherit;">no</em> assets or operations. After considering taking action to assert our rights in the matter, and based on the acknowledgement that such course of action is <em style="font: inherit;">not</em> without its procedural and substantive challenges in Hong Kong and/or China and, importantly, in view of Michelle Zhang dba Solee Science &amp; Technology USA (&#8220;Solee&#8221;) (see below), a company located in New Jersey, then becoming the&#160;independent distributor for Milestone China and its subsidiaries, and due to the good working relationship then developing between Milestone Scientific and Solee and to the reduction of Milestone Scientific&#8217;s credit exposure to a Chinese entity, management is <em style="font: inherit;">not</em> pursuing any legal action at this time to recover our equity interest. The Company does <em style="font: inherit;">not</em> believe it is prudent at this time to continue to pursue its investigation of any options it <em style="font: inherit;"> may </em>have regarding its Chinese distributor, and therefore, in order to preserve cash the Company is for the time being suspending its investigation.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">At this time, Milestone Scientific has <em style="font: inherit;">not</em> received any consideration, does <em style="font: inherit;">not</em> know if any of such consideration promised to Milestone China for its interest in Anhui has been paid and, if paid, whether it can recover its share of such consideration. Unless circumstances change, Milestone Scientific does <em style="font: inherit;">not</em> expect it will receive any of the consideration received by Milestone China for its assets without pursuing legal action. As a result, Milestone Scientific has <em style="font: inherit;">not</em> recorded a gain or receivable related to the transfer of Anhui.&#160;As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>the investment in Milestone China was zero.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Related Party Transactions</i>&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Milestone China Distribution Agreement</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone China had been Milestone Scientific&#8217;s exclusive distributor in China. During <em style="font: inherit;">2017</em> and prior to the payment default during <em style="font: inherit;">2018,</em> Milestone Scientific agreed to sell inventory to Milestone China and its agent. During <em style="font: inherit;">2018,</em> Milestone Scientific entered into a payment arrangement with Milestone China to satisfy past due receivables from Milestone China and its agents which amounted to $2.8 million at the time of the payment arrangement. Milestone Scientific collected $950,000 under this arrangement, until Milestone China defaulted on the payment arrangements.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Beginning in mid-<em style="font: inherit;"> November 2021, </em>Milestone Scientific entered into discussions with Michelle Zhang dba Solee Science &amp; Technology USA (&#8220;Solee&#8221;), a company located in New Jersey, to become Milestone Scientific&#8217;s independent distributor for China, replacing its former distributor Milestone China and its subsidiaries. On <em style="font: inherit;"> November 22, 2021, </em>Wand Dental, Inc., a United States subsidiary of Milestone Scientific, entered into a Buy and Sell Agreement with Solee, pursuant to which Milestone Scientific granted Solee the right to sell Milestone Scientific&#8217;s STA instruments, associated handpieces, and spare parts in China to Anhui.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2022, </em>Milestone Scientific shipped instruments or handpieces to Solee for sale to Anhui and recognized&#160;revenue of approximately $630,000.&#160;For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2021, </em>Milestone Scientific shipped instruments or handpieces to Solee for sale to Anhui and recognized&#160;revenue of approximately $2.1 million. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> the Company had no deposits from Solee for future shipment of goods included in accrued expenses on the accompanying&#160;consolidated balance sheet.&#160;&#160;As of <em style="font: inherit;"> December 31, 2021, </em>the Company had approximately $89,000 of deposits from Solee for future shipment of goods included in accrued expenses on the accompanying consolidated balance sheet.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Gross Profit Deferral</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Due to timing differences of when the inventory sold to Milestone China, Anhui or their agent is recognized and when Milestone China and Anhui sells the acquired inventory to <em style="font: inherit;">third</em> parties, an elimination of the recorded profit is required as of the balance sheet date. In accordance with ASC <em style="font: inherit;">323</em>&#160;<i>Investment </i>Equity Method and Joint Ventures, Milestone Scientific has deferred its ownership percentage of the gross profit associated with recognized revenue from sales to Milestone China, Solee as an agent, and Anhui until that product is sold to <em style="font: inherit;">third</em> parties.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">As of <em style="font: inherit;"> December 31, 2022&#160;</em>and&#160;<em style="font: inherit;">2021,</em> the Company&#160;had no&#160;deferred profit&#160;in the consolidated balance sheets. For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2021&#160;</em>Milestone Scientific recorded loss on equity investment of approximately $242,000 in relation to gross profit previously deferred on product sold to Milestone China, Anhui, and Solee, recorded as deferred profit and divesture-equity investment on the accompanying consolidated statement of operations.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110562640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note G - Furniture, Fixtures and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE G</b>&#8212;<b> FURNITURE, FIXTURES AND EQUIPMENT </b>&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">24,734</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">24,734</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">178,058</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">174,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Molds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Trade show displays</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">151,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">151,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Computers and software</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">280,066</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">275,364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tooling Safety Wand</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">125,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">125,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tooling equipment-STA &amp; Wand</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">11,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">11,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">EPI and IA Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">82,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">82,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">STA Trials Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">923,757</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">915,144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(905,611</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(891,431</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,713</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Depreciation expense was&#160;$14,180&#160;and $22,205 for the years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em>&#160;respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110485776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note H - Patents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE H</b>&#160;&#8212;<b> PATENTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2022</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Patents-foundation intellectual property</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,377,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,149,907</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">227,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,377,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,149,907</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">227,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Patents-foundation intellectual property</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,377,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,100,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">277,619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,377,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,100,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">277,619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 to 20 years. Amortization expense was <span style="-sec-ix-hidden:c96107252">$49,663</span> and&#160;$53,011 for the years ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021</em> , respectively.&#160;The annual amortization expense expected to be recorded for existing intangibles assets for the years <em style="font: inherit;">2023</em>&#160;through <em style="font: inherit;">2027</em>&#160;is&#160;approximately $52,000, $34,000, $28,000, $28,000 and $86,000, respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110375776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note I - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE I</b>&#160;&#8212;<b> STOCKHOLDERS</b>&#8217;<b> EQUITY</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">At the annual shareholders meeting in <em style="font: inherit;">2021,</em> the Company received approval to&#160;increase its authorized shares of common stock from 85,000,000 to&#160;100,000,000 shares.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>WARRANTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The following table summarizes information about shares issuable under warrants outstanding at <em style="font: inherit;"> December 31, 2022:</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Warrant shares outstanding</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Weighted Average exercise price</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Weighted Average remaining life</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Intrinsic value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Outstanding at January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,268,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,187,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,268,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>SHARES TO BE ISSUED</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021</em>&#160;, there were 2,057,976 and 1,891,979, respectively&#160;shares to be issued whose issuance has been deferred under the terms of an employment agreements with the former Interim Chief Executive Officer,&#160;former Chief Financial Officer, and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> there were 382,697&#160;and 174,364, respectively&#160;shares to be issued to non-employees, that will be issued to non-employees for services rendered. The number of shares was fixed at the date of grant and were fully vested upon grant date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The following table summarizes information about shares to be issue at <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Shares-to-be-issued, outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,066,343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,428,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted in current period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">524,814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">93,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Issued in current period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(150,484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(455,904</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Shares-to be issued outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,440,673</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,066,343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110312384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note J - Stock Option Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE J</b>&#160;&#8212;<b> STOCK OPTION PLANS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Milestone Scientific Inc. <em style="font: inherit;">2020</em> Equity Compensation Plan, as amended and restated (the <em style="font: inherit;">"2020</em> Plan"), provides for awards of restricted common, stock restricted stock units, options to purchase and other awards, up to a maximum 4,000,000 shares of common stock and expires in <em style="font: inherit;"> June 2031. </em>Options <em style="font: inherit;"> may </em>be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price <em style="font: inherit;">not</em> less than the fair market value of common stock on the date of grant. Generally, options become exercisable over a <span style="-sec-ix-hidden:c96107357">three</span>-year period from the grant date and expire <span style="-sec-ix-hidden:c96107358">five</span> years after the date of grant.&#160;As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em>&#160;the Company had&#160;323,190&#160;and 811,597, respectively, remaining options available for grants under the&#160;Plan.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 8, 2021, </em>as part of its Succession Plan going into effect on <em style="font: inherit;"> April 23, 2021, </em>the Company announced that Leonard Osser, the Interim Chief Executive Officer, would be accepting the role of Vice Chairman of the Board of Directors. As part of accepting this role, he would be granted options to purchase 2,000,000 shares of common stock, exercisable at the fair market value of the common stock on the date of grant, vesting over the <span style="-sec-ix-hidden:c96107363">five</span>-year period after he steps down as&#160;Interim Chief Executive Officer of the Company or <span style="-sec-ix-hidden:c96107364">ten</span> years from the date of grant, whichever shall end first. The options were issued pursuant to the <em style="font: inherit;">2020</em> Plan.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific recognizes compensation expense over the requisite service period and in the case of performance-based options over the period of the expected performance. For the years ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> Milestone Scientific recognized approximately $961,000 and $763,000 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> there was $2.5&#160;million and $3.2 million of total unrecognized compensation cost related to non-vested options, respectively.&#160;Milestone Scientific expects to recognize these costs over a weighted average period of 3.09 and 3.49 years as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">A summary of option activity for employees under the plans and changes the year&#160;ended&#160;<em style="font: inherit;"> December 31, 2022 </em>is presented below:</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Averaged Exercise Price $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Life (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Options Value $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,843,693</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7.69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">49,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">216,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Forfeited or expired during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,059,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">6.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,026,987</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The weighted-average grant date fair value per share of options granted to employees during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was $0.82 and $1.56, respectively. The aggregate intrinsic value of options granted to employees exercised was $0 and $290,688 for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended <em style="font: inherit;"> December 31, 2022, </em>risk free interest rate of 2.45%, Volatility of 89.60% (which is based on the Company&#8217;s historical volatility over the expected term), expected term of <span style="-sec-ix-hidden:c96107384">3</span>&#160;years, 0% dividend rate and closing price of the stock of $1.52.&#160; &#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">A summary of option activity for non-employees under the plans and changes during the year&#160;ended&#160;<em style="font: inherit;"> December 31, 2022 </em>is presented below:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Averaged Exercise Price $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Life (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Options Value $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">83,330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">49,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">8,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">91,663</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,083</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">77,776</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,083</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. For the years ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> Milestone Scientific recognized approximately $22,900 and $27,600 expense related to non-employee options, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended <em style="font: inherit;"> December 31, 2022, </em>risk free interest rate of 4.12%, Volatility of 91.46%&#160;expected term of 5 years, 0% dividend rate and closing price of the stock of $0.73.&#160;&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">The information below summarizes the restricted stock award activity for year ended <em style="font: inherit;"> December 31, 2022:</em></p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Grant-Date Fair Value per Award</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-vested as January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">96,557</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">975,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(449,695</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(186,717</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-vested as December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">435,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022, </em>there were 49,615 restricted shares granted and deferred under the terms of an employment agreements with the Territory Manager of Milestone Scientific. Such shares will be issued to each party upon completion of 2 years of employment. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company recognized negative stock compensation expense and stock compensation expense of approximately ($20,000) and $70,000, respectively. As of <em style="font: inherit;"> December 31, 2022, </em>the total unrecognized compensation expense was $37,500 related to unvested restricted stock awards for Territory Managers, which the Company expects to recognize over an estimated weighted-average period of 1.03&#160;years.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of&#160;<em style="font: inherit;"> December 31, 2022,&#160;</em>the Company entered into&#160;restricted stock agreements with&#160;members of the Board of Directors of the Company. The Company granted&#160;899,390&#160;restricted stock awards with a fair market value of $0.82&#160;per share. Such&#160;restricted stock vests as follows:&#160;25%&#160;on the grant date in <em style="font: inherit;"> June 2022, </em>and&#160;25%&#160;quarterly, on the&#160;<em style="font: inherit;">first</em>&#160;day of the following months:&#160;&#160;<em style="font: inherit;"> October 2022,&#160;</em><em style="font: inherit;"> January 2023,&#160;</em>and&#160;<em style="font: inherit;"> April 2023.&#160;</em>These awards&#160;vest immediately upon a change of control as defined in the agreements. For the&#160;year ended&#160;<em style="font: inherit;"> December 31, 2022,&#160;</em>the Company recognized approximately $549,000 for restricted stock expenses recorded in general and administrative expenses on the statement of operation.&#160;As of&#160;<em style="font: inherit;"> December 31, 2022,&#160;</em>the total unrecognized stock compensation expense was approximately $160,000&#160;related to non-vested restricted stock awards with the members of the Board of Directors, which the Company expects to recognize over an estimated weighted average period of&#160;0.25&#160;years.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110387696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note K - Employment Contract and Consulting Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_EmploymentAndConsultingAgreementsTextBlock', window );">Employment and Consulting Agreements [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE K</b>&#8211;<b>EMPLOYMENT CONTRACT AND CONSULTING AGREEMENTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Employment Contracts</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with&#160;Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $100,000 for&#160;years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em>&#160;and&#160;<em style="font: inherit;">2021,</em> respectively.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Director of Clinical Affairs&#8217; royalty fee was approximately $442,000&#160;and $446,000 for the years ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> respectively.&#160;Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of&#160; $154,000 and $158,000 for the year ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> respectively. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $120,000&#160;and $123,000, respectively, which is included in accounts payable, related party and accrued expense, related party, in the&#160;consolidated balance sheet.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 2, 2021, </em>Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company&#8217;s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning <em style="font: inherit;"> May 9, 2027, </em>half of the royalty (2.5%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated <em style="font: inherit;"> February 25, 2021 </em>to reduce from 5% to 2.5% the payments due to them on <em style="font: inherit;"> May 9, 2027 </em>and thereafter, with respect to dental products.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Pursuant to a Succession Agreement dated <em style="font: inherit;"> April 6, 2021 </em>between Mr. Osser and the Company: (i) the Employment Agreement dated as of <em style="font: inherit;"> July 10, 2017 </em>between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the &#8220;China Operations Agreement&#8221;), and (ii) the Consulting Agreement dated as of <em style="font: inherit;"> July 10, 2017 (</em>the &#8220;Consulting Agreement&#8221;) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement.&#160; Compensation under the China Operations Agreement and the Consulting Agreement are payable for <em style="font: inherit;">9.5</em>&#160;years from <em style="font: inherit;"> May 19, 2021.&#160;</em>The Company recorded expense of $200,000 and $125,000&#160;related to the Managing Director, China Operations for the year ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#160;The Company recorded expense of $200,000 and $125,000&#160;related to the US Asian Consulting Group, LLC for the year ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAndConsultingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employment and consulting agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAndConsultingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110341952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE L</b>&#160;&#8212;<b> INCOME TAXES</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Due to Milestone Scientific's history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets. At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> no recognition was given to the utilization of the remaining net operating loss carry forwards in each of these periods.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Deferred tax attributes resulting from differences between financial accounting amounts and tax bases of assets and liabilities at&#160;<em style="font: inherit;"> December 31, 2022&#160;</em>and&#160;<em style="font: inherit;">2021</em>&#160;are as follows: &#160;&#160;&#160;&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Allowance for Doubtful Accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">2,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">2,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Warranty Reserve</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">2,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">3,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Impaired Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Capitalized Sec. 174 R&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">242,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Inventory Reserve</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">242,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">108,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Deferred Officer's Compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">428,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">439,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Depreciation and Amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(56,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(52,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net Operating Loss Carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">19,315,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">18,895,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tax Credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">688,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">660,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">155,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">45,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Subtotal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">21,018,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">20,100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(21,018,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(20,100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-current deferred tax asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> &#160;federal net operating loss carry-forwards are approximately $71,700,000 and $68,300,000, respectively. As of <em style="font: inherit;"> December 31, 2022, </em>Milestone Scientific has net operating losses generated before <em style="font: inherit;"> December 31, 2017 </em>will be available to offset future income, if any, through <em style="font: inherit;"> December 2037. </em>Net operating losses generated in <em style="font: inherit;">2018</em> or after can be carried forward indefinitely.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">State net operating losses were approximately $60,500,000 and <span style="-sec-ix-hidden:c96107516">$63,400,000</span> for the periods ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. Net operating losses will be available to offset future taxable income, if any, through <em style="font: inherit;"> December 2041.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The utilization of Milestone Scientific's net operating losses <em style="font: inherit;"> may </em>be subject to a substantial limitation due to the "change of ownership provisions" under Section <em style="font: inherit;">382</em> of the Internal Revenue Code and similar state provisions. Such limitation <em style="font: inherit;"> may </em>result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a 100% valuation allowance for all of its deferred tax assets due to uncertainty as to their future realization.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure, and transition. At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> we had no uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Statements of Operations. No interest and penalties are present for periods open. Tax returns for the <em style="font: inherit;">2019,</em> <span style="-sec-ix-hidden:c96107527">2020,</span> and <em style="font: inherit;">2021</em> years are subject to audit by federal and state jurisdictions.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">A reconciliation of the statutory tax rates for the years ended <em style="font: inherit;"> December 31, </em>is as follows:&#160; &#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; width: 179px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 12px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Statutory Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">21.00</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">State income tax - all states</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-2.74</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-2.57</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">NOL Expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-4.69</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-9.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-0.56</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-7.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Subtotal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10.44</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">11.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-10.44</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-11.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Effective tax Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-0.00</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110185600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note M - Segment and Geographic Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock', window );">Product Sales and Significant Customers and Vendors Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE M</b>&#160;&#8212;<b> SEGMENT AND GEOGRAPHIC DATA</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company conducts its business through <span style="-sec-ix-hidden:c96107620">two</span> reportable segments: Dental and Medical. These segments offer different products and services to different customer base.&#160;The Company provides&#160;general corporate services to its segments; however, these services are <em style="font: inherit;">not</em> considered when making operating decisions and assessing segment performance. These services are reported under &#8220;Corporate Services&#8221; below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments,&#160;financing activities and public company compliance.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The following tables present information about our reportable and operating segments:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Sales</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Net Sales:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">8,753,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,152,511</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">52,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">152,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,805,906</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,304,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Operating Income (Loss):</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,121,815</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,475,059</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,788,105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,105,854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,161,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,747,713</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,827,473</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,378,508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Depreciation and Amortization:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,805</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,351</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">62,172</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">63,755</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">73,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Income (loss) before taxes and equity in earnings of affiliates:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,116,598</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,544,730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,794,089</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,111,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,095,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,552,259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total loss before taxes and equity in earnings of affiliate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,772,866</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,118,688</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Total Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,875,978</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">6,163,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">620,373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,373,511</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,205,735</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,273,064</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,702,086</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,809,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;">The following table presents information about our operations by geographic area as of <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021.</em>&#160;Net sales by geographic area are based on the respective locations of our subsidiaries.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2022</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Domestic: US</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grand Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grand Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">524,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">532,215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">560,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">560,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,653,914</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">25,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,679,164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,905,354</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">35,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,940,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">78,493</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">78,493</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">69,271</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70,571</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,257,122</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,289,872</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,535,049</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,571,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: Rest of World</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Dental</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Medical</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,413,525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,413,525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,226,486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">70,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,296,486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,391,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">20,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,411,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,246,302</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">44,900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,291,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,797</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,797</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,346</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,866,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,886,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,519,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">115,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,635,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: China</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Dental</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Medical</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">270,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">270,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">303,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">303,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">359,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">359,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,795,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,795,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">629,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">629,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,098,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,098,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Total Product Sales</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,753,156</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>52,750</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,805,906</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>10,152,511</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>152,200</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>10,304,711</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of product sales and significant customers and vendors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110396080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note N - Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE N-- CONCENTRATIONS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Scientific has informal arrangements with <em style="font: inherit;">third</em>-party U.S. manufacturers of the STA, <i>CompuDent</i> and <i>CompuMed</i> devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. Consequently, advances on contracts have been classified as current at <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021.</em>&#160;The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific&#8217;s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Scientific&#8217;s financial condition, business, and results of operations.&#160;&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We had <span style="-sec-ix-hidden:c96107779">two</span>&#160;customers that accounted for 32%, and 11%&#160;amount of revenue respectively for the year ended <em style="font: inherit;"> December 31, 2022.&#160;</em>We had <span style="-sec-ix-hidden:c96107782">two</span>&#160;customers that accounted for 35%, and 20%&#160;amount of revenue respectively for the year ended <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We had <span style="-sec-ix-hidden:c96107785">two</span>&#160;customers that accounted for 33%, and 20% amount of accounts receivable, respectively as of <em style="font: inherit;"> December 31, 2022.&#160;</em>We had <span style="-sec-ix-hidden:c96107788">three</span> customers that accounted for 29%, 28%, and 13% amount of accounts receivable, respectively as of <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">We had <span style="-sec-ix-hidden:c96107792">one</span> vendor&#160;that accounted for 42%,&#160;of accounts payable and accounts payable related party, respectively as of <em style="font: inherit;"> December 31, 2022.&#160;</em>We had <span style="-sec-ix-hidden:c96107794">two</span> vendor&#160;that accounted for 14% and 34 %,&#160;of accounts payable and accounts payable related party, respectively as of <em style="font: inherit;"> December 31, 2021.</em></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110304208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note O - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE O</b>&#160;<b>-- RELATED PARTY TRANSACTIONS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>United Systems</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">Milestone Scientific has a supply agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal supplier &#160;of its handpieces, pursuant to which it procures manufactured products under specific purchase orders, but without minimum purchase commitments.&#160;Purchases from this supplier were approximately $3.4 million and <span style="-sec-ix-hidden:c96107810">$1.7</span>&#160;million for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#160; As <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;"> December 31, 2021, </em>Milestone Scientific owed this supplier approximately $819,000&#160;and $548,000, respectively, which is included in accounts payable&#160;and accrued expenses related party on the&#160;consolidated balance sheets. In <em style="font: inherit;"> June 2021, </em>the Company signed a <em style="font: inherit;">ten</em>-year agreement with United Systems for supplier of the handpieces.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Milestone China</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">See Note F.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Other</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with&#160; Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $100,000 for&#160;years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em>&#160;and&#160;<em style="font: inherit;">2021,</em> respectively.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Director of Clinical Affairs&#8217; royalty fee was approximately $442,000&#160;and $446,000 for the years ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> respectively.&#160;Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of&#160; $154,000 and $158,000 for the year ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> respectively. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $120,000&#160;and $123,000, respectively, which is included in accounts payable, related party and accrued expense, related party, in the&#160;consolidated balance sheet.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 2, 2021, </em>Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company&#8217;s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning <em style="font: inherit;"> May 9, 2027, </em>half of the royalty (2.5%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated <em style="font: inherit;"> February 25, 2021 </em>to reduce from 5% to 2.5% the payments due to them on <em style="font: inherit;"> May 9, 2027 </em>and thereafter, with respect to dental products.</p>
   <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify;">Pursuant to a Succession Agreement dated <em style="font: inherit;"> April 6, 2021 </em>between Mr. Osser and the Company: (i) the Employment Agreement dated as of <em style="font: inherit;"> July 10, 2017 </em>between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the &#8220;China Operations Agreement&#8221;), and (ii) the Consulting Agreement dated as of <em style="font: inherit;"> July 10, 2017 (</em>the &#8220;Consulting Agreement&#8221;) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement.&#160; Compensation under the China Operations Agreement and the Consulting Agreement are payable for <em style="font: inherit;">9.5</em>&#160;years from <em style="font: inherit;"> May 19, </em><em style="font: inherit;">2021.The</em> Company recorded expense of $200,000 and $125,000&#160;related to the Managing Director, China Operations for the year ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#160;The Company recorded expense of $200,000 and $125,000&#160;related to the US Asian Consulting Group, LLC for the year ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110422976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note P - Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE P</b>&#160;&#8212;<b> COMMITMENTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>(<em style="font: inherit;">1</em>) </b>&#160;<b>Contract Manufacturing Agreement</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has informal arrangements with <em style="font: inherit;">third</em>-party manufacturers of the STA, CompuDent&#174; and CompuMed&#174; devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment.&#160;The company entered a new purchase commitment for the delivery of 2,040 STA CompuDent&#174; instruments. As of <em style="font: inherit;"> December 31, 2022, </em>the purchase order commitment was approximately $1.7&#160;million, and&#160;approximately $1.2&#160;million was paid and reported in advances on contracts in the&#160;consolidated balance sheet. As of&#160; <em style="font: inherit;"> December&#160; </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em>&#160;the purchase order commitment was approximately $2.6 million, approximately $1.3 million was paid and &#160;reported in advances on contracts in the consolidated balance sheet. As of <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021</em>&#160;the company also has advances on an open purchase order for long lead items for a future purchase order for the manufacturing of Epidural instrument&#160;of approximately&#160;$76,000 and $34,000, respectively.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>(<em style="font: inherit;">2</em>)</b>&#160;<b> Leases</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Operating Leases</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> August 2019, </em>the Company made the&#160;decision to <em style="font: inherit;">not</em> renew its&#160;existing office lease for its corporate headquarters located in Livingston, New Jersey and instead signed a new <span style="-sec-ix-hidden:c96107913">seven</span> year lease in a new facility located in Roseland, New Jersey (the &#8220;Roseland Facility&#8221;), which commenced of <em style="font: inherit;"> January 8, 2021 . </em>Under the Roseland Facility lease, rent payments commence on <em style="font: inherit;"> April 1, 2021 , </em>and the monthly lease payments escalate annually on <em style="font: inherit;"> January 1 </em>of each year, and range from $9,275 to $10,898 per month over the lease term. The Company is also required to pay a fixed electric charge equal to $2.00 per square foot which is &#160;paid in equal monthly installments over the lease term or $11,130 annually. These fixed monthly payments have been included in the measurement of the operating lease liability and related operating lease right-of-use asset as the Company has elected the practical expedient to <em style="font: inherit;">not</em> separate lease and non-lease components for all leases.&#160;The Company is also required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises more than new base year amounts, which are accounted for as variable lease expenses.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022, </em>total&#160;finance&#160;right-of-use assets were $17,645 and total finance liabilities were $20,063&#160;of which $9,365 and $10,698 were classified as current and non-current, respectively.&#160;As of <em style="font: inherit;"> December 31, 2022, </em>total operating right-of use assets <span style="-sec-ix-hidden:c96107924">were$443,685</span> and total operating lease liabilities were $476,980, of which $91,701 and $385,279&#160;were classified as current and non-current, respectively.&#160; As of <em style="font: inherit;"> December 31, 2021, </em>total&#160; finance&#160;right-of-use assets were $26,294 and total finance liabilities were $28,607 of which $8,545 and $20,062 were classified as current and non-current, respectively.&#160;As of <em style="font: inherit;"> December 31, 2021, </em>total operating right-of use assets were $524,217&#160;and total operating lease liabilities were $557,981, of which $81,001 and <em style="font: inherit;">$476,980</em> were classified as current and non-current, respectively.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">As the Company&#8217;s leases do <em style="font: inherit;">not</em> provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the Medical Device industry.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The expected lease terms include non-cancellable&#160;lease periods. Renewal option periods are <em style="font: inherit;">not</em> included in the determination of the lease terms as they were <em style="font: inherit;">not</em> reasonably certain to be exercised.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The components of lease expense were as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash paid for operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">127,995</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">127,526</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash paid for finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">663,009</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Property and equipment obtained in exchange for new finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">43,242</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Weighted Average Remaining Lease Term</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Finance leases (years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107961">2.04 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107962">3.04 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Operating leases (years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107963">4.25 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107964">5.25 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Weighted-average discount rate &#8211; operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">9.20</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">9.20</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Weighted-average discount rate &#8211; finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">9.20</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">9.20</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Maturity of lease liabilities as of December 31, 2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><em style="font: inherit;">Operating Leases</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><em style="font: inherit;">Finance Leases</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">130,778</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">133,560</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">136,343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">433</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">139,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,477</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">575,283</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">21,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Less: interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(98,303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,850</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">476,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,063</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110526128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Q - Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE Q</b>&#160;&#8212;<b> BENEFIT PLAN</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does <em style="font: inherit;">not</em> contribute to this plan, but does pay the administrative costs of the plan, which were <em style="font: inherit;">not</em> significant.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110329936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note R - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>NOTE R</b>&#160;&#8212;<b> SUBSEQUENT EVENTS</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> January 3, 2023 </em>,the Company launched an E-Commerce platform,&#160;selling and shipping&#160;STA Single Tooth Anesthesia System&#174;&#160;(STA) and handpieces directly to dental office, and dental&#160;groups within the US.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> January 4, 2023, </em>Leslie Bernhard tendered her resignation to Milestone Scientific Inc. (the "Company&#8221;) as a director, Chairman of the Audit Committee and Chairman of the Board of the Company. Ms. Bernhard&#8217;s resignation comes after nearly <em style="font: inherit;">20</em> years of service as a director of the Company. Ms. Bernhard indicated that her decision to resign was <em style="font: inherit;">not</em> the result of a disagreement with the Company. The Company thanks Ms. Bernhard for her long, dedicated service on the Board and wishes her well in her future pursuits.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">In connection with Ms. Bernhard&#8217;s resignation, on <em style="font: inherit;"> January 4, 2023, </em>the Company&#8217;s Board of Directors (the "Board&#8221;) unanimously appointed Neal Goldman, who has been a member of the Board since <em style="font: inherit;">2019,</em> as Chairman of the Board. Mr. Goldman is the President and Founder of Goldman Capital Management, Inc., a family office since <em style="font: inherit;">2018,</em> which was previously an investment advisory firm founded in <em style="font: inherit;">1985.</em> Mr. Goldman was First Vice President of Research at Shearson Lehman Hutton. He has also held senior positions as a money manager and research analyst with a variety of firms including Neuberger Berman, Moseley Hallgarten Estabrook and Weeden, Bruns Nordeman, and Russ and Company. Mr. Goldman has served as Chairman of Charles &amp; Colvard, Ltd. since <em style="font: inherit;">2016</em> and served on the board of directors of Imageware Systems, Inc. until <em style="font: inherit;"> November 2020. </em>He also serves on the board of directors of Koil Energy Solutions Inc. Prior to their respective acquisitions, he served on the boards of Blyth Industries and IPASS Corporation. Mr. Goldman received his B.A. degree in Economics from The City University of New York (City College).</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Also on <em style="font: inherit;"> January 4, 2023, </em>the Board unanimously appointed Arjan Haverhals as a director of the Company. Mr. Haverhals has been the Company&#8217;s Chief Executive Officer since <em style="font: inherit;"> May 2021 </em>and President since <em style="font: inherit;"> September 2020. </em>Mr. Haverhals has also been the President and Chief Executive Officer of the Company&#8217;s Dental Division (Wand Dental, Inc.) since <em style="font: inherit;"> June 2020.</em></p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> January 10, 2023, </em>the Company&#160;announced it has entered into a distribution agreement granting TEKMIKA Health Technologies exclusive distribution rights to market Milestone&#8217;s STA Single Tooth Anesthesia System&#174;&#160;(STA) in Brazil. TEKMIKA Health Technologies is a leading distributor in Brazil, focused on importing, promotion, marketing and distribution of high-tech medical equipment and device.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">On <em style="font: inherit;"> January 12, 2023, </em>the Company announced it has entered into a distribution agreement with&#160;Sweden &amp; Martina, a leading European dental distributor and manufacturer. Under the agreement, Sweden &amp; Martina has been awarded the exclusive rights to market Milestone&#8217;s STA Single Tooth Anesthesia System&#174;&#160;(STA) in the new markets of Spain, Portugal and France. In addition, Sweden &amp; Martina will replace the Company&#8217;s current distributor in Italy and become its exclusive STA distributor in this market.</p>
   <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> February 6, 2023, </em>Milestone Scientific Inc. (the "Company&#8221;) announced the appointment of Peter Milligan as the Company&#8217;s Chief Financial Officer, on a part-time basis, effective <em style="font: inherit;">February1,</em> <em style="font: inherit;">2023.</em> In connection with serving as the Company&#8217;s Chief Financial Officer, Mr. Milligan will be entitled to receive an annual salary of $120,000 and be eligible to receive an annual incentive bonus with a target of 40% of his annual cash compensation, which shall be payable in shares of the Company&#8217;s common stock. Mr. Milligan will also be entitled to receive $100,000 in shares of the Company&#8217;s common stock on an annual basis, of which, $50,000 shall have a grant date of <em style="font: inherit;"> February 1 </em>and $50,000 shall have a grant date as of <em style="font: inherit;"> August 1 </em>of each year beginning in <em style="font: inherit;">2023,</em> valued at the closing price of the Company&#8217;s common stock on the NYSE American on the grant date, and which shares are to be issued to Mr. Milligan following the expiration of <em style="font: inherit;">sixty</em> (<em style="font: inherit;">60</em>) days after the termination of his employment with the Company.&#160;Mr.&#160;Milligan holds an M.B.A. from New York University with a concentration in Finance and Economics and a B.B.A. in Accounting from Hofstra University. There are <em style="font: inherit;">no</em> family relationships between Mr.&#160;Milligan and any of the Company&#8217;s directors or executive officers, and there is <em style="font: inherit;">no</em> arrangement or understanding between Mr.&#160;Milligan or any other person and the Company or any of its subsidiaries pursuant to which he was appointed as an officer of the Company. There are <em style="font: inherit;">no</em> transactions between Mr.&#160;Milligan or any of his immediate family members and the Company or any of its subsidiaries that would be required to be reported under Item <em style="font: inherit;">404</em>(a) of Regulation&#160;S-K.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> February&#160;&#160;</em><em style="font: inherit;">27,</em> <em style="font: inherit;">2023,</em> the Company &#160;announced that its CompuFlo&#174; Epidural System has received <em style="font: inherit;">510</em>(k) FDA clearance for use in the thoracic region of the spine, including the cervical thoracic junction. This approval expands upon the Company&#8217;s prior approval of CompuFlo for use within the lumbar region of the spine, where the focus has been on labor and delivery.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;&#160;&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712202339360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">1.</em></b>&#160;<b> Principles of Consolidation</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The accompanying&#160;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&#160;("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC)&#160;include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Medical (majority owned).&#160; All significant, intra-entity transactions and balances have been eliminated in the consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">2.</em> Use of Estimates</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">The preparation of consolidated&#160;financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, stock compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">3.</em></b>&#160;<b> Revenue Recognition</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following <em style="font: inherit;">five</em> steps:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">identification of the promised goods or services in the contract;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">iii.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">measurement of the transaction price, including the constraint on variable consideration;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">iv.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">allocation of the transaction price to the performance obligations based on estimated selling prices; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">v.</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC <em style="font: inherit;">606.</em></p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and <em style="font: inherit;">third</em> parties.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has <em style="font: inherit;">no</em> obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Sales Returns</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers&#8217; return rights and the Company&#8217;s historical experience with returns and the amount of product in the distribution channel <em style="font: inherit;">not</em> consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, adjustments to the allowance for product returns <em style="font: inherit;"> may </em>be required.&#160;The Company recorded allowance of approximately $179,000 for sales&#160;returns from Henry Schein due to the termination of&#160; the&#160;contract on <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Financing and Payment</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company's payment terms differ by geography and customer, but payment is required within <em style="font: inherit;">90</em> days from the date of shipment or delivery.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Disaggregation of Revenue</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#160;operates in <span style="-sec-ix-hidden:c96106949">two</span> operating segments: dental and medical. Therefore, results of the Company operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note M&#160;for revenues by geographical market, based on the customer&#8217;s location, and product category for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2022, </em>and&#160;<em style="font: inherit;">2021.</em></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"><b><em style="font: inherit;">4.</em></b>&#160;<b> Variable Interest Entities</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&#8217;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific has&#160;completed the VIE analysis relating to Milestone China and&#160;Anhui Maishida Medical Technology, Co. Ltd. (&#8220;Anhui&#8221;).</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific has determined that due to the loss of equity investment in Anhui, the company <em style="font: inherit;">no</em> longer has significant influence of Anhui and therefore Anhui is <em style="font: inherit;">not</em> a variable interest. Milestone Scientific&#160;has a variable interest in Milestone China, it considered the guidance in ASC <em style="font: inherit;">810,</em> &#8220;Consolidation&#8221; as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary.&#160;Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Power Criterion: The power to direct the activities that most significantly impact the entity&#8217;s economic performance; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific does <em style="font: inherit;">not</em> have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has <em style="font: inherit;">not</em> been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO of Milestone China who have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is <em style="font: inherit;">not</em> the primary beneficiary under ASC <em style="font: inherit;">810.</em> Accordingly, Milestone China has <em style="font: inherit;">not</em> been consolidated into the financial statements of Milestone Scientific and is accounted for under the equity method. See Note F.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">5.</em></b>&#160;<b> Cash and Cash Equivalents</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific considers all highly liquid investments purchased with an original maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> Milestone Scientific has approximately $8.7 million and $14.8 million, respectively, invested in cash. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> Milestone Scientific had approximately $8.3&#160;million and $13.9&#160;million, respectively, invested in cash that exceeded the Federal Deposit Insurance Corporation insurance limit of <em style="font: inherit;">$250,000.</em></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">6.</em></b>&#160;<b> Accounts Receivable</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the ability or inability of its customers to make payments on amounts billed. Most credit sales are due within <em style="font: inherit;">90</em> days from invoicing. There have <em style="font: inherit;">not</em> been any significant credit losses incurred to date.&#160;As of <em style="font: inherit;"> December 31, 2022&#160;</em>and&#160;<em style="font: inherit;">2021,</em>&#160;accounts receivable was recorded, net of allowance for doubtful accounts of <span style="-sec-ix-hidden:c96106999">$10,000.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">7.</em></b>&#160;<b> Inventories</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Inventories principally consist of finished goods and component parts stated at the lower of cost (<em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method) or net realizable value. Inventory quantities&#160;on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected&#160;future sales, potential technological obsolescence, and product expiration requirements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">The valuation allowance creates a new cost basis for the inventory, and it is <em style="font: inherit;">not</em>&#160;subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation&#160;allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the&#160;underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">8.</em></b>&#160;&#160;<b>Equity Method Investments</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Investments in which Milestone Scientific can exercise significant influence, but do <em style="font: inherit;">not</em> control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the provision for income tax on the Consolidated Statements of&#160; Operations.&#160;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments <em style="font: inherit;"> may </em>be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">9.</em></b>&#160;<b> Furniture, Fixture and Equipment</b>&#160;&#160;<b> </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:c96107013">three</span>&#160;to <span style="-sec-ix-hidden:c96107014">seven</span> years. The costs of maintenance and repairs are charged to operations as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">10.</em></b>&#160;<b> Intangible Assets </b>&#8211;<b> Patents and Developed Technology</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are recorded at acquisition cost and be amortized at the estimated useful life.&#160; Patent defense costs, to the extent applicable, are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">11.</em>&#160;</b><b>Impairment of Long-Lived Assets</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company&#8217;s impairment review process is based upon an estimate of future undiscounted cash flow. Factors the Company considers that could trigger an impairment review include the following:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant under performance relative to expected historical or projected future operating results;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant changes in the manner of our use of the acquired assets or the strategy for our overall business;</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant negative industry or economic trends; and</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: 14px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8226;</p> </td><td style="vertical-align: top; width: 1730px; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">significant technological changes, which would render the technology obsolete.</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">12.</em> Note Payable</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> April 27, 2020, </em>the Company received a loan (the &#8220;Loan&#8221;) from Savoy Bank. in the aggregate amount of approximately&#160;<span style="-sec-ix-hidden:c96107022">$276,000,</span> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the CARES Act, which was enacted <em style="font: inherit;"> March 27, 2020. </em>The Company received forgiveness for the Loan during the year ended <em style="font: inherit;"> December 31, 2021 </em>and recorded a gain on debt extinguishment of <span style="-sec-ix-hidden:c96107023">$276,180.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">13.</em></b>&#160;<b> Research and Development</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development costs, which consist principally of new product development costs payable to <em style="font: inherit;">third</em> parties, are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">14.</em></b>&#160;<b> Income Taxes</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Milestone Scientific accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> we had no uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Consolidated Statements of Operations. No interest and penalties are present for periods open. Tax returns for the <em style="font: inherit;">2019,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2021</em> years are subject to audit by federal and state jurisdictions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">15.</em></b>&#160;<b> Basic and Diluted Net Loss Per Common Share</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific presents &#8220;basic&#8221; earnings (loss) per common share applicable to common stockholders and, if applicable, &#8220;diluted&#8221; earnings (loss) per common&#160;share applicable to common stockholders pursuant to the provisions of ASC <em style="font: inherit;">260,</em> &#8220;Earnings per Share&#8221;. Basic earnings (loss) per common share is calculated by&#160;dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares of&#160;70,607,338 and 68,829,860 during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of&#160;additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and&#160;warrants were issued during the period.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Since Milestone Scientific had net losses in the years ended <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em> the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (&#8220;RSA&#8221;) and warrants, were <em style="font: inherit;">not</em> included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA and warrants&#160;totaled 7,855,160 and 7,291,800 on <em style="font: inherit;"> December 31,&#160;</em><em style="font: inherit;">2022</em>&#160;and <em style="font: inherit;">2021,</em> respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">16.</em></b>&#160;<b> Fair Value of Financial Instruments</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required to classify fair value measurements in <em style="font: inherit;">one</em> of the following categories</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">1</em> inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company&#160;can access at the measurement date.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">2</em> inputs which are defined as inputs other than quoted prices included within Level <em style="font: inherit;">1</em> that are observable for the assets or liabilities, either directly or indirectly.</p> </td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;">&#160;</td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p> </td><td style="vertical-align: top; width: auto; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">3</em> inputs are defined as unobservable inputs for the assets or liabilities.</p> </td></tr>
</tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and <em style="font: inherit;"> may </em>affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&#160;As of <em style="font: inherit;"> December 31, 2022&#160;</em>and <em style="font: inherit;">2021,</em>&#160;the Company does <em style="font: inherit;">not</em> have any assets or liabilities that were measured at fair value on a recurring basis.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">17.</em> Stock-Based Compensation</b>&#160;<br/> &#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone Scientific accounts for stock-based compensation under ASC Topic <em style="font: inherit;">718,</em> Share-Based Payment. ASC Topic <em style="font: inherit;">718</em> requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Comparability Adjustment [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">18.</em></b>&#160;&#160;<b>Reclassifications</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Certain reclassification has&#160;been made to the <em style="font: inherit;">2021</em> consolidated&#160;financial statements to conform to the <em style="font: inherit;">2022</em> consolidated&#160;financial statement presentation. These reclassifications had <em style="font: inherit;">no</em> effect on net loss or cash flows as previously reported.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><em style="font: inherit;">19.</em></b>&#160;<b> Recent Accounting Pronouncements</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> August 2020, </em>FASB issued&#160;ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em>&#160;&#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;, which, generally, provides guidance for accounting regarding derivatives relating to entities common stock and earnings per share. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em>&#160;is effective for all entities with fiscal years beginning after <em style="font: inherit;"> December 15, 2021, </em>including interim periods therein. The adoption of this standard did <em style="font: inherit;">not</em> have an impact on the Company's consolidated financial statement.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>), which amends the guidance on measuring credit losses for certain financial assets measured at amortized cost, including trade receivables. The FASB has subsequently issued several updates to the standard, providing additional guidance on certain topics covered by the standard. This update requires entities to recognize an allowance for credit losses using a forward-looking expected loss impairment model, taking into consideration historical experience, current conditions, and supportable forecasts that impact collectability.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em> <i>Financial Instruments - Credit Losses (Topic, <em style="font: inherit;">326</em>), Derivatives and hedging (Topic <em style="font: inherit;">815</em>), and Leases (Topic <em style="font: inherit;">842</em>): Effective</i>&#160;<i>dates</i>, which deferred the effective&#160;date of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> for the Company. As&#160;a result of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em>&#160;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for all entities with fiscal years beginning&#160;after <em style="font: inherit;"> December 15, 2022, </em>including interim periods.&#160;The adoption of this update is <em style="font: inherit;">not</em> expected to have a material impact on the Company's&#160;consolidated financial statement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712102386016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note D - Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,315,263</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">342,465</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">334,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,119,709</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Component parts and other materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">142,948</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,792,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,541,513</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712102386016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note G - Furniture, Fixtures and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">24,734</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">24,734</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">178,058</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">174,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Molds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Trade show displays</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">151,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">151,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Computers and software</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">280,066</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">275,364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tooling Safety Wand</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">125,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">125,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tooling equipment-STA &amp; Wand</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">11,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">11,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">EPI and IA Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">82,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">82,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">STA Trials Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">923,757</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">915,144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(905,611</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(891,431</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,713</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712112059632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note H - Patents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2022</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Patents-foundation intellectual property</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,377,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,149,907</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">227,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,377,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,149,907</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">227,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated Amortization</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Net</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Patents-foundation intellectual property</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,377,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,100,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">277,619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,377,863</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,100,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">277,619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104987792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note I - Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Warrant shares outstanding</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Weighted Average exercise price</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Weighted Average remaining life</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Intrinsic value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Outstanding at January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,268,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,187,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,268,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock', window );">Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Shares-to-be-issued, outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,066,343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,428,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted in current period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">524,814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">93,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Issued in current period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(150,484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(455,904</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Shares-to be issued outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,440,673</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,066,343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712111032160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note J - Stock Option Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Averaged Exercise Price $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Life (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Options Value $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,843,693</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7.69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">49,246</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">216,296</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Forfeited or expired during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,059,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">6.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,026,987</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Averaged Exercise Price $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Life (Years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Options Value $</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">83,330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">49,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">8,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercised during 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Options outstanding December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">91,663</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,083</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">77,776</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,083</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Weighted Average Grant-Date Fair Value per Award</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-vested as January 1, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">96,557</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">975,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(449,695</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(186,717</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-vested as December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">435,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110894672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Allowance for Doubtful Accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">2,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">2,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Warranty Reserve</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">2,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">3,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Impaired Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Capitalized Sec. 174 R&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">242,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Inventory Reserve</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">242,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">108,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Deferred Officer's Compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">428,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">439,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Depreciation and Amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(56,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(52,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Net Operating Loss Carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">19,315,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">18,895,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Tax Credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">688,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">660,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">155,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">45,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Subtotal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">21,018,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">20,100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(21,018,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; text-align: right;">(20,100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Non-current deferred tax asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; width: 179px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 12px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Statutory Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">21.00</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">State income tax - all states</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-2.74</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-2.57</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">NOL Expiration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-4.69</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-9.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-0.56</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-7.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Subtotal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10.44</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">11.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-10.44</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-11.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Effective tax Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 166px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-0.00</td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">0.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712111311408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note M - Segment and Geographic Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Sales</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Net Sales:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">8,753,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,152,511</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">52,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">152,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,805,906</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,304,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Operating Income (Loss):</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,121,815</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,475,059</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,788,105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,105,854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,161,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,747,713</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,827,473</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,378,508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Depreciation and Amortization:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,805</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,351</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">4,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">62,172</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">63,755</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">73,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Income (loss) before taxes and equity in earnings of affiliates:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,116,598</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,544,730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,794,089</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">(4,111,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,095,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,552,259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total loss before taxes and equity in earnings of affiliate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,772,866</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,118,688</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Total Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,875,978</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">6,163,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">620,373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,373,511</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,205,735</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,273,064</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,702,086</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,809,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_SalesByProductAndByGeographicalRegionTableTextBlock', window );">Sales by Product and by Geographical Region [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2022</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Domestic: US</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grand Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Grand Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">524,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">7,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">532,215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">560,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">560,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,653,914</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">25,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,679,164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,905,354</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">35,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">2,940,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">78,493</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">78,493</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">69,271</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70,571</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,257,122</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,289,872</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,535,049</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,571,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: Rest of World</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Dental</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Medical</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,413,525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,413,525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,226,486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">70,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,296,486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,391,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">20,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,411,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,246,302</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">44,900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">3,291,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,797</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,797</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,346</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,866,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,886,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,519,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">115,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,635,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>International: China</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Dental</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Medical</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Dental</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Medical</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b><em style="font: inherit;">Grand Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">270,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">270,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">303,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">303,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Handpieces</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">359,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">359,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,795,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">1,795,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Accessories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">629,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">629,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,098,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,098,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td><td style="font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Total Product Sales</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,753,156</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>52,750</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,805,906</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>10,152,511</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>152,200</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>10,304,711</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SalesByProductAndByGeographicalRegionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of sales by product and by geographical region.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SalesByProductAndByGeographicalRegionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104079248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note P - Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_LeaseCostAndOtherInformationTableTextBlock', window );">Lease, Cost and Other Information [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash paid for operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">127,995</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">127,526</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Cash paid for finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">663,009</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Property and equipment obtained in exchange for new finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">43,242</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><b>Weighted Average Remaining Lease Term</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Finance leases (years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107961">2.04 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107962">3.04 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Operating leases (years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107963">4.25 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c96107964">5.25 years</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Weighted-average discount rate &#8211; operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">9.20</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">9.20</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="margin: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;;">Weighted-average discount rate &#8211; finance leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">9.20</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0px;">9.20</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Maturity of lease liabilities as of December 31, 2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><em style="font: inherit;">Operating Leases</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><em style="font: inherit;">Finance Leases</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">130,778</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">133,560</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">10,740</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">136,343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">433</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">139,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,477</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">575,283</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">21,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Less: interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(98,303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,850</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">476,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,063</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_LeaseCostAndOtherInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost and other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_LeaseCostAndOtherInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110451264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note A - Organization and Business (Details Textual)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of Countries in which Entity Operates</a></td>
<td class="nump">60<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110265280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note B - Liquidity and Uncertainties (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Total</a></td>
<td class="num">$ (116,410,405)<span></span>
</td>
<td class="num">$ (107,704,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss), Total</a></td>
<td class="num">$ (8,827,473)<span></span>
</td>
<td class="num">$ (7,378,508)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104149536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note C - Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_AllowanceForSalesReturns', window );">Allowance for Sales Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">276,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic, Total (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,607,338<span></span>
</td>
<td class="nump">68,829,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,855,160<span></span>
</td>
<td class="nump">7,291,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mlss_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program CARES Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AllowanceForSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for sales returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AllowanceForSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mlss_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mlss_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712102211808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note D - Inventories (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mlss_SlowMovingMedicalFinishedGoodsMember', window );">Slow Moving Medical Finished Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">$ 582,000<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mlss_SlowMovingDentalFinishedGoodsMember', window );">Slow Moving Dental Finished Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mlss_SlowMovingMedicalFinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mlss_SlowMovingMedicalFinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mlss_SlowMovingDentalFinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mlss_SlowMovingDentalFinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712103709184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note D - Inventories - Summary of Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Component parts and other materials</a></td>
<td class="nump">$ 142,948<span></span>
</td>
<td class="nump">$ 79,339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">1,792,335<span></span>
</td>
<td class="nump">1,541,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net</a></td>
<td class="num">(1,315,263)<span></span>
</td>
<td class="num">(342,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net</a></td>
<td class="nump">1,315,263<span></span>
</td>
<td class="nump">342,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net</a></td>
<td class="num">(334,124)<span></span>
</td>
<td class="num">(1,119,709)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net</a></td>
<td class="nump">$ 334,124<span></span>
</td>
<td class="nump">$ 1,119,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110522816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note E - Advances on Contracts (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on Inventory Purchases</a></td>
<td class="nump">$ 1,325,301<span></span>
</td>
<td class="nump">$ 1,309,260<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104594048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note F - Investment in and Transactions With Equity Investees (Details Textual)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 242,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financing Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfFinanceReceivables', window );">Proceeds from Collection of Finance Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(242,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Accounts Receivable from Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss', window );">Equity Method Investment, Deferred Intercompany Profit (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneBeijingMember', window );">Milestone Beijing [Member] | Milestone China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_AnhuiMember', window );">Anhui [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_AnhuiMember', window );">Anhui [Member] | Milestone China [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">28.40%<span></span>
</td>
<td class="nump">28.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from Sale of Equity Method Investments</a></td>
<td class="nump">$ 440,351<span></span>
</td>
<td class="nump">&#165; 2,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of deferred intercompany profits and losses on transactions between the Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting,as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfFinanceReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the collection of receivables arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfFinanceReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mlss_AccountsReceivableFromRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mlss_AccountsReceivableFromRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mlss_InstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneBeijingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneBeijingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mlss_MilestoneChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mlss_MilestoneChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_AnhuiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_AnhuiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110362368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note G - Furniture, Fixtures and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="nump">$ 14,180<span></span>
</td>
<td class="nump">$ 22,205<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104562384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note G - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">$ 18,146<span></span>
</td>
<td class="nump">$ 23,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">24,734<span></span>
</td>
<td class="nump">24,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_OfficeFurnitureAndEquipmentMember', window );">Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">178,058<span></span>
</td>
<td class="nump">174,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Tools, Dies and Molds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_TradeShowDisplaysMember', window );">Trade Show Displays [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">151,462<span></span>
</td>
<td class="nump">151,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ComputerAndSoftwareMember', window );">Computer and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">280,066<span></span>
</td>
<td class="nump">275,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingSafetyWandMember', window );">Tooling Safety Wand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">125,022<span></span>
</td>
<td class="nump">125,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingEquipmentSTAAndWandMember', window );">Tooling Equipment - STA and Wand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_EPIAndIAInstrumentsMember', window );">EPI and IA Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">82,363<span></span>
</td>
<td class="nump">82,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_STATrialsInstrumentsMember', window );">STA Trials Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">63,752<span></span>
</td>
<td class="nump">63,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">923,757<span></span>
</td>
<td class="nump">915,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(905,611)<span></span>
</td>
<td class="num">(891,431)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">$ 18,146<span></span>
</td>
<td class="nump">$ 23,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_TradeShowDisplaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_TradeShowDisplaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ComputerAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ComputerAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingSafetyWandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingSafetyWandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingEquipmentSTAAndWandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingEquipmentSTAAndWandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_EPIAndIAInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_EPIAndIAInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_STATrialsInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_STATrialsInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712108143216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note H - Patents (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 49,663<span></span>
</td>
<td class="nump">$ 51,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Asset, Expected Amortization, Year One</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Asset, Expected Amortization, Year Two</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Asset, Expected Amortization, Year Three</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Asset, Expected Amortization, Year Four</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite-Lived Intangible Asset, Expected Amortization, Year Five</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 49,663<span></span>
</td>
<td class="nump">$ 53,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life (Year)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104409904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note H - Patents - Summary of Patents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents, cost</a></td>
<td class="nump">$ 1,377,863<span></span>
</td>
<td class="nump">$ 1,377,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Patents, accumulated amortization</a></td>
<td class="num">(1,149,907)<span></span>
</td>
<td class="num">(1,100,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents-foundation intellectual property</a></td>
<td class="nump">227,956<span></span>
</td>
<td class="nump">277,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_FoundationIntellectualPropertyPatentsMember', window );">Foundation Intellectual Property Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents, cost</a></td>
<td class="nump">1,377,863<span></span>
</td>
<td class="nump">1,377,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Patents, accumulated amortization</a></td>
<td class="num">(1,149,907)<span></span>
</td>
<td class="num">(1,100,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents-foundation intellectual property</a></td>
<td class="nump">$ 227,956<span></span>
</td>
<td class="nump">$ 277,619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_FoundationIntellectualPropertyPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_FoundationIntellectualPropertyPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712107120800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note I - Stockholders' Equity (Details Textual) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)</a></td>
<td class="nump">2,440,673<span></span>
</td>
<td class="nump">2,066,343<span></span>
</td>
<td class="nump">2,428,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember', window );">Chief Executive Officer, Chief Financial Officer and Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)</a></td>
<td class="nump">2,057,976<span></span>
</td>
<td class="nump">1,891,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_NonemployeesMember', window );">Non-Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="nump">382,697<span></span>
</td>
<td class="nump">174,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_NonemployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_NonemployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712105005696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note I - Stockholders' Equity - Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, number of shares (in shares)</a></td>
<td class="nump">4,268,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding , weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm', window );">Outstanding, weighted average remaining life (Year)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Outstanding, intrinsic value</a></td>
<td class="nump">$ 1,187,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Issued, number of shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice', window );">Issued, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Exercised, number of shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding , number of shares (in shares)</a></td>
<td class="nump">4,268,221<span></span>
</td>
<td class="nump">4,268,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding , weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average remaining term of warrants and rights outstanding,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712109277760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note I - Stockholders' Equity - Summary of Shares to be Issued (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Shares-to-be-issued, outstanding (in shares)</a></td>
<td class="nump">2,066,343<span></span>
</td>
<td class="nump">2,428,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_DeferredCompensationArrangementWithIndividualSharesGranted', window );">Granted in current period (in shares)</a></td>
<td class="nump">524,814<span></span>
</td>
<td class="nump">93,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Issued in current period (in shares)</a></td>
<td class="num">(150,484)<span></span>
</td>
<td class="num">(455,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Shares-to be issued outstanding (in shares)</a></td>
<td class="nump">2,440,673<span></span>
</td>
<td class="nump">2,066,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DeferredCompensationArrangementWithIndividualSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares granted pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DeferredCompensationArrangementWithIndividualSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104661104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note J - Stock Option Plans (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,440,673<span></span>
</td>
<td class="nump">2,066,343<span></span>
</td>
<td class="nump">2,428,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-Based Payment Arrangement, Amount Capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961,000<span></span>
</td>
<td class="nump">$ 763,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 2 days<span></span>
</td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 290,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,900<span></span>
</td>
<td class="nump">27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,000)<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Territory Manager [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Board of Directors [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Board of Directors [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mlss_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member] | Vice Chairman of the Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mlss_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,190<span></span>
</td>
<td class="nump">811,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mlss_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Vice Chairman of the Board of Directors [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mlss_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Vice Chairman of the Board of Directors [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_TerritoryManagerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_TerritoryManagerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mlss_The2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mlss_The2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_ViceChairmanOfTheBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_ViceChairmanOfTheBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712107188064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note J - Stock Option Plans - Summary of Option Activity for Employees (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="nump">2,843,693<span></span>
</td>
<td class="nump">2,843,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, outstanding (Year)</a></td>
<td class="text">6 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 49,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="nump">216,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life, granted (Year)</a></td>
<td class="text">2 years 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options forfeited and expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited or expired (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="nump">3,059,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">1,026,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable (Year)</a></td>
<td class="text">4 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="nump">83,330<span></span>
</td>
<td class="nump">83,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, outstanding (Year)</a></td>
<td class="text">2 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,663<span></span>
</td>
<td class="nump">83,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable (Year)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life, granted (Year)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment award options grants in period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104389744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note J - Stock Option Plans - Schedule of Restricted Stock (Details) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested as January 1, 2022 (in shares)</a></td>
<td class="nump">96,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested as January 1, 2022 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Shares (in shares)</a></td>
<td class="nump">975,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant-Date Fair Value per Award (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Shares (in shares)</a></td>
<td class="num">(449,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Cancelled, Shares (in shares)</a></td>
<td class="num">(186,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, Shares (in shares)</a></td>
<td class="nump">435,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712102284192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note K - Employment Contract and Consulting Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 02, 2021</div></th>
<th class="th"><div>Feb. 25, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember', window );">Director of Clinical Affairs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,000<span></span>
</td>
<td class="nump">$ 446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Accounts Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_InterimChiefExecutiveOfficerMember', window );">Interim Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_RoyaltyOnNetSalesPercentage', window );">Royalty on Net Sales, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember', window );">Previous President and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Increase (Decrease) in Deferred Compensation</a></td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensation', window );">Employment Agreement, Base Compensation</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Increase (Decrease) in Deferred Compensation</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensation', window );">Employment Agreement, Base Compensation</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember', window );">Consulting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAgreementBaseCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of annual base compensation pursuant to the employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAgreementBaseCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_RoyaltyOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty percentage on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_RoyaltyOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_InterimChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_InterimChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712102227888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating Loss Carryforwards, Valuation Allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_PercentageOfValuationAllowance', window );">Percentage of Valuation Allowance</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 71,700,000<span></span>
</td>
<td class="nump">68,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2019 2020 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 60,500,000<span></span>
</td>
<td class="nump">$ 63,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_PercentageOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_PercentageOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104938256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note L - Income Taxes - Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for Doubtful Accounts</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves', window );">Warranty Reserve</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Impaired Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized Sec. 174 R&amp;D</a></td>
<td class="nump">242,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory Reserve</a></td>
<td class="nump">242,000<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Deferred Officer's Compensation</a></td>
<td class="nump">428,000<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent', window );">Depreciation and Amortization</a></td>
<td class="num">(56,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss Carryforwards</a></td>
<td class="nump">19,315,000<span></span>
</td>
<td class="nump">18,895,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax Credits</a></td>
<td class="nump">688,000<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">21,018,000<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21,018,000)<span></span>
</td>
<td class="num">(20,100,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Non-current deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712110907248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax - all states</a></td>
<td class="num">(2.74%)<span></span>
</td>
<td class="nump">7.44%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(2.57%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent', window );">NOL Expiration</a></td>
<td class="num">(4.69%)<span></span>
</td>
<td class="num">(9.13%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.56%)<span></span>
</td>
<td class="num">(7.79%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation', window );">Subtotal</a></td>
<td class="nump">10.44%<span></span>
</td>
<td class="nump">11.52%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(10.44%)<span></span>
</td>
<td class="num">(11.52%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax Rate</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation at federal statutory rate and state and local income tax rate and stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from net operating loss adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712105023184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note M - Segment and Geographic Data (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712107288864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note M - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">$ 8,805,906<span></span>
</td>
<td class="nump">$ 10,304,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="num">(8,827,473)<span></span>
</td>
<td class="num">(7,378,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">63,755<span></span>
</td>
<td class="nump">73,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before taxes and equity in earnings of affiliates</a></td>
<td class="num">(8,772,866)<span></span>
</td>
<td class="num">(7,118,688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,702,086<span></span>
</td>
<td class="nump">19,809,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="num">(5,161,183)<span></span>
</td>
<td class="num">(5,747,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">55,875<span></span>
</td>
<td class="nump">62,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before taxes and equity in earnings of affiliates</a></td>
<td class="num">(5,095,375)<span></span>
</td>
<td class="num">(5,552,259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,205,735<span></span>
</td>
<td class="nump">12,273,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">8,753,156<span></span>
</td>
<td class="nump">10,152,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">8,753,156<span></span>
</td>
<td class="nump">10,152,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="nump">1,121,815<span></span>
</td>
<td class="nump">2,475,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">3,805<span></span>
</td>
<td class="nump">4,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before taxes and equity in earnings of affiliates</a></td>
<td class="nump">1,116,598<span></span>
</td>
<td class="nump">2,544,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,875,978<span></span>
</td>
<td class="nump">6,163,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">52,750<span></span>
</td>
<td class="nump">152,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">52,750<span></span>
</td>
<td class="nump">152,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="num">(4,788,105)<span></span>
</td>
<td class="num">(4,105,854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">4,075<span></span>
</td>
<td class="nump">7,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before taxes and equity in earnings of affiliates</a></td>
<td class="num">(4,794,089)<span></span>
</td>
<td class="num">(4,111,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 620,373<span></span>
</td>
<td class="nump">$ 1,373,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712111693840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note M - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">$ 8,805,906<span></span>
</td>
<td class="nump">$ 10,304,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">8,753,156<span></span>
</td>
<td class="nump">10,152,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">52,750<span></span>
</td>
<td class="nump">152,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mlss_DomesticMember', window );">Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">3,289,872<span></span>
</td>
<td class="nump">3,571,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mlss_DomesticMember', window );">Domestic [Member] | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">3,257,122<span></span>
</td>
<td class="nump">3,535,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mlss_DomesticMember', window );">Domestic [Member] | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">32,750<span></span>
</td>
<td class="nump">36,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mlss_RestOfWorldMember', window );">Rest of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">4,886,070<span></span>
</td>
<td class="nump">4,635,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mlss_RestOfWorldMember', window );">Rest of World [Member] | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">4,866,070<span></span>
</td>
<td class="nump">4,519,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mlss_RestOfWorldMember', window );">Rest of World [Member] | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">115,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">629,964<span></span>
</td>
<td class="nump">2,098,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">629,964<span></span>
</td>
<td class="nump">2,098,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">532,215<span></span>
</td>
<td class="nump">560,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | Domestic [Member] | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">524,715<span></span>
</td>
<td class="nump">560,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | Domestic [Member] | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | Rest of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">1,413,525<span></span>
</td>
<td class="nump">1,296,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | Rest of World [Member] | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">1,413,525<span></span>
</td>
<td class="nump">1,226,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | Rest of World [Member] | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | CHINA | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | CHINA | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">2,679,164<span></span>
</td>
<td class="nump">2,940,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | Domestic [Member] | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">2,653,914<span></span>
</td>
<td class="nump">2,905,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | Domestic [Member] | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">25,250<span></span>
</td>
<td class="nump">35,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | Rest of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">3,411,748<span></span>
</td>
<td class="nump">3,291,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | Rest of World [Member] | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">3,391,748<span></span>
</td>
<td class="nump">3,246,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | Rest of World [Member] | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">44,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">359,964<span></span>
</td>
<td class="nump">1,795,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | CHINA | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">359,964<span></span>
</td>
<td class="nump">1,795,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember', window );">Handpieces [Member] | CHINA | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">78,493<span></span>
</td>
<td class="nump">70,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | Domestic [Member] | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">78,493<span></span>
</td>
<td class="nump">69,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | Domestic [Member] | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | Rest of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">60,797<span></span>
</td>
<td class="nump">47,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | Rest of World [Member] | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">60,797<span></span>
</td>
<td class="nump">46,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | Rest of World [Member] | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | CHINA | Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember', window );">Accessories [Member] | CHINA | Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mlss_DomesticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mlss_DomesticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mlss_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mlss_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mlss_InstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mlss_InstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mlss_HandpiecesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mlss_HandpiecesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mlss_AccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mlss_AccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712111804512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note N - Concentrations (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_NumberOfMajorCustomers', window );">Number of Major Customers</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_NumberOfMajorCustomers', window );">Number of Major Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_NumberOfMajorCustomers', window );">Number of Major Customers</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_NumberOfMajorCustomers', window );">Number of Major Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_NumberOfVendors', window );">Number of Vendors</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of major customers of the reporting entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_NumberOfVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of vendors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_NumberOfVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mlss_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mlss_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mlss_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mlss_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mlss_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mlss_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=mlss_VendorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=mlss_VendorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=mlss_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=mlss_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712107237312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note O - Related Party Transactions (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 02, 2021</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InterimChiefExecutiveOfficerMember', window );">Interim Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_RoyaltyOnNetSalesPercentage', window );">Royalty on Net Sales, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_DirectorClinicalAffairMember', window );">Director Clinical Affair [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_RoyaltyOnNetSalesPercentage', window );">Royalty on Net Sales, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember', window );">Director of Clinical Affairs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,000<span></span>
</td>
<td class="nump">$ 446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Accounts Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember', window );">Previous President and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Increase (Decrease) in Deferred Compensation</a></td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensation', window );">Employment Agreement, Base Compensation</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Increase (Decrease) in Deferred Compensation</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensation', window );">Employment Agreement, Base Compensation</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mlss_ManagingDirectorChinaOperationsMember', window );">Managing Director, China Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mlss_ManufacturingAgreementForHandpiecesMember', window );">Manufacturing Agreement for Handpieces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related Party Transaction, Purchases from Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mlss_ManufacturingAgreementForHandpiecesMember', window );">Manufacturing Agreement for Handpieces [Member] | Accounts Payable, Related Parties, Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to Related Parties, Current, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="nump">548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember', window );">Consulting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAgreementBaseCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of annual base compensation pursuant to the employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAgreementBaseCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_RoyaltyOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty percentage on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_RoyaltyOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InterimChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InterimChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_DirectorClinicalAffairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_DirectorClinicalAffairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mlss_ManagingDirectorChinaOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mlss_ManagingDirectorChinaOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mlss_ManufacturingAgreementForHandpiecesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mlss_ManufacturingAgreementForHandpiecesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mlss_AccountsPayableRelatedPartiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mlss_AccountsPayableRelatedPartiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712109423040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note P - Commitments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on Inventory Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,325,301<span></span>
</td>
<td class="nump">$ 1,309,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,645<span></span>
</td>
<td class="nump">26,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance Lease, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,063<span></span>
</td>
<td class="nump">28,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance Lease, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,365<span></span>
</td>
<td class="nump">8,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance Lease, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,698<span></span>
</td>
<td class="nump">20,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,685<span></span>
</td>
<td class="nump">524,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,980<span></span>
</td>
<td class="nump">557,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,701<span></span>
</td>
<td class="nump">81,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,279<span></span>
</td>
<td class="nump">476,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember', window );">Office Lease for Headquarter in Roseland, New Jersey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_LesseeOperatingLeaseElectricCharge', window );">Lessee, Operating Lease, Electric Charge Per Square Foot</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_LesseeOperatingLeaseElectricPaymentsAnnually', window );">Lessee, Operating Lease, Electric Payments, Annually</a></td>
<td class="nump">11,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember', window );">Office Lease for Headquarter in Roseland, New Jersey [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_OperatingLeasesMonthlyRentExpense', window );">Operating Leases, Monthly Rent Expense</a></td>
<td class="nump">9,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember', window );">Office Lease for Headquarter in Roseland, New Jersey [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_OperatingLeasesMonthlyRentExpense', window );">Operating Leases, Monthly Rent Expense</a></td>
<td class="nump">$ 10,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_PurchaseCommitmentForDevicesMember', window );">Purchase Commitment for Devices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_PurchaseCommitmentNumberOfUnits', window );">Purchase Commitment Number Of Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase Commitment, Remaining Minimum Amount Committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on Inventory Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_PurchaseCommitmentForDevicesBeginningIn2021Member', window );">Purchase Commitment For Devices Beginning In 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on Inventory Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_LesseeOperatingLeaseElectricCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents electric charge for operating lease per square foot.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_LesseeOperatingLeaseElectricCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_LesseeOperatingLeaseElectricPaymentsAnnually">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual electric payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_LesseeOperatingLeaseElectricPaymentsAnnually</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_OperatingLeasesMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monthly rent expense of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_OperatingLeasesMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_PurchaseCommitmentNumberOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units commitment to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_PurchaseCommitmentNumberOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_PurchaseCommitmentForDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_PurchaseCommitmentForDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_PurchaseCommitmentForDevicesBeginningIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_PurchaseCommitmentForDevicesBeginningIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104196976">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note P - Commitments - Lease Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 127,995<span></span>
</td>
<td class="nump">$ 127,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses', window );">Cash paid for finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,740<span></span>
</td>
<td class="nump">10,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(663,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Property and equipment obtained in exchange for new finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (43,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases (years) (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years 14 days<span></span>
</td>
<td class="text">3 years 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases (years) (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years 3 months<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; operating leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; finance leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">For the nine months ended September 30, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for finance lease liabilities including accrues expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712109165488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note P - Commitments - Maturities of Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023, Operating Leases</a></td>
<td class="nump">$ 130,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023, Finance Leases</a></td>
<td class="nump">10,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024, Operating Leases</a></td>
<td class="nump">133,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024, Finance Leases</a></td>
<td class="nump">10,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025, Operating Leases</a></td>
<td class="nump">136,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025, Finance Leases</a></td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026, Operating Leases</a></td>
<td class="nump">139,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026, Finance Leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027, Operating Leases</a></td>
<td class="nump">35,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027, Finance Leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">575,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, Finance Leases</a></td>
<td class="nump">21,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(98,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest, Finance Leases</a></td>
<td class="num">(1,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">476,980<span></span>
</td>
<td class="nump">$ 557,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities, Finance Leases</a></td>
<td class="nump">$ 20,063<span></span>
</td>
<td class="nump">$ 28,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140712104333280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note R - Subsequent Events (Details Textual) - Chief Financial Officer [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Feb. 06, 2023</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mlss_IncentiveBonusPercentageOfAnnualCashCompensation', window );">Incentive Bonus, Percentage of Annual Cash Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_IncentiveBonusPercentageOfAnnualCashCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the incentive bonus as a percentage of annual cash compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_IncentiveBonusPercentageOfAnnualCashCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>mlss20221231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mlss="http://www.milestonescientific.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mlss-20221231.xsd" xlink:type="simple"/>
    <context id="d_2022-01-01_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2023-03-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-04-27_2020-04-27_DebtInstrumentAxis-PaycheckProtectionProgramCARESActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mlss:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-27</startDate>
            <endDate>2020-04-27</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mlss:SlowMovingMedicalFinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mlss:SlowMovingMedicalFinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingDentalFinishedGoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mlss:SlowMovingDentalFinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PublicUtilitiesInventoryAxis-SlowMovingDentalFinishedGoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mlss:SlowMovingDentalFinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-30</instant>
        </period>
    </context>
    <context id="i_2014-06-30_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneBeijingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneBeijingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-30</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AnhuiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AnhuiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="d_2021-10-08_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AnhuiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="i_2018-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsReceivableFromRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsReceivableFromRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:TradeShowDisplaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:TradeShowDisplaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingSafetyWandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingSafetyWandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingEquipmentSTAAndWandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingEquipmentSTAAndWandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:EPIAndIAInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:EPIAndIAInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:STATrialsInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:STATrialsInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mlss:FoundationIntellectualPropertyPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mlss:FoundationIntellectualPropertyPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_TitleOfIndividualAxis-NonemployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_TitleOfIndividualAxis-NonemployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-04-23_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ViceChairmanOfTheBoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-23</instant>
        </period>
    </context>
    <context id="d_2021-04-23_2021-04-23_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ViceChairmanOfTheBoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-23</startDate>
            <endDate>2021-04-23</endDate>
        </period>
    </context>
    <context id="d_2021-04-23_2021-04-23_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ViceChairmanOfTheBoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-23</startDate>
            <endDate>2021-04-23</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-TerritoryManagerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:TerritoryManagerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-TerritoryManagerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:TerritoryManagerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-03-02_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-02</instant>
        </period>
    </context>
    <context id="i_2021-02-25_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-25</instant>
        </period>
    </context>
    <context id="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementGeographicalAxis-DomesticMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementGeographicalAxis-RestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:HandpiecesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mlss:AccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementGeographicalAxis-CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mlss:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">mlss:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">mlss:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">mlss:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_BalanceSheetLocationAxis-AccountsPayableRelatedPartiesCurrentMember_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsPayableRelatedPartiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_BalanceSheetLocationAxis-AccountsPayableRelatedPartiesCurrentMember_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsPayableRelatedPartiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-InterimChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mlss:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-02</instant>
        </period>
    </context>
    <context id="i_2021-03-01_RelatedPartyTransactionsByRelatedPartyAxis-DirectorClinicalAffairMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mlss:DirectorClinicalAffairMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-DirectorClinicalAffairMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mlss:DirectorClinicalAffairMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-02</instant>
        </period>
    </context>
    <context id="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-10</startDate>
            <endDate>2017-07-10</endDate>
        </period>
    </context>
    <context id="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-10</startDate>
            <endDate>2017-07-10</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ManagingDirectorChinaOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ManagingDirectorChinaOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ManagingDirectorChinaOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mlss:ManagingDirectorChinaOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesBeginningIn2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesBeginningIn2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesBeginningIn2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mlss:PurchaseCommitmentForDevicesBeginningIn2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-01-08_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mlss:OfficeLeaseForHeadquarterInRoselandNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-08</instant>
        </period>
    </context>
    <context id="d_2019-08-01_2019-08-31_RangeAxis-MinimumMember_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mlss:OfficeLeaseForHeadquarterInRoselandNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="d_2019-08-01_2019-08-31_RangeAxis-MaximumMember_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mlss:OfficeLeaseForHeadquarterInRoselandNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="d_2019-08-01_2019-08-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mlss:OfficeLeaseForHeadquarterInRoselandNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="d_2023-02-06_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="i_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-06</instant>
        </period>
    </context>
    <context id="d_2023-02-01_2023-02-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="d_2023-08-01_2023-08-01_StatementScenarioAxis-ScenarioPlanMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000855683</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="CNY">
        <measure>iso4217:CNY</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2022-01-01_2022-12-31"
      id="thunderdome-EntityCentralIndexKey">0000855683</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2022-01-01_2022-12-31"
      id="thunderdome-EntityRegistrantName">MILESTONE SCIENTIFIC INC.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2022-01-01_2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2022-01-01_2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2022-01-01_2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2022-01-01_2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2022-12-31"
      id="c96106584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-12-31"
      id="c96106585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106589"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106590"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106592"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106593"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106595"
      unitRef="Share">69306497</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106597"
      unitRef="Share">69273164</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106596"
      unitRef="Share">68153336</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106598"
      unitRef="Share">68120003</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockShares
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106605"
      unitRef="Share">33333</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106607"
      unitRef="Share">33333</us-gaap:TreasuryStockShares>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106949"
      unitRef="Pure">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106999"
      unitRef="USD">10000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"
      id="c96107013">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"
      id="c96107014">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2020-04-27_2020-04-27_DebtInstrumentAxis-PaycheckProtectionProgramCARESActMember"
      decimals="INF"
      id="c96107022"
      unitRef="USD">276000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107023"
      unitRef="USD">276180</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96107032"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96107035"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2021-12-31_PublicUtilitiesInventoryAxis-SlowMovingDentalFinishedGoodsMember"
      decimals="-3"
      id="c96107135"
      unitRef="USD">0</us-gaap:InventoryValuationReserves>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c96107149"
      unitRef="USD">1300000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2021-12-31"
      decimals="-5"
      id="c96107150"
      unitRef="USD">1300000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"
      decimals="3"
      id="c96107160"
      unitRef="Pure">0.284</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss
      contextRef="i_2021-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="-3"
      id="c96107193"
      unitRef="USD">0</mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember"
      decimals="INF"
      id="c96107252"
      unitRef="USD">49663</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember"
      id="c96107357">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember"
      id="c96107358">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-04-23_2021-04-23_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      id="c96107363">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-04-23_2021-04-23_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      id="c96107364">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_RangeAxis-MinimumMember"
      id="c96107384">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember"
      decimals="INF"
      id="c96107504"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96107532"
      unitRef="USD">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="INF"
      id="c96107516"
      unitRef="USD">63400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96107533"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96107535"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:OpenTaxYear
      contextRef="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      id="c96107527">2019 2020 2021</us-gaap:OpenTaxYear>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107620"
      unitRef="Pure">2</us-gaap:NumberOfReportableSegments>
    <mlss:NumberOfMajorCustomers
      contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c96107779"
      unitRef="Pure">2</mlss:NumberOfMajorCustomers>
    <mlss:NumberOfMajorCustomers
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="INF"
      id="c96107782"
      unitRef="Pure">2</mlss:NumberOfMajorCustomers>
    <mlss:NumberOfMajorCustomers
      contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember"
      decimals="INF"
      id="c96107785"
      unitRef="Pure">2</mlss:NumberOfMajorCustomers>
    <mlss:NumberOfMajorCustomers
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="INF"
      id="c96107788"
      unitRef="Pure">3</mlss:NumberOfMajorCustomers>
    <mlss:NumberOfVendors
      contextRef="i_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"
      decimals="INF"
      id="c96107792"
      unitRef="Pure">1</mlss:NumberOfVendors>
    <mlss:NumberOfVendors
      contextRef="i_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember"
      decimals="INF"
      id="c96107794"
      unitRef="Pure">2</mlss:NumberOfVendors>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember"
      decimals="-5"
      id="c96107810"
      unitRef="USD">1700000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="d_2021-01-01_2021-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember"
      decimals="INF"
      id="c96107850"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2021-01-08_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"
      id="c96107913">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107924"
      unitRef="USD">443685</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2022-12-31" id="c96107961">P2Y14D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2021-12-31" id="c96107962">P3Y14D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2022-12-31" id="c96107963">P4Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2021-12-31" id="c96107964">P5Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <dei:DocumentType contextRef="d_2022-01-01_2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2022-01-01_2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2022-01-01_2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2022-01-01_2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2022-01-01_2022-12-31">001-14053</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2022-01-01_2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2022-01-01_2022-12-31">13-3545623</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2022-01-01_2022-12-31">425 Eagle Rock Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2022-01-01_2022-12-31">Roseland</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2022-01-01_2022-12-31">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2022-01-01_2022-12-31">07068</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2022-01-01_2022-12-31">973</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2022-01-01_2022-12-31">535-2717</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2022-01-01_2022-12-31">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2022-01-01_2022-12-31">MLSS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2022-01-01_2022-12-31">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2022-01-01_2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2022-01-01_2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2022-01-01_2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2022-01-01_2022-12-31">No</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2022-01-01_2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2022-01-01_2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2022-01-01_2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2022-01-01_2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="d_2022-01-01_2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="i_2022-06-30" decimals="INF" unitRef="USD">43102239</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2023-03-30" decimals="INF" unitRef="Share">69998525</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="d_2022-01-01_2022-12-31">688</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="d_2021-01-01_2021-12-31">711</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2022-01-01_2022-12-31">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2022-01-01_2022-12-31">East Hanover, New Jersey</dei:AuditorLocation>
    <dei:AuditorName contextRef="d_2021-01-01_2021-12-31">Friedman LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2021-01-01_2021-12-31">East Hanover, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106537"
      unitRef="USD">8715279</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106538"
      unitRef="USD">14764346</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106539"
      unitRef="USD">693717</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106540"
      unitRef="USD">943272</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106541"
      unitRef="USD">443872</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106542"
      unitRef="USD">375360</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106543"
      unitRef="USD">1792335</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106544"
      unitRef="USD">1541513</us-gaap:InventoryNet>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106545"
      unitRef="USD">1325301</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106546"
      unitRef="USD">1309260</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106547"
      unitRef="USD">12970504</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106548"
      unitRef="USD">18933751</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106549"
      unitRef="USD">18146</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106550"
      unitRef="USD">23713</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106551"
      unitRef="USD">227956</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106552"
      unitRef="USD">277619</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106553"
      unitRef="USD">17645</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106554"
      unitRef="USD">26294</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106555"
      unitRef="USD">443685</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106556"
      unitRef="USD">524217</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106557"
      unitRef="USD">24150</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106558"
      unitRef="USD">24150</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106559"
      unitRef="USD">13702086</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106560"
      unitRef="USD">19809744</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106563"
      unitRef="USD">1102729</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106564"
      unitRef="USD">780428</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106565"
      unitRef="USD">803492</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106566"
      unitRef="USD">395857</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106567"
      unitRef="USD">1124839</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106568"
      unitRef="USD">1417248</us-gaap:AccruedLiabilitiesCurrent>
    <mlss:AccruedExpensesRelatedParty
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106569"
      unitRef="USD">167549</mlss:AccruedExpensesRelatedParty>
    <mlss:AccruedExpensesRelatedParty
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106570"
      unitRef="USD">414241</mlss:AccruedExpensesRelatedParty>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106571"
      unitRef="USD">9365</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106572"
      unitRef="USD">8545</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106573"
      unitRef="USD">91701</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106574"
      unitRef="USD">81001</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106575"
      unitRef="USD">3299675</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106576"
      unitRef="USD">3097320</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106577"
      unitRef="USD">10698</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106578"
      unitRef="USD">20062</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106579"
      unitRef="USD">385279</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106580"
      unitRef="USD">476980</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106581"
      unitRef="USD">3695652</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106583"
      unitRef="USD">3594362</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106587"
      unitRef="USD">69306</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106588"
      unitRef="USD">68153</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106599"
      unitRef="USD">127478325</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106600"
      unitRef="USD">124915560</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106601"
      unitRef="USD">-116410405</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106602"
      unitRef="USD">-107704274</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106603"
      unitRef="USD">911516</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106604"
      unitRef="USD">911516</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106608"
      unitRef="USD">10225710</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106609"
      unitRef="USD">16367923</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106611"
      unitRef="USD">-219276</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106612"
      unitRef="USD">-152541</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106613"
      unitRef="USD">10006434</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106615"
      unitRef="USD">16215382</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106616"
      unitRef="USD">13702086</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106617"
      unitRef="USD">19809744</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106623"
      unitRef="USD">8805906</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106624"
      unitRef="USD">10304711</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106625"
      unitRef="USD">3905092</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106626"
      unitRef="USD">3992811</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106627"
      unitRef="USD">4900814</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106628"
      unitRef="USD">6311900</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106629"
      unitRef="USD">12514323</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106630"
      unitRef="USD">12738362</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106631"
      unitRef="USD">1150209</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106632"
      unitRef="USD">878210</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106633"
      unitRef="USD">63755</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106634"
      unitRef="USD">73836</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106635"
      unitRef="USD">13728287</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106636"
      unitRef="USD">13690408</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106637"
      unitRef="USD">-8827473</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106638"
      unitRef="USD">-7378508</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106639"
      unitRef="USD">54607</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106640"
      unitRef="USD">-16360</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106641"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106642"
      unitRef="USD">276180</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106643"
      unitRef="USD">-8772866</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106644"
      unitRef="USD">-7118688</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106645"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106646"
      unitRef="USD">333</us-gaap:IncomeTaxExpenseBenefit>
    <mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106647"
      unitRef="USD">-8772866</mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106648"
      unitRef="USD">-7119021</mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106649"
      unitRef="USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106650"
      unitRef="USD">242589</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106651"
      unitRef="USD">-8772866</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106652"
      unitRef="USD">-6876432</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106653"
      unitRef="USD">-66735</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106654"
      unitRef="USD">-58115</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106655"
      unitRef="USD">-8706131</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106656"
      unitRef="USD">-6818317</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106658"
      unitRef="USDPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106659"
      unitRef="USDPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106663"
      unitRef="Share">70607338</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106664"
      unitRef="Share">68829860</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106667"
      unitRef="Share">64171435</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106668"
      unitRef="USD">64171</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106669"
      unitRef="USD">117934696</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106670"
      unitRef="USD">-100885957</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106671"
      unitRef="USD">-94426</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106672"
      unitRef="USD">-911516</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96106673"
      unitRef="USD">16106968</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106675"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106676"
      unitRef="USD">790915</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106677"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106678"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106680"
      unitRef="USD">790915</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <mlss:StockToBeIssuedDuringPeriodSharesSharebasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106681"
      unitRef="Share">7075</mlss:StockToBeIssuedDuringPeriodSharesSharebasedCompensation>
    <mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106682"
      unitRef="USD">7</mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation>
    <mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106683"
      unitRef="USD">-7</mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation>
    <mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106684"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation>
    <mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106685"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation>
    <mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106686"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation>
    <mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106687"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueSharebasedCompensation>
    <mlss:StockToBeIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106688"
      unitRef="Share">40010</mlss:StockToBeIssuedDuringPeriodSharesIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106689"
      unitRef="USD">40</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106690"
      unitRef="USD">-40</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106691"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106692"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106693"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember"
      decimals="INF"
      id="c96106694"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106695"
      unitRef="Share">18879</mlss:StockToBeIssuedDuringPeriodSharesIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106696"
      unitRef="USD">19</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106697"
      unitRef="USD">-19</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106698"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106699"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106700"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember"
      decimals="INF"
      id="c96106701"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106704"
      unitRef="USD">100000</mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106708"
      unitRef="USD">100000</mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106709"
      unitRef="Share">826499</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106710"
      unitRef="USD">826</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106711"
      unitRef="USD">1381060</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106712"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106713"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106714"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106715"
      unitRef="USD">1381886</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106716"
      unitRef="Share">18345</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106717"
      unitRef="USD">18</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106718"
      unitRef="USD">107482</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106719"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106722"
      unitRef="USD">107500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106723"
      unitRef="Share">289661</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106724"
      unitRef="USD">290</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106725"
      unitRef="USD">770044</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106726"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-ConsultantMember"
      decimals="INF"
      id="c96106729"
      unitRef="USD">770334</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106730"
      unitRef="Share">277767</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106731"
      unitRef="USD">278</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106732"
      unitRef="USD">617889</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106733"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BoardOfDirectorsMember"
      decimals="INF"
      id="c96106736"
      unitRef="USD">618167</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodSharesEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106737"
      unitRef="Share">402490</mlss:StockToBeIssuedDuringPeriodSharesEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106738"
      unitRef="USD">402</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106739"
      unitRef="USD">-402</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106740"
      unitRef="USD">0</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106741"
      unitRef="USD">0</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106742"
      unitRef="USD">0</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106743"
      unitRef="USD">0</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106744"
      unitRef="Share">2101175</mlss:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mlss:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106745"
      unitRef="USD">2102</mlss:StockIssuedDuringPeriodValueWarrantsExercised>
    <mlss:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106746"
      unitRef="USD">3213942</mlss:StockIssuedDuringPeriodValueWarrantsExercised>
    <mlss:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106747"
      unitRef="USD">0</mlss:StockIssuedDuringPeriodValueWarrantsExercised>
    <mlss:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106748"
      unitRef="USD">0</mlss:StockIssuedDuringPeriodValueWarrantsExercised>
    <mlss:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106749"
      unitRef="USD">0</mlss:StockIssuedDuringPeriodValueWarrantsExercised>
    <mlss:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106750"
      unitRef="USD">3216044</mlss:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106754"
      unitRef="USD">-6818317</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106755"
      unitRef="USD">-58115</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106757"
      unitRef="USD">-6876432</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106758"
      unitRef="Share">68153336</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106759"
      unitRef="USD">68153</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106760"
      unitRef="USD">124915560</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106761"
      unitRef="USD">-107704274</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106762"
      unitRef="USD">-152541</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106763"
      unitRef="USD">-911516</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106764"
      unitRef="USD">16215382</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106767"
      unitRef="USD">1499302</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106771"
      unitRef="USD">1499302</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106773"
      unitRef="USD">0</mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106774"
      unitRef="USD">264385</mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106778"
      unitRef="USD">264385</mlss:StockToBeIssuedDuringPeriodValueEmployeeBonuses>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106779"
      unitRef="Share">30196</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106780"
      unitRef="USD">30</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106781"
      unitRef="USD">39973</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106782"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106783"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106784"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106785"
      unitRef="USD">40003</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106786"
      unitRef="Share">577074</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106787"
      unitRef="USD">577</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106788"
      unitRef="USD">746774</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106789"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106790"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106791"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-ConsultantMember"
      decimals="INF"
      id="c96106792"
      unitRef="USD">747351</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <mlss:StockToBeIssuedDuringPeriodSharesEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106793"
      unitRef="Share">147338</mlss:StockToBeIssuedDuringPeriodSharesEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106794"
      unitRef="USD">147</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106795"
      unitRef="USD">-147</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      id="c96106796"
      unitRef="USD"
      xsi:nil="true"/>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      id="c96106797"
      unitRef="USD"
      xsi:nil="true"/>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      id="c96106798"
      unitRef="USD"
      xsi:nil="true"/>
    <mlss:StockIssuedDuringPeriodValueEmployeeBonuses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106799"
      unitRef="USD">0</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106800"
      unitRef="Share">398553</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106801"
      unitRef="USD">399</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106802"
      unitRef="USD">12478</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106803"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106804"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106805"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BoardOfDirectorsMember"
      decimals="INF"
      id="c96106806"
      unitRef="USD">12877</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ProfitLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106810"
      unitRef="USD">-8706131</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106811"
      unitRef="USD">-66735</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106813"
      unitRef="USD">-8772866</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106814"
      unitRef="Share">69306497</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96106815"
      unitRef="USD">69306</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96106816"
      unitRef="USD">127478325</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96106817"
      unitRef="USD">-116410405</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="INF"
      id="c96106818"
      unitRef="USD">-219276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-TreasuryStockMember"
      decimals="INF"
      id="c96106819"
      unitRef="USD">-911516</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106820"
      unitRef="USD">10006434</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106824"
      unitRef="USD">-8772866</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106825"
      unitRef="USD">-6876432</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106827"
      unitRef="USD">14180</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106828"
      unitRef="USD">22205</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106829"
      unitRef="USD">49663</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106830"
      unitRef="USD">51630</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106831"
      unitRef="USD">1499302</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106832"
      unitRef="USD">790915</us-gaap:ShareBasedCompensation>
    <mlss:SharebasedCompensationBonusPaidInStock
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106833"
      unitRef="USD">317265</mlss:SharebasedCompensationBonusPaidInStock>
    <mlss:SharebasedCompensationBonusPaidInStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106834"
      unitRef="USD">793110</mlss:SharebasedCompensationBonusPaidInStock>
    <mlss:ExpensesPaidStock
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106835"
      unitRef="USD">747351</mlss:ExpensesPaidStock>
    <mlss:ExpensesPaidStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106836"
      unitRef="USD">707861</mlss:ExpensesPaidStock>
    <us-gaap:InventoryLIFOReserveEffectOnIncomeNet
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106837"
      unitRef="USD">582299</us-gaap:InventoryLIFOReserveEffectOnIncomeNet>
    <us-gaap:InventoryLIFOReserveEffectOnIncomeNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106838"
      unitRef="USD">0</us-gaap:InventoryLIFOReserveEffectOnIncomeNet>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106839"
      unitRef="USD">80533</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106840"
      unitRef="USD">73552</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106842"
      unitRef="USD">276180</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106843"
      unitRef="USD">-0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106844"
      unitRef="USD">242589</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106846"
      unitRef="USD">-249555</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106847"
      unitRef="USD">-137384</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106848"
      unitRef="USD">833121</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106849"
      unitRef="USD">-878666</us-gaap:IncreaseDecreaseInInventories>
    <mlss:IncreaseDecreaseToAdvancesToContractManufacturer
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106850"
      unitRef="USD">16041</mlss:IncreaseDecreaseToAdvancesToContractManufacturer>
    <mlss:IncreaseDecreaseToAdvancesToContractManufacturer
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106851"
      unitRef="USD">895058</mlss:IncreaseDecreaseToAdvancesToContractManufacturer>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106852"
      unitRef="USD">68512</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106853"
      unitRef="USD">-40555</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106854"
      unitRef="USD">322300</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106855"
      unitRef="USD">297456</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106856"
      unitRef="USD">407636</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106857"
      unitRef="USD">10719</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106858"
      unitRef="USD">-292495</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106859"
      unitRef="USD">562824</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mlss:IncreaseDecreaseInAccruedLiabilitiesRelatedParties
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106860"
      unitRef="USD">-246692</mlss:IncreaseDecreaseInAccruedLiabilitiesRelatedParties>
    <mlss:IncreaseDecreaseInAccruedLiabilitiesRelatedParties
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106861"
      unitRef="USD">-47493</mlss:IncreaseDecreaseInAccruedLiabilitiesRelatedParties>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106862"
      unitRef="USD">-72353</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106863"
      unitRef="USD">-62789</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106864"
      unitRef="USD">-6031996</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106865"
      unitRef="USD">-4033664</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106867"
      unitRef="USD">8527</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106868"
      unitRef="USD">15189</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106869"
      unitRef="USD">-8527</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106870"
      unitRef="USD">-15189</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106872"
      unitRef="USD">8544</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106873"
      unitRef="USD">8648</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106874"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106875"
      unitRef="USD">3216044</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106876"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106877"
      unitRef="USD">1381886</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106878"
      unitRef="USD">-8544</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106879"
      unitRef="USD">4589282</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106880"
      unitRef="USD">-6049067</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96106881"
      unitRef="USD">540429</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106882"
      unitRef="USD">14764346</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96106883"
      unitRef="USD">14223917</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106884"
      unitRef="USD">8715279</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96106885"
      unitRef="USD">14764346</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340311">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE A &lt;/b&gt;&#x2014;&lt;b&gt; ORGANIZATION AND BUSINESS &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;All references in this report to &#x201c;Milestone Scientific,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;we,&#x201d; the &#x201c;Company&#x201d; or &#x201c;Milestone&#x201d; refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C&lt;i&gt;ompuDent&lt;/i&gt;&#xae;&lt;i&gt;; CompuMed&lt;/i&gt;&#xae;&lt;i&gt;; CompuFlo&lt;/i&gt;&#xae;&lt;i&gt;; DPS Dynamic Pressure Sensing technology&lt;/i&gt;&#xae;&lt;i&gt;; Milestone Scientific &lt;/i&gt;&#xae;&lt;i&gt;;&lt;/i&gt;&#160;&lt;i&gt;the Milestone logo &lt;/i&gt;&#xae;&lt;i&gt;; SafetyWand&lt;/i&gt;&#xae;&lt;i&gt;; STA Single Tooth Anesthesia System&lt;/i&gt;&#xae;&lt;i&gt;; and The Wand &lt;/i&gt;&#xae;&lt;i&gt;.&lt;/i&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific was incorporated in the State of Delaware in &lt;em style="font: inherit;"&gt; August 1989. &lt;/em&gt;Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using &lt;i&gt;The Wand&lt;/i&gt;&#xae;, a single use disposable handpiece. The device is marketed in dentistry under the trademark &lt;i&gt;CompuDent&lt;/i&gt;&#xae;&lt;i&gt;, &lt;/i&gt;and &lt;i&gt;STA Single Tooth Anesthesia System&lt;/i&gt;&#xae; and in medicine under the trademark &lt;i&gt;CompuMed&lt;/i&gt;&#xae;&lt;i&gt;. CompuDent&lt;/i&gt;&#xae; is suitable for all dental procedures that require local anesthetic. &lt;i&gt;CompuMed&lt;/i&gt;&#xae; is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics, and many other disciplines. The dental devices are sold in the United States, Canada and in 60 other countries. Certain medical devices have obtained CE mark approval and&#160;can be marketed and sold in most European countries.&#160;In &lt;em style="font: inherit;"&gt; June 2017,&#160;&lt;/em&gt;Milestone Scientific received &lt;em style="font: inherit;"&gt;510&lt;/em&gt;(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the&lt;i&gt; CompuFlo&lt;/i&gt;&#xae; Epidural Computer Controlled Anesthesia System (&#x201c;Epidural&#x201d;).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;We are in the process of&#160;meeting&#160;with medical facilities and device distributors within the United States, Middle East and Europe.&#160; Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its new CompuPulse System,&#160;which combines the benefits of our CompuWave technology with a manual syringe.&#160;The new CompuPulse System allows &lt;em style="font: inherit;"&gt;one&lt;/em&gt; to identify a pulsatile pressure waveform in a variety of applications, thereby improving the reliability and safety of a drug delivery procedure. Importantly, &lt;em style="font: inherit;"&gt;not&lt;/em&gt; all procedures require the sophistication of our CompuFlo system, which precisely controls the administration and flow rate of medication as it is being administered. This new technology provides an efficient and low-cost alternative for procedures where a manual syringe &lt;em style="font: inherit;"&gt; may &lt;/em&gt;suffice, while still providing the ability to verify needle and subsequent catheter placement.&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96106888"
      unitRef="Pure">60</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340312">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;NOTE B-&lt;/b&gt;&#160;&lt;b&gt; LIQUIDITY&lt;/b&gt;&#160;&lt;b&gt;AND UNCERTAINTIES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the consolidated financial statements are issued. Total operating losses since inception of $116.4 million.&#160; The operating losses were&#160;$8.8&#160;million and $7.4&#160;million, for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively. Management has prepared cashflow forecasts covering a period of &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months from the date of issuance of these financial statements. These forecasts include several revenue and operating expense assumptions which indicate that the Company&#x2019;s current cash and liquidity is sufficient to finance the operating requirements for at least the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months Management believes that the Company&#160;will have sufficient cash reserves to meet its anticipated obligations for at least the next &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months from the filing date of this report.&#160;Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company&#x2019;s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;In addition to its employees, the Company relies on (i) distributors, agents, and &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If the Company, or any of these entities encounter any disruptions to its or their respective operations or facilities, or if the Company or any of these &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then the Company or they &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be prevented or delayed from effectively operating its or their business, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The coronavirus (COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt;) adversely impacted the Company's operations, our distributors and suppliers in recent years. Notwithstanding the reopening of dental offices, hospitals, and pain clinics throughout the country and the rest of the world, revenues for years ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; were adversely affected. Any business interruptions, resulting from COVID-&lt;em style="font: inherit;"&gt;19,&lt;/em&gt; or new variant, could significantly disrupt our operations further and could have a material adverse impact on our business in the future.&lt;/p&gt;
   &lt;p style="font-size: 9pt; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Sanctions imposed by the United States and other western democracies, against Russia because of Ukraine conflict, and any expansion of the conflict, is likely to have unpredictable and wide-ranging effects on the domestic and global economy and financial markets, which could have an adverse effect on our business and results of operations. The conflict has caused market volatility, a sharp increase in certain commodity prices, and an increasing number and frequency of cybersecurity threats. As direct impact from the conflict, we have experienced a decrease in international sales to Ukraine and halted all sales to Russia. We will continue to monitor the situation carefully and, if necessary, take action to protect our business, operations, and financial condition.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c96106894"
      unitRef="USD">-116400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96106895"
      unitRef="USD">-8800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c96106896"
      unitRef="USD">-7400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340313">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE C&lt;/b&gt;&#160;&#x2014;&lt;b&gt; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Principles of Consolidation&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The accompanying&#160;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&#160;("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC)&#160;include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Medical (majority owned).&#160; All significant, intra-entity transactions and balances have been eliminated in the consolidation.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt; Use of Estimates&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The preparation of consolidated&#160;financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, stock compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Revenue Recognition&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt; steps:&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;i.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;identification of the promised goods or services in the contract;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;ii.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;iii.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;measurement of the transaction price, including the constraint on variable consideration;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;iv.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;allocation of the transaction price to the performance obligations based on estimated selling prices; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;v.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Sales Returns&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers&#x2019; return rights and the Company&#x2019;s historical experience with returns and the amount of product in the distribution channel &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, adjustments to the allowance for product returns &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required.&#160;The Company recorded allowance of approximately $179,000 for sales&#160;returns from Henry Schein due to the termination of&#160; the&#160;contract on &lt;em style="font: inherit;"&gt; December 31, 2022.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Financing and Payment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company's payment terms differ by geography and customer, but payment is required within &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days from the date of shipment or delivery.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company&#160;operates in &lt;span style="-sec-ix-hidden:c96106949"&gt;two&lt;/span&gt; operating segments: dental and medical. Therefore, results of the Company operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note M&#160;for revenues by geographical market, based on the customer&#x2019;s location, and product category for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;em style="font: inherit;"/&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Variable Interest Entities&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&#x2019;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific has&#160;completed the VIE analysis relating to Milestone China and&#160;Anhui Maishida Medical Technology, Co. Ltd. (&#x201c;Anhui&#x201d;).&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific has determined that due to the loss of equity investment in Anhui, the company &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer has significant influence of Anhui and therefore Anhui is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a variable interest. Milestone Scientific&#160;has a variable interest in Milestone China, it considered the guidance in ASC &lt;em style="font: inherit;"&gt;810,&lt;/em&gt; &#x201c;Consolidation&#x201d; as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary.&#160;Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Power Criterion: The power to direct the activities that most significantly impact the entity&#x2019;s economic performance; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO of Milestone China who have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the primary beneficiary under ASC &lt;em style="font: inherit;"&gt;810.&lt;/em&gt; Accordingly, Milestone China has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been consolidated into the financial statements of Milestone Scientific and is accounted for under the equity method. See Note F.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Milestone Scientific considers all highly liquid investments purchased with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Milestone Scientific has approximately $8.7 million and $14.8 million, respectively, invested in cash. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Milestone Scientific had approximately $8.3&#160;million and $13.9&#160;million, respectively, invested in cash that exceeded the Federal Deposit Insurance Corporation insurance limit of &lt;em style="font: inherit;"&gt;$250,000.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"/&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Accounts Receivable&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the ability or inability of its customers to make payments on amounts billed. Most credit sales are due within &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days from invoicing. There have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been any significant credit losses incurred to date.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;accounts receivable was recorded, net of allowance for doubtful accounts of &lt;span style="-sec-ix-hidden:c96106999"&gt;$10,000.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Inventories&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Inventories principally consist of finished goods and component parts stated at the lower of cost (&lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out method) or net realizable value. Inventory quantities&#160;on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected&#160;future sales, potential technological obsolescence, and product expiration requirements.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The valuation allowance creates a new cost basis for the inventory, and it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation&#160;allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the&#160;underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&lt;b&gt;Equity Method Investments&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Investments in which Milestone Scientific can exercise significant influence, but do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the provision for income tax on the Consolidated Statements of&#160; Operations.&#160;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Furniture, Fixture and Equipment&lt;/b&gt;&#160;&#160;&lt;b&gt; &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from &lt;span style="-sec-ix-hidden:c96107013"&gt;three&lt;/span&gt;&#160;to &lt;span style="-sec-ix-hidden:c96107014"&gt;seven&lt;/span&gt; years. The costs of maintenance and repairs are charged to operations as incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Intangible Assets &lt;/b&gt;&#x2013;&lt;b&gt; Patents and Developed Technology&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are recorded at acquisition cost and be amortized at the estimated useful life.&#160; Patent defense costs, to the extent applicable, are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&#160;&lt;/b&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. The Company&#x2019;s impairment review process is based upon an estimate of future undiscounted cash flow. Factors the Company considers that could trigger an impairment review include the following:&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: 14px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 1730px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;significant under performance relative to expected historical or projected future operating results;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: 14px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 1730px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;significant changes in the manner of our use of the acquired assets or the strategy for our overall business;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: 14px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 1730px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;significant negative industry or economic trends; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: 14px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 1730px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;significant technological changes, which would render the technology obsolete.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt; Note Payable&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; April 27, 2020, &lt;/em&gt;the Company received a loan (the &#x201c;Loan&#x201d;) from Savoy Bank. in the aggregate amount of approximately&#160;&lt;span style="-sec-ix-hidden:c96107022"&gt;$276,000,&lt;/span&gt; pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under Division A, Title I of the CARES Act, which was enacted &lt;em style="font: inherit;"&gt; March 27, 2020. &lt;/em&gt;The Company received forgiveness for the Loan during the year ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and recorded a gain on debt extinguishment of &lt;span style="-sec-ix-hidden:c96107023"&gt;$276,180.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Research and Development&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Research and development costs, which consist principally of new product development costs payable to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;14.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Income Taxes&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Milestone Scientific accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; we had no uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Consolidated Statements of Operations. No interest and penalties are present for periods open. Tax returns for the &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; years are subject to audit by federal and state jurisdictions.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;15.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Basic and Diluted Net Loss Per Common Share&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific presents &#x201c;basic&#x201d; earnings (loss) per common share applicable to common stockholders and, if applicable, &#x201c;diluted&#x201d; earnings (loss) per common&#160;share applicable to common stockholders pursuant to the provisions of ASC &lt;em style="font: inherit;"&gt;260,&lt;/em&gt; &#x201c;Earnings per Share&#x201d;. Basic earnings (loss) per common share is calculated by&#160;dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares of&#160;70,607,338 and 68,829,860 during the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of&#160;additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and&#160;warrants were issued during the period.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Since Milestone Scientific had net losses in the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (&#x201c;RSA&#x201d;) and warrants, were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA and warrants&#160;totaled 7,855,160 and 7,291,800 on &lt;em style="font: inherit;"&gt; December 31,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;16.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required to classify fair value measurements in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the following categories&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company&#160;can access at the measurement date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs which are defined as inputs other than quoted prices included within Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; that are observable for the assets or liabilities, either directly or indirectly.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs are defined as unobservable inputs for the assets or liabilities.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any assets or liabilities that were measured at fair value on a recurring basis.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;17.&lt;/em&gt; Stock-Based Compensation&lt;/b&gt;&#160;&lt;br/&gt; &#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific accounts for stock-based compensation under ASC Topic &lt;em style="font: inherit;"&gt;718,&lt;/em&gt; Share-Based Payment. ASC Topic &lt;em style="font: inherit;"&gt;718&lt;/em&gt; requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;18.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Certain reclassification has&#160;been made to the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; consolidated&#160;financial statements to conform to the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; consolidated&#160;financial statement presentation. These reclassifications had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; effect on net loss or cash flows as previously reported.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;19.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;FASB issued&#160;ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06,&lt;/em&gt;&#160;&#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20&lt;/em&gt;) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;, which, generally, provides guidance for accounting regarding derivatives relating to entities common stock and earnings per share. ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06&lt;/em&gt;&#160;is effective for all entities with fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2021, &lt;/em&gt;including interim periods therein. The adoption of this standard did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an impact on the Company's consolidated financial statement.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&#x201d;&lt;/em&gt;), which amends the guidance on measuring credit losses for certain financial assets measured at amortized cost, including trade receivables. The FASB has subsequently issued several updates to the standard, providing additional guidance on certain topics covered by the standard. This update requires entities to recognize an allowance for credit losses using a forward-looking expected loss impairment model, taking into consideration historical experience, current conditions, and supportable forecasts that impact collectability.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses (Topic, &lt;em style="font: inherit;"&gt;326&lt;/em&gt;), Derivatives and hedging (Topic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;), and Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;): Effective&lt;/i&gt;&#160;&lt;i&gt;dates&lt;/i&gt;, which deferred the effective&#160;date of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; for the Company. As&#160;a result of ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt;&#160;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is effective for all entities with fiscal years beginning&#160;after &lt;em style="font: inherit;"&gt; December 15, 2022, &lt;/em&gt;including interim periods.&#160;The adoption of this update is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to have a material impact on the Company's&#160;consolidated financial statement.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"/&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109271">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Principles of Consolidation&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The accompanying&#160;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&#160;("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC)&#160;include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Medical (majority owned).&#160; All significant, intra-entity transactions and balances have been eliminated in the consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2022-01-01_2022-12-31" id="c96109273">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt; Use of Estimates&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The preparation of consolidated&#160;financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, stock compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109283">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Revenue Recognition&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt; steps:&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;i.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;identification of the promised goods or services in the contract;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;ii.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;iii.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;measurement of the transaction price, including the constraint on variable consideration;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;iv.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;allocation of the transaction price to the performance obligations based on estimated selling prices; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;v.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Sales Returns&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers&#x2019; return rights and the Company&#x2019;s historical experience with returns and the amount of product in the distribution channel &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, adjustments to the allowance for product returns &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required.&#160;The Company recorded allowance of approximately $179,000 for sales&#160;returns from Henry Schein due to the termination of&#160; the&#160;contract on &lt;em style="font: inherit;"&gt; December 31, 2022.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Financing and Payment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company's payment terms differ by geography and customer, but payment is required within &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days from the date of shipment or delivery.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company&#160;operates in &lt;span style="-sec-ix-hidden:c96106949"&gt;two&lt;/span&gt; operating segments: dental and medical. Therefore, results of the Company operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note M&#160;for revenues by geographical market, based on the customer&#x2019;s location, and product category for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <mlss:AllowanceForSalesReturns
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96106939"
      unitRef="USD">179000</mlss:AllowanceForSalesReturns>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="d_2022-01-01_2022-12-31" id="c96109288">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Variable Interest Entities&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&#x2019;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Milestone Scientific has&#160;completed the VIE analysis relating to Milestone China and&#160;Anhui Maishida Medical Technology, Co. Ltd. (&#x201c;Anhui&#x201d;).&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific has determined that due to the loss of equity investment in Anhui, the company &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer has significant influence of Anhui and therefore Anhui is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a variable interest. Milestone Scientific&#160;has a variable interest in Milestone China, it considered the guidance in ASC &lt;em style="font: inherit;"&gt;810,&lt;/em&gt; &#x201c;Consolidation&#x201d; as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary.&#160;Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Power Criterion: The power to direct the activities that most significantly impact the entity&#x2019;s economic performance; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO of Milestone China who have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the primary beneficiary under ASC &lt;em style="font: inherit;"&gt;810.&lt;/em&gt; Accordingly, Milestone China has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been consolidated into the financial statements of Milestone Scientific and is accounted for under the equity method. See Note F.&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109294">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Milestone Scientific considers all highly liquid investments purchased with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Milestone Scientific has approximately $8.7 million and $14.8 million, respectively, invested in cash. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Milestone Scientific had approximately $8.3&#160;million and $13.9&#160;million, respectively, invested in cash that exceeded the Federal Deposit Insurance Corporation insurance limit of &lt;em style="font: inherit;"&gt;$250,000.&lt;/em&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c96106985"
      unitRef="USD">8700000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i_2021-12-31"
      decimals="-5"
      id="c96106986"
      unitRef="USD">14800000</us-gaap:ShortTermInvestments>
    <us-gaap:CashUninsuredAmount
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c96106989"
      unitRef="USD">8300000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="i_2021-12-31"
      decimals="-5"
      id="c96106990"
      unitRef="USD">13900000</us-gaap:CashUninsuredAmount>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="d_2022-01-01_2022-12-31" id="c96109296">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Accounts Receivable&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the ability or inability of its customers to make payments on amounts billed. Most credit sales are due within &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days from invoicing. There have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been any significant credit losses incurred to date.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;accounts receivable was recorded, net of allowance for doubtful accounts of &lt;span style="-sec-ix-hidden:c96106999"&gt;$10,000.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107000"
      unitRef="USD">10000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109301">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Inventories&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Inventories principally consist of finished goods and component parts stated at the lower of cost (&lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out method) or net realizable value. Inventory quantities&#160;on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected&#160;future sales, potential technological obsolescence, and product expiration requirements.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The valuation allowance creates a new cost basis for the inventory, and it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation&#160;allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the&#160;underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="d_2022-01-01_2022-12-31" id="c96109308">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&lt;b&gt;Equity Method Investments&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Investments in which Milestone Scientific can exercise significant influence, but do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the provision for income tax on the Consolidated Statements of&#160; Operations.&#160;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109310">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Furniture, Fixture and Equipment&lt;/b&gt;&#160;&#160;&lt;b&gt; &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from &lt;span style="-sec-ix-hidden:c96107013"&gt;three&lt;/span&gt;&#160;to &lt;span style="-sec-ix-hidden:c96107014"&gt;seven&lt;/span&gt; years. The costs of maintenance and repairs are charged to operations as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2022-01-01_2022-12-31" id="c96109312">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Intangible Assets &lt;/b&gt;&#x2013;&lt;b&gt; Patents and Developed Technology&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are recorded at acquisition cost and be amortized at the estimated useful life.&#160; Patent defense costs, to the extent applicable, are expensed as incurred.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109313">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&#160;&lt;/b&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. The Company&#x2019;s impairment review process is based upon an estimate of future undiscounted cash flow. Factors the Company considers that could trigger an impairment review include the following:&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: 14px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 1730px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;significant under performance relative to expected historical or projected future operating results;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: 14px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 1730px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;significant changes in the manner of our use of the acquired assets or the strategy for our overall business;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: 14px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 1730px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;significant negative industry or economic trends; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: 14px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: 1730px; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;significant technological changes, which would render the technology obsolete.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109315">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt; Note Payable&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; April 27, 2020, &lt;/em&gt;the Company received a loan (the &#x201c;Loan&#x201d;) from Savoy Bank. in the aggregate amount of approximately&#160;&lt;span style="-sec-ix-hidden:c96107022"&gt;$276,000,&lt;/span&gt; pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under Division A, Title I of the CARES Act, which was enacted &lt;em style="font: inherit;"&gt; March 27, 2020. &lt;/em&gt;The Company received forgiveness for the Loan during the year ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and recorded a gain on debt extinguishment of &lt;span style="-sec-ix-hidden:c96107023"&gt;$276,180.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2022-01-01_2022-12-31" id="c96109316">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Research and Development&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Research and development costs, which consist principally of new product development costs payable to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, are expensed as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109318">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;14.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Income Taxes&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Milestone Scientific accounts for income taxes under the asset and liability method which requires deferred tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; we had no uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Consolidated Statements of Operations. No interest and penalties are present for periods open. Tax returns for the &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; years are subject to audit by federal and state jurisdictions.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96107031"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96107034"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109322">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;15.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Basic and Diluted Net Loss Per Common Share&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific presents &#x201c;basic&#x201d; earnings (loss) per common share applicable to common stockholders and, if applicable, &#x201c;diluted&#x201d; earnings (loss) per common&#160;share applicable to common stockholders pursuant to the provisions of ASC &lt;em style="font: inherit;"&gt;260,&lt;/em&gt; &#x201c;Earnings per Share&#x201d;. Basic earnings (loss) per common share is calculated by&#160;dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares of&#160;70,607,338 and 68,829,860 during the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of&#160;additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and&#160;warrants were issued during the period.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Since Milestone Scientific had net losses in the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (&#x201c;RSA&#x201d;) and warrants, were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA and warrants&#160;totaled 7,855,160 and 7,291,800 on &lt;em style="font: inherit;"&gt; December 31,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107042"
      unitRef="Share">70607338</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107044"
      unitRef="Share">68829860</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107049"
      unitRef="Share">7855160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107050"
      unitRef="Share">7291800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2022-01-01_2022-12-31" id="c96109323">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;16.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required to classify fair value measurements in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the following categories&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company&#160;can access at the measurement date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs which are defined as inputs other than quoted prices included within Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; that are observable for the assets or liabilities, either directly or indirectly.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs are defined as unobservable inputs for the assets or liabilities.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any assets or liabilities that were measured at fair value on a recurring basis.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2022-01-01_2022-12-31" id="c96109324">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;17.&lt;/em&gt; Stock-Based Compensation&lt;/b&gt;&#160;&lt;br/&gt; &#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific accounts for stock-based compensation under ASC Topic &lt;em style="font: inherit;"&gt;718,&lt;/em&gt; Share-Based Payment. ASC Topic &lt;em style="font: inherit;"&gt;718&lt;/em&gt; requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2022-01-01_2022-12-31" id="c96109325">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;18.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Certain reclassification has&#160;been made to the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; consolidated&#160;financial statements to conform to the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; consolidated&#160;financial statement presentation. These reclassifications had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; effect on net loss or cash flows as previously reported.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96109326">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;19.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;FASB issued&#160;ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06,&lt;/em&gt;&#160;&#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20&lt;/em&gt;) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;, which, generally, provides guidance for accounting regarding derivatives relating to entities common stock and earnings per share. ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06&lt;/em&gt;&#160;is effective for all entities with fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2021, &lt;/em&gt;including interim periods therein. The adoption of this standard did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an impact on the Company's consolidated financial statement.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&#x201d;&lt;/em&gt;), which amends the guidance on measuring credit losses for certain financial assets measured at amortized cost, including trade receivables. The FASB has subsequently issued several updates to the standard, providing additional guidance on certain topics covered by the standard. This update requires entities to recognize an allowance for credit losses using a forward-looking expected loss impairment model, taking into consideration historical experience, current conditions, and supportable forecasts that impact collectability.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses (Topic, &lt;em style="font: inherit;"&gt;326&lt;/em&gt;), Derivatives and hedging (Topic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;), and Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;): Effective&lt;/i&gt;&#160;&lt;i&gt;dates&lt;/i&gt;, which deferred the effective&#160;date of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; for the Company. As&#160;a result of ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt;&#160;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is effective for all entities with fiscal years beginning&#160;after &lt;em style="font: inherit;"&gt; December 15, 2022, &lt;/em&gt;including interim periods.&#160;The adoption of this update is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to have a material impact on the Company's&#160;consolidated financial statement.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340314">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE D&lt;/b&gt;&#160;&#x2014;&lt;b&gt; INVENTORIES &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,315,263&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;342,465&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;334,124&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,119,709&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Component parts and other materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;142,948&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;79,339&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total inventories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,792,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,541,513&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The Company recorded an allowance on slow moving Medical finished goods of approximately $582,000,&#160;and $450,000 as of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively due to the slow adoption of the epidural instruments and handpieces. The Company recorded an allowance on slow moving Dental finished goods of approximately $0 as of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&lt;/p&gt;
  </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340315">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,315,263&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;342,465&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;334,124&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,119,709&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Component parts and other materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;142,948&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;79,339&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total inventories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,792,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,541,513&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107139"
      unitRef="USD">1315263</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107140"
      unitRef="USD">342465</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107141"
      unitRef="USD">334124</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107142"
      unitRef="USD">1119709</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107143"
      unitRef="USD">142948</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107144"
      unitRef="USD">79339</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107145"
      unitRef="USD">1792335</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107146"
      unitRef="USD">1541513</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember"
      decimals="INF"
      id="c96107130"
      unitRef="USD">582000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2021-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember"
      decimals="INF"
      id="c96107131"
      unitRef="USD">450000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingDentalFinishedGoodsMember"
      decimals="-3"
      id="c96107133"
      unitRef="USD">0</us-gaap:InventoryValuationReserves>
    <mlss:AdvancesToContractManufacturerTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340316">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;NOTE E&lt;/b&gt;&#160;&#x2014;&lt;b&gt; ADVANCES ON CONTRACTS &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The advances on contracts represent funding of future dental STA "Single Tooth Anesthesia System" and epidural inventory purchases&#160;and epidural replacements parts. The balance of the advances as of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; was approximately &lt;span style="-sec-ix-hidden:c96107149"&gt;&lt;span style="-sec-ix-hidden:c96107150"&gt;$1.3&lt;/span&gt;&lt;/span&gt; million.&#160;&lt;/p&gt;
  </mlss:AdvancesToContractManufacturerTextBlock>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340317">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE F&lt;/b&gt;&#160;&#x2013;&#160;&lt;b&gt;INVESTMENT IN AND TRANSACTIONS WITH EQUITY INVESTEES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Milestone China Ltd.&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Ownership &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2014, &lt;/em&gt;Milestone Scientific invested $1 million in Milestone China Ltd. (&#x201c;Milestone China&#x201d;) by contributing dental instruments to Milestone China for a 40% ownership interest. Milestone China owns approximately 75% of Milestone Beijing Medical Equipment Company, Ltd (&#x201c;Milestone Beijing&#x201d;). At the time, Milestone Beijing had primary responsibility for the sales, marketing, and distribution of the Company&#x2019;s dental products in China. Milestone Scientific recorded its investment in Milestone China under the equity method of accounting.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; Milestone China and certain manufacturing/marketing affiliates entered into a reorganization agreement (the &#x201c;Transaction&#x201d;) pursuant to which Milestone China was to merge into an affiliated manufacturing company, Anhui Maishida Medical Technology, Co. Ltd. (&#x201c;Anhui&#x201d;), with Anhui as the surviving entity and to have complete responsibility for sales, marketing, and distribution for the Company&#x2019;s dental products in China. After completion of the Transaction, Milestone Scientific was expected to have an approximate 28.4% direct ownership in Anhui. Due to the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic, the regulatory approval of the planned Transaction was delayed while applicable government offices were closed in China and Hong Kong. Until the completion of the transaction Milestone Scientific's &lt;em style="font: inherit;"&gt;28.4%&lt;/em&gt; in Anhui was held by Milestone China.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;On &lt;em style="font: inherit;"&gt; November 23, 2021, &lt;/em&gt;management of Milestone Scientific became aware that on &lt;em style="font: inherit;"&gt; October 8, 2021, &lt;/em&gt;without approval from Milestone Scientific, (i) Milestone China entered into an Equity Transfer Agreement whereby Milestone China&#x2019;s &lt;span style="-sec-ix-hidden:c96107160"&gt;28.4%&lt;/span&gt; equity stake in Anhui was transferred to Lidong Zhang, the CEO of Milestone China and Anhui, in exchange for RMB 2,840 million (approximately $440,351) of which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; amounts have been or are expected to be received, see below, and (ii) Anhui held a shareholders&#x2019; meeting at which the Equity Transfer Agreement was approved by the shareholders of Anhui, eliminating Milestone China&#x2019;s equity interest in Anhui and Milestone Scientific&#x2019;s indirect equity interest in Anhui. Based on a review of the minutes of the Anhui shareholders&#x2019; meeting, Milestone China was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; listed as a shareholder in such meeting due to the executed Equity Transfer Agreement between Lidong Zhang and Milestone China.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Though management believes that this conveyance by Milestone China to Lidong Zhang is outside of the laws of Hong Kong and/or China, as &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be applicable, at this juncture Milestone Scientific has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; ownership in Anhui and Milestone China has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assets or operations. After considering taking action to assert our rights in the matter, and based on the acknowledgement that such course of action is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; without its procedural and substantive challenges in Hong Kong and/or China and, importantly, in view of Michelle Zhang dba Solee Science &amp;amp; Technology USA (&#x201c;Solee&#x201d;) (see below), a company located in New Jersey, then becoming the&#160;independent distributor for Milestone China and its subsidiaries, and due to the good working relationship then developing between Milestone Scientific and Solee and to the reduction of Milestone Scientific&#x2019;s credit exposure to a Chinese entity, management is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; pursuing any legal action at this time to recover our equity interest. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it is prudent at this time to continue to pursue its investigation of any options it &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have regarding its Chinese distributor, and therefore, in order to preserve cash the Company is for the time being suspending its investigation.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;At this time, Milestone Scientific has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; received any consideration, does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; know if any of such consideration promised to Milestone China for its interest in Anhui has been paid and, if paid, whether it can recover its share of such consideration. Unless circumstances change, Milestone Scientific does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect it will receive any of the consideration received by Milestone China for its assets without pursuing legal action. As a result, Milestone Scientific has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recorded a gain or receivable related to the transfer of Anhui.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the investment in Milestone China was zero.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Related Party Transactions&lt;/i&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Milestone China Distribution Agreement&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone China had been Milestone Scientific&#x2019;s exclusive distributor in China. During &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; and prior to the payment default during &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; Milestone Scientific agreed to sell inventory to Milestone China and its agent. During &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; Milestone Scientific entered into a payment arrangement with Milestone China to satisfy past due receivables from Milestone China and its agents which amounted to $2.8 million at the time of the payment arrangement. Milestone Scientific collected $950,000 under this arrangement, until Milestone China defaulted on the payment arrangements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Beginning in mid-&lt;em style="font: inherit;"&gt; November 2021, &lt;/em&gt;Milestone Scientific entered into discussions with Michelle Zhang dba Solee Science &amp;amp; Technology USA (&#x201c;Solee&#x201d;), a company located in New Jersey, to become Milestone Scientific&#x2019;s independent distributor for China, replacing its former distributor Milestone China and its subsidiaries. On &lt;em style="font: inherit;"&gt; November 22, 2021, &lt;/em&gt;Wand Dental, Inc., a United States subsidiary of Milestone Scientific, entered into a Buy and Sell Agreement with Solee, pursuant to which Milestone Scientific granted Solee the right to sell Milestone Scientific&#x2019;s STA instruments, associated handpieces, and spare parts in China to Anhui.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;For the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;Milestone Scientific shipped instruments or handpieces to Solee for sale to Anhui and recognized&#160;revenue of approximately $630,000.&#160;For the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;Milestone Scientific shipped instruments or handpieces to Solee for sale to Anhui and recognized&#160;revenue of approximately $2.1 million. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company had no deposits from Solee for future shipment of goods included in accrued expenses on the accompanying&#160;consolidated balance sheet.&#160;&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company had approximately $89,000 of deposits from Solee for future shipment of goods included in accrued expenses on the accompanying consolidated balance sheet.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;Gross Profit Deferral&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Due to timing differences of when the inventory sold to Milestone China, Anhui or their agent is recognized and when Milestone China and Anhui sells the acquired inventory to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, an elimination of the recorded profit is required as of the balance sheet date. In accordance with ASC &lt;em style="font: inherit;"&gt;323&lt;/em&gt;&#160;&lt;i&gt;Investment &lt;/i&gt;Equity Method and Joint Ventures, Milestone Scientific has deferred its ownership percentage of the gross profit associated with recognized revenue from sales to Milestone China, Solee as an agent, and Anhui until that product is sold to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company&#160;had no&#160;deferred profit&#160;in the consolidated balance sheets. For the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2021&#160;&lt;/em&gt;Milestone Scientific recorded loss on equity investment of approximately $242,000 in relation to gross profit previously deferred on product sold to Milestone China, Anhui, and Solee, recorded as deferred profit and divesture-equity investment on the accompanying consolidated statement of operations.&#160;&lt;/p&gt;
  </us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="-6"
      id="c96107151"
      unitRef="USD">1000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="1"
      id="c96107152"
      unitRef="Pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i_2014-06-30_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneBeijingMember"
      decimals="2"
      id="c96107153"
      unitRef="Pure">0.75</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i_2021-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember"
      decimals="3"
      id="c96107156"
      unitRef="Pure">0.284</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="d_2021-10-08_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"
      decimals="-7"
      id="c96107161"
      unitRef="CNY">2840000000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="d_2021-10-08_2021-10-08_LegalEntityAxis-MilestoneChinaMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AnhuiMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"
      decimals="INF"
      id="c96107162"
      unitRef="USD">440351</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:NotesReceivableNet
      contextRef="i_2018-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="-5"
      id="c96107177"
      unitRef="USD">2800000</us-gaap:NotesReceivableNet>
    <us-gaap:ProceedsFromCollectionOfFinanceReceivables
      contextRef="d_2018-01-01_2018-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="INF"
      id="c96107178"
      unitRef="USD">950000</us-gaap:ProceedsFromCollectionOfFinanceReceivables>
    <us-gaap:RevenueFromRelatedParties
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="INF"
      id="c96107180"
      unitRef="USD">630000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="-5"
      id="c96107182"
      unitRef="USD">2100000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2022-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="-3"
      id="c96107185"
      unitRef="USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2021-12-31_ProductOrServiceAxis-InstrumentsMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="INF"
      id="c96107186"
      unitRef="USD">89000</us-gaap:ContractWithCustomerLiability>
    <mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss
      contextRef="i_2022-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="-3"
      id="c96107192"
      unitRef="USD">0</mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember"
      decimals="INF"
      id="c96107195"
      unitRef="USD">-242000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340318">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE G&lt;/b&gt;&#x2014;&lt;b&gt; FURNITURE, FIXTURES AND EQUIPMENT &lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;24,734&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;24,734&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Office furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;178,058&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;174,147&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Molds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Trade show displays&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;151,462&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;151,462&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Computers and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;280,066&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;275,364&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Tooling Safety Wand&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;125,022&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;125,022&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Tooling equipment-STA &amp;amp; Wand&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;11,100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;11,100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;EPI and IA Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;82,363&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;82,363&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;STA Trials Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;923,757&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;915,144&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Less accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(905,611&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(891,431&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;18,146&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;23,713&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Depreciation expense was&#160;$14,180&#160;and $22,205 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;respectively.&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340319">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;24,734&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;24,734&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Office furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;178,058&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;174,147&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Molds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Trade show displays&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;151,462&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;151,462&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Computers and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;280,066&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;275,364&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Tooling Safety Wand&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;125,022&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;125,022&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Tooling equipment-STA &amp;amp; Wand&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;11,100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;11,100&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;EPI and IA Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;82,363&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;82,363&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;STA Trials Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;923,757&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;915,144&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Less accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(905,611&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(891,431&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;18,146&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;23,713&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="INF"
      id="c96107226"
      unitRef="USD">24734</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="INF"
      id="c96107227"
      unitRef="USD">24734</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember"
      decimals="INF"
      id="c96107228"
      unitRef="USD">178058</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember"
      decimals="INF"
      id="c96107229"
      unitRef="USD">174147</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember"
      decimals="INF"
      id="c96107230"
      unitRef="USD">7200</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember"
      decimals="INF"
      id="c96107231"
      unitRef="USD">7200</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember"
      decimals="INF"
      id="c96107232"
      unitRef="USD">151462</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember"
      decimals="INF"
      id="c96107233"
      unitRef="USD">151462</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember"
      decimals="INF"
      id="c96107234"
      unitRef="USD">280066</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember"
      decimals="INF"
      id="c96107235"
      unitRef="USD">275364</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember"
      decimals="INF"
      id="c96107236"
      unitRef="USD">125022</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember"
      decimals="INF"
      id="c96107237"
      unitRef="USD">125022</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember"
      decimals="INF"
      id="c96107238"
      unitRef="USD">11100</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember"
      decimals="INF"
      id="c96107239"
      unitRef="USD">11100</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember"
      decimals="INF"
      id="c96107240"
      unitRef="USD">82363</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember"
      decimals="INF"
      id="c96107241"
      unitRef="USD">82363</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember"
      decimals="INF"
      id="c96107242"
      unitRef="USD">63752</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember"
      decimals="INF"
      id="c96107243"
      unitRef="USD">63752</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="INF"
      id="c96107244"
      unitRef="USD">923757</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="INF"
      id="c96107245"
      unitRef="USD">915144</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="INF"
      id="c96107246"
      unitRef="USD">905611</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="INF"
      id="c96107247"
      unitRef="USD">891431</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="INF"
      id="c96107248"
      unitRef="USD">18146</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="INF"
      id="c96107249"
      unitRef="USD">23713</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107221"
      unitRef="USD">14180</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107222"
      unitRef="USD">22205</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340320">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE H&lt;/b&gt;&#160;&#x2014;&lt;b&gt; PATENTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Cost&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Accumulated Amortization&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Net&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Patents-foundation intellectual property&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,377,863&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,149,907&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;227,956&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,377,863&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1,149,907&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;227,956&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Cost&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Accumulated Amortization&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Net&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Patents-foundation intellectual property&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,377,863&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,100,244&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;277,619&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,377,863&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1,100,244&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;277,619&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 to 20 years. Amortization expense was &lt;span style="-sec-ix-hidden:c96107252"&gt;$49,663&lt;/span&gt; and&#160;$53,011 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; , respectively.&#160;The annual amortization expense expected to be recorded for existing intangibles assets for the years &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;through &lt;em style="font: inherit;"&gt;2027&lt;/em&gt;&#160;is&#160;approximately $52,000, $34,000, $28,000, $28,000 and $86,000, respectively.&lt;/p&gt;
  </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="d_2022-01-01_2022-12-31"
      id="c98E01A96-4ED6-4F24-B2A6-47C9B3D5DAC9">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Cost&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Accumulated Amortization&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Net&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Patents-foundation intellectual property&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,377,863&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,149,907&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;227,956&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,377,863&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1,149,907&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;227,956&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Cost&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Accumulated Amortization&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Net&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Patents-foundation intellectual property&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,377,863&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,100,244&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;277,619&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,377,863&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1,100,244&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;277,619&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember"
      decimals="INF"
      id="c96107268"
      unitRef="USD">1377863</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember"
      decimals="INF"
      id="c96107269"
      unitRef="USD">1149907</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember"
      decimals="INF"
      id="c96107270"
      unitRef="USD">227956</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107271"
      unitRef="USD">1377863</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107272"
      unitRef="USD">1149907</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107273"
      unitRef="USD">227956</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember"
      decimals="INF"
      id="c96107280"
      unitRef="USD">1377863</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember"
      decimals="INF"
      id="c96107281"
      unitRef="USD">1100244</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember"
      decimals="INF"
      id="c96107282"
      unitRef="USD">277619</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107283"
      unitRef="USD">1377863</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107284"
      unitRef="USD">1100244</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107285"
      unitRef="USD">277619</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MinimumMember"
      id="c96107250">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MaximumMember"
      id="c96107251">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2021-01-01_2021-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember"
      decimals="INF"
      id="c96107253"
      unitRef="USD">53011</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107257"
      unitRef="USD">52000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107258"
      unitRef="USD">34000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107259"
      unitRef="USD">28000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107260"
      unitRef="USD">28000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107261"
      unitRef="USD">86000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340323">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE I&lt;/b&gt;&#160;&#x2014;&lt;b&gt; STOCKHOLDERS&lt;/b&gt;&#x2019;&lt;b&gt; EQUITY&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;At the annual shareholders meeting in &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company received approval to&#160;increase its authorized shares of common stock from 85,000,000 to&#160;100,000,000 shares.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;WARRANTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The following table summarizes information about shares issuable under warrants outstanding at &lt;em style="font: inherit;"&gt; December 31, 2022:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Warrant shares outstanding&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Weighted Average exercise price&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Weighted Average remaining life&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Intrinsic value&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at January 1, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4,268,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,187,546&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Outstanding and exercisable at December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,268,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;SHARES TO BE ISSUED&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;, there were 2,057,976 and 1,891,979, respectively&#160;shares to be issued whose issuance has been deferred under the terms of an employment agreements with the former Interim Chief Executive Officer,&#160;former Chief Financial Officer, and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there were 382,697&#160;and 174,364, respectively&#160;shares to be issued to non-employees, that will be issued to non-employees for services rendered. The number of shares was fixed at the date of grant and were fully vested upon grant date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The following table summarizes information about shares to be issue at &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Shares-to-be-issued, outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,066,343&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,428,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Granted in current period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;524,814&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;93,918&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Issued in current period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(150,484&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(455,904&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Shares-to be issued outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,440,673&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,066,343&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96107287"
      unitRef="Share">85000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107288"
      unitRef="Share">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340324">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Warrant shares outstanding&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Weighted Average exercise price&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Weighted Average remaining life&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;Intrinsic value&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at January 1, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4,268,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,187,546&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Outstanding and exercisable at December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,268,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107327"
      unitRef="Share">4268221</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107328"
      unitRef="USDPerShare">2.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mlss:WarrantsAndRightsOutstandingWeightedAverageRemainingTerm contextRef="d_2021-01-01_2021-12-31" id="c96107329">P1Y6M</mlss:WarrantsAndRightsOutstandingWeightedAverageRemainingTerm>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107330"
      unitRef="USD">1187546</us-gaap:WarrantsAndRightsOutstanding>
    <mlss:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107331"
      unitRef="Share">0</mlss:ClassOfWarrantOrRightIssuedDuringPeriod>
    <mlss:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107332"
      unitRef="USDPerShare">0</mlss:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice>
    <mlss:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107335"
      unitRef="Share">-0</mlss:ClassOfWarrantOrRightExercisedDuringPeriod>
    <mlss:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107336"
      unitRef="USDPerShare">0</mlss:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107339"
      unitRef="Share">4268221</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107340"
      unitRef="USDPerShare">2.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mlss:WarrantsAndRightsOutstandingWeightedAverageRemainingTerm contextRef="d_2022-01-01_2022-12-31" id="c96107341">P0Y6M</mlss:WarrantsAndRightsOutstandingWeightedAverageRemainingTerm>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember"
      decimals="INF"
      id="c96107291"
      unitRef="Share">2057976</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="i_2021-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember"
      decimals="INF"
      id="c96107292"
      unitRef="Share">1891979</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2022-12-31_TitleOfIndividualAxis-NonemployeesMember"
      decimals="INF"
      id="c96107294"
      unitRef="Share">382697</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2021-12-31_TitleOfIndividualAxis-NonemployeesMember"
      decimals="INF"
      id="c96107295"
      unitRef="Share">174364</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <mlss:DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340325">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Shares-to-be-issued, outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,066,343&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,428,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Granted in current period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;524,814&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;93,918&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Issued in current period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(150,484&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(455,904&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Shares-to be issued outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,440,673&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,066,343&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </mlss:DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107345"
      unitRef="Share">2066343</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96107346"
      unitRef="Share">2428329</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <mlss:DeferredCompensationArrangementWithIndividualSharesGranted
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107347"
      unitRef="Share">524814</mlss:DeferredCompensationArrangementWithIndividualSharesGranted>
    <mlss:DeferredCompensationArrangementWithIndividualSharesGranted
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107348"
      unitRef="Share">93918</mlss:DeferredCompensationArrangementWithIndividualSharesGranted>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107349"
      unitRef="Share">150484</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107350"
      unitRef="Share">455904</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107351"
      unitRef="Share">2440673</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107352"
      unitRef="Share">2066343</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340326">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE J&lt;/b&gt;&#160;&#x2014;&lt;b&gt; STOCK OPTION PLANS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The Milestone Scientific Inc. &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Compensation Plan, as amended and restated (the &lt;em style="font: inherit;"&gt;"2020&lt;/em&gt; Plan"), provides for awards of restricted common, stock restricted stock units, options to purchase and other awards, up to a maximum 4,000,000 shares of common stock and expires in &lt;em style="font: inherit;"&gt; June 2031. &lt;/em&gt;Options &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price &lt;em style="font: inherit;"&gt;not&lt;/em&gt; less than the fair market value of common stock on the date of grant. Generally, options become exercisable over a &lt;span style="-sec-ix-hidden:c96107357"&gt;three&lt;/span&gt;-year period from the grant date and expire &lt;span style="-sec-ix-hidden:c96107358"&gt;five&lt;/span&gt; years after the date of grant.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;the Company had&#160;323,190&#160;and 811,597, respectively, remaining options available for grants under the&#160;Plan.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; April 8, 2021, &lt;/em&gt;as part of its Succession Plan going into effect on &lt;em style="font: inherit;"&gt; April 23, 2021, &lt;/em&gt;the Company announced that Leonard Osser, the Interim Chief Executive Officer, would be accepting the role of Vice Chairman of the Board of Directors. As part of accepting this role, he would be granted options to purchase 2,000,000 shares of common stock, exercisable at the fair market value of the common stock on the date of grant, vesting over the &lt;span style="-sec-ix-hidden:c96107363"&gt;five&lt;/span&gt;-year period after he steps down as&#160;Interim Chief Executive Officer of the Company or &lt;span style="-sec-ix-hidden:c96107364"&gt;ten&lt;/span&gt; years from the date of grant, whichever shall end first. The options were issued pursuant to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Milestone Scientific recognizes compensation expense over the requisite service period and in the case of performance-based options over the period of the expected performance. For the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; Milestone Scientific recognized approximately $961,000 and $763,000 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there was $2.5&#160;million and $3.2 million of total unrecognized compensation cost related to non-vested options, respectively.&#160;Milestone Scientific expects to recognize these costs over a weighted average period of 3.09 and 3.49 years as of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;A summary of option activity for employees under the plans and changes the year&#160;ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;is presented below:&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Averaged Exercise Price $&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic Options Value $&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Options outstanding January 1, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,843,693&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.39&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7.69&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;49,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Granted during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;216,296&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercised during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Forfeited or expired during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Options outstanding December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,059,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.36&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;6.38&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,026,987&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4.93&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The weighted-average grant date fair value per share of options granted to employees during the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; was $0.82 and $1.56, respectively. The aggregate intrinsic value of options granted to employees exercised was $0 and $290,688 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;risk free interest rate of 2.45%, Volatility of 89.60% (which is based on the Company&#x2019;s historical volatility over the expected term), expected term of &lt;span style="-sec-ix-hidden:c96107384"&gt;3&lt;/span&gt;&#160;years, 0% dividend rate and closing price of the stock of $1.52.&#160; &#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;A summary of option activity for non-employees under the plans and changes during the year&#160;ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;is presented below:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Averaged Exercise Price $&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic Options Value $&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Options outstanding January 1, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;83,330&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3.33&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;49,748&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Granted during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;8,333&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;0.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercised during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Options outstanding December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;91,663&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.55&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,083&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;77,776&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,083&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. For the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; Milestone Scientific recognized approximately $22,900 and $27,600 expense related to non-employee options, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;risk free interest rate of 4.12%, Volatility of 91.46%&#160;expected term of 5 years, 0% dividend rate and closing price of the stock of $0.73.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;The information below summarizes the restricted stock award activity for year ended &lt;em style="font: inherit;"&gt; December 31, 2022:&lt;/em&gt;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average Grant-Date Fair Value per Award&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Non-vested as January 1, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;96,557&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.33&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;975,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;0.86&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(449,695&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(186,717&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Non-vested as December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;435,293&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;there were 49,615 restricted shares granted and deferred under the terms of an employment agreements with the Territory Manager of Milestone Scientific. Such shares will be issued to each party upon completion of 2 years of employment. For the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company recognized negative stock compensation expense and stock compensation expense of approximately ($20,000) and $70,000, respectively. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;the total unrecognized compensation expense was $37,500 related to unvested restricted stock awards for Territory Managers, which the Company expects to recognize over an estimated weighted-average period of 1.03&#160;years.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2022,&#160;&lt;/em&gt;the Company entered into&#160;restricted stock agreements with&#160;members of the Board of Directors of the Company. The Company granted&#160;899,390&#160;restricted stock awards with a fair market value of $0.82&#160;per share. Such&#160;restricted stock vests as follows:&#160;25%&#160;on the grant date in &lt;em style="font: inherit;"&gt; June 2022, &lt;/em&gt;and&#160;25%&#160;quarterly, on the&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;day of the following months:&#160;&#160;&lt;em style="font: inherit;"&gt; October 2022,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt; January 2023,&#160;&lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt; April 2023.&#160;&lt;/em&gt;These awards&#160;vest immediately upon a change of control as defined in the agreements. For the&#160;year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022,&#160;&lt;/em&gt;the Company recognized approximately $549,000 for restricted stock expenses recorded in general and administrative expenses on the statement of operation.&#160;As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2022,&#160;&lt;/em&gt;the total unrecognized stock compensation expense was approximately $160,000&#160;related to non-vested restricted stock awards with the members of the Board of Directors, which the Company expects to recognize over an estimated weighted average period of&#160;0.25&#160;years.&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember"
      decimals="INF"
      id="c96107355"
      unitRef="Share">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember"
      decimals="INF"
      id="c96107360"
      unitRef="Share">323190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020EquityIncentivePlanMember"
      decimals="INF"
      id="c96107361"
      unitRef="Share">811597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-04-23_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ViceChairmanOfTheBoardOfDirectorsMember"
      decimals="INF"
      id="c96107362"
      unitRef="Share">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c96107368"
      unitRef="USD">961000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c96107369"
      unitRef="USD">763000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c96107371"
      unitRef="USD">2.5</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c96107372"
      unitRef="USD">3200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c96107373">P3Y1M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c96107374">P3Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="d_2022-01-01_2022-12-31"
      id="F1125605-D8CB-4A9B-892B-549E9EB3911D">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Averaged Exercise Price $&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic Options Value $&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Options outstanding January 1, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,843,693&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.39&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7.69&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;49,246&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Granted during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;216,296&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercised during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Forfeited or expired during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Options outstanding December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,059,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.36&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;6.38&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,026,987&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4.93&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Averaged Exercise Price $&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic Options Value $&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Options outstanding January 1, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;83,330&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3.33&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;49,748&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Granted during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;8,333&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;0.73&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercised during 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Options outstanding December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;91,663&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.55&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,083&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;77,776&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,083&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107415"
      unitRef="Share">2843693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107416"
      unitRef="USDPerShare">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      id="c96107417">P7Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107418"
      unitRef="USD">49246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107419"
      unitRef="Share">216296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107420"
      unitRef="USDPerShare">1.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mlss:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      id="c96107421">P2Y2M23D</mlss:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107423"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107424"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107427"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107428"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107431"
      unitRef="Share">3059989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107432"
      unitRef="USDPerShare">2.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      id="c96107433">P6Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107435"
      unitRef="Share">1026987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107436"
      unitRef="USDPerShare">2.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      id="c96107437">P4Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c96107377"
      unitRef="USDPerShare">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c96107378"
      unitRef="USDPerShare">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c96107379"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c96107380"
      unitRef="USD">290688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="4"
      id="c96107382"
      unitRef="Pure">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="3"
      id="c96107383"
      unitRef="Pure">0.8960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c96107385"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="c96107386"
      unitRef="USDPerShare">1.52</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107443"
      unitRef="Share">83330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107444"
      unitRef="USDPerShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      id="c96107445">P3Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107446"
      unitRef="USD">49748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-01-01_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107447"
      unitRef="Share">8333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107448"
      unitRef="USDPerShare">0.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      id="c96107449">P4Y9M18D</mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107451"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107452"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107455"
      unitRef="Share">91663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107456"
      unitRef="USDPerShare">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      id="c96107457">P2Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107458"
      unitRef="USD">1083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2022-12-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107459"
      unitRef="Share">77776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107460"
      unitRef="USDPerShare">1.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      id="c96107461">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107462"
      unitRef="USD">1083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107388"
      unitRef="USD">22900</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107389"
      unitRef="USD">27600</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="4"
      id="c96107390"
      unitRef="Pure">0.0412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="4"
      id="c96107391"
      unitRef="Pure">0.9146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      id="c96107392">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c96107393"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="c96107394"
      unitRef="USDPerShare">0.73</us-gaap:SharePrice>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      id="c2340329">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Shares&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average Grant-Date Fair Value per Award&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Non-vested as January 1, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;96,557&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2.33&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;975,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;0.86&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(449,695&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(186,717&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Non-vested as December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;435,293&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107465"
      unitRef="Share">96557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107466"
      unitRef="USDPerShare">2.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107467"
      unitRef="Share">975148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107468"
      unitRef="USDPerShare">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107469"
      unitRef="Share">449695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107471"
      unitRef="Share">186717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107473"
      unitRef="Share">435293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107474"
      unitRef="USDPerShare">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-TerritoryManagerMember"
      decimals="INF"
      id="c96107396"
      unitRef="Share">49615</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-TerritoryManagerMember"
      id="c96107397">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107399"
      unitRef="USD">-20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107400"
      unitRef="USD">70000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c96107401"
      unitRef="USD">37500</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      id="c96107402">P1Y10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember"
      decimals="INF"
      id="c96107403"
      unitRef="Share">899390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharePrice
      contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember"
      decimals="INF"
      id="c96107404"
      unitRef="USDPerShare">0.82</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="c96107405"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      decimals="2"
      id="c96107406"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember"
      decimals="INF"
      id="c96107408"
      unitRef="USD">549000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember"
      decimals="INF"
      id="c96107409"
      unitRef="USD">160000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-BoardOfDirectorsMember"
      id="c96107410">P0Y3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <mlss:EmploymentAndConsultingAgreementsTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340330">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE K&lt;/b&gt;&#x2013;&lt;b&gt;EMPLOYMENT CONTRACT AND CONSULTING AGREEMENTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Employment Contracts&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with&#160;Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $100,000 for&#160;years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Director of Clinical Affairs&#x2019; royalty fee was approximately $442,000&#160;and $446,000 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of&#160; $154,000 and $158,000 for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $120,000&#160;and $123,000, respectively, which is included in accounts payable, related party and accrued expense, related party, in the&#160;consolidated balance sheet.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 2, 2021, &lt;/em&gt;Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company&#x2019;s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning &lt;em style="font: inherit;"&gt; May 9, 2027, &lt;/em&gt;half of the royalty (2.5%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated &lt;em style="font: inherit;"&gt; February 25, 2021 &lt;/em&gt;to reduce from 5% to 2.5% the payments due to them on &lt;em style="font: inherit;"&gt; May 9, 2027 &lt;/em&gt;and thereafter, with respect to dental products.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Pursuant to a Succession Agreement dated &lt;em style="font: inherit;"&gt; April 6, 2021 &lt;/em&gt;between Mr. Osser and the Company: (i) the Employment Agreement dated as of &lt;em style="font: inherit;"&gt; July 10, 2017 &lt;/em&gt;between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the &#x201c;China Operations Agreement&#x201d;), and (ii) the Consulting Agreement dated as of &lt;em style="font: inherit;"&gt; July 10, 2017 (&lt;/em&gt;the &#x201c;Consulting Agreement&#x201d;) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement.&#160; Compensation under the China Operations Agreement and the Consulting Agreement are payable for &lt;em style="font: inherit;"&gt;9.5&lt;/em&gt;&#160;years from &lt;em style="font: inherit;"&gt; May 19, 2021.&#160;&lt;/em&gt;The Company recorded expense of $200,000 and $125,000&#160;related to the Managing Director, China Operations for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;The Company recorded expense of $200,000 and $125,000&#160;related to the US Asian Consulting Group, LLC for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
  </mlss:EmploymentAndConsultingAgreementsTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember"
      decimals="INF"
      id="c96107475"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RoyaltyExpense
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107479"
      unitRef="USD">442000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107480"
      unitRef="USD">446000</us-gaap:RoyaltyExpense>
    <us-gaap:ProfessionalFees
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107482"
      unitRef="USD">154000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107483"
      unitRef="USD">158000</us-gaap:ProfessionalFees>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107487"
      unitRef="USD">120000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107488"
      unitRef="USD">123000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <mlss:RoyaltyOnNetSalesPercentage
      contextRef="i_2021-03-02_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember"
      decimals="3"
      id="c96107489"
      unitRef="Pure">0.025</mlss:RoyaltyOnNetSalesPercentage>
    <mlss:RoyaltyOnNetSalesPercentage
      contextRef="i_2021-02-25_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember"
      decimals="2"
      id="c96107490"
      unitRef="Pure">0.05</mlss:RoyaltyOnNetSalesPercentage>
    <mlss:RoyaltyOnNetSalesPercentage
      contextRef="i_2021-03-02_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember"
      decimals="3"
      id="c96107491"
      unitRef="Pure">0.025</mlss:RoyaltyOnNetSalesPercentage>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"
      decimals="INF"
      id="c96107493"
      unitRef="USD">-100000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <mlss:EmploymentAgreementBaseCompensation
      contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"
      decimals="INF"
      id="c96107494"
      unitRef="USD">200000</mlss:EmploymentAgreementBaseCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96107495"
      unitRef="USD">100000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <mlss:EmploymentAgreementBaseCompensation
      contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96107496"
      unitRef="USD">200000</mlss:EmploymentAgreementBaseCompensation>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"
      decimals="INF"
      id="c96107498"
      unitRef="USD">200000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"
      decimals="INF"
      id="c96107499"
      unitRef="USD">125000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96107501"
      unitRef="USD">200000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96107502"
      unitRef="USD">125000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340331">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE L&lt;/b&gt;&#160;&#x2014;&lt;b&gt; INCOME TAXES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Due to Milestone Scientific's history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets. At &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; no recognition was given to the utilization of the remaining net operating loss carry forwards in each of these periods.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax attributes resulting from differences between financial accounting amounts and tax bases of assets and liabilities at&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;are as follows: &#160;&#160;&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Allowance for Doubtful Accounts&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Warranty Reserve&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Impaired Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Capitalized Sec. 174 R&amp;amp;D&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;242,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Inventory Reserve&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;242,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;108,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Deferred Officer's Compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;428,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;439,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Depreciation and Amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;(56,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;(52,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Net Operating Loss Carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;19,315,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;18,895,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Tax Credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;688,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;660,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;155,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;45,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Subtotal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;21,018,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;20,100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;(21,018,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;(20,100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Non-current deferred tax asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; &#160;federal net operating loss carry-forwards are approximately $71,700,000 and $68,300,000, respectively. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;Milestone Scientific has net operating losses generated before &lt;em style="font: inherit;"&gt; December 31, 2017 &lt;/em&gt;will be available to offset future income, if any, through &lt;em style="font: inherit;"&gt; December 2037. &lt;/em&gt;Net operating losses generated in &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; or after can be carried forward indefinitely.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;State net operating losses were approximately $60,500,000 and &lt;span style="-sec-ix-hidden:c96107516"&gt;$63,400,000&lt;/span&gt; for the periods ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively. Net operating losses will be available to offset future taxable income, if any, through &lt;em style="font: inherit;"&gt; December 2041.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;The utilization of Milestone Scientific's net operating losses &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be subject to a substantial limitation due to the "change of ownership provisions" under Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code and similar state provisions. Such limitation &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a 100% valuation allowance for all of its deferred tax assets due to uncertainty as to their future realization.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure, and transition. At &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; we had no uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Statements of Operations. No interest and penalties are present for periods open. Tax returns for the &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; &lt;span style="-sec-ix-hidden:c96107527"&gt;2020,&lt;/span&gt; and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; years are subject to audit by federal and state jurisdictions.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;"&gt;A reconciliation of the statutory tax rates for the years ended &lt;em style="font: inherit;"&gt; December 31, &lt;/em&gt;is as follows:&#160; &#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; width: 179px;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 12px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Statutory Rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;21.00&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;State income tax - all states&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-2.74&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7.44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Stock compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-2.57&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;NOL Expiration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-4.69&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-9.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-0.56&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-7.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Subtotal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10.44&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;11.52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Valuation Allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-10.44&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-11.52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Effective tax Rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-0.00&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96107507"
      unitRef="USD">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340332">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Allowance for Doubtful Accounts&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Warranty Reserve&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Impaired Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Capitalized Sec. 174 R&amp;amp;D&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;242,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Inventory Reserve&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;242,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;108,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Deferred Officer's Compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;428,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;439,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Depreciation and Amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;(56,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;(52,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Net Operating Loss Carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;19,315,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;18,895,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Tax Credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;688,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;660,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;155,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;45,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Subtotal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;21,018,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;20,100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;(21,018,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;(20,100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Non-current deferred tax asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107576"
      unitRef="USD">2000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107577"
      unitRef="USD">2000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107578"
      unitRef="USD">2000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107579"
      unitRef="USD">3000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107580"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107581"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <mlss:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107582"
      unitRef="USD">242000</mlss:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <mlss:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107583"
      unitRef="USD">0</mlss:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107584"
      unitRef="USD">242000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107585"
      unitRef="USD">108000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107586"
      unitRef="USD">428000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107587"
      unitRef="USD">439000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107588"
      unitRef="USD">-56000</mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent>
    <mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107589"
      unitRef="USD">-52000</mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107590"
      unitRef="USD">19315000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107591"
      unitRef="USD">18895000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107592"
      unitRef="USD">688000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107593"
      unitRef="USD">660000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107594"
      unitRef="USD">155000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107595"
      unitRef="USD">45000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107596"
      unitRef="USD">21018000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107597"
      unitRef="USD">20100000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107598"
      unitRef="USD">21018000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107599"
      unitRef="USD">20100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107600"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107601"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="INF"
      id="c96107511"
      unitRef="USD">71700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="INF"
      id="c96107512"
      unitRef="USD">68300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="INF"
      id="c96107515"
      unitRef="USD">60500000</us-gaap:OperatingLossCarryforwards>
    <mlss:PercentageOfValuationAllowance
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c96107520"
      unitRef="Pure">1</mlss:PercentageOfValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96107523"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96107524"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340333">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; width: 179px;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 12px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Statutory Rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;21.00&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;State income tax - all states&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-2.74&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7.44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Stock compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-2.57&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;NOL Expiration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-4.69&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-9.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-0.56&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-7.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Subtotal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10.44&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;11.52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Valuation Allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-10.44&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-11.52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Effective tax Rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 166px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-0.00&lt;/td&gt;&lt;td style="width: 12px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c96107604"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="2"
      id="c96107605"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2022-01-01_2022-12-31"
      decimals="4"
      id="c96107606"
      unitRef="Pure">-0.0274</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2021-01-01_2021-12-31"
      decimals="4"
      id="c96107607"
      unitRef="Pure">0.0744</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2022-01-01_2022-12-31"
      decimals="4"
      id="c96107608"
      unitRef="Pure">-0.0257</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96107609"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <mlss:EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent
      contextRef="d_2022-01-01_2022-12-31"
      decimals="4"
      id="c96107610"
      unitRef="Pure">-0.0469</mlss:EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent>
    <mlss:EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent
      contextRef="d_2021-01-01_2021-12-31"
      decimals="4"
      id="c96107611"
      unitRef="Pure">-0.0913</mlss:EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="4"
      id="c96107612"
      unitRef="Pure">-0.0056</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="4"
      id="c96107613"
      unitRef="Pure">-0.0779</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="4"
      id="c96107614"
      unitRef="Pure">0.1044</mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation>
    <mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="4"
      id="c96107615"
      unitRef="Pure">0.1152</mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2022-01-01_2022-12-31"
      decimals="4"
      id="c96107616"
      unitRef="Pure">-0.1044</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2021-01-01_2021-12-31"
      decimals="4"
      id="c96107617"
      unitRef="Pure">-0.1152</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96107618"
      unitRef="Pure">-0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96107619"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340334">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE M&lt;/b&gt;&#160;&#x2014;&lt;b&gt; SEGMENT AND GEOGRAPHIC DATA&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company conducts its business through &lt;span style="-sec-ix-hidden:c96107620"&gt;two&lt;/span&gt; reportable segments: Dental and Medical. These segments offer different products and services to different customer base.&#160;The Company provides&#160;general corporate services to its segments; however, these services are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; considered when making operating decisions and assessing segment performance. These services are reported under &#x201c;Corporate Services&#x201d; below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments,&#160;financing activities and public company compliance.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The following tables present information about our reportable and operating segments:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Net Sales:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;8,753,156&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,152,511&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;52,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;152,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total net sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,805,906&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,304,711&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Operating Income (Loss):&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,121,815&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,475,059&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(4,788,105&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(4,105,854&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Corporate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,161,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,747,713&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total operating loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(8,827,473&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(7,378,508&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Depreciation and Amortization:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,805&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4,351&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4,075&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7,313&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Corporate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55,875&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;62,172&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;63,755&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;73,836&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Income (loss) before taxes and equity in earnings of affiliates:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,116,598&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,544,730&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(4,794,089&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(4,111,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Corporate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,095,375&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,552,259&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total loss before taxes and equity in earnings of affiliate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(8,772,866&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(7,118,688&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total Assets&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,875,978&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;6,163,169&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;620,373&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,373,511&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Corporate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,205,735&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,273,064&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,702,086&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;19,809,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: left;"&gt;The following table presents information about our operations by geographic area as of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&#160;Net sales by geographic area are based on the respective locations of our subsidiaries.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 22%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Domestic: US&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;524,715&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;532,215&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;560,424&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;560,424&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Handpieces&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,653,914&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;25,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,679,164&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,905,354&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;35,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,940,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Accessories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;78,493&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;78,493&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;69,271&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;70,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Grand Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,257,122&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;32,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,289,872&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,535,049&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;36,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,571,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;International: Rest of World&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,413,525&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,413,525&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,226,486&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;70,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,296,486&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Handpieces&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,391,748&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;20,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,411,748&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,246,302&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;44,900&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,291,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Accessories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;60,797&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;60,797&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,546&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;47,346&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Grand Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,866,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,886,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,519,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;115,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,635,034&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;International: China&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;270,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;270,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;303,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;303,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Handpieces&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;359,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;359,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,795,128&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,795,128&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Accessories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Grand Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;629,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;629,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,098,128&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,098,128&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total Product Sales&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;8,753,156&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;52,750&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;8,805,906&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;10,152,511&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;152,200&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;10,304,711&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

  </mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340335">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Net Sales:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;8,753,156&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,152,511&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;52,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;152,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total net sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,805,906&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,304,711&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Operating Income (Loss):&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,121,815&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,475,059&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(4,788,105&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(4,105,854&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Corporate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,161,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,747,713&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total operating loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(8,827,473&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(7,378,508&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Depreciation and Amortization:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,805&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4,351&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;4,075&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7,313&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Corporate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55,875&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;62,172&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;63,755&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;73,836&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Income (loss) before taxes and equity in earnings of affiliates:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,116,598&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,544,730&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(4,794,089&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;(4,111,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Corporate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,095,375&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,552,259&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total loss before taxes and equity in earnings of affiliate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(8,772,866&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(7,118,688&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total Assets&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Dental&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,875,978&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;6,163,169&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Medical&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;620,373&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,373,511&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Corporate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,205,735&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,273,064&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,702,086&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;19,809,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107629"
      unitRef="USD">8753156</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107630"
      unitRef="USD">10152511</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107631"
      unitRef="USD">52750</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107632"
      unitRef="USD">152200</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107633"
      unitRef="USD">8805906</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107634"
      unitRef="USD">10304711</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107637"
      unitRef="USD">1121815</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107638"
      unitRef="USD">2475059</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107639"
      unitRef="USD">-4788105</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107640"
      unitRef="USD">-4105854</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"
      decimals="INF"
      id="c96107641"
      unitRef="USD">-5161183</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"
      decimals="INF"
      id="c96107642"
      unitRef="USD">-5747713</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107643"
      unitRef="USD">-8827473</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107644"
      unitRef="USD">-7378508</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107647"
      unitRef="USD">3805</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107648"
      unitRef="USD">4351</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107649"
      unitRef="USD">4075</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107650"
      unitRef="USD">7313</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"
      decimals="INF"
      id="c96107651"
      unitRef="USD">55875</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"
      decimals="INF"
      id="c96107652"
      unitRef="USD">62172</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107653"
      unitRef="USD">63755</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107654"
      unitRef="USD">73836</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107657"
      unitRef="USD">1116598</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107658"
      unitRef="USD">2544730</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107659"
      unitRef="USD">-4794089</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107660"
      unitRef="USD">-4111159</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2022-01-01_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"
      decimals="INF"
      id="c96107661"
      unitRef="USD">-5095375</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"
      decimals="INF"
      id="c96107662"
      unitRef="USD">-5552259</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107663"
      unitRef="USD">-8772866</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107664"
      unitRef="USD">-7118688</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:Assets
      contextRef="i_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107667"
      unitRef="USD">3875978</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107668"
      unitRef="USD">6163169</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107669"
      unitRef="USD">620373</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107670"
      unitRef="USD">1373511</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"
      decimals="INF"
      id="c96107671"
      unitRef="USD">9205735</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember"
      decimals="INF"
      id="c96107672"
      unitRef="USD">12273064</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107673"
      unitRef="USD">13702086</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107674"
      unitRef="USD">19809744</us-gaap:Assets>
    <mlss:SalesByProductAndByGeographicalRegionTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340336">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 22%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Domestic: US&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;524,715&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;7,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;532,215&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;560,424&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;560,424&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Handpieces&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,653,914&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;25,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,679,164&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,905,354&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;35,200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;2,940,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Accessories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;78,493&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;78,493&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;69,271&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;70,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Grand Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,257,122&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;32,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,289,872&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,535,049&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;36,500&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,571,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;International: Rest of World&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,413,525&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,413,525&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,226,486&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;70,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,296,486&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Handpieces&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,391,748&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;20,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,411,748&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,246,302&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;44,900&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;3,291,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Accessories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;60,797&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;60,797&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,546&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;47,346&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Grand Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,866,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,886,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,519,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;115,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,635,034&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;International: China&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Dental&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Medical&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Grand Total&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Instruments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;270,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;270,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;303,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;303,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Handpieces&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;359,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;359,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,795,128&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;1,795,128&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Accessories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Grand Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;629,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;629,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,098,128&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,098,128&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total Product Sales&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;8,753,156&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;52,750&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;8,805,906&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;10,152,511&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;152,200&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;10,304,711&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </mlss:SalesByProductAndByGeographicalRegionTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107687"
      unitRef="USD">524715</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107688"
      unitRef="USD">7500</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107689"
      unitRef="USD">532215</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107690"
      unitRef="USD">560424</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107691"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107692"
      unitRef="USD">560424</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107693"
      unitRef="USD">2653914</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107694"
      unitRef="USD">25250</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107695"
      unitRef="USD">2679164</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107696"
      unitRef="USD">2905354</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107697"
      unitRef="USD">35200</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107698"
      unitRef="USD">2940554</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107699"
      unitRef="USD">78493</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107700"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107701"
      unitRef="USD">78493</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107702"
      unitRef="USD">69271</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107703"
      unitRef="USD">1300</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107704"
      unitRef="USD">70571</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107705"
      unitRef="USD">3257122</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107706"
      unitRef="USD">32750</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107707"
      unitRef="USD">3289872</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107708"
      unitRef="USD">3535049</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107709"
      unitRef="USD">36500</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementGeographicalAxis-DomesticMember"
      decimals="INF"
      id="c96107710"
      unitRef="USD">3571549</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107717"
      unitRef="USD">1413525</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107718"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107719"
      unitRef="USD">1413525</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107720"
      unitRef="USD">1226486</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107721"
      unitRef="USD">70000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107722"
      unitRef="USD">1296486</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107723"
      unitRef="USD">3391748</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107724"
      unitRef="USD">20000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107725"
      unitRef="USD">3411748</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107726"
      unitRef="USD">3246302</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107727"
      unitRef="USD">44900</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107728"
      unitRef="USD">3291202</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107729"
      unitRef="USD">60797</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107730"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107731"
      unitRef="USD">60797</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107732"
      unitRef="USD">46546</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107733"
      unitRef="USD">800</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107734"
      unitRef="USD">47346</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107735"
      unitRef="USD">4866070</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107736"
      unitRef="USD">20000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107737"
      unitRef="USD">4886070</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107738"
      unitRef="USD">4519334</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107739"
      unitRef="USD">115700</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementGeographicalAxis-RestOfWorldMember"
      decimals="INF"
      id="c96107740"
      unitRef="USD">4635034</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107747"
      unitRef="USD">270000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107748"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107749"
      unitRef="USD">270000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107750"
      unitRef="USD">303000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107751"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-InstrumentsMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107752"
      unitRef="USD">303000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107753"
      unitRef="USD">359964</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107754"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107755"
      unitRef="USD">359964</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107756"
      unitRef="USD">1795128</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107757"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-HandpiecesMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107758"
      unitRef="USD">1795128</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107759"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107760"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107761"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107762"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107763"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-AccessoriesMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107764"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107765"
      unitRef="USD">629964</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107766"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107767"
      unitRef="USD">629964</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107768"
      unitRef="USD">2098128</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107769"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementGeographicalAxis-CN"
      decimals="INF"
      id="c96107770"
      unitRef="USD">2098128</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107771"
      unitRef="USD">8753156</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107772"
      unitRef="USD">52750</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107773"
      unitRef="USD">8805906</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember"
      decimals="INF"
      id="c96107774"
      unitRef="USD">10152511</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember"
      decimals="INF"
      id="c96107775"
      unitRef="USD">152200</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107776"
      unitRef="USD">10304711</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340337">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE N-- CONCENTRATIONS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Milestone Scientific has informal arrangements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party U.S. manufacturers of the STA, &lt;i&gt;CompuDent&lt;/i&gt; and &lt;i&gt;CompuMed&lt;/i&gt; devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. Consequently, advances on contracts have been classified as current at &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&#160;The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific&#x2019;s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Scientific&#x2019;s financial condition, business, and results of operations.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;We had &lt;span style="-sec-ix-hidden:c96107779"&gt;two&lt;/span&gt;&#160;customers that accounted for 32%, and 11%&#160;amount of revenue respectively for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022.&#160;&lt;/em&gt;We had &lt;span style="-sec-ix-hidden:c96107782"&gt;two&lt;/span&gt;&#160;customers that accounted for 35%, and 20%&#160;amount of revenue respectively for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;We had &lt;span style="-sec-ix-hidden:c96107785"&gt;two&lt;/span&gt;&#160;customers that accounted for 33%, and 20% amount of accounts receivable, respectively as of &lt;em style="font: inherit;"&gt; December 31, 2022.&#160;&lt;/em&gt;We had &lt;span style="-sec-ix-hidden:c96107788"&gt;three&lt;/span&gt; customers that accounted for 29%, 28%, and 13% amount of accounts receivable, respectively as of &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;We had &lt;span style="-sec-ix-hidden:c96107792"&gt;one&lt;/span&gt; vendor&#160;that accounted for 42%,&#160;of accounts payable and accounts payable related party, respectively as of &lt;em style="font: inherit;"&gt; December 31, 2022.&#160;&lt;/em&gt;We had &lt;span style="-sec-ix-hidden:c96107794"&gt;two&lt;/span&gt; vendor&#160;that accounted for 14% and 34 %,&#160;of accounts payable and accounts payable related party, respectively as of &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
  </us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"
      decimals="2"
      id="c96107780"
      unitRef="Pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="2"
      id="c96107781"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"
      decimals="2"
      id="c96107783"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="1"
      id="c96107784"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"
      decimals="2"
      id="c96107786"
      unitRef="Pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="1"
      id="c96107787"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"
      decimals="2"
      id="c96107789"
      unitRef="Pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="2"
      id="c96107790"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember"
      decimals="2"
      id="c96107791"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorOneMember"
      decimals="2"
      id="c96107793"
      unitRef="Pure">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorOneMember"
      decimals="2"
      id="c96107795"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsPayableMember_ConcentrationRiskByTypeAxis-SupplierConcentrationRiskMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis-VendorTwoMember"
      decimals="2"
      id="c96107796"
      unitRef="Pure">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340338">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE O&lt;/b&gt;&#160;&lt;b&gt;-- RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;United Systems&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Milestone Scientific has a supply agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal supplier &#160;of its handpieces, pursuant to which it procures manufactured products under specific purchase orders, but without minimum purchase commitments.&#160;Purchases from this supplier were approximately $3.4 million and &lt;span style="-sec-ix-hidden:c96107810"&gt;$1.7&lt;/span&gt;&#160;million for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160; As &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;Milestone Scientific owed this supplier approximately $819,000&#160;and $548,000, respectively, which is included in accounts payable&#160;and accrued expenses related party on the&#160;consolidated balance sheets. In &lt;em style="font: inherit;"&gt; June 2021, &lt;/em&gt;the Company signed a &lt;em style="font: inherit;"&gt;ten&lt;/em&gt;-year agreement with United Systems for supplier of the handpieces.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Milestone China&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;See Note F.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;K. Tucker Andersen, a significant stockholder of Milestone Scientific, has an agreement with&#160; Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $100,000 for&#160;years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Director of Clinical Affairs&#x2019; royalty fee was approximately $442,000&#160;and $446,000 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of&#160; $154,000 and $158,000 for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $120,000&#160;and $123,000, respectively, which is included in accounts payable, related party and accrued expense, related party, in the&#160;consolidated balance sheet.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 2, 2021, &lt;/em&gt;Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company&#x2019;s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning &lt;em style="font: inherit;"&gt; May 9, 2027, &lt;/em&gt;half of the royalty (2.5%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated &lt;em style="font: inherit;"&gt; February 25, 2021 &lt;/em&gt;to reduce from 5% to 2.5% the payments due to them on &lt;em style="font: inherit;"&gt; May 9, 2027 &lt;/em&gt;and thereafter, with respect to dental products.&lt;/p&gt;
   &lt;p style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;Pursuant to a Succession Agreement dated &lt;em style="font: inherit;"&gt; April 6, 2021 &lt;/em&gt;between Mr. Osser and the Company: (i) the Employment Agreement dated as of &lt;em style="font: inherit;"&gt; July 10, 2017 &lt;/em&gt;between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the &#x201c;China Operations Agreement&#x201d;), and (ii) the Consulting Agreement dated as of &lt;em style="font: inherit;"&gt; July 10, 2017 (&lt;/em&gt;the &#x201c;Consulting Agreement&#x201d;) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement.&#160; Compensation under the China Operations Agreement and the Consulting Agreement are payable for &lt;em style="font: inherit;"&gt;9.5&lt;/em&gt;&#160;years from &lt;em style="font: inherit;"&gt; May 19, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2021.The&lt;/em&gt; Company recorded expense of $200,000 and $125,000&#160;related to the Managing Director, China Operations for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;The Company recorded expense of $200,000 and $125,000&#160;related to the US Asian Consulting Group, LLC for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember"
      decimals="-5"
      id="c96107809"
      unitRef="USD">3400000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i_2022-12-31_BalanceSheetLocationAxis-AccountsPayableRelatedPartiesCurrentMember_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember"
      decimals="INF"
      id="c96107813"
      unitRef="USD">819000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i_2021-12-31_BalanceSheetLocationAxis-AccountsPayableRelatedPartiesCurrentMember_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember"
      decimals="INF"
      id="c96107814"
      unitRef="USD">548000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember"
      decimals="INF"
      id="c96107817"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RoyaltyExpense
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107821"
      unitRef="USD">442000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107822"
      unitRef="USD">446000</us-gaap:RoyaltyExpense>
    <us-gaap:ProfessionalFees
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107824"
      unitRef="USD">154000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107825"
      unitRef="USD">158000</us-gaap:ProfessionalFees>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107828"
      unitRef="USD">120000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i_2021-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember"
      decimals="INF"
      id="c96107829"
      unitRef="USD">123000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <mlss:RoyaltyOnNetSalesPercentage
      contextRef="i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-InterimChiefExecutiveOfficerMember"
      decimals="3"
      id="c96107830"
      unitRef="Pure">0.025</mlss:RoyaltyOnNetSalesPercentage>
    <mlss:RoyaltyOnNetSalesPercentage
      contextRef="i_2021-03-01_RelatedPartyTransactionsByRelatedPartyAxis-DirectorClinicalAffairMember"
      decimals="2"
      id="c96107832"
      unitRef="Pure">0.05</mlss:RoyaltyOnNetSalesPercentage>
    <mlss:RoyaltyOnNetSalesPercentage
      contextRef="i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-DirectorClinicalAffairMember"
      decimals="3"
      id="c96107833"
      unitRef="Pure">0.025</mlss:RoyaltyOnNetSalesPercentage>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"
      decimals="INF"
      id="c96107834"
      unitRef="USD">-100000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <mlss:EmploymentAgreementBaseCompensation
      contextRef="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember"
      decimals="INF"
      id="c96107836"
      unitRef="USD">200000</mlss:EmploymentAgreementBaseCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96107837"
      unitRef="USD">-100000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <mlss:EmploymentAgreementBaseCompensation
      contextRef="d_2017-07-10_2017-07-10_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96107838"
      unitRef="USD">200000</mlss:EmploymentAgreementBaseCompensation>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ManagingDirectorChinaOperationsMember"
      decimals="INF"
      id="c96107842"
      unitRef="USD">200000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ManagingDirectorChinaOperationsMember"
      decimals="INF"
      id="c96107844"
      unitRef="USD">125000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96107846"
      unitRef="USD">200000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96107848"
      unitRef="USD">125000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340339">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE P&lt;/b&gt;&#160;&#x2014;&lt;b&gt; COMMITMENTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) &lt;/b&gt;&#160;&lt;b&gt;Contract Manufacturing Agreement&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific has informal arrangements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party manufacturers of the STA, CompuDent&#xae; and CompuMed&#xae; devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment.&#160;The company entered a new purchase commitment for the delivery of 2,040 STA CompuDent&#xae; instruments. As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;the purchase order commitment was approximately $1.7&#160;million, and&#160;approximately $1.2&#160;million was paid and reported in advances on contracts in the&#160;consolidated balance sheet. As of&#160; &lt;em style="font: inherit;"&gt; December&#160; &lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;the purchase order commitment was approximately $2.6 million, approximately $1.3 million was paid and &#160;reported in advances on contracts in the consolidated balance sheet. As of &lt;em style="font: inherit;"&gt; December 31, 2022&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;the company also has advances on an open purchase order for long lead items for a future purchase order for the manufacturing of Epidural instrument&#160;of approximately&#160;$76,000 and $34,000, respectively.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&lt;/b&gt;&#160;&lt;b&gt; Leases&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; August 2019, &lt;/em&gt;the Company made the&#160;decision to &lt;em style="font: inherit;"&gt;not&lt;/em&gt; renew its&#160;existing office lease for its corporate headquarters located in Livingston, New Jersey and instead signed a new &lt;span style="-sec-ix-hidden:c96107913"&gt;seven&lt;/span&gt; year lease in a new facility located in Roseland, New Jersey (the &#x201c;Roseland Facility&#x201d;), which commenced of &lt;em style="font: inherit;"&gt; January 8, 2021 . &lt;/em&gt;Under the Roseland Facility lease, rent payments commence on &lt;em style="font: inherit;"&gt; April 1, 2021 , &lt;/em&gt;and the monthly lease payments escalate annually on &lt;em style="font: inherit;"&gt; January 1 &lt;/em&gt;of each year, and range from $9,275 to $10,898 per month over the lease term. The Company is also required to pay a fixed electric charge equal to $2.00 per square foot which is &#160;paid in equal monthly installments over the lease term or $11,130 annually. These fixed monthly payments have been included in the measurement of the operating lease liability and related operating lease right-of-use asset as the Company has elected the practical expedient to &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separate lease and non-lease components for all leases.&#160;The Company is also required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises more than new base year amounts, which are accounted for as variable lease expenses.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;total&#160;finance&#160;right-of-use assets were $17,645 and total finance liabilities were $20,063&#160;of which $9,365 and $10,698 were classified as current and non-current, respectively.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;total operating right-of use assets &lt;span style="-sec-ix-hidden:c96107924"&gt;were$443,685&lt;/span&gt; and total operating lease liabilities were $476,980, of which $91,701 and $385,279&#160;were classified as current and non-current, respectively.&#160; As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;total&#160; finance&#160;right-of-use assets were $26,294 and total finance liabilities were $28,607 of which $8,545 and $20,062 were classified as current and non-current, respectively.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;total operating right-of use assets were $524,217&#160;and total operating lease liabilities were $557,981, of which $81,001 and &lt;em style="font: inherit;"&gt;$476,980&lt;/em&gt; were classified as current and non-current, respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;As the Company&#x2019;s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the Medical Device industry.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 9pt;"&gt;&lt;td style="vertical-align: top; width: auto; text-align: justify; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: top; width: auto; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The expected lease terms include non-cancellable&#160;lease periods. Renewal option periods are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the determination of the lease terms as they were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; reasonably certain to be exercised.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The components of lease expense were as follows:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Cash paid for operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;127,995&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;127,526&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Cash paid for finance lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;663,009&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment obtained in exchange for new finance lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;43,242&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Finance leases (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c96107961"&gt;2.04 years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c96107962"&gt;3.04 years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Operating leases (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c96107963"&gt;4.25 years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c96107964"&gt;5.25 years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0px;"&gt;9.20&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0px;"&gt;9.20&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted-average discount rate &#x2013; finance leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0px;"&gt;9.20&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0px;"&gt;9.20&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Maturity of lease liabilities as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating Leases&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Finance Leases&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;130,778&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;133,560&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;136,343&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;433&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;139,125&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,477&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total future minimum lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;575,283&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;21,913&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Less: interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(98,303&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,850&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Present value of lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;476,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,063&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mlss:PurchaseCommitmentNumberOfUnits
      contextRef="d_2022-01-01_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember"
      decimals="INF"
      id="c96107899"
      unitRef="Pure">2040</mlss:PurchaseCommitmentNumberOfUnits>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember"
      decimals="-5"
      id="c96107900"
      unitRef="USD">1700000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember"
      decimals="-5"
      id="c96107902"
      unitRef="USD">1200000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember"
      decimals="-5"
      id="c96107905"
      unitRef="USD">2600000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember"
      decimals="-5"
      id="c96107906"
      unitRef="USD">1300000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesBeginningIn2021Member"
      decimals="INF"
      id="c96107908"
      unitRef="USD">76000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2021-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesBeginningIn2021Member"
      decimals="INF"
      id="c96107909"
      unitRef="USD">34000</us-gaap:AdvancesOnInventoryPurchases>
    <mlss:OperatingLeasesMonthlyRentExpense
      contextRef="d_2019-08-01_2019-08-31_RangeAxis-MinimumMember_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"
      decimals="INF"
      id="c96107914"
      unitRef="USD">9275</mlss:OperatingLeasesMonthlyRentExpense>
    <mlss:OperatingLeasesMonthlyRentExpense
      contextRef="d_2019-08-01_2019-08-31_RangeAxis-MaximumMember_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"
      decimals="INF"
      id="c96107915"
      unitRef="USD">10898</mlss:OperatingLeasesMonthlyRentExpense>
    <mlss:LesseeOperatingLeaseElectricCharge
      contextRef="d_2019-08-01_2019-08-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"
      decimals="INF"
      id="c96107916"
      unitRef="USD">2.00</mlss:LesseeOperatingLeaseElectricCharge>
    <mlss:LesseeOperatingLeaseElectricPaymentsAnnually
      contextRef="d_2019-08-01_2019-08-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember"
      decimals="INF"
      id="c96107917"
      unitRef="USD">11130</mlss:LesseeOperatingLeaseElectricPaymentsAnnually>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107919"
      unitRef="USD">17645</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107920"
      unitRef="USD">20063</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107921"
      unitRef="USD">9365</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107922"
      unitRef="USD">10698</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107925"
      unitRef="USD">476980</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107926"
      unitRef="USD">91701</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107928"
      unitRef="USD">385279</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107929"
      unitRef="USD">26294</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107930"
      unitRef="USD">28607</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107932"
      unitRef="USD">8545</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107933"
      unitRef="USD">20062</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107934"
      unitRef="USD">524217</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107935"
      unitRef="USD">557981</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96107936"
      unitRef="USD">81001</us-gaap:OperatingLeaseLiabilityCurrent>
    <mlss:LeaseCostAndOtherInformationTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340340">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Cash paid for operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;127,995&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;127,526&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Cash paid for finance lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;663,009&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment obtained in exchange for new finance lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;43,242&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Finance leases (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c96107961"&gt;2.04 years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c96107962"&gt;3.04 years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Operating leases (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c96107963"&gt;4.25 years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c96107964"&gt;5.25 years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0px;"&gt;9.20&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0px;"&gt;9.20&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted-average discount rate &#x2013; finance leases&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0px;"&gt;9.20&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0px;"&gt;9.20&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </mlss:LeaseCostAndOtherInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107952"
      unitRef="USD">127995</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107953"
      unitRef="USD">127526</us-gaap:OperatingLeasePayments>
    <mlss:FinanceLeasePrincipalPaymentsIncludingAccruedExpenses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107954"
      unitRef="USD">10740</mlss:FinanceLeasePrincipalPaymentsIncludingAccruedExpenses>
    <mlss:FinanceLeasePrincipalPaymentsIncludingAccruedExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107955"
      unitRef="USD">10740</mlss:FinanceLeasePrincipalPaymentsIncludingAccruedExpenses>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107956"
      unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107957"
      unitRef="USD">663009</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96107958"
      unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96107959"
      unitRef="USD">43242</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2022-12-31"
      decimals="3"
      id="c96107965"
      unitRef="Pure">0.0920</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2021-12-31"
      decimals="3"
      id="c96107966"
      unitRef="Pure">0.0920</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2022-12-31"
      decimals="3"
      id="c96107967"
      unitRef="Pure">0.0920</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2021-12-31"
      decimals="3"
      id="c96107968"
      unitRef="Pure">0.0920</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340341">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Maturity of lease liabilities as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating Leases&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Finance Leases&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;130,778&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;133,560&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;10,740&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;136,343&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;433&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;139,125&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,477&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Total future minimum lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;575,283&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;21,913&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Less: interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(98,303&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,850&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Present value of lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;476,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,063&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107971"
      unitRef="USD">130778</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107972"
      unitRef="USD">10740</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107973"
      unitRef="USD">133560</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107974"
      unitRef="USD">10740</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107975"
      unitRef="USD">136343</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107976"
      unitRef="USD">433</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107977"
      unitRef="USD">139125</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107978"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107979"
      unitRef="USD">35477</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107980"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107981"
      unitRef="USD">575283</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107982"
      unitRef="USD">21913</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107983"
      unitRef="USD">98303</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107984"
      unitRef="USD">1850</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107985"
      unitRef="USD">476980</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96107986"
      unitRef="USD">20063</us-gaap:FinanceLeaseLiability>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340342">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE Q&lt;/b&gt;&#160;&#x2014;&lt;b&gt; BENEFIT PLAN&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; contribute to this plan, but does pay the administrative costs of the plan, which were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; significant.&lt;/p&gt;
  </us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2340343">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;NOTE R&lt;/b&gt;&#160;&#x2014;&lt;b&gt; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 3, 2023 &lt;/em&gt;,the Company launched an E-Commerce platform,&#160;selling and shipping&#160;STA Single Tooth Anesthesia System&#xae;&#160;(STA) and handpieces directly to dental office, and dental&#160;groups within the US.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 4, 2023, &lt;/em&gt;Leslie Bernhard tendered her resignation to Milestone Scientific Inc. (the "Company&#x201d;) as a director, Chairman of the Audit Committee and Chairman of the Board of the Company. Ms. Bernhard&#x2019;s resignation comes after nearly &lt;em style="font: inherit;"&gt;20&lt;/em&gt; years of service as a director of the Company. Ms. Bernhard indicated that her decision to resign was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the result of a disagreement with the Company. The Company thanks Ms. Bernhard for her long, dedicated service on the Board and wishes her well in her future pursuits.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;In connection with Ms. Bernhard&#x2019;s resignation, on &lt;em style="font: inherit;"&gt; January 4, 2023, &lt;/em&gt;the Company&#x2019;s Board of Directors (the "Board&#x201d;) unanimously appointed Neal Goldman, who has been a member of the Board since &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; as Chairman of the Board. Mr. Goldman is the President and Founder of Goldman Capital Management, Inc., a family office since &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; which was previously an investment advisory firm founded in &lt;em style="font: inherit;"&gt;1985.&lt;/em&gt; Mr. Goldman was First Vice President of Research at Shearson Lehman Hutton. He has also held senior positions as a money manager and research analyst with a variety of firms including Neuberger Berman, Moseley Hallgarten Estabrook and Weeden, Bruns Nordeman, and Russ and Company. Mr. Goldman has served as Chairman of Charles &amp;amp; Colvard, Ltd. since &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; and served on the board of directors of Imageware Systems, Inc. until &lt;em style="font: inherit;"&gt; November 2020. &lt;/em&gt;He also serves on the board of directors of Koil Energy Solutions Inc. Prior to their respective acquisitions, he served on the boards of Blyth Industries and IPASS Corporation. Mr. Goldman received his B.A. degree in Economics from The City University of New York (City College).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;Also on &lt;em style="font: inherit;"&gt; January 4, 2023, &lt;/em&gt;the Board unanimously appointed Arjan Haverhals as a director of the Company. Mr. Haverhals has been the Company&#x2019;s Chief Executive Officer since &lt;em style="font: inherit;"&gt; May 2021 &lt;/em&gt;and President since &lt;em style="font: inherit;"&gt; September 2020. &lt;/em&gt;Mr. Haverhals has also been the President and Chief Executive Officer of the Company&#x2019;s Dental Division (Wand Dental, Inc.) since &lt;em style="font: inherit;"&gt; June 2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 10, 2023, &lt;/em&gt;the Company&#160;announced it has entered into a distribution agreement granting TEKMIKA Health Technologies exclusive distribution rights to market Milestone&#x2019;s STA Single Tooth Anesthesia System&#xae;&#160;(STA) in Brazil. TEKMIKA Health Technologies is a leading distributor in Brazil, focused on importing, promotion, marketing and distribution of high-tech medical equipment and device.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;On &lt;em style="font: inherit;"&gt; January 12, 2023, &lt;/em&gt;the Company announced it has entered into a distribution agreement with&#160;Sweden &amp;amp; Martina, a leading European dental distributor and manufacturer. Under the agreement, Sweden &amp;amp; Martina has been awarded the exclusive rights to market Milestone&#x2019;s STA Single Tooth Anesthesia System&#xae;&#160;(STA) in the new markets of Spain, Portugal and France. In addition, Sweden &amp;amp; Martina will replace the Company&#x2019;s current distributor in Italy and become its exclusive STA distributor in this market.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; February 6, 2023, &lt;/em&gt;Milestone Scientific Inc. (the "Company&#x201d;) announced the appointment of Peter Milligan as the Company&#x2019;s Chief Financial Officer, on a part-time basis, effective &lt;em style="font: inherit;"&gt;February1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; In connection with serving as the Company&#x2019;s Chief Financial Officer, Mr. Milligan will be entitled to receive an annual salary of $120,000 and be eligible to receive an annual incentive bonus with a target of 40% of his annual cash compensation, which shall be payable in shares of the Company&#x2019;s common stock. Mr. Milligan will also be entitled to receive $100,000 in shares of the Company&#x2019;s common stock on an annual basis, of which, $50,000 shall have a grant date of &lt;em style="font: inherit;"&gt; February 1 &lt;/em&gt;and $50,000 shall have a grant date as of &lt;em style="font: inherit;"&gt; August 1 &lt;/em&gt;of each year beginning in &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; valued at the closing price of the Company&#x2019;s common stock on the NYSE American on the grant date, and which shares are to be issued to Mr. Milligan following the expiration of &lt;em style="font: inherit;"&gt;sixty&lt;/em&gt; (&lt;em style="font: inherit;"&gt;60&lt;/em&gt;) days after the termination of his employment with the Company.&#160;Mr.&#160;Milligan holds an M.B.A. from New York University with a concentration in Finance and Economics and a B.B.A. in Accounting from Hofstra University. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; family relationships between Mr.&#160;Milligan and any of the Company&#x2019;s directors or executive officers, and there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; arrangement or understanding between Mr.&#160;Milligan or any other person and the Company or any of its subsidiaries pursuant to which he was appointed as an officer of the Company. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; transactions between Mr.&#160;Milligan or any of his immediate family members and the Company or any of its subsidiaries that would be required to be reported under Item &lt;em style="font: inherit;"&gt;404&lt;/em&gt;(a) of Regulation&#160;S-K.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; February&#160;&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;27,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; the Company &#160;announced that its CompuFlo&#xae; Epidural System has received &lt;em style="font: inherit;"&gt;510&lt;/em&gt;(k) FDA clearance for use in the thoracic region of the spine, including the cervical thoracic junction. This approval expands upon the Company&#x2019;s prior approval of CompuFlo for use within the lumbar region of the spine, where the focus has been on labor and delivery.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="d_2023-02-06_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"
      decimals="INF"
      id="c96107998"
      unitRef="USD">120000</us-gaap:OfficersCompensation>
    <mlss:IncentiveBonusPercentageOfAnnualCashCompensation
      contextRef="d_2023-02-06_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"
      decimals="1"
      id="c96107999"
      unitRef="Pure">0.40</mlss:IncentiveBonusPercentageOfAnnualCashCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2023-02-06_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"
      decimals="INF"
      id="c96108000"
      unitRef="Share">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-02-01_2023-02-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"
      decimals="INF"
      id="c96108001"
      unitRef="Share">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-08-01_2023-08-01_StatementScenarioAxis-ScenarioPlanMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"
      decimals="INF"
      id="c96108003"
      unitRef="Share">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c96107956"
          xlink:label="c96107956"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c96107957"
          xlink:label="c96107957"
          xlink:type="locator"/>
        <link:footnote id="fabee3baa-b46a-463f-af9a-7d2dd726a667" xlink:label="fabee3baa-b46a-463f-af9a-7d2dd726a667" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">For the nine months ended September 30, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c96107956"
          xlink:to="fabee3baa-b46a-463f-af9a-7d2dd726a667"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c96107957"
          xlink:to="fabee3baa-b46a-463f-af9a-7d2dd726a667"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M+D84RUF+#<6W^7K-)ZX4C_.7&T8#)K(OZ,^?.5>[C>P']HN*I_\'4$L#!!0
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M,8KZ,UI]8O6J^A+UH*W5R^IP(04DX S@_EQKNSUQ'[=V'S.G_P-02P,$%
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M=@76SJC7]34MG6VBDNB2M)/NT^\HV9(C4=H&](UMR<?3[^Y(_D^</4GU5>\
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MJL6HEJ!:BFJW>K,+39CCL=$\CD<;QU M0[7\#7=)/8Z//6'ZN1-Q]3J)BK:
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MU1R6;I:("0KK4,M!W<P\L))CC[&H]]#&&@=JIT@!I@3/ $TH&;H( 0[AHDN
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M^KE5S.39L*,34/E'4]/YDQ/.M2< %0 A_5OSRS T^1"'T_6>>(W;4V8#[4^
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MQNWOZZG&6:>QDHF"2R.4!,T7%ZUQ]^RR1_).X%;PC=D; T4R5^J.)N^SBU9
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M5M%/5]2;HW8*M+Y0U/=4'^Z NML?_0=02P,$%     @ ,XE^5MJJDF7P!0
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MESDOSO&-);4SP/.IPH6U7;@-NJ^VP;]02P,$%     @ ,XE^5J^V=!9_ @
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M@S*-V -S&?WW6:=JYQ_U5XYZ7T\1 XDJ)36MUGF[077=].>?\&;*+9G><VE
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ML*0W$QHO0/N%IA[:3KR![A4V_@]02P,$%     @ ,XE^5F18Z=LW!0  %0P
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M KU?2;H4M1O[@>X_@=G_4$L#!!0    ( #.)?E89A??,@P(  &D%   9
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M?CHA=M*+G9QB3^^1I W2]O?BX-<#/G.H3/;X^YC>TXS+KP\+ON?Y8KFXN7V
MU9?+)=Q)A=Q@&F&=2=Y+%C*#4C@0<,U[:LSABB_5RDT3'.1; Z@4!$*QF1V@
MDENY40A8U<J\8'O V1Z#4 M+8 H&H>270"CV/0?6--N2%U^L48H]E#?!HFYP
M7%)NF%@;\K]CAQL?M'^%=AM,[EA'HZEU0C_;OR.7K7W^I;>/T)VP6ZD=*"P8
M.AQ\/(O ML9N S)U,-/&$%LS#$M^"]'Z!%XO#/=9%_@-^M<U_0M02P,$%
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M'",'U UL-G&R"5!<<7SC#I1G@W1GH%=9%)QT"*HW,T.X=KL\:=8$ORGT'^K
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M["4$_IVL1N;X:(F\BF4U2G75 []LQ3_B]8,+THD7]= :.I,:3*SMU8-L^(+
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MK98&X/W<F#I^H072+_;>_S]02P,$%     @ ,XE^5IJD VZ. @  E 4  !D
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M<*\L8?XI]6^QR?\5&\=AVN\W"FAAD(Q>%;LC==<%B;:JMD2]\KW)0$[:;%/
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MX_A$O$''>&#C#4XP5N (OL?/>2?O>YLS<J%JEN+,HT.@4#ZC-__X6S0*/Y_
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MI(Q7P/.YQE6R8_P!_1^KR;]02P,$%     @ ,XE^5@II0;&Z P  !0D  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC59M;]LX#/XKA+<;6L")WYVD
M2P(TW88;L&Y!U[M].-P'Q682H;:527+3_/NC9,=)NS2W+S9%DX\>4J3H\5;(
M![5&U/!4%I6:.&NM-U>>I[(UEDSUQ08K^K(4LF2:EG+EJ8U$EENGLO!"WT^]
MDO'*F8ZM;BZG8U'K@E<XEZ#JLF1R-\-";"=.X.P5=WRUUD;A3<<;ML+OJ/_:
MS"6MO XEYR56BHL*)"XGSG5P-4N,O37XF^-6'<E@(ED(\6 6G_.)XQM"6&"F
M#0*CUR/>8%$8(*+QL\5TNBV-X[&\1_]D8Z=8%DSAC2A^\%RO)\[0@1R7K"[T
MG=C^B6T\EF F"F6?L&ULT]B!K%9:E*TS,2AYU;S94YN'(X>A_XI#V#J$EG>S
MD67Y@6DV'4NQ!6FL"<T(-E3K3>1X90[ENY;TE9.?GGX5&F$./;@19<DUI5LK
MN+AGBP+5Y=C3M(4Q]+(6;M; A:_ !2'<BDJO%7RL<LR? WC$K2,8[@G.PK.(
M'S#K0Q2X$/IA> 8OZ@*.+%YT)F %38"GXFN\X]/>ID6NU(9E.'&H!Q3*1W2F
M[]X$J?_^#+>XXQ:?0Y]^0:HOEXY":6!5#M_T&B5\KIK>,T7\CR4.]_BD85:(
M[.'?4S&<WX4RBN6"@/=9A9>: &Z86L.&\1QH;Z K0-+^U0H*PQ *SA:\X)I3
M)M]"$ [<T2AII21,7W@O><6J#$_X!KX[B/W]RUX(/;'LU63&E$*J1+'0=+%@
M#KP"?,K6K%JA!:VHW\_1N@@NJ:C3-')]?P1S:6SUSF85?]9\8PK]//KKM'L0
M1VX8A_##]CSY7S\2$_*]0W,/&D;V*.F<9 F?CH&(V0Z95)<0]OT8K S10?SV
M/*:#>=P/D]8F.8A[!CW6,LBYRD1-L1$*PKLWPS (WK_,E()1/_3AC_WK-U&6
MSP-YAG&F^I.N^I/_J7XZ<RK_0PK:?OC2YG[GPBW3M23I-QOA[(:GF[G;02Q/
M'#U31O]K![W@K+I#;Y=D%)D&B:C4!T,C-35/^IBTD9ND_I$N(5WJ1G%$E189
M14J*D1O0AYY9#B!*W'@PH-6]T*R 94VLT0P(7M9E2WS#=LU]G@P2-QP24.".
M@@A,HJ^HYC52U!HN1D,W\B.XI*9QAXE/PMRD@X[_D14UGL[$6X@'J3L:^B2%
MONNG$9RJ >]H-)4H5W8 *[#5U4RI3MO-^.MFM!W,FQ^$6R97O%+$94FN?G]
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M2V%HR6S#+T$7 \)]8T.K)R=.[O3ORK]02P,$%     @ ,XE^5H-$Y.QK @
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MPP-RXJ&DL>-+]O#=V6()*,DE58*)E:G?15&T=<LIFN@"EJQ@>'Q"'B12OJN
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MH2\Z($R 'E]P??AU'7.6]E>G]"]02P,$%     @ ,XE^5C3XX1;O 0  &00
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M!#H'D170SQ><J\>+K(+J6/GT/U!+ P04    "  SB7Y649 DDR4"  "Z!
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M4L;#*\S)M)O2*D[78=C6VN'H!K'$QP6,=\#[C<:!ZQ0?H'^NLM]02P,$%
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M,SDW;@39W8CY65:W-6R:V1&/U6PH-+/^G>;&">P(:MN,"Z34B/9%ZXC3)O*
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MUPW4^R%3*4U>T!T4&7'K/U!+ P04    "  SB7Y6;87[)JP"  "2"   &0
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MW(!-1[*ROD263*HKJ6ZNU4\#<!V@YC.F+I*VH^^E[C<D_@-02P,$%     @
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M[LE L[JQJ@>"%E6K,:-"-B[5;2)[46"J0,['5+8;S4!U+VUWZ_\!4$L#!!0
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M($)27HBK!7H6"Y\K-LEFJ1SS%QX.T$TF:&BCP&B)+045F(O7H\)AL$' H$&
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M!F?^FJ6LTUH'5*X!10M!T0@4FDZRDF[<O6LW$#M,4$VF1MO<8?IN8^Z%;)9
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MXQ&&@S!]*P;M,27O;_AB^. ./_,@8>":4ASOB#A^5T+]\XE$#X3^RX=\O??
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M.28M1*5%6+2VYMY&<\_>&NKZ79-K(6@^+Q* K)E:D$_YC#VQV8JF)VU+2W/
M?N5CWR2H-+^B[<O#H,/.]8;;DPS4Z"(L6CLG-MU"U]XNK-K55(MO*Q3LE*/U
M16T/HM("5%J(2HNP:.U<V?0(77N3\+O+A<'6#VQ'N;!MV%TM8/;J E1:B$J+
ML&AMY3>=1-?>2OR>:F&X5?IU5PN'V?GV2(_6'),6HM(B+%I;\TV?T;4W&O_/
M:@&U'XE*\]WM5F-WM=#5DNRJ%E![DEBT=DYLNI*NO2W9^+C]H.$L!OLW13ON
M:*%1FY&HM "5%J+2(BQ:.VDV'4EW3TNR\7WBA7S1XX>DQ;J:D]<Q0I)$\*QY
M2I:#2\NU,\%0>Y>H-+^B#?=4,<&!=B%J=!$6K4R*?F-%309B7BR6DJ3X5%4N
M(ZF/U@NRKHME2&^.^^YE4"ZKVF#*55ZW5,R93HP4$HUT3L_U Q/EPJER1_%E
ML6[GD2O%LV)S 70&PACH\PGGZG7'7*!>OC;Y%U!+ P04    "  SB7Y6*#"W
M,V(#  !6"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6RM5FUOTS 0
M_BM60 BDL;RT3;O15EI;$* -*O:"$.*#EUQ;"\<N]F7M^/783I:U6YJ-:?W0
MQ,[=<\_C.]O77TGU6R\ D*PS+O3 6R N#WU?)PO(J-Z72Q#FRTRJC*(9JKFO
MEPIHZIPR[D=!$/L99<(;]MW<5 W[,D?.!$P5T7F6474] BY7 R_T;B:^L?D"
M[80_["_I'$X!SY=3949^A9*R#(1F4A %LX%W%!Z.0^?@+"X8K/3&.[%2+J7\
M;0>?TH$76$; (4$+0<WC"L; N44R//Z4H%X5TSINOM^@?W#BC9A+JF$L^7>6
MXF+@]3R2PHSF'+_)U4<H!74L7B*Y=O]D5=AV8X\DN4:9E<Z&0<9$\:3K<B$V
M',)=#E'I$-UU:.]P:)4.+2>T8.9D32C285_)%5'6VJ#9%[<VSMNH8<*F\125
M^<J,'PZ_2 1R3-Z23R*1&9 SN@9-7D\ *>.:G,$:<\K?&(/STPEY_?)-WT<3
MUCK[21EB5(2(=H0((W(B!2XT>2]22+<!?,.W(AW=D!Y%C8@32/9)*]PC41!%
M-83&CW</&^BTJC5L.;SV#KRO2U 4F9B38ZDU&5.EKLT&6U&5ZCUR07E.7<D>
M<;-IJ$B@;@V+$!T7PNZ]JV'0]Z\V1359;/%N5[S;C;RGH!(0:'8KD;/'\BP@
M#S98A'=X-@:UQ]*A7M($!IXY=S2H*_"&KUZ$<?"N(16=2E*G4=*Y4)#(N6!_
M(;6U3$8@8,;0Y,$4GTW1B/)=TCH/IJ"PB!].05SQC9_*]W9#DBD(RI&9C4E%
M:CX@F)5#\GYM#G,->^1,(N5UBN(&OH6B)HLM1=U*4;=1T<20UL@21_PHQX54
M#*_)SQ/(+D']JF/9"/CX@BD$/1/8EO9>I;WWY(.@3GCO7L%UPVY@?W>RU+N7
MI;C7VC;<(GQ0$3YXB+!PB?H!5-4Q;':/@O# 'J)!S4E:$&_T?V(VPN#V;@L:
M^9TB-;>;W3/',J&<?,X5TRDK&HBFBFS&_=^2?"ZT[578N.'#9ZW*$FZS+..@
M4U>6=9:M=EU=^AL=2@9J[AHW31*9"RSN_6JV:@Z/7$MT9WYDFT;7^=S"%!WG
M"55S)C3A,#.0P7[7T%)%$U<,4"Y='W0IT715[G5A&E]0UL!\GTG3"Y4#&Z!J
MI8?_ %!+ P04    "  SB7Y6LT&[M'8#  #:"P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6R-EF%OVS80AO\*(0Q="RR1*$NVW-D&4AO# G1)$*_M
M9T8^V40E4B,I.^FOWU%2%*>BU'RQ1>KN^-R)Y'N+DU3?]0' D,<B%WKI'8PI
M/_J^3@]0,'TI2Q#X)I.J8 :':N_K4@';U4Y%[H=!,/4+QH6W6M1S=VJUD)7)
MN8 [1715%$P]?8)<GI8>]9XG[OG^8.R$OUJ4; ];,%_*.X4COXNRXP4(S:4@
M"K*E=T4_KFED'6J+KQQ.^NR9V%0>I/QN!]>[I1=8(L@A-38$P[\CK"'/;23D
M^*\-ZG5K6L?SY^?H?]7)8S(/3,-:YM_XSAR67N*1'62LRLV]//T-;4*QC9?*
M7->_Y-383B./I)4VLFB=D:#@HOEGCVTASASHD$/8.H1O=9BT#I,ZT8:L3FO#
M#%LME#P19:TQFGVH:U-[8S9<V,^X-0K?<O0SJQMI@'PF%^1:I+( \B][!(W#
M#62@%.SL!+G2&HPF[S=@&,_U!WS_9;LA[W_[L/ -0MA0?MHN^*E9,!Q8< /I
M)9G0/T@8A*'#??UV=_K:W<?4N_S#+O^PCA<-Q+O*<2,SD0+!(T$VLGHP6963
MJS25E3#:E5\3,*X#VE-R7.&9"1;^\3R+7QB]8IUTK)-1UF],*2;,$[D'#>H(
M+K@FPG0<KF\T&82+.KAH%.ZZ*!FW&Z;9+"ZVJ+?LSV!C%J^HXHXJ'J5:LY(;
MEO,?"+:U6X?.(G+_CA7EGQL78MPO7^0H8-]L@'/:<4['JR>.((Q4H]]V^C:X
MOAD-DL'O.^L(9Z.$W85PFV4\!?6[)FM9H)IH9N]C%^^L!Q*%29_783:9#_(F
M'6_R"UZ4M92S1BP$[LM"*L-_#-(F/8R+>-JG=9D-'^UY1SL?I;U!P;XM02&=
MV)//4F-U\;0_X:5T8FKG/$[S_G>>3VC<1W88)LD\'H2FP8MX!*/85AS6N"FX
M^\"WWN<K3Q/'#G#9V=(/\9V)&QWENS4'4$XRVJ])["B=PRX:*=R+ZM!QV=FB
MSDB\F)QL8?^<TX"ZZN:P#&@P4KD7J:'C6O.5Y55[=IX5TLG:EY*+(5B7Z3CM
MB_;0<?&YD>(BK?!Z$L;V<,U%97!S,BM&3O"H)] ]X#&3!M0_:[QLU_L/4WLN
M-,DA0Y_@<H;.JFDDFX&19=V+/4B#G5W]>,#F&Y0UP/>9Q'ZL'=CVKFOG5_\#
M4$L#!!0    ( #.)?E9  +3X"P,  ,T)   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;(U6:V_:,!3]*U:D24S:\B(A4 %2H9U6J2_1K?MLP@VQZL3,
M=@K]][.=- 5JPOA ;.>>XW,<^UZ/MXR_B!Q HEU!2S%Q<BDW%YXGTAP*+%RV
M@5*]R1@OL%1=OO;$A@->&5!!O=#W!UZ!2>E,QV;LD4_'K)*4E/#(D:B* O.W
M&5"VG3B!\SZP(.M<Z@%O.M[@-3R!_+UYY*KGM2PK4D I""L1AVSB7 87\\#7
M !/Q3& K]MI(6UDR]J([-ZN)XVM%0"&5F@*KQRO,@5+-I'3\;4B==DX-W&^_
ML_\PYI69)18P9_0/6<E\X@P=M((,5U0NV/8G-(9BS9<R*LP_VM:QR<!!:24D
M*QJP4E"0LG[B7;,0>X#@%"!L .$Q(#H!Z#> OC%:*S.VKK#$TS%G6\1UM&+3
M#;,V!JW<D%)_QB?)U5NB<')ZSR2@6_0=W90I*P#]PCL0JKN E)4IH02;U689
MDCF@)XEE)1E_TW%H@:6*[5V!Q(2*KV-/*D&:UDN;R6?UY.&)R8,0W;%2Y@)=
MERM8'1)XRDEK)WRW,PL[&:\@=5$_^(9"/PPM@N;_#P\ZY/3;U>T;ON@$W\=Z
MZ;6R+5"-'QF\/G*O4]_54[_NBSX3=" M:J5%9Z4!(O57E^IK?D>84B3TL+ I
M[:;KA6X2?;'M@7D-5"=]7[Z?1/W1_L_N)F[=Q&?<L/0%*2\JO0FS96T6NCF4
MA3BQ6X@_?P"[WD&K=] YU_W#+;K>;0@_J;4;WXO<P<BN]0QPY ;]8^"!A:2U
MD'0R/:B$P&W*NV$]WXT'=N5G@(F;?+)\H'S8*A]V;Y9J*9G$U"9^:-NL@1]%
M1T?2'A?$H7U?C%IIHTYISYA6=<:]I*K"XC*U9HUNDE[@N]&)PW@.&;AQV+G(
M@?]16?Q.LNLL U.D37HYE0#/D*CMXOMV*PVRZU1Z>X6Q +XV]P6A\D15RKJH
MM*/MG>325.*C\9F^JYB"^T%37W3N,%^34B *F:+TW43E"E[?'>J.9!M3?I=,
MJF)NFKFZ;P'7 >I]QE0);CIZ@O8&-_T'4$L#!!0    ( #.)?E9XX@;F]0$
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M+@6?B:HV,-_G4NK'1MU!>[\__1=02P,$%     @ ,XE^5B(DZ*\A"   QD4
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MZGR3;%$T?Z/G;6P\B":/19DMMXVK$2SGJ\W_]-MV(?8:$.EH0+<-Z&$#[FC
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M<K3-FJ.7;A+ZDLH2<K-BA,BM/KJ5R7 TZL-6Z76T03_-SC7/M'/,0:5"4%H
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ML3$^@[QJ?+\LM,*I),MVY\IO',Q%!QGG,J&R#M/V5Z9AG],4Y$@VG<%5Y44
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M<;-AVL #BP.17I9KO-IXA^SN ZRFNSH$VRG>B=A.\5P#XLX;>,2QN]I8'/#
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M W]A87W!JV)LF/]8OD*1Y?ZAYF115>>P[E9=:UZN7H%<O;YY\@]02P,$%
M  @ ,XE^5B=EU:4, @  A"4  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<\W9.V[;0!2%X:T(7(!']S6V \M5&K>!-T#(HP<LB02'0>S=1Y +Z1 I
MTA@\%3$D>/D7Q =B^/2K'-IQWYWJ;M_7Q<?Q<*JK9C>._8^4ZGI7CFV]Z_IR
M.E_9=,.Q'<_+89OZ=OW>;DO2Y3*GX79&\_QT.W/Q^MF7_YG8;3;[=?G9K7\?
MRVG\Q^#TIQO>ZZZ4L5F\ML.VC*LF?1RNIVNZ'.3N/+E9O+RMFN'E39HT=Y!"
MD,X?9!!D\P<Y!/G\00%!,7]0AJ \?] ]!-W/'_0 00_S!SU"T./\0;)$&9<$
M21.L";06Y%H(O!8$6PC$%B1;",P61%L(U!9D6PC<%H1;".06I%L([!;$6PCT
M5M1;"?16U%L)]-;)QS:!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!
MWHIZ*X'>AGH;@=Z&>AN!WH9Z&X'>-MDL(=#;4&\CT-M0;R/0VU!O(]#;4&\C
MT-M0;R/0VU!O(]#;46\GT-M1;R?0VU%O)]#;46\GT-LGF]T$>COJ[01Z.^KM
M!'H[ZNT$>COJ[01Z.^KM!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>@?J'01ZQ^1G
M)8'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=X9]<X$>F?4.Q/HG5'O3*!W1KWS=^I=
MQ\]#J=>>KS4^_SNI'L_WENOC+\NODY-7Y8)SNJVHSW\!4$L#!!0    ( #.)
M?E;NU>T8Y@$  /4D   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:74_",!0&
MX+]"=FM8Z=?\B'"CWJH7_H&Z'61A6YNV(/Q[NP$F&B4:3'QO6*#M><]ZDN>*
MZZ>MHS#:M$T7IMDB1G?%6"@7U)J06T==6IE;WYJ8OOH7YDRY-"_$Q&12L-)V
MD;HXCGV-;'9]2W.S:N+H;I-^#K7MIIFG)F2CF]W&/FN:&>>:NC0QK;-U5WU*
M&>\3\G1RV!,6M0MG:4/&ODSH5[X/V)][6)/W=46C1^/CO6G3+K9I6(C;AD)^
MO,07/=KYO"ZILN6J34?RX#R9*BR(8MODNZ)GQY-CNF':??*3\X<RQP+3SD=O
M74@3\_3[N,-(^M-CEPJ1C_7Q5WQ/3*5/?C_JIUU1]</L=+VOUB^'>00V/$Z_
MXX\S?J__RSX$2!\2I \%TH<&Z:, Z>,<I(\+D#XN0?K@$Y1&4$3E**1R%%,Y
M"JH<156.PBI'<96CP,I19!4HL@H4606*K )%5H$BJT"15:#(*E!D%2BR"A19
M)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP215:%(JM"D56AR*I09%4HLBH4
M616*K I%5H4BJT*15:/(JE%DU2BR:A19-8JL&D56C2*K1I%5H\BJ460M4&0M
M4&0M4&0M_E/69VN7?QP_///6U-TAGPW_=IJ] 5!+ 0(4 Q0    ( #.)?E8'
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @ ,XE^5F1A5Q_M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ,XE^5IE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  SB7Y6:H\Y6A$(  !@/   &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ,XE^5MY+PI[1!@  V!P
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M965T-BYX;6Q02P$"% ,4    "  SB7Y6A':^JDP$  " "0  &
M    @(&0-@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M,XE^5N,+9G:5!   @@D  !@              ("!$CL  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #.)?E9HT&O]8A    @L   8
M          " @=T_  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  SB7Y6:0=!N]X"   O!@  &0              @(%U4   >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #.)?E;_DZWOJ@(  +8%
M   9              " @8I3  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ ,XE^5BFG]FD=!   $@D  !D              ("!:U8
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  SB7Y6!OC@
M]WP#   E!P  &0              @(&_6@  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( #.)?E:N<(A@  ,  ,T&   9
M  " @7)>  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M,XE^5I=/XQ.: P  ,@@  !D              ("!J6$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  SB7Y6;BQL5Y8%  "!#P  &0
M            @(%Z90  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( #.)?E8 SB)_>0,  *\'   9              " @4=K  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ,XE^5K$C:SE'!0
M^0L  !D              ("!]VX  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  SB7Y6VJJ29? %  #!#0  &0              @(%U
M=   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #.)?E:O
MMG06?P(  ,H%   9              " @9QZ  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ ,XE^5C@\%XY%!   D0D  !D
M     ("!4GT  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #.)?E::I -NC@(  )0%   9              "
M@?F>  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ,XE^
M5D^Z;+DH P  JP8  !D              ("!OJ$  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  SB7Y6*<Z!BYD"   @!@  &0
M        @($=I0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( #.)?E;-^YM$2P,  +H'   9              " @>VG  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ,XE^5GLD3DO\ P  #PL
M !D              ("!;ZL  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  SB7Y6X@8N<,@#  "'"   &0              @(&BKP
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #.)?E9!!;KH
M?P4  &0-   9              " @:&S  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ ,XE^5@II0;&Z P  !0D  !D
M ("!5[D  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  S
MB7Y6T113;M@!  "# P  &0              @(%(O0  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( #.)?E:#1.3L:P(  (P%   9
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M970S.2YX;6Q02P$"% ,4    "  SB7Y6-"HV]!(&  !B+@  &0
M    @($PSP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M #.)?E91D"23)0(  +H$   9              " @7G5  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ ,XE^5NYF=3M4!   >18  !D
M             ("!U=<  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  SB7Y6S)&J_VL#   =#P  &0              @(%@W   >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #.)?E9MA?LFK (
M )((   9              " @0+@  !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ ,XE^5B/4""$D P  Z0H  !D              ("!
MY>(  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  SB7Y6
MSG_LST4#  #:#   &0              @(% Y@  >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( #.)?E:1).VZH@(   P'   9
M      " @;SI  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ ,XE^5GX/X:[W"0  L%L  !D              ("!E>P  'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  SB7Y6]-N1<(4&   4+0
M&0              @('#]@  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( #.)?E9>CWZJZ@(  *((   9              " @7_]  !X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ ,XE^5G:L#@V)
M!0  RB8  !D              ("!H  ! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    "  SB7Y6*#"W,V(#  !6"P  &0
M@(%@!@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( #.)
M?E:S0;NT=@,  -H+   9              " @?D) 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ ,XE^5D  M/@+ P  S0D  !D
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M=#4X+GAM;%!+ 0(4 Q0    ( #.)?E9/C=>5O@8  !PX   9
M  " @20E 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
M,XE^5MDG1P4?!@  S"8  !D              ("!&2P! 'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6Q02P$"% ,4    "  SB7Y6T6708+P#   ,#   &0
M            @(%O,@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4
M Q0    ( #.)?E;A48-;BP,  % 0   9              " @6(V 0!X;"]W
M;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ ,XE^5K( N'QL P
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M2P$"% ,4    "  SB7Y6)V75I0P"  "$)0  &@              @ %T1P$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  SB7Y6[M7M
M&.8!  #U)   $P              @ &X20$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     1P!' &@3  #/2P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>289</ContextCount>
  <ElementCount>336</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note A - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business</Role>
      <ShortName>Note A - Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note B - Liquidity and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties</Role>
      <ShortName>Note B - Liquidity and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note C - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies</Role>
      <ShortName>Note C - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note D - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-d-inventories</Role>
      <ShortName>Note D - Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note E - Advances on Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts</Role>
      <ShortName>Note E - Advances on Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note F - Investment in and Transactions With Equity Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees</Role>
      <ShortName>Note F - Investment in and Transactions With Equity Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note G - Furniture, Fixtures and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-</Role>
      <ShortName>Note G - Furniture, Fixtures and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note H - Patents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-h-patents</Role>
      <ShortName>Note H - Patents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note I - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity</Role>
      <ShortName>Note I - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note J - Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans</Role>
      <ShortName>Note J - Stock Option Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note K - Employment Contract and Consulting Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements</Role>
      <ShortName>Note K - Employment Contract and Consulting Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note L - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes</Role>
      <ShortName>Note L - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note M - Segment and Geographic Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data</Role>
      <ShortName>Note M - Segment and Geographic Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note N - Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations</Role>
      <ShortName>Note N - Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note O - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions</Role>
      <ShortName>Note O - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note P - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-p-commitments</Role>
      <ShortName>Note P - Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note Q - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan</Role>
      <ShortName>Note Q - Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note R - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events</Role>
      <ShortName>Note R - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note D - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables</Role>
      <ShortName>Note D - Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-d-inventories</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note G - Furniture, Fixtures and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables</Role>
      <ShortName>Note G - Furniture, Fixtures and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note H - Patents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables</Role>
      <ShortName>Note H - Patents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-h-patents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note I - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables</Role>
      <ShortName>Note I - Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note J - Stock Option Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables</Role>
      <ShortName>Note J - Stock Option Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note L - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables</Role>
      <ShortName>Note L - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note M - Segment and Geographic Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables</Role>
      <ShortName>Note M - Segment and Geographic Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note P - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables</Role>
      <ShortName>Note P - Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-p-commitments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note A - Organization and Business (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual</Role>
      <ShortName>Note A - Organization and Business (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note B - Liquidity and Uncertainties (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual</Role>
      <ShortName>Note B - Liquidity and Uncertainties (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note C - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note C - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note D - Inventories (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual</Role>
      <ShortName>Note D - Inventories (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note D - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details</Role>
      <ShortName>Note D - Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note E - Advances on Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual</Role>
      <ShortName>Note E - Advances on Contracts (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note F - Investment in and Transactions With Equity Investees (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual</Role>
      <ShortName>Note F - Investment in and Transactions With Equity Investees (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note G - Furniture, Fixtures and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual</Role>
      <ShortName>Note G - Furniture, Fixtures and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note G - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details</Role>
      <ShortName>Note G - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note H - Patents (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual</Role>
      <ShortName>Note H - Patents (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note H - Patents - Summary of Patents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details</Role>
      <ShortName>Note H - Patents - Summary of Patents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note I - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual</Role>
      <ShortName>Note I - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note I - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details</Role>
      <ShortName>Note I - Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note I - Stockholders' Equity - Summary of Shares to be Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details</Role>
      <ShortName>Note I - Stockholders' Equity - Summary of Shares to be Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note J - Stock Option Plans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual</Role>
      <ShortName>Note J - Stock Option Plans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note J - Stock Option Plans - Summary of Option Activity for Employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details</Role>
      <ShortName>Note J - Stock Option Plans - Summary of Option Activity for Employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note J - Stock Option Plans - Schedule of Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details</Role>
      <ShortName>Note J - Stock Option Plans - Schedule of Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note K - Employment Contract and Consulting Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual</Role>
      <ShortName>Note K - Employment Contract and Consulting Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note L - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual</Role>
      <ShortName>Note L - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note L - Income Taxes - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details</Role>
      <ShortName>Note L - Income Taxes - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note L - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details</Role>
      <ShortName>Note L - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note M - Segment and Geographic Data (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual</Role>
      <ShortName>Note M - Segment and Geographic Data (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note M - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details</Role>
      <ShortName>Note M - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note M - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details</Role>
      <ShortName>Note M - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note N - Concentrations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual</Role>
      <ShortName>Note N - Concentrations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note O - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual</Role>
      <ShortName>Note O - Related Party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note P - Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual</Role>
      <ShortName>Note P - Commitments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note P - Commitments - Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details</Role>
      <ShortName>Note P - Commitments - Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Note P - Commitments - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details</Role>
      <ShortName>Note P - Commitments - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mlss20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Note R - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual</Role>
      <ShortName>Note R - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mlss20221231_10k.htm 23, 24</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mlss20221231_10k.htm 44, 58, 6551, 6787</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mlss20221231_10k.htm 4381</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 13 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mlss20221231_10k.htm 4840, 4904, 4936, 4968, 5032, 5160, 5192, 5256, 5352, 5384, 5416, 5448, 5512</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mlss20221231_10k.htm 6306</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mlss20221231_10k.htm 6553, 6789</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mlss20221231_10k.htm 6760</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 51 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss, mlss:NumberOfMajorCustomers, mlss:NumberOfVendors, us-gaap:AdvancesOnInventoryPurchases, us-gaap:AllowanceForDoubtfulAccountsReceivable, us-gaap:AmortizationOfIntangibleAssets, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EquityMethodInvestmentOwnershipPercentage, us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1, us-gaap:GainsLossesOnExtinguishmentOfDebt, us-gaap:InventoryValuationReserves, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:NumberOfOperatingSegments, us-gaap:NumberOfReportableSegments, us-gaap:OperatingLeaseRightOfUseAsset, us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1, us-gaap:OperatingLossCarryforwards, us-gaap:OperatingLossCarryforwardsValuationAllowance, us-gaap:ProceedsFromNotesPayable, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty, us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:TreasuryStockShares, us-gaap:UnrecognizedTaxBenefits, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense -  mlss20221231_10k.htm 8, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64</Log>
    <Log type="Warning">[dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorFirmId must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorFirmId fact are Context: d_2021-01-01_2021-12-31, Unit: (none), Rule Element Id: 2. mlss20221231_10k.htm 4224</Log>
    <Log type="Warning">[dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorLocation must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorLocation fact are Context: d_2021-01-01_2021-12-31, Unit: (none), Rule Element Id: 2. mlss20221231_10k.htm 4334</Log>
    <Log type="Warning">[dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorName must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorName fact are Context: d_2021-01-01_2021-12-31, Unit: (none), Rule Element Id: 2. mlss20221231_10k.htm 4330</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="mlss20221231_10k.htm">mlss20221231_10k.htm</File>
    <File>ex_490434.htm</File>
    <File>ex_490435.htm</File>
    <File>ex_490441.htm</File>
    <File>ex_490442.htm</File>
    <File>ex_490443.htm</File>
    <File>ex_490444.htm</File>
    <File>ex_492741.htm</File>
    <File>ex_492742.htm</File>
    <File>mlss-20221231.xsd</File>
    <File>mlss-20221231_cal.xml</File>
    <File>mlss-20221231_def.xml</File>
    <File>mlss-20221231_lab.xml</File>
    <File>mlss-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="736">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mlss20221231_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 30,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 736,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 289,
   "dts": {
    "calculationLink": {
     "local": [
      "mlss-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mlss-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mlss20221231_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mlss-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mlss-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mlss-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 518,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 45,
    "http://www.milestonescientific.com/20221231": 7,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 58
   },
   "keyCustom": 46,
   "keyStandard": 290,
   "memberCustom": 45,
   "memberStandard": 31,
   "nsprefix": "mlss",
   "nsuri": "http://www.milestonescientific.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note D - Inventories",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
     "shortName": "Note D - Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mlss:AdvancesToContractManufacturerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note E - Advances on Contracts",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts",
     "shortName": "Note E - Advances on Contracts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mlss:AdvancesToContractManufacturerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note F - Investment in and Transactions With Equity Investees",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
     "shortName": "Note F - Investment in and Transactions With Equity Investees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note G - Furniture, Fixtures and Equipment",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-",
     "shortName": "Note G - Furniture, Fixtures and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note H - Patents",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
     "shortName": "Note H - Patents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note I - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
     "shortName": "Note I - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note J - Stock Option Plans",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
     "shortName": "Note J - Stock Option Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mlss:EmploymentAndConsultingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note K - Employment Contract and Consulting Agreements",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
     "shortName": "Note K - Employment Contract and Consulting Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mlss:EmploymentAndConsultingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note L - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
     "shortName": "Note L - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note M - Segment and Geographic Data",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data",
     "shortName": "Note M - Segment and Geographic Data",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note N - Concentrations",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
     "shortName": "Note N - Concentrations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note O - Related Party Transactions",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
     "shortName": "Note O - Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note P - Commitments",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
     "shortName": "Note P - Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note Q - Benefit Plan",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan",
     "shortName": "Note Q - Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note R - Subsequent Events",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
     "shortName": "Note R - Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note D - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables",
     "shortName": "Note D - Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note G - Furniture, Fixtures and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables",
     "shortName": "Note G - Furniture, Fixtures and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note H - Patents (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables",
     "shortName": "Note H - Patents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note I - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables",
     "shortName": "Note I - Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note J - Stock Option Plans (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables",
     "shortName": "Note J - Stock Option Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note L - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables",
     "shortName": "Note L - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note M - Segment and Geographic Data (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables",
     "shortName": "Note M - Segment and Geographic Data (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mlss:LeaseCostAndOtherInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note P - Commitments (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables",
     "shortName": "Note P - Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mlss:LeaseCostAndOtherInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note A - Organization and Business (Details Textual)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual",
     "shortName": "Note A - Organization and Business (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note B - Liquidity and Uncertainties (Details Textual)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual",
     "shortName": "Note B - Liquidity and Uncertainties (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mlss:AllowanceForSalesReturns",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note C - Summary of Significant Accounting Policies (Details Textual)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note C - Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mlss:AllowanceForSalesReturns",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note D - Inventories (Details Textual)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual",
     "shortName": "Note D - Inventories (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note D - Inventories - Summary of Inventories (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
     "shortName": "Note D - Inventories - Summary of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note E - Advances on Contracts (Details Textual)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual",
     "shortName": "Note E - Advances on Contracts (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note F - Investment in and Transactions With Equity Investees (Details Textual)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
     "shortName": "Note F - Investment in and Transactions With Equity Investees (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note G - Furniture, Fixtures and Equipment (Details Textual)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual",
     "shortName": "Note G - Furniture, Fixtures and Equipment (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note G - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details",
     "shortName": "Note G - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note H - Patents (Details Textual)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
     "shortName": "Note H - Patents (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note H - Patents - Summary of Patents (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details",
     "shortName": "Note H - Patents - Summary of Patents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Note I - Stockholders' Equity (Details Textual)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual",
     "shortName": "Note I - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Note I - Stockholders' Equity - Warrants (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details",
     "shortName": "Note I - Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "mlss:WarrantsAndRightsOutstandingWeightedAverageRemainingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "mlss:DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Note I - Stockholders' Equity - Summary of Shares to be Issued (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details",
     "shortName": "Note I - Stockholders' Equity - Summary of Shares to be Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "mlss:DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "mlss:DeferredCompensationArrangementWithIndividualSharesGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "mlss:DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Note J - Stock Option Plans (Details Textual)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
     "shortName": "Note J - Stock Option Plans (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Note J - Stock Option Plans - Summary of Option Activity for Employees (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
     "shortName": "Note J - Stock Option Plans - Summary of Option Activity for Employees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Note J - Stock Option Plans - Schedule of Restricted Stock (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
     "shortName": "Note J - Stock Option Plans - Schedule of Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "mlss:EmploymentAndConsultingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Note K - Employment Contract and Consulting Agreements (Details Textual)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
     "shortName": "Note K - Employment Contract and Consulting Agreements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "mlss:EmploymentAndConsultingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2021-03-02_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember",
      "decimals": "3",
      "lang": null,
      "name": "mlss:RoyaltyOnNetSalesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Note L - Income Taxes (Details Textual)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual",
     "shortName": "Note L - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Note L - Income Taxes - Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details",
     "shortName": "Note L - Income Taxes - Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Note L - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details",
     "shortName": "Note L - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Note M - Segment and Geographic Data (Details Textual)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual",
     "shortName": "Note M - Segment and Geographic Data (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Note M - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
     "shortName": "Note M - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Note M - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details",
     "shortName": "Note M - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "mlss:SalesByProductAndByGeographicalRegionTableTextBlock",
       "mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_StatementGeographicalAxis-DomesticMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Note N - Concentrations (Details Textual)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual",
     "shortName": "Note N - Concentrations (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-InterimChiefExecutiveOfficerMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "mlss:RoyaltyOnNetSalesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Note O - Related Party Transactions (Details Textual)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual",
     "shortName": "Note O - Related Party Transactions (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2021-03-02_RelatedPartyTransactionsByRelatedPartyAxis-InterimChiefExecutiveOfficerMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "mlss:RoyaltyOnNetSalesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Note P - Commitments (Details Textual)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual",
     "shortName": "Note P - Commitments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2019-08-01_2019-08-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-OfficeLeaseForHeadquarterInRoselandNewJerseyMember",
      "decimals": "INF",
      "lang": null,
      "name": "mlss:LesseeOperatingLeaseElectricCharge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "mlss:LeaseCostAndOtherInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Note P - Commitments - Lease Expense (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details",
     "shortName": "Note P - Commitments - Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "mlss:LeaseCostAndOtherInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Note P - Commitments - Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details",
     "shortName": "Note P - Commitments - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2023-08-01_2023-08-01_StatementScenarioAxis-ScenarioPlanMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Note R - Subsequent Events (Details Textual)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual",
     "shortName": "Note R - Subsequent Events (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2023-08-01_2023-08-01_StatementScenarioAxis-ScenarioPlanMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note A - Organization and Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business",
     "shortName": "Note A - Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note B - Liquidity and Uncertainties",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties",
     "shortName": "Note B - Liquidity and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note C - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
     "shortName": "Note C - Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mlss20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 80,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information",
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business",
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information",
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business",
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mlss_AccessoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to accessories.",
        "label": "Accessories [Member]"
       }
      }
     },
     "localname": "AccessoriesMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_AccountsPayableRelatedPartiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about accounts payable, related parties, current.",
        "label": "Accounts Payable, Related Parties, Current [Member]"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_AccountsReceivableFromRelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts receivable from related parties.",
        "label": "Accounts Receivable from Related Parties [Member]"
       }
      }
     },
     "localname": "AccountsReceivableFromRelatedPartiesMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_AccruedExpensesRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accrued expenses to related parties.",
        "label": "Accrued expenses, related party"
       }
      }
     },
     "localname": "AccruedExpensesRelatedParty",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_AdvancesToContractManufacturerTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances to contract manufacturer.",
        "label": "Advances to Contract Manufacturer [Text Block]"
       }
      }
     },
     "localname": "AdvancesToContractManufacturerTextBlock",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mlss_AllowanceForSalesReturns": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for sales returns.",
        "label": "mlss_AllowanceForSalesReturns",
        "terseLabel": "Allowance for Sales Returns"
       }
      }
     },
     "localname": "AllowanceForSalesReturns",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_AnhuiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Anhui Maishida Medical Technology, Co. Ltd. (Anhui).",
        "label": "Anhui [Member]"
       }
      }
     },
     "localname": "AnhuiMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_BoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the board of directors of the company.",
        "label": "Board of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the Chief Executive Officer, Chief Financial Officer and employees.",
        "label": "Chief Executive Officer, Chief Financial Officer and Employees [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "mlss_ClassOfWarrantOrRightExercisedDuringPeriod",
        "negatedLabel": "Exercised, number of shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during period.",
        "label": "Exercised, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "mlss_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights issued during period.",
        "label": "Issued, number of shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights issued during period.",
        "label": "Issued, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "mlss_ComputerAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to computer and software.",
        "label": "Computer and Software [Member]"
       }
      }
     },
     "localname": "ComputerAndSoftwareMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to consultant.",
        "label": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents consulting services.",
        "label": "Consulting Services [Member]"
       }
      }
     },
     "localname": "ConsultingServicesMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unspecified major customer one.",
        "label": "Customer One [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to a third customer.",
        "label": "Customer Three [Member]"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unspecified major customer two.",
        "label": "Customer Two [Member]"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.",
        "label": "Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mlss_DeferredCompensationArrangementWithIndividualSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares granted pursuant to the terms of a deferred compensation arrangement.",
        "label": "Granted in current period (in shares)"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesGranted",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "mlss_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.",
        "label": "Capitalized Sec. 174 R&amp;D"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.",
        "label": "mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent",
        "terseLabel": "Depreciation and Amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciationAndAmortizationNoncurrent",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_DentalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Dental segment.",
        "label": "Dental Segment [Member]"
       }
      }
     },
     "localname": "DentalSegmentMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_DirectorClinicalAffairMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the Director Clinical Affair.",
        "label": "Director Clinical Affair [Member]"
       }
      }
     },
     "localname": "DirectorClinicalAffairMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_DirectorOfClinicalAffairsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A personnel of the company with the title \"Director of Clinical Affairs.\"",
        "label": "Director of Clinical Affairs [Member]"
       }
      }
     },
     "localname": "DirectorOfClinicalAffairsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_DomesticMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The domestic country of the reporting entity.",
        "label": "Domestic [Member]"
       }
      }
     },
     "localname": "DomesticMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_EPIAndIAInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to EPI and IA instruments.",
        "label": "EPI and IA Instruments [Member]"
       }
      }
     },
     "localname": "EPIAndIAInstrumentsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation at federal statutory rate and state and local income tax rate and stock-based compensation.",
        "label": "mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details"
     ],
     "xbrltype": "percentItemType"
    },
    "mlss_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
       "order": 0.0,
       "parentTag": "mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from net operating loss adjustments.",
        "label": "NOL Expiration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details"
     ],
     "xbrltype": "percentItemType"
    },
    "mlss_EmploymentAgreementBaseCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of annual base compensation pursuant to the employment agreement.",
        "label": "mlss_EmploymentAgreementBaseCompensation",
        "terseLabel": "Employment Agreement, Base Compensation"
       }
      }
     },
     "localname": "EmploymentAgreementBaseCompensation",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_EmploymentAndConsultingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for employment and consulting agreements.",
        "label": "Employment and Consulting Agreements [Text Block]"
       }
      }
     },
     "localname": "EmploymentAndConsultingAgreementsTextBlock",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of deferred intercompany profits and losses on transactions between the Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting,as of the balance sheet date.",
        "label": "mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss",
        "terseLabel": "Equity Method Investment, Deferred Intercompany Profit (Loss)"
       }
      }
     },
     "localname": "EquityMethodInvestmentDeferredIntercompanyProfitLoss",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_ExpensesPaidStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses paid for with stock in lieu of cash during the period.",
        "label": "Expense paid in stock"
       }
      }
     },
     "localname": "ExpensesPaidStock",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for finance lease liabilities including accrues expense.",
        "label": "mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPaymentsIncludingAccruedExpenses",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_FoundationIntellectualPropertyPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to foundation intellectual property patents.",
        "label": "Foundation Intellectual Property Patents [Member]"
       }
      }
     },
     "localname": "FoundationIntellectualPropertyPatentsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_HandpiecesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents handpieces.",
        "label": "Handpieces [Member]"
       }
      }
     },
     "localname": "HandpiecesMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_IncentiveBonusPercentageOfAnnualCashCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the incentive bonus as a percentage of annual cash compensation.",
        "label": "mlss_IncentiveBonusPercentageOfAnnualCashCompensation",
        "terseLabel": "Incentive Bonus, Percentage of Annual Cash Compensation"
       }
      }
     },
     "localname": "IncentiveBonusPercentageOfAnnualCashCompensation",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, before income or loss from equity method investments, extraordinary items, and noncontrolling interest, but after income taxes.",
        "label": "mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments",
        "totalLabel": "Loss before equity investment"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of accrued liabilities to related parties.",
        "label": "(Decrease) in accrued expenses, related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesRelatedParties",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_IncreaseDecreaseToAdvancesToContractManufacturer": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease to advances to contract manufacturer.",
        "label": "mlss_IncreaseDecreaseToAdvancesToContractManufacturer",
        "negatedLabel": "(Increase) in advances on contracts"
       }
      }
     },
     "localname": "IncreaseDecreaseToAdvancesToContractManufacturer",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_InstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A product of the reporting entity.",
        "label": "Instruments [Member]"
       }
      }
     },
     "localname": "InstrumentsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_InterimChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Interim Chief Executive Officer of the company.",
        "label": "Interim Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "InterimChiefExecutiveOfficerMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_LeaseCostAndOtherInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost and other information.",
        "label": "Lease, Cost and Other Information [Table Text Block]"
       }
      }
     },
     "localname": "LeaseCostAndOtherInformationTableTextBlock",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mlss_LesseeOperatingLeaseElectricCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents electric charge for operating lease per square foot.",
        "label": "mlss_LesseeOperatingLeaseElectricCharge",
        "terseLabel": "Lessee, Operating Lease, Electric Charge Per Square Foot"
       }
      }
     },
     "localname": "LesseeOperatingLeaseElectricCharge",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_LesseeOperatingLeaseElectricPaymentsAnnually": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the annual electric payments for operating lease.",
        "label": "mlss_LesseeOperatingLeaseElectricPaymentsAnnually",
        "terseLabel": "Lessee, Operating Lease, Electric Payments, Annually"
       }
      }
     },
     "localname": "LesseeOperatingLeaseElectricPaymentsAnnually",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_ManagingDirectorChinaOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents managing director for China Operations",
        "label": "Managing Director, China Operations [Member]"
       }
      }
     },
     "localname": "ManagingDirectorChinaOperationsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ManufacturingAgreementForHandpiecesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the manufacturing agreement for handpieces.",
        "label": "Manufacturing Agreement for Handpieces [Member]"
       }
      }
     },
     "localname": "ManufacturingAgreementForHandpiecesMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_MedicalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the medical segment.",
        "label": "Medical Segment [Member]"
       }
      }
     },
     "localname": "MedicalSegmentMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_MilestoneBeijingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Milestone Beijing.",
        "label": "Milestone Beijing [Member]"
       }
      }
     },
     "localname": "MilestoneBeijingMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_MilestoneChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Milestone China, an equity method investment of the reporting entity.",
        "label": "Milestone China [Member]"
       }
      }
     },
     "localname": "MilestoneChinaMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_NonemployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to non-employees.",
        "label": "Non-Employees [Member]"
       }
      }
     },
     "localname": "NonemployeesMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_NumberOfMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of major customers of the reporting entity during the period.",
        "label": "mlss_NumberOfMajorCustomers",
        "terseLabel": "Number of Major Customers"
       }
      }
     },
     "localname": "NumberOfMajorCustomers",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "mlss_NumberOfVendors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of vendors.",
        "label": "mlss_NumberOfVendors",
        "terseLabel": "Number of Vendors"
       }
      }
     },
     "localname": "NumberOfVendors",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "mlss_OfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to office furniture and equipment.",
        "label": "Office Furniture and Equipment [Member]"
       }
      }
     },
     "localname": "OfficeFurnitureAndEquipmentMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_OfficeLeaseForHeadquarterInRoselandNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to office lease for headquarter in Roseland, New Jersey.",
        "label": "Office Lease for Headquarter in Roseland, New Jersey [Member]"
       }
      }
     },
     "localname": "OfficeLeaseForHeadquarterInRoselandNewJerseyMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_OperatingLeasesMonthlyRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the monthly rent expense of operating lease.",
        "label": "mlss_OperatingLeasesMonthlyRentExpense",
        "terseLabel": "Operating Leases, Monthly Rent Expense"
       }
      }
     },
     "localname": "OperatingLeasesMonthlyRentExpense",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding the Paycheck Protection Program under the CARES Act.",
        "label": "Paycheck Protection Program CARES Act [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_PercentageOfValuationAllowance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of valuation allowance.",
        "label": "mlss_PercentageOfValuationAllowance",
        "terseLabel": "Percentage of Valuation Allowance"
       }
      }
     },
     "localname": "PercentageOfValuationAllowance",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "mlss_PreviousPresidentAndChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the previous president and chief executive officer of the company.",
        "label": "Previous President and Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "PreviousPresidentAndChiefExecutiveOfficerMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of product sales and significant customers and vendors.",
        "label": "Product Sales and Significant Customers and Vendors Disclosure [Text Block]"
       }
      }
     },
     "localname": "ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mlss_PurchaseCommitmentForDevicesBeginningIn2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase commitment beginning in 2021.",
        "label": "Purchase Commitment For Devices Beginning In 2021 [Member]"
       }
      }
     },
     "localname": "PurchaseCommitmentForDevicesBeginningIn2021Member",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_PurchaseCommitmentForDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the purchase commitment for devices.",
        "label": "Purchase Commitment for Devices [Member]"
       }
      }
     },
     "localname": "PurchaseCommitmentForDevicesMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_PurchaseCommitmentNumberOfUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of units commitment to purchase.",
        "label": "mlss_PurchaseCommitmentNumberOfUnits",
        "terseLabel": "Purchase Commitment Number Of Units"
       }
      }
     },
     "localname": "PurchaseCommitmentNumberOfUnits",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "mlss_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the rest of the world, excluding domestic sales and sales to China.",
        "label": "Rest of World [Member]"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_RoyaltyOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty percentage on net sales.",
        "label": "mlss_RoyaltyOnNetSalesPercentage",
        "terseLabel": "Royalty on Net Sales, Percentage"
       }
      }
     },
     "localname": "RoyaltyOnNetSalesPercentage",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "mlss_STATrialsInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to STA trials instruments.",
        "label": "STA Trials Instruments [Member]"
       }
      }
     },
     "localname": "STATrialsInstrumentsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_SalesByProductAndByGeographicalRegionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of sales by product and by geographical region.",
        "label": "Sales by Product and by Geographical Region [Table Text Block]"
       }
      }
     },
     "localname": "SalesByProductAndByGeographicalRegionTableTextBlock",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment award options grants in period weighted average remaining contractual term.",
        "label": "Weighted average remaining contractual life, granted (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "durationItemType"
    },
    "mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted.",
        "label": "mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
        "terseLabel": "Weighted average remaining contractual life, granted (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "durationItemType"
    },
    "mlss_SharebasedCompensationBonusPaidInStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncash share-based compensation bonuses paid in stock.",
        "label": "Employees paid in stock"
       }
      }
     },
     "localname": "SharebasedCompensationBonusPaidInStock",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_SlowMovingDentalFinishedGoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the slow moving dental finished goods.",
        "label": "Slow Moving Dental Finished Goods [Member]"
       }
      }
     },
     "localname": "SlowMovingDentalFinishedGoodsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_SlowMovingMedicalFinishedGoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the slow moving medical finished goods.",
        "label": "Slow Moving Medical Finished Goods [Member]"
       }
      }
     },
     "localname": "SlowMovingMedicalFinishedGoodsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for warrants exercised.",
        "label": "Common stock issued for warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mlss_StockIssuedDuringPeriodValueEmployeeBonuses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued for employee bonuses during the period.",
        "label": "Common stock issued to employee for bonus expensed in prior periods",
        "verboseLabel": "Common stock issued to employees for bonuses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBonuses",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents value of stock issued during period for warrants exercised.",
        "label": "Common stock issued for warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock to be issued for employee bonuses during the period.",
        "label": "Common stock issued to employees for bonuses (in shares)",
        "verboseLabel": "Common stock issued to employee for bonus expensed in prior periods (in shares)"
       }
      }
     },
     "localname": "StockToBeIssuedDuringPeriodSharesEmployeeBonuses",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares to be issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Common stock to be issued for payment of services expensed in prior periods (in shares)"
       }
      }
     },
     "localname": "StockToBeIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mlss_StockToBeIssuedDuringPeriodSharesSharebasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) to be issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Common stock issued to employee for compensation expensed in prior periods (in shares)"
       }
      }
     },
     "localname": "StockToBeIssuedDuringPeriodSharesSharebasedCompensation",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock to be issued for employee bonuses during the period.",
        "label": "Common stock to be issued to employees for bonuses"
       }
      }
     },
     "localname": "StockToBeIssuedDuringPeriodValueEmployeeBonuses",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_StockToBeIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock to be issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Common stock to be issued for payment of services expensed in prior periods"
       }
      }
     },
     "localname": "StockToBeIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_StockToBeIssuedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock (or other type of equity) to be issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Common stock issued to employee for compensation expensed in prior periods"
       }
      }
     },
     "localname": "StockToBeIssuedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mlss_TerritoryManagerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents territory manager.",
        "label": "Territory Manager [Member]"
       }
      }
     },
     "localname": "TerritoryManagerMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_The2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2020 Equity Incentive Plan.",
        "label": "The 2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "The2020EquityIncentivePlanMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ToolingEquipmentSTAAndWandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to tooling equipments for STA and wand.",
        "label": "Tooling Equipment - STA and Wand [Member]"
       }
      }
     },
     "localname": "ToolingEquipmentSTAAndWandMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ToolingSafetyWandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to tooling safety wand.",
        "label": "Tooling Safety Wand [Member]"
       }
      }
     },
     "localname": "ToolingSafetyWandMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_TradeShowDisplaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to trade show displays.",
        "label": "Trade Show Displays [Member]"
       }
      }
     },
     "localname": "TradeShowDisplaysMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_VendorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to one vendor.",
        "label": "Vendor One [Member]"
       }
      }
     },
     "localname": "VendorOneMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_VendorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to vendor two.",
        "label": "Vendor Two [Member]"
       }
      }
     },
     "localname": "VendorTwoMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_ViceChairmanOfTheBoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the vice chairman of the board of directors.",
        "label": "Vice Chairman of the Board of Directors [Member]"
       }
      }
     },
     "localname": "ViceChairmanOfTheBoardOfDirectorsMember",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average remaining term of warrants and rights outstanding,",
        "label": "Outstanding, weighted average remaining life (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingWeightedAverageRemainingTerm",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details"
     ],
     "xbrltype": "durationItemType"
    },
    "mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding and to be issued\u2014"
       }
      }
     },
     "localname": "WeightedAverageSharesOutstandingBasicAndDilutedAbstract",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-d-inventories-summary-of-inventories-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note D - Inventories - Summary of Inventories (Details)"
       }
      }
     },
     "localname": "statement-statement-note-d-inventories-summary-of-inventories-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-d-inventories-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note D - Inventories"
       }
      }
     },
     "localname": "statement-statement-note-d-inventories-tables",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note G - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-g-furniture-fixtures-and-equipment-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note G - Furniture, Fixtures and Equipment"
       }
      }
     },
     "localname": "statement-statement-note-g-furniture-fixtures-and-equipment-tables",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-h-patents-summary-of-patents-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note H - Patents - Summary of Patents (Details)"
       }
      }
     },
     "localname": "statement-statement-note-h-patents-summary-of-patents-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-h-patents-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note H - Patents"
       }
      }
     },
     "localname": "statement-statement-note-h-patents-tables",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note I - Stockholders' Equity - Summary of Shares to be Issued (Details)"
       }
      }
     },
     "localname": "statement-statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-i-stockholders-equity-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note I - Stockholders' Equity"
       }
      }
     },
     "localname": "statement-statement-note-i-stockholders-equity-tables",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-i-stockholders-equity-warrants-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note I - Stockholders' Equity - Warrants (Details)"
       }
      }
     },
     "localname": "statement-statement-note-i-stockholders-equity-warrants-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note J - Stock Option Plans - Schedule of Restricted Stock (Details)"
       }
      }
     },
     "localname": "statement-statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note J - Stock Option Plans - Summary of Option Activity for Employees (Details)"
       }
      }
     },
     "localname": "statement-statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-j-stock-option-plans-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note J - Stock Option Plans"
       }
      }
     },
     "localname": "statement-statement-note-j-stock-option-plans-tables",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-l-income-taxes-deferred-tax-assets-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note L - Income Taxes - Deferred Tax Assets (Details)"
       }
      }
     },
     "localname": "statement-statement-note-l-income-taxes-deferred-tax-assets-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note L - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)"
       }
      }
     },
     "localname": "statement-statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-l-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note L - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-l-income-taxes-tables",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note M - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)"
       }
      }
     },
     "localname": "statement-statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note M - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)"
       }
      }
     },
     "localname": "statement-statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-m-segment-and-geographic-data-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note M - Segment and Geographic Data"
       }
      }
     },
     "localname": "statement-statement-note-m-segment-and-geographic-data-tables",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-p-commitments-lease-expense-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note P - Commitments - Lease Expense (Details)"
       }
      }
     },
     "localname": "statement-statement-note-p-commitments-lease-expense-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-p-commitments-maturities-of-lease-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note P - Commitments - Maturities of Lease Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-p-commitments-maturities-of-lease-liabilities-details",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-note-p-commitments-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note P - Commitments"
       }
      }
     },
     "localname": "statement-statement-note-p-commitments-tables",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mlss_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.milestonescientific.com/20221231",
     "xbrltype": "stringItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r205",
      "r236",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r256",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r308",
      "r310",
      "r311",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r205",
      "r236",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r256",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r308",
      "r310",
      "r311",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r316",
      "r330",
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r260",
      "r549",
      "r604",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r362",
      "r475",
      "r500",
      "r523",
      "r524",
      "r546",
      "r551",
      "r561",
      "r603",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r362",
      "r475",
      "r500",
      "r523",
      "r524",
      "r546",
      "r551",
      "r561",
      "r603",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r260",
      "r549",
      "r604",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r257",
      "r480",
      "r547",
      "r559",
      "r598",
      "r599",
      "r604",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r257",
      "r480",
      "r547",
      "r559",
      "r598",
      "r599",
      "r604",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r349",
      "r362",
      "r394",
      "r395",
      "r396",
      "r474",
      "r475",
      "r500",
      "r523",
      "r524",
      "r546",
      "r551",
      "r561",
      "r597",
      "r603",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r349",
      "r362",
      "r394",
      "r395",
      "r396",
      "r474",
      "r475",
      "r500",
      "r523",
      "r524",
      "r546",
      "r551",
      "r561",
      "r597",
      "r603",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r522",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r522",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r203",
      "r204",
      "r316",
      "r330",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r219",
      "r363",
      "r571",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r258",
      "r259",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r548",
      "r560",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r507",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r548",
      "r560",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r219",
      "r363",
      "r571",
      "r572",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r595",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r558"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r18",
      "r137",
      "r138",
      "r587"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable, related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r136",
      "r147",
      "r161",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties.",
        "label": "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent",
        "terseLabel": "Accounts Payable, Related Parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r79",
      "r181"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedTerseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r588",
      "r589",
      "r590",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r107",
      "r108",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.",
        "label": "Advances on contracts",
        "terseLabel": "Advances on Inventory Purchases"
       }
      }
     },
     "localname": "AdvancesOnInventoryPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r185",
      "r265",
      "r271",
      "r272",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r43",
      "r69",
      "r73"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangibles",
        "terseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r139",
      "r154",
      "r184",
      "r200",
      "r244",
      "r249",
      "r255",
      "r268",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r309",
      "r311",
      "r312",
      "r436",
      "r440",
      "r446",
      "r558",
      "r601",
      "r602",
      "r642"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r176",
      "r188",
      "r200",
      "r268",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r309",
      "r311",
      "r312",
      "r436",
      "r440",
      "r446",
      "r558",
      "r601",
      "r602",
      "r642"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r179",
      "r525"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r40",
      "r45",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r40",
      "r134"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "us-gaap_CashUninsuredAmount",
        "terseLabel": "Cash, Uninsured Amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "periodEndLabel": "Outstanding , weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding , weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "periodEndLabel": "Outstanding , number of shares (in shares)",
        "periodStartLabel": "Outstanding, number of shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r148",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r294",
      "r295",
      "r509",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r588",
      "r589",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r9",
      "r558"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $.001;authorized 100,000,000 shares; 69,306,497 shares issued and 69,273,164 shares outstanding as of December 31, 2022; 68,153,336 shares issued and 68,120,003 shares outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r52",
      "r53",
      "r131",
      "r132",
      "r260",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r52",
      "r53",
      "r131",
      "r132",
      "r260",
      "r506",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r52",
      "r53",
      "r131",
      "r132",
      "r260",
      "r508",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r52",
      "r53",
      "r131",
      "r132",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "us-gaap_ConcentrationRiskPercentage1",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r52",
      "r53",
      "r131",
      "r132",
      "r260",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r344",
      "r345",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "us-gaap_ContractWithCustomerLiability",
        "terseLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r61",
      "r248",
      "r249",
      "r250",
      "r251",
      "r256",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r32",
      "r480"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r51",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r140",
      "r141",
      "r152",
      "r205",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r454",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r22",
      "r205",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r454",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "auth_ref": [
      "r93",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.",
        "label": "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Compensation Expense"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.",
        "label": "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance",
        "periodEndLabel": "Shares-to be issued outstanding (in shares)",
        "periodStartLabel": "Shares-to-be-issued, outstanding (in shares)",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.",
        "label": "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued",
        "negatedLabel": "Issued in current period (in shares)"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r115",
      "r633"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "us-gaap_DeferredTaxAssetsInventory",
        "terseLabel": "Inventory Reserve"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Non-current deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r115",
      "r633"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net Operating Loss Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r115",
      "r633"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "us-gaap_DeferredTaxAssetsOther",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r114",
      "r115",
      "r633"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Tax Credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r115",
      "r633"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Officer's Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r115",
      "r633"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": {
     "auth_ref": [
      "r115",
      "r633"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.",
        "label": "Impaired Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": {
     "auth_ref": [
      "r115",
      "r633"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.",
        "label": "Warranty Reserve"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r43",
      "r77"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense",
        "terseLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r43",
      "r77"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r43",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "us-gaap_DepreciationDepletionAndAmortization",
        "verboseLabel": "Depreciation and Amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r368",
      "r400",
      "r401",
      "r403",
      "r408",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r96",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r18",
      "r302",
      "r303",
      "r304",
      "r310",
      "r311",
      "r312",
      "r468",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_DueToRelatedPartiesCurrent",
        "terseLabel": "Due to Related Parties, Current, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share applicable to common stockholders\u2014"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r195",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r227",
      "r444",
      "r445",
      "r495",
      "r498",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "us-gaap_EarningsPerShareBasic",
        "terseLabel": "Basic and Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r201",
      "r413",
      "r429"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
       "order": 4.0,
       "parentTag": "mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Statutory Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r631",
      "r634"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Valuation Allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r631",
      "r634"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
       "order": 1.0,
       "parentTag": "mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r631",
      "r634"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
       "order": 2.0,
       "parentTag": "mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r631",
      "r634"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details": {
       "order": 3.0,
       "parentTag": "mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State income tax - all states"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
        "terseLabel": "Share-Based Payment Arrangement, Amount Capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r87",
      "r172",
      "r192",
      "r193",
      "r194",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r229",
      "r270",
      "r343",
      "r404",
      "r405",
      "r406",
      "r425",
      "r426",
      "r443",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r464",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "us-gaap_EquityMethodInvestmentOwnershipPercentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r63",
      "r245",
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "us-gaap_EquityMethodInvestments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r39",
      "r65",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r456",
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Present value of lease liabilities, Finance Leases",
        "terseLabel": "Finance Lease, Liability, Total"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Current portion of finance lease liabilities",
        "terseLabel": "Finance Lease, Liability, Current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Non-current portion of finance lease liabilities",
        "terseLabel": "Finance Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
        "totalLabel": "Total future minimum lease payments, Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "2023, Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027, Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour",
        "terseLabel": "2026, Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree",
        "terseLabel": "2025, Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo",
        "terseLabel": "2024, Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount",
        "negatedTerseLabel": "Less: interest, Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "us-gaap_FinanceLeasePrincipalPayments",
        "negatedLabel": "Payments finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Right of use assets finance lease",
        "terseLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r462",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Weighted-average discount rate \u2013 finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r461",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance leases (years) (Year)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r182",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
        "negatedTerseLabel": "Patents, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r72",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "us-gaap_FiniteLivedIntangibleAssetsGross",
        "verboseLabel": "Patents, cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r72",
      "r481"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Intangibles, net",
        "terseLabel": "Patents-foundation intellectual property"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r43",
      "r85",
      "r86"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on debt extinguishment-PPP",
        "negatedTerseLabel": "Gain on debt extinguishment-PPP",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt, Total"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r365",
      "r367",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r365",
      "r367",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r31",
      "r200",
      "r244",
      "r248",
      "r254",
      "r256",
      "r268",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r309",
      "r311",
      "r312",
      "r446",
      "r539",
      "r601"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "us-gaap_GrossProfit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r244",
      "r248",
      "r254",
      "r256",
      "r539"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
        "totalLabel": "Loss before provision for income taxes and equity investments",
        "verboseLabel": "Income (loss) before taxes and equity in earnings of affiliates"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r28",
      "r43",
      "r63",
      "r149",
      "r162",
      "r241"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Deferred profit and divesture-equity investment (See Note F)",
        "negatedLabel": "Deferred profit and divesture-equity investment (See Note F)",
        "terseLabel": "Income (Loss) from Equity Method Investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r201",
      "r414",
      "r418",
      "r423",
      "r427",
      "r430",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r202",
      "r217",
      "r218",
      "r242",
      "r412",
      "r428",
      "r431",
      "r499"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r191",
      "r410",
      "r411",
      "r418",
      "r419",
      "r422",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase in accounts payable, related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "(Decrease) increase in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.",
        "label": "us-gaap_IncreaseDecreaseInDeferredCompensation",
        "terseLabel": "Increase (Decrease) in Deferred Compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInInventories",
        "negatedLabel": "(Increase) decrease in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r583",
      "r638"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Decrease operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r71",
      "r477",
      "r478",
      "r479",
      "r481",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income (expense)"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r67",
      "r527"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods, net",
        "negatedLabel": "Finished goods, net"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserveEffectOnIncomeNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods and any LIFO decrement which have been reflected in the statement of income during the period.",
        "label": "Inventory Reserve"
       }
      }
     },
     "localname": "InventoryLIFOReserveEffectOnIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r187",
      "r526",
      "r558"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "us-gaap_InventoryNet",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r178",
      "r186",
      "r228",
      "r275",
      "r276",
      "r277",
      "r476",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r66",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "us-gaap_InventoryValuationReserves",
        "terseLabel": "Inventory Valuation Reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r67",
      "r528"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Component parts and other materials"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "2023, Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027, Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
        "terseLabel": "2026, Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
        "terseLabel": "2025, Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "terseLabel": "2024, Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedTerseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19",
      "r200",
      "r268",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r309",
      "r311",
      "r312",
      "r437",
      "r440",
      "r441",
      "r446",
      "r538",
      "r601",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r144",
      "r158",
      "r558",
      "r586",
      "r596",
      "r636"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r177",
      "r200",
      "r268",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r309",
      "r311",
      "r312",
      "r437",
      "r440",
      "r441",
      "r446",
      "r558",
      "r601",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r27",
      "r143",
      "r157",
      "r200",
      "r268",
      "r300",
      "r303",
      "r304",
      "r305",
      "r311",
      "r312",
      "r446"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash used in (provided by) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r40",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r44",
      "r150",
      "r163",
      "r175",
      "r189",
      "r190",
      "r194",
      "r200",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r222",
      "r244",
      "r248",
      "r254",
      "r256",
      "r268",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r309",
      "r311",
      "r312",
      "r445",
      "r446",
      "r539",
      "r601"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "us-gaap_NetIncomeLoss",
        "totalLabel": "Net loss attributable to Milestone Scientific Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r120",
      "r125",
      "r189",
      "r190",
      "r217",
      "r218",
      "r579"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
        "negatedLabel": "Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r117",
      "r343",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r261",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "us-gaap_NotesReceivableNet",
        "terseLabel": "Financing Receivable, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "us-gaap_NumberOfCountriesInWhichEntityOperates",
        "terseLabel": "Number of Countries in which Entity Operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "us-gaap_NumberOfReportableSegments",
        "terseLabel": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficersCompensation": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "us-gaap_OfficersCompensation",
        "terseLabel": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold"
       }
      }
     },
     "localname": "OfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "us-gaap_OpenTaxYear",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r244",
      "r248",
      "r254",
      "r256",
      "r539"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "terseLabel": "Operating Income (Loss), Total",
        "totalLabel": "Loss from operations",
        "verboseLabel": "Operating Income (Loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease liabilities",
        "terseLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current portion of operating lease liabilities",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Non-current portion of operating lease liabilities",
        "terseLabel": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r458",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets operating lease",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r584"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r462",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate \u2013 operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r461",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating leases (years) (Year)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_OperatingLossCarryforwardsValuationAllowance",
        "terseLabel": "Operating Loss Carryforwards, Valuation Allowance"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of furniture, fixtures, and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r578"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCollectionOfFinanceReceivables": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the collection of receivables arising from the financing of goods and services.",
        "label": "us-gaap_ProceedsFromCollectionOfFinanceReceivables",
        "terseLabel": "Proceeds from Collection of Finance Receivables"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfFinanceReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "us-gaap_ProceedsFromNotesPayable",
        "terseLabel": "Proceeds from Notes Payable, Total"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
        "terseLabel": "Proceeds from Sale of Equity Method Investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r106"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "us-gaap_ProceedsFromStockOptionsExercised",
        "terseLabel": "Common stock issued to employee for option exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r164",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "us-gaap_ProfessionalFees",
        "terseLabel": "Professional Fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r175",
      "r189",
      "r190",
      "r196",
      "r200",
      "r209",
      "r217",
      "r218",
      "r244",
      "r248",
      "r254",
      "r256",
      "r268",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r309",
      "r311",
      "r312",
      "r435",
      "r438",
      "r439",
      "r445",
      "r446",
      "r496",
      "r539",
      "r555",
      "r556",
      "r579",
      "r601"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "us-gaap_ProfitLoss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r78",
      "r180"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Furniture, fixtures and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r80",
      "r159",
      "r497",
      "r558"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Furniture, fixtures and equipment, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r7",
      "r142",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r7",
      "r142",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r7",
      "r142",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted",
        "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r353",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r171",
      "r467",
      "r468",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
        "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty",
        "terseLabel": "Related Party Transaction, Purchases from Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r353",
      "r467",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r465",
      "r466",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r109",
      "r167",
      "r650"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r88",
      "r156",
      "r504",
      "r505",
      "r558"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r172",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r270",
      "r404",
      "r405",
      "r406",
      "r425",
      "r426",
      "r443",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r235",
      "r236",
      "r247",
      "r252",
      "r253",
      "r257",
      "r258",
      "r260",
      "r346",
      "r347",
      "r480"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Product sales, net",
        "verboseLabel": "Product sales, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r30",
      "r165",
      "r302",
      "r303",
      "r304",
      "r310",
      "r311",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "us-gaap_RevenueFromRelatedParties",
        "terseLabel": "Revenue from Related Parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r460",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
        "negatedLabel": "Property and equipment obtained in exchange for new finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r460",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
        "negatedLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities (1)"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "us-gaap_RoyaltyExpense",
        "terseLabel": "Royalty Expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r260",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario, Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r2",
      "r15",
      "r16",
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r98",
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r91",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r260",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r292",
      "r293",
      "r540",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted, Shares (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted, Weighted Average Grant-Date Fair Value per Award (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodEndLabel": "Non-vested, Shares (in shares)",
        "periodStartLabel": "Non-vested as January 1, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Non-vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share)",
        "periodStartLabel": "Non-vested as January 1, 2022 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Vested, Shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
        "negatedLabel": "Cancelled, Shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
        "negatedLabel": "Number of options forfeited and expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted average exercise price, forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of options granted (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Number of options (in shares)",
        "periodStartLabel": "Number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted average exercise price, outstanding (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r372",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r367",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r365",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "us-gaap_SharePrice",
        "terseLabel": "Share Price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, exercisable (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, outstanding (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "us-gaap_SharesIssued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r145",
      "r146",
      "r153",
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "us-gaap_ShortTermInvestments",
        "terseLabel": "Short-Term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r48",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r174",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r260",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r291",
      "r292",
      "r293",
      "r540",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r26",
      "r87",
      "r172",
      "r192",
      "r193",
      "r194",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r229",
      "r270",
      "r343",
      "r404",
      "r405",
      "r406",
      "r425",
      "r426",
      "r443",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r464",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business",
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r229",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business",
      "http://www.milestonescientific.com/20221231/role/statement-note-a-organization-and-business-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties",
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts",
      "http://www.milestonescientific.com/20221231/role/statement-note-e-advances-on-contracts-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees",
      "http://www.milestonescientific.com/20221231/role/statement-note-f-investment-in-and-transactions-with-equity-investees-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-summary-of-patents-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-summary-of-shares-to-be-issued-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-schedule-of-restricted-stock-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements",
      "http://www.milestonescientific.com/20221231/role/statement-note-k-employment-contract-and-consulting-agreements-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-deferred-tax-assets-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-reconciliation-of-the-statutory-tax-rates-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-summary-of-operations-by-geographic-area-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions",
      "http://www.milestonescientific.com/20221231/role/statement-note-o-related-party-transactions-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-lease-expense-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-maturities-of-lease-liabilities-details",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-q-benefit-plan",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Common stock issued for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r9",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Common stock issued to employee for compensation (in shares)",
        "terseLabel": "Common stock issued to employee for compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r87",
      "r88",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Common stock issued to employee for stock options exercised (in shares)",
        "negatedLabel": "Number of options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-summary-of-option-activity-for-employees-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Common stock issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r9",
      "r88",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation",
        "terseLabel": "Common stock issued for compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Common stock issued to employee for stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r12",
      "r13",
      "r62",
      "r558",
      "r586",
      "r596",
      "r636"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total Milestone Scientific, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r117",
      "r118",
      "r124",
      "r172",
      "r173",
      "r193",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r270",
      "r343",
      "r404",
      "r405",
      "r406",
      "r425",
      "r426",
      "r443",
      "r447",
      "r448",
      "r452",
      "r464",
      "r502",
      "r503",
      "r586",
      "r596",
      "r636"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r199",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r453",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r453",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r453",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events",
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r471",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-r-subsequent-events"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-b-liquidity-and-uncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations",
      "http://www.milestonescientific.com/20221231/role/statement-note-n-concentrations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-d-inventories-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-h-patents-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-m-segment-and-geographic-data-tables",
      "http://www.milestonescientific.com/20221231/role/statement-note-p-commitments-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.",
        "label": "Tools, Dies and Molds [Member]"
       }
      }
     },
     "localname": "ToolsDiesAndMoldsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-g-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r263",
      "r264",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r25",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r25",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury stock, at cost, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r25",
      "r89",
      "r90"
     ],
     "calculation": {
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "us-gaap_TreasuryStockValue",
        "negatedLabel": "Treasury stock, at cost, 33,333 shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r409",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "terseLabel": "Unrecognized Tax Benefits, Ending Balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual",
      "http://www.milestonescientific.com/20221231/role/statement-note-l-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans",
      "http://www.milestonescientific.com/20221231/role/statement-note-j-stock-option-plans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Outstanding, intrinsic value"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-note-i-stockholders-equity-warrants-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r220",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic and Diluted (in shares)",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Basic, Total (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.milestonescientific.com/20221231/role/statement-consolidated-statements-of-operations",
      "http://www.milestonescientific.com/20221231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r564": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r565": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r566": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r567": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r568": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r569": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001437749-23-008658-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-008658-xbrl.zip
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MY6$-Q\79=AS.F)U1#+]^NA;JY[,X%G"V9LH.;?<\3V8!6#=E)7.>Q6,G[E_
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M7W0[]57WZ$^X/-/Y&C:[YM3PG5@4J^"E'O#NVUKJX$FG,GC R+V.\- 2OG,
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M-Z@!CI4<*:W"C%7O.K>\P42 1>PD^"^9+M2C46Q<MQ.J&U<#NSZJ]"Q#?L<
M8F4Z)@/QK0%A7*&:]P8V0=6=8(H]1-7@^QU0'R-_9]L$U,N)U$UD'\YB*@I^
MDC=!_ODUA1XD]@8DFWZNK_K2"8YE#O2IMAS9)ORQ[TUD@)Q;$U?,Q9=/<[IB
M=%.,QUV&TB(@H(2HE#7PLX/6X^+ ?)N@]3KE[ET,\ EJ6[K%*RL0NP?G09X*
MFV6-XQQ?D'M+XU76![3P\T&,XK$ XG,#G8A!]^X8%[9Q8* 5NS;,#*B)1[UF
M^9G%BQ1)*?W\L(FY*P*:\DCJ<?8MX<Z$5I](M^>^*_;=KUB0'7H?]>'2JVU"
M[U\X7(J/]O(;U"^0#&?T(@IO^8;1= ]U?*>>1%RRB>_M^+D4C0T8K*I4"$1K
M:7QD(7/Y2JX04^R^!Y2"-3VS,CZYFKW93NASHQ!RW$ :$U_U\2]VYT;KX"7Z
MAS_4U_<!F.!,%FWOHU>Q\Y8<'BV%UC\Y/OK&P5UHU$MP'%]20;+Q82<_\\:?
M;T]FV].6*<E/K!-3_1258JS\XE/'FR<7]P)7>S"2#HC7$)7,T='3G*?6 +&M
M%&$,3"$?NTFF>G[!JJDP4ZQ$G$:K ]8^UMEQV$8@.]IFD-WK*&859#]\:Y!!
M?18.)-%%RE,DM3FL@!YCHP23_/AP8O6$6-,9.6Z?\[N6!ZFJM9T1KDY+FYA/
M+F$76/M*>7MG$;]3[G_S5\M>8_E/Q7OIL/\<'W;%T>'1\?_3JW,'_F#EW;F'
M\OQ]O/Y<*BK$FWE&_RL)Q0>\I;F:B$Q+[\\[OU[\?M7[</'VLO?3Q\N+7_A-
MZ(6K']Z^N?JXTE86/6>G=QMYBQ<?WO[V[_>WWF#!+W>O^4 4!_RR]_#L(+YQ
M_E]02P,$%     @ ,XE^5K 3^'N&!   210   T   !E>%\T.3 T-#,N:'1M
M[5AM;]LV$/Z<_(J#A[8)X#?9;>=8C@'541*C26S8"K!]I"0JXD"1*DD[<7_]
MCI(<9VZ*M>AJ%\& !+*.Y-WQ>,]S1PU2D_'A(*4D'AX># PSG XO@^LK\&-F
MI!JT2A&.9=00B%*B-#6GM85)&KW:L)0*DM'36B)51DPCIH9&ADE1@T@*0P7.
M-I33/)6"G@I9&QX.6J7!02CC%6BSXL5R81H)R1A?]>'UIX4T;L RJN&&WL-,
M9D24PCH4XCIHJECB0K%.L\^T#TX[-R[D)(Z9N.M#FPEH-QTF7(@62DO5![(P
MTK4>Y,^9W;+G;E07FHO7)5&,"-,7=K?<-?3!- AG=Z*OV%UJW(RH.R;Z.!_6
M_SU<BZ$*A_Y#RD)FH-MI.H-6.!RT\N'A5WQYL^7,FV_Q9F,<#;X6H<[=?=OX
ML9A&F#Y4?3VH(W\6C,_'(R\83V[VY\;T=C:_]6X""";@]/;GQVUSWAPU8>Z/
M;#S Z;YKU_?GC3<'[VPR#?PS>!*@_?FS#LM)^SU,SB&X]&'NS3YX-_Z\,?GC
MRO\3O%%@1SKM=F??N/E%L?E,<)UWA;FQL'PO2NZ'>V92,"D%(L2"<% TE\J
M3.":<:H-U@*81PQ/C"4L@K&(FG#T^K=>I]-V'V<4[XY[#*CP'.TCP3<^(N&K
M0G.._"]CH,*R/9S1B&8A5=!UZGB G4ZY?2 :$M07;SR:4ZP&S##<.A$Q^ ]8
MU,0=A9',,J:U]1[_[,R8& HI513=/K*"RL%9L9FU=W48U\%3?Q$!EV1)54HX
M5J=1RFB"RM&884L*DP3WB>X]C4 =4((!6-4AQP*UP#B#D<@@4 %9ZV8)8KL-
M$LO<X$:>3K43;#JCUF)K1(5$4-V8/'"Z B\J(F[3N8[CQ/1WF'&&A)Q"*%5,
MU6FMC=T Y;RJS8_O.B?1^OW[$_2>Q2;%G^U7E1\-3A/3+XI\)2B*<G]=]@\.
M#[#)4?C#/N.UR:4]A8CPBD>,S"O5OS=[KY[LR\3_LA+L4BC7@G.2/Q1&<<5_
M#S_4[#2+4%O]W^M:#RW\7.<"3,<2)Y L.%\A.60YMZ![!**BGQ9,T0Q)0-L\
MU15W.-TC@IA7R"Q'\?%C;F]@^PC9*L&=D^[;$B*H*Z8Q(O/DK5N>&D)\.TKX
MM"F ;6B1H_\#8E> Z/[DG.O\""#>[P 03)27))OE]G)$F$!"9V6U6:.%,(5P
MR175%AAU.TPX!UR&!:\HI3I'I.AZL2IA@HC(RE$AWMFL:EO6<-:"%^B06"@+
MD_H?Q><70<7+:'[.;*=P35240K==]!_=%[6_EFYMMS@[L[TONUL=7!GQJHW;
MF1-'4\40WCGAI?TO&LKC%Y5G'FCD9N1$B74*F8V7U9_IJE-&_BX8+L5B'U(J
MD";EDF')M\WPYF9A"?">(6F&MLNH:#9<;<U(%DHPG9:+O_5FH(!AMZ(-21)8
MY"BQ70PJ;>[P'&*VA(@3K4]K5]X\:$R]"[_Q8>9['^VGK2>CTXOS8+8E2Y.&
MDO=?"FWW =.+F]OKC36<8;_6/?- +UKVZ]UPT"H^(?X-4$L#!!0    ( #.)
M?E:D$ -;<P0  !T6   -    97A?-#DP-#0T+FAT;>U8;6_;-A#^W/R*@X>E
M*2"_MT-B.P)41TZ-)K%A*\#VD9*HB !%J225Q/WU.U*RDSCIL Q=XFX%$L@Z
M'N^-]]P=-4IUQMU12DGL[KT9::8Y=3\%YV?@QTSG<M2N2'MO<#6CFD"4$JFH
M/FZ4.FD>-MR**DA&CQM)+C.BFS'5--(L%PV(<J&I0&Y-.2W27-!CD3?<O5&[
M4CD*\W@%2J^XW2YT,R$9XZL!O U81A5<T!M8Y!D1;QVP% <4E2P9@N56["L=
M0+=3Z"$4)(Z9N!ITF(!6EXFAT5,\*7S_2YGKX9:&BOB$8$NX)I(1H0<@C)-\
M"!F15TP, %DV_X>&7=-;W22<7>&B9%>I1D-&H>O?IBQD&OJ]5F_4#MU1NW#W
MOF'@(^>'=T99FQZ85%M4&V26&^Z^"%4Q_#_H>+G#C#"3J42CQOXBF$ZF8R^8
MSBYVS+;YY6)YZ5T$$,R@>[ACQEVVEJUQ"Y;^V$0.NOT/'6?'3/26X)W,YH%_
M O="N6-&K@-XU/D-9A,(/OFP]!8?O0M_V9S]?N;_ =XX,"N]3J?WV@!]"1U;
M*IZGX4' &^Y4F+8EJA8&-TRGH%,*1(B2<)"TR*6&/(%SQJG2V-)@&3$\&9:P
M"*8B:L'!_B^'O5YGN.&P[]WA.T"!$U2/J=#\C)D@K>0"&UH> Q6F?<$)C6@6
M4@G]KH/GU^M5W@-1D*"\^,ZB)8U*R31#SXF(P;_%WBRN*(SS+&-*&>OQSW#&
M1%-(J:1H]H$AU 8NK#-KZQR8.C#'YBV-;YAR1#@P3AE-8,($$1%#_V<)NHD<
M]P/@8&9*]'_E0%%*56*40>=8?J &O%*M"NS&"Q+GA48_[K,:!I/,*-5Z1F1(
M!%7-V2VG*_ B&W"3S ZN$SUX[7S[SCHT"3F%,)<QE<>-#LY-E/-ZGMF\JX)$
MZ_?G0^"&Q3K%GYU?:SN:G"9Z0$J=KPEV6*DH#3OQX4 H\8=YQFN5U^:D(\+K
MFI2Q..:TEEYO7;NFXW^PV>[X_AA'R=V6C;:1OVNF!9CS%18A*3E?80'*"FZ
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M>;@9<, 4.([JSV0ZHTPXH;:>*D%C(W!#/224":HL(O^Y:3E7OG*/CMV3HW=
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MG\6] _JJ;>E9'\_[$B_TY0CNN&JIRW"@%EQGB(EY(;IB4<VU9"RI_%@?W!O
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M1>['T0:W.K8(C$9D;8%$'RZOOUQR#YC:P\?M(:2>CBU(Z&/;2Z>=]QBHT4V
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M(U+?2F"R926AI*J\#O0^4#FV>ND(F.R;VIC5"5YA,GIJZ%12,3!90F54*MD
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M:%K;!_-G,'_6!",S?[:GBM(J#9B1O(X-FA7YEIEKLC#- UA28>9R 2:<[2H
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MU$'=BN9VI-[J-M3U(W5EMV&A\>A:DTQ$E^C+DJ5B=O-]Z81^;C9&8_IPN>E
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MJZDTZFB'T'(N+L&2BX<>7MX5X_]%LGB=4.TF-NYL@>".195>9+;N4Y>I%_&
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MR#(+>#>'C3(K@?]@A)%E-K"E"AUK?@./%OW1YD9PZTX[VEP*>'QA1YN58=B
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MW#$O9O./C,7584[Y)HEH?B_.\U?(X!V<TG]!UYQ&2;68!#W3E;R4?Z\^*@
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M0FATA^U(,%>/T/(.00C6SR,THQLE[F^6T='YA!JB4DGRZ+P_8;A@JCE\+J#
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MN=,<:@+5L+VNG"M8^A-BQ$+>:P[RCJ@PQ%"]7K!UF-WC)[8@Y3GO1II!U.9
M=^XOF!A)U-"$9ZJS AU:QVZ?AZ[--U<15%'%V(RN%+ ":+TQ 2&JK/.NS4:O
MZ8<;&6HT/Q?U/9T6\JI>PL$!O69R62_1;)]QDL8*JFVL'42W#?7G>KX;FN;:
MS0YXZ^IMTXPOG'X;E1*BS#UOGK>QJG<VNG+KD_-:@:[GKWH9+T8'JD 7DA&P
MA7AY..ANH+\B)Y>TO)Z]^?'C]X"M<\5^''I$O*[PUCT2<GE;9X&7M?VV?"J
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M]1V5@:;$B$090+LQ#4-6).=: ;0(SB(! 24-!D1A8L3SIK[_2R\&.&.X T<
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MU@,HY846)9^1V2CEJ+C1]M( H:9<@T0]1CO H&%73T*%L>=J34CZ* -"I,.
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M(#Q/NY>WBPR3_6N:'_/9P607'U;F9L9Z8>02Q*PS;UK!YX4(#)T?G>#M<L1
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M].AZ/;0D4<EH+E!4T6515HOFS!;\^#;&9*+!.6_R0\V7#<DY#E[P2"(\LF9
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MP9<EH0 %8E(X&2' MAB]#ET@@08Q."%K7^M(G,J%J(S)X6QU^H_V=\T[G_9
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M#Z$GR$D"SL^1'0)19B+-42Q A#E)JG.<P-GHT>]+::])EM"5+](^3P3+37\
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M8D>OG/0ZK4Z:=OO9>;L*9FII*6@8):EPK6+,3L>C?3A1+\:G15!:EP,=<WI
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MEZC'_IDENW:SRHA[$3!47U<L(XHHHY-7.,MP7%$(MP5+-5KM;NED4/KR*$O
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MI*P0^_+[9O>ZSA.^Y)X0SX"1$ 7LTP-YOS"A['P58[J.\_F"/1@^T32[AM2
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MC'139XQ&<\3YY6*!^&&!#C6-[]C;XK>PY FCMU[?FNR;#QD,9,% -F8Z3\]
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MPK_5)E01%?*6?9)ROF*"+H"0EG8GI< JRCPQ>-#B\ADE=434?,$.#42%99\
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M"K]#Y SER6H=TR_2$%=H-\>\; ]D20*-H=U<\_*P?7VGKYJ-MSW<<O#B _L
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MZ-\"R@.@_.?IH=PX4=\?CSO&+Y^3%7?+WK&3\7*Q0,(=;E@BHA^=('U<C%:
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M&D-LIV.S9=>RSRH]&L\94V4>;;)#-1ZKU7@T0_ T7E^'VB?:DR34.SFB\NX
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M#Y1G<3):EV:)+#^>A;IH82*V+?F2<P #!&9LMI=B,$9,-%V3%C,-1KN.''H
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MO0Q*(8AHR1\^P*$6!XB6E#-U3/2.,@(ZL;W#Y)UG"J9=3-V- MD^(.:#J>,
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MN+U(GA'CW>X8@X2D['[A_WF,"\2^^?]02P,$%     @ ,XE^5DSZ$Q@Q^ $
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M3N!=<,AD1S_&,DKO3FUWWF)W>HLN6OXXRWNA\G_+5*AP@2?1%1!.G$R(SRY
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M\IT7,WAY+)?.IN[B9U/W06?3#-EWM!U*0:XB:PM#MW%$M8=LB=H:%&T^/3$
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MC-4J?&_ZT6VU.YMS,(;#8Q(UJFS?O)Q(NWU'3X8W O0CXFVSO;G=X.T9\(:
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M?:_EZ)Q($@;8CE4D(D!&6.OX89&W7;EM-[&[8O\/$Y-SO-[XTPT0?#+WI::
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MO8;GP8GOI3FH\NDPQABT2?W,AB*;WL6U2&<ID&[6&WD#HB,*O->;SFY[H#S
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MPM6W@9L3^"E__P(7GI[F&9DVL+M*^--5#\+ 5KNS11C8V6OM[;UO;6]NSV"
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M[.<#V(/7W7N_-T<P#VEJ(IEN-++3,6_1/KZ*V9"FC[XV5MM^8:P*ED49/"H
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MDOK Y/-<YP]CY@,V(@JI=C9.)&Y "P\LT  0I?K(P[ +GUZH'< Y"2_EOE4
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MGR;V)X.S5#<ZY\Z'3,EE^N-6KFBS 1KY*7B.'W*+2-)R[ @BTT\T G4QXCY
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M.@,JS=N$4,4#=#:V"-B32>:NPAM=.0[3+2'_HNM$]0OJ7>$,Y8W ;:\%575
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M0$(OA!])RPTIR:257H\9Z!>'^Y0MZ\'RKOWH;576A-.*5P.'BRG"09\FNRG
MQ9,AB<<G6KM$X (O=2)3Y#KJN)?X%)] WX^&X#_EXO(=-L@H1^E=MIZU-MV/
M*&8C'Y4N5LMV?-B5 W>UR>X,M_<N07HMO)^$6BED;Y%R)VZ;B'GKD&K'M&*"
M(F\>N)[C<U;@X+:;,;,QW6)FZW' :.IND=J^I/+&FO)NW/.R;0ST?=?-.(-)
M[?UW-GV/*I <R189U_7//Y/4OV"I/\.CY0$EI-#[14EQ.1!^Z3H^FU(E^>'S
MT]/H6ZT8^/G%VS.M#_A.4Y)T+D)W;HQUZ.CS,A(P%B0(6BW5W^.IH=L\[OG(
M%.P$8\$[5UA>(V']*Z>)GUUD$PJ<$TZR,&2\+PCX15+&N/E\D&HJ.V<OC\!X
MZ2<\QMD%_[(2'XS]-+"'192"1NHKI,R4RE,_)U$G(1XQ+*5@N7&K +RODIJ9
MPE!X*P(8'/:JD.XVC)]2/BA$LZE/G%TG=.5B^C6[PZMD+4%F4J($DLK:*_'K
MUQ-67&$/H:5<Y?AX_CE+]Z-S=#4I,M16C5=_4O8JD#\U[T/PXPE6J[&>&CD/
MZ%]P^HP[:#&0NVHKHA+C];#H?=RXT-\"=.?"RNIRDG4[-$F/K.2#76; D4=\
MO,A*,DI9VH:E#!E\D;")"2U2AVQ.&*_&JY;K.0H8/F80P!Y'D-=)*35<(IP4
M >HF,RFQP ?.IO>22^3+Q3Z%0,T'I[_&J(#TG-A)*NPU7%VJ\$DN>%:V4^7J
M<R3D?:'\R]\?G ^C\C N\H:_9X0/3ME,K1+SLC3#47.I7U9S\D*+BP592@"#
M2RE?4.&+O>C%IE?T"O&E% 1VI3CD0_$SU@D/3U31?% 748\><Z2B)D:%4-2N
MVU.;9YI% 7&ML4"'W)[.V 9+Q74][-KW=?%^] OUMS!;"L=L,;R7I.4*3Q@]
M.,_>NYLH?*57%$9%SO>4&ZIG!>/S_#@=4:+6I*!@,#:5+2<P:X8GXTX<;/F)
MN3V]D(22UQZX!+J'89,>A]WQ[HIMOOZ6FH&(R?6#L3/)>B-L1I83!I0U7N%/
M_LJ01S#;\TP^1?+$:B;$4/2.P#=W#8@0&P&=W^(HZ:VA7&+ AL#W%BC>:AZ
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M<JS:R@7/<T[XU4DA-=>Z.!UG/0[=(Z8< QR\U'$O5EO;N'0/L:_C7_O;5(8
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MA2@!ZH^.]ZW#SOO>7.O&F*$UEUC0^4?I/ZF@0;XG3KJ-OG!_#N5$%<+NHQB
M[EJYC@6 VPH 3\<"P+$ \,M:$UP5^$(N14I<V!KS(5UC>'1)Y_ C#/(#6YF!
M]N;D\.#;]]_!KH'2Q4"("<R8PJ2V6925(&C8^!\_9_#JH<X9+'DFTY5NK_#
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M34OP!TI8YZ9) @81PDY]R)9,7W5T\F?5903,P45TV"?82-<%=;0(9#1)/ U
M$*!8;\1B]&&_Q ?$BJZ[+>0=_4;8^3.TTSSI, *A-,X[MJ$HU,S5P&4%\]DA
M:RD1 U 3+?5*(FX,1=PY;MZECD\$4R:!Y4(+<.FJN8<\5<>';SPN\X-E3%6[
M!J08SF$7.G0)_V4U"Y$W/ *B8LR^D[0%,V1M8@A5+$!4'R=4K!6*TQ$2JX34
M,%M+53-<LLJ(X=+PM2)H<1O(NAZ/$?$*V()5//Q.CEJ9Z/S-5V#"KPK<CI<%
M#)@H"+D><5APA%C""#'=T53&0!<LQL/I5B\GV#_H3,3PDO&WZ+\2(R$4VSP#
M@2&L:(UG$KB^Q$$".:Z9X>-0+ZRF3<E[*.\*[3A2!Y.'TA,?'92*CO.DFB1@
M*.R]^9"[M>D4.MIPGKQSC_&'T#V8]2DFP]^4AS,(-(R3BOV[) C4;$'-9NMM
M*3HNA'>VILK6\W. ^X)#MD+#$.H.J)JA(D=2SIG(<4?M/:[KZ5PZ;IX</-%S
M?X4L^ "U83C!VD ^C)U&0>'1XFBQE\E-2:0;(^QFZ'2@BBGLGT%E3'V5*L_D
MS9&.*&=P2P6)O'3)>R5R1  YYE.8BJ+'\4T,L:K_NU2*;PQN^]C(>E<0\P K
M+HAZ3H(O@JC+H'J#QT:77*3>($$7A$_GB]BRY>#)"A02$Z>W#O=DX&6DS2")
M$I8(10!Z&WUP8B>+O#D2A!6H=;!4RGSS/=1$ ^9LN:!_O;E;&FLT,D4P(2G=
M7P'VMUH.CU#<&6J.(1]']8WY--55PY098,)IW98?)\CO/+AS-U%V@T,9VB,L
M!$M2.#BX *8?PZ]>%S?:%B[>9(E-#>-':UEC?/()#L-3W_PJ==L-KWV^WAV+
MMG:R:.O96+0U%FU]IH'ZS@-(;M< :O!?4"M [GP)E1+#N&Z0-Q9D+.-G"*HD
M];.Q<TB@^7S+$A.G:2Z]LC;L<5A_;]11DUVAV.T'!%VEV\)Z^+(K:-$8/Y%Z
MY3>)?[Z_X^5C?B+6-/_U#6@(/+$K]'2+N?]WO4JF^N_/'N3V:R)IF[)_3]#O
M]*9H)F6Z5E715)VQA#<$7=2D^I$+#%=,DUS/^3)+TSPHU6?[3_^\,=*P5DUZ
M@T<VY<H_[\G0TVYSBX].IC/>Y$\8/>_#W8V?O.-@=9,5"A9OOJX;WWW(6\,<
M0FR.;DP7?JS@RN'+)(@._(PR/XK_*/Z[*?[<%UC:5G;YU:QSSRBBTH"!,)Z%
M\2P\B+/@*9CT/J#@4P;RWV@F@D 'W'PM 1K/S\D$H^B_MS_G)>_?JU66ME@:
MQH08XS$9C\F#."8$8B/4W)IQ&H_%>"P>^;%(B@),I*F" T\0\)OYP_EG,9M6
MKLGZ?+S$DT%MPA5'D25>;@N!/7]Z65F&<(Q)\T\!>'$+WV5@"U%B:FG(T5$1
MF$YZ 7-D)A,ZVRQ-XQ$>C_##/\*2'%T*:RPQ\JCEEV=35]1EI86%/5X?.&KC
M,1B/P8,X!H'DQ.!1=,Z&)78FB+ND\=!$TD-8KI"Y%P$;29)J1NT0LH#>73B>
MG/'D/(B30Q6.EK*9O"0F+K&5-UT?J<.SYZ'[9X(/SV"%':J(\;R,Y^5!G!>/
M&A3H#'LP$J/$CQ+_D"1^"XLIJ7[3"#7*^RCO#T+>Z<]>PY-]5,!@LU6B*.7,
MN;%1+8J0O^EX"L93\!!.0>@W"ITPVZI,ZH9:Q )\O*NHM)= 7J2?YN,+5O8_
MY2@]Z"*[7Y(AL$QTLR9N75(O7J6%WM*7]8[H&[@FDAN<$"/6%8S>H(@@$F-'
M_ZV&]^9QWZCU#1G4WH"ED-D4[( JYF)M)+DJ*_Q";LO^$*BVP9I]*0HD?.8R
M;^$76HE)&^V'6G?_ '-M7&'XF-I"F7D8#IH(/HGKAUH[&!TMZ&4CAV'9_%0Z
MKV6F1<TU4.$\F_$]3%*%0;U!%6HLZ%RYR3IN7!UFB'==MW[;Y,O<T8[ VTQZ
MAJN>$A8>\WEZYJMI4B\B8F(C7GGM52SAVG6.KD[N6]PWO5XX,7I1M_=TFA W
M!N6FW#23Y@.F!XVY!V;BHC4EB$MDCR#J0=P]!/9^9!U= WO4VXK2 QR0\,OB
MBO0+-35<'I439CG=5>87T'93QY U==@([+%I13>9*"YC'%7E9;/0=WKT;%ZB
M3A<J=8NX:EEWL!L(1YU?G+I)8V"\J6@9Y8)(25OA2P0)Y*YAF?3^QTC44''Z
M=5+FPVB#$OX8!(]/[MO _25V^%5-U=PK/%GO>3B0EW!57 J]K30^!Y*"6'NM
MKVFR-I%_DO1*H39T3*;7C'AZJ8T/=P[? $_F!L.Q6[3W5K.YNAB?L;G)6N@D
M%Z%;;,9M](0-T!;"P4TX^N\=1C1J;F[,^7@',2 =\7F2T$'M0JXJ#\-G@5^Z
M?>TDGP$>GMG!'5,%+[-VJ5HA"\WR%TR46JB*[5@D?=AX-GX,GQXN&@%L]+DR
M.^-"I%2JXW#=F6C+ZIJ>DX(&#:1-/,J)JPWQFL($O.L/0ZC^QCZ/.W'!1W_Y
M2Y889L45QX@@4A$>B9J '6%N7IE&'K=VA[;6;"SJ[I]*!-*!?[Q4,!E&*L"V
M0D49\*8GN9,(F$-5<-ASR:&2%3.DN]0;ALT"R^Z&D6QLA[0H3::C1 7!VLPH
M:\3QFOZG!26K(&7"@N+O-1,KX(HZ?+"2U"/\AT=23+0>8I4G<)-0A[AG8T6V
MW:Q&&LL,XP:&1OFRK-XS,U3>RI+P/#OH+XEIXUB4-;=K3@D<HHJ%,(EG9^_G
M,#6YB@0>K>$X@:Q"JA13F]LUQFI';7)7I4I@<VE\"WG<&8B)*'ZG"6&(B+%D
M3)0Q"FI0)_,\\*JQVB+T=D02+]&KSY#8$&$W9@36TBPR./P8LZ0*%U$NRBBG
MI'7=SY'G#[[W>ZD8\U\:]@8>B5_><2@4[^?HX%C!9[Q3]G<.,".7IKIPT3^3
M2\-BF0A0"++A(26S_ZKQ^G@7"+2<.=R0'4PQ6"T$CR"R>6]#;U2^0V.-=R,^
M&@9<\;82R-%RSJP)] 0:%\@.$HOA#7TIK'_X1PDZY@GA0R-9 _%FQ<2"@!=:
M&ATR/!Z*Q479>$BZ6,00@^)ERDOEOP_O:]B+BU)Q?"5:H*Y6!Q]51X]]\TMW
MU93;(M?0P^"2(<Z07I*TL!BJ$#9=D!)8+^.Q<?#,A3 Z3FE><CS#>W+, =UD
M>^IA!TXV05/PWN9G8M,%M+B-*$H8M,+],"DXA@*,I:$6AG^(X-A(_&:RYD"_
MPFZ3&9(MRC+E0:_+UN<#AOST]4;0CYGEC-VR__@@0)GE6<&3DI01^DJQ#$$D
M&ECH>I.<'+;H7_]S_BHZ6SK,,15;R)H1^9Z^?8,\@(^_&+B*U&%3BT $;X,4
M2=T>OL6EPR]Y/3./%OZ1*"_!Y*XB_A[>^;W9L(0I+*'VIX6LJ["&7JJ%CLTQ
M1&?RN$*&;_I;$C(+Q$I8*T)49WD%@YUD;+V<P-6M! >__//\7!D.E()\4S@[
M#_M+W1=44)F$ZV5#?G29(,.DLID$08LE4DAQ.DD="-'7!@:-)Y+&LT 8HUZR
M-H114YF9ZEJOZJ29*JNN%3/TGLHB]PK7H.ZROC6=6A-T@5K4US3J$O4L!M#G
M"*JG4^5KRX^5@N$!*)(+\A%3,O>C8DXETMAP2>(+.$+KDWX-,A60L=R)1FH>
M.RAX4M]Z?Q)H'(P<[B0P]?2.Z"@$NDKY)I*+:)8).TW7IF2JXU6W*V#C_K'
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MB 6!"#%!0^<B$39"04&W';IZ\6_8B:##*=%WTFTT@D 73X'W1 (J!K^ SOA
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M$K,1!,4=A",H(0^394&Z*975%[.N@,4X-JH.H_(S*C3BR34:+1.1O92^><I
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M/;Y35O.DR/Z7+2F\N$T4!R.<<L]W7ZY1(;*ZQU,\GN+'=HI?T;6F+,#SO)S
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M?GHL4ONJ16IDZRKM>G2.O,W7562,UN_.W3=&8NP.WW@P<42_CJ/:5=EL8*]
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M@_5A^R/0"T^N:_EA;>AD"BR),37# YW ;"F+A-;$F,6W6!$L7.%D:'L^)IS
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M1WC@!(]0\91V>/J!_H2_? QBL/(4USF=O[-P'>/)HV&*F9UMC);)KVM[%HL
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M&FW6FXLJLLPNFH6NY UAW]Q>"C<7B3WUX"X>L#F[,(!R-F8SHDV6XO.C?;O
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M.*-]1JYBX32(A9. ?/IYXU1!#H([E1W>()'MN '6C0^298A=(L@CA=LZR!T
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M>  !SV89,Q_$9C"R?7@;9'" ,O>1$A_6 A^ "+4#']X8&>,ARF;\/6M&S+_
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M8 [P*,R5[4U\<H)6_&Q"KJ_OR-U%]_:<]"_)S8S!^XO]\S,(?_B+>O!;QYC
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M<Y+V$S+UJ(]//#1L;_PJ81S& (TV@2]X^%7X> KK\9<O,75].V!<,0RY@E&
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MG7?A.6?C4)R\;0^,WXA;!,,:)K;OX[Y'EV1/54N.SZ;!08A:,Q,I'4-K%8D
MCXX%V(BWF>\=>1BY?O+3$!CP%0.@0,ET'+9_ K&/ IN3DMT)L.$^!@;<T*.&
M[SJ,M.!MS3QV:^/1G<$E1A0';:U6:XC&H4<IKBO694CHZ"M2? UKQ@8K@J(%
MP0?_##U8"#Y" J ^:ND%>*.9(^'&PN/ O>"9J/,$[,X^#)\*M5WX5*&:L]'S
M<F I6'WFN6/B H\EGH"WIP;F.R-=T,V&QTV1F PO] V?A9L%=^)SR'#/D7OQ
MCEGO1AYA3_$)(T4[G7E3I"!<)!10^*VW,HH.A]Q8<5"&O9& FSPN0Q>\1",$
M=S.4BXX+9I\YBFY\K&QYF^!$<SQ#"R@$&;=M7)-:,X]'%H%9<.>8BK+]/_R5
M/! 1+(V#WN$/*<F]RTM )N?*SN*B'J'$EG(&KB40,_'E^''H3]A0!RXE(;@,
MV!0_0"5GPU+HLVVQ :@@V V&$BXP)JBJN$"W;-\<NWYXS96/Q34QWTEC[+N)
M^S\;XYD1Q-=.M1S9=$#FB@"QT#O!#O"P4'O"#,:)85'L(C_7_!(:Q"\8(X+_
M+MT"F0%M[= $-Y+F=/K:03@_TK%-GT-).A<,L*.X1[ 72;'Y&!MT"6=@YRR4
M <Y[,G OT (P85-9+3#Y;@3 %;7UUQ?O&3\[!\R$/SM3)_/7-I/S0\_E&AE,
M)@_E!/"Y[5IS5;92[8;ZW4,C8C*9.7SD 4J-)=-PX>/0'.27QT]L6 \-[3$#
MGNA$^1BZRTR^<=;T\;))MF<W#Y^'"[OPPND6 ES]1/T( N#9'3^'Q@ZS3VWF
M&H)]")ZX\\0DDC][_!=7=!+>%0,:8_H3T&T]S5G3PODZ(,,H7S8?!<H6!$K,
M3-W^6JJSQ7OBR>;W:O)OX(V,!P/F!Q"6"_/KOY51=,VG'@(VC @MQ+YP"+C!
M-Q5T%*I,>+-%3I@-93$&,OY@*G+.2*&^ _Z<AW1,ZG&S$FP)'J59.'0!.BYQ
M$B2V L'+F@8\+!-&93[6GRKO@?O:-9EJSPCPG@%VSV^&@]:!Q%;X5Q 4]'6/
M<(__WXE3,3;SZC^3T\Y^]OW]):5-5-H+#'>8-B[U:/#5J5K]S&Z.$\%1NE9D
M9HM/B*;D/UE^,9%/69_WJ:/Z$%G'@\DZYDDR*M+N,XSO),.4%5E&4H_TXMOG
M!7Z1D 'RIQ?7[Z9(+8K4HD@MBM2B2"T>56IQ07>+/*/(,]:>1W>:9WR7G432
M420=E[ M\6"4A$%O>_@6Z2MC*:RN7V0:JR)84,VEY\ 6<X%\$OLQ9"4S&!?%
MIB@9">(GC!(]Z32Q7,IM$6,,?S,;#>R3%^,UR=21=DX7Y9AHP@022(>7D3NF
M7'J_1!E1D%(@M!+K"074B@4Q7$BAR,'O^A3,%MS[<#%^M)H5%T!YY"2E[%M*
MN;!0VV3FYVM(V5K: 6\Y,]01'!( -YP)PJKL0P9)>IRX3Q.@[8(Z0BMZ,IU'
M6-[ +[2N&5QF.$&>^,;86/1OHQN_QD$:AZ)2!\GR'Z9:<)F4 =FG"[<,%2HG
M+S-+(KLC[0H(O/F]D-N?V OTH,&T9<*&KW'FPT.SU8 ^HR:FY@"!Z,(0BT["
M]].SL.'W@.\2+0Z8B9E<."!Q;(71RX4-M>%R<)<0L@OT2;U=@FA@Y%H6BYZA
ME)"2I)NPY.^_9[ ?J/KAKG,"19%"(*^/,G@"G,:,<9 [CR"I:$ 7[_(P CT_
MIH;%K4$R H<>MN4I=(>B-'1T!^[*.T@KM!:8]16$5 +['@QT]']BB0R6H).T
M]6*3(V&!AK8-I_L$+$?7<L?NTVOHJ4<F2=)IF-M-;#ES4AP!IW^QO_X&A 6#
M#@""7D\8*^?6">(3[51FL7SY9)=LJ: 8&KIC0!ZC=A@(F[@^\N\8*.TL4!\]
M?0Z.,'[-GPA^!"!*50&?]TC@O.U-%]*9N=>[:=_2\*Z-Y4QQ[J/X[=0+E70N
MG:U8;9K#Q.32]Q:^O[4^H(#B895D) JL1(,[@G/'FTMEWV1.*KSG@@D61/'7
MN7X#I3%"6<?I]F+XH7(.F&+C[_)_^[,A:!],@8%Q"0ZB:?NA ;3^W+[@*,%1
MU>6HWCP DN0H^A/S!9B@!8?5G6#,B5MTC,N03>8&A+1@&Z;:7Y%3RB)4:"?"
M(OZ@[*[<N(GS"K87?@:/#^J)&X86?08'9QI=/K)24 R$IBA?G;3P,5OL<#8F
M8WM(WUC14KPH"LMW)YBU"4US6!BS_C >;W-+E/FIW!P-;4]FJX=FKS_/*,.M
M0P'%[Q9P0S=*<X1/,K>_7]#/HLX(8^S6W"P6<D7(E;K(%9ZR778WYGY7HC8W
M=CB2_E840F=,1<V1@UX,,V##2$[$KPLJ'UW/B)W>"*CLET%!" X=O/0)V-;1
M!2(_EXD6\]4<AUD:VP_CT^&-F;@$">8RR?HX\VWV_#A[H+),7OW2][1F],D*
M;%'\_D[Q.XL6L]IWX"^LKSX*_SYW)7H:WC)7HC]Z6)8;%ES'0T[J6'!]H'VZ
M--&GJ_P^7<5E+C./?-KG>,?^=6_P<'O3(X.+?N_FH7^%M>DWEV3PXWS0O^QW
M[_N]03S7:H\+79@[==Z][MY<P)I_Z_4>]KF\M1/ .)XW]DQ"\ ]MYP%_&G/5
MHJ!3SYK+XI"_%;):I_G+BJ?+M"\+1W.PX6>:B[-LV?/AK6F2 X>XJG(#=(S6
MAG\UFVFC7!,^PQ:>6+KW5-P%X8EP'-?_?%#?%_FY(/A&Q>W4.7KOR!&0A4Z2
M-_\,7@.X##9^E#(CC4Z^IGJ!@J('25%EYQ1=;DN\H5!I-ID\V:E0B61JJ_U+
MF9&*[F 0:;<#XB9QP=I?<$N6+<<.*(U-+Z(4 CMSGS[ZK*J4%!<\A@L>@(HM
MDU_Q!&%\.!/KEIZ-\<K._5'D8KOT4#IYB[AVFG'YYU4WTI9.US-?LN";A]',
M*\_@R47;^I\/9J>ER*VFIB^&,.UD!PTR<VS^]H_!Y8<P"CKS3Y\,8_H9:=9U
M+/Q/;TZP;G!A>!X>%?X;U@>"]0Z@ILR)Q@HC(X!;_ P^.[.)Y086-6U PP<2
MO@ 7NW]S]>%K6]*5IJ3JG2@^&JW\:UGDVATX!/!"X+53@*?L&7A*0]);#4EK
MM"J!/&'4+?A>4;&Y!PXQD)U5DS@T.$@=\=ZU]\V=G;QJ(:+2?4RD&QJ$]G@^
MIFQU-- '>B4X4@"L(( UY+SBOWB =1H:&!MJ)0 F_(*DR+_SZ-2P+598X_CA
M20->'F,NN/A"!^R 196\.B D6X]3#6RU6R19EU%J*TYM *>V*\*I F=%X4S-
MJPIVAC--;TI:2ZX$SH03D-0(_?FQ.2'S=\"+6EZ9'Q'F%:RQG,ZWI'=42=.:
ME6 [ :FB(-7(*]Z+@!18,5)3T2H!*6';+X1SK&>#5<J[#F\V!)0Y3)D>5I*=
M<OK!Q:8_">M'P>@F2P3_^5@!/LV\T'7LW,P=&0H)?NO$C'TW\\R1 8Y=7O;6
M5##49*4<]LZV>_51+,>%ZU;N@-0N<"UW)+4L!Z087 L_9;%K=X!-]$20:M?6
M9>[\=0%A D65.KHL->5&)>Q+ :JB0)4[-UT$J-I21],DO5F252.<E@W$^M7,
M ^K//"J1(9"2]<_!G 26+$UYPTB1D=X-3^;.2-]YV+,^>+T; V&[CM6+:)4_
MK-"6E(J4B A\%82O9NZ$=/'X4K'@H18QJYI9]7TG,)PG^W&,AU&%H-\-(^9.
M.U_9./K@VGZFUIQ0W"++SXJJ+G6:0M;7"V*Y,\X[@9BN2RVE&K7.PMI/BOM[
M-E?%'6)GGFA^)^_03+%;JT^%_-\!<^9.0?-9;O0:*<-(=SO\X7/NS&GG V,V
M1#JZ7O#*G8XN'%YJ2U([U0@=[M;,C_IG?+OZZS\:IY=7/^#'DU//>CH-1FP$
MCN5.Z*DYQGZIIQ[UW9EG4O_TPO?OPS].1\%D?(J=T/H!G9P^J\^G1MB9^ZU6
M26(Q382'(^R<ITB(IYSPRW@0\/VOK8+Z@EI< ]?<Z=;;Z"F+ RR67[;:[PO$
M8G>PI(W.G?_;P48WU8:D9CCRL'9KA"VW,(Z)58T?<"+NJ++QS=QIO40)\(WK
MF-MD8H )E>9!Y> %FJN)YMSYQ*-&LX@]OZTH.60%]BYO:8 3RYVQ,;&+S+7'
M4^S9%[E. N0_3\L(GC-^H4FZK$IRNZ3X=<:=JI$6.V)(M_*?X-T&TAVI+7<D
MO5%2W*0@2)?LBY7M>]?]:R5;(I5Z]AI\341"DH;D=;][WK_N/_1[ ]Y6^N'V
MXO??;J\O>_>#J/L_Z?WOC_[#/T3C/''!BEU0.(5IC2['-A\ :U/1[5)<L'(7
M% HXM9'9U'C%_D4UB>94M]=@*W=)242J.TZI[0YV2(JL2KI:C4HO@;2=("UW
M=4F12-/;LM10VY7 F;#7UHE^*9Y=.#6\X/4@-<'^<W3K63)_PX)%EKSGE+H#
M0H&9O16#MF5-:G1$'[-Z 2U_!X&= 4WK-*5VLQJ]4X43L*0)O!E-;6T9ZH;#
MS/)6G4GS]PO@!+N>1UJV]0;4AM36A#=0+WSE;QU0-+X:BBZI#>$%5%_V"R]@
M]WRY<0'.9.S[$5.&'6;]A&7VFI,M6[K4; BA7RMPZ1N7PNP&7 VE 1)?](VI
MGL2/\G13UV/@<8>+!TF3"3PA_G? H=LT%8A/_46VV>MVXR8DK24.E=8+7MLT
M%"@87FVP+ZH!+V'TOZ,"E@ZB'KP2.*I#/7KNI/+B@=&"E(HBZ:(/LH#U]K#.
MG<'>!:S;BB0?%JR%W[.Z#?*AZ[?]<_AZULV=Z2XJZ*Q):J<CM?1JV)\"6$4!
M*W=FNSA@R1U=TE0QDJMZ,O[&=4Y-$=_:+X?F3FNG!B"V[36@R%*K4XW,HX!8
M41#+G=G>"<1469);U:B@$R9_!G4@8EV''!3(W;YB15!@6^[7VDU)U4M*HXMX
M5XVAW<[=QF)'T&[H+:G3%HV:#E8!\IC7P>NW(VYMT\Y=+9"(=^0-=+0Z3:G5
M+,FR%1V;C@G6:1G+3<-X>6'=[#0DK2R'371M$E^K65/SBAL]%^YD8@<X]2K=
MW"E<&53P@O[4<**KG?K4/+5_GHYLRZ+.YT@"-^9WQV^G-_2NUE-5_X(9]KU9
MSKX+A7'07Q-^;%*D#P+7_&/DCD&5^7%?.!QTNN*$4@4E@[C@T5Q0)&&6S3$7
ME2*PL(2G"LFS,9Y1\N<LRK(#C_O^USKRAZ]GK#@OU*CL/[\:LV#D>K!:BV2Y
MB)KM7AKFE&5)YO]?O"7Q1P;8U[]FNA\8 JV.I,DMJ='1%R] ;-_'4YEX$#_+
MI71V*577)*756+J4.PO\ "Z$^2[#Q_S7)37IY)%Z1%, 9+*J9EMO"V[2EI2F
M)FE::[OUMOFE,'$J:QNO5SG(*.;^<Q3K(S*YRS8X@S,5_3?D['QA&<X*E4BB
M"TP5A:G<=1H%88J)JTI@2MCS"UT'PMB2,0:#P+:([1#3F-J!,1:BO7@V[.2?
M^!'3Z0[(U'<N.)$2W)FS*$_5I8;>EC15E&?7"6HM.?\DCIU!K2%UE*;4;-6B
M8+MFSF'7-&>3&6\X8]&A;=J!T  Y47:RCB]SEQ'<T\"P'6KU#,\!E\Q/4.R2
M$RP77Q(?]@'\0V!0!1Q@198:\OYTP4>!MX+QEKL+P>[Q)NN2#O:TJN]OWO5'
MX12D%*MYU/!GWFL4*C0"@) ?2!DB2BVYF25XUY+U#U\UC%]IJ7&[@U0]]2N1
M72M8<K<ZB."U;5"AHRA24]E7I"KS)AZ<2CLR'.?N;7"<.!9NT]NZ[N_VF(*N
M="@9F%C:98-Y))&^8YYQ%1HFS/][7::\ZE)A_^R^/MZ1%N'.I(Z2)0T]1I_<
MYUM5M2GI2C7"&P)912$K+6B;24$4AJR6I+5TJ:.*#$KU-  >[8*O>>YXC(ER
M&X "#LQA!L^.R_)3<H?BOMN !6#G?DCL+0,AJH(E(X=B  HX5Q3.N2-]!<-9
M::I2<V\=IX4_L[T_XV]8Y7MH@F#U2;FJ28(\9_I:2N[0W%N+%9S8\0Q+ .]X
MVXYN$'CVXRS 840/[J+QLY7\0/])QA),K:1LP/$=<STR+DCK?)C3;RN1"UJ2
MJC0EK7U4IV(W]0DK=4*H!E\31M#:9AVLG+YV1M'Q=CUH*6G-2S=MYM%UK,(B
M?)JDRZHDMTL* AR?[7/,8$\[4+)IBX\BP=Z1VG)'TAN'9>AS'?DI>'2M5_P+
M;;^OY+\(6=9+R]HFPZ(EPMZ6B$\]>[BLCZ)53-GMOGRR[&?^JA1]N #Q?\W\
MP!Z^XDE@2N'K =PC<,F%Z[ 8"RL?Y:T];5"A@P#>F/=_V/>2E_81MC'JUW'W
M[?SW#\N@D^5?TE@R?(<Q.WOK0XB"A>M=/=S'%TRNQJ3H'OQ*$C<)?[]P@='P
MU'-?HD^6/S+I>$SNOMW\^+[V'HF-4^0W<%S:;=@??B]"KDX;T7UCK"V\3KX<
MQ4;C7?=;[_3\OM?]_;1[]="[_TR,\8OQZD<<B+1RZ,*C_TI&E.^C.OWY*PEM
MRC_)[']IYF;XT0?R*6W3?[M,WW2D7A%;_G![<6T[?\QWBB,JZV9MP[G+$B)=
M=:3 GSU[&O;Y0\R?8*]R)83LAZ_?^]>]P</M38\,+OJ]FX?^5?^"=&\NR>#'
M^:!_V>_>]WN#/4J3>*$7MS>#V^O^9?>A!XM[@/]\A^4.R.T5N;WKW7<?^O"%
M*BST'[WN_8#T;BYAG9>]B][W\]X]'N"MPMI24,EYAFG74&XP\P+Y;XJ=D)RG
M^&]_:ICQWYQ3A[;S@#^-Q<"BM%;/FLLRG;\5RH9.\Y<5#Y=I6]@SVHY%':89
M?OX:RQEN-42"HJ X22RK2.&M$TJY,#P9%OW^SP?U?3565"'##N&>MO9%0^[+
M(_N'3I)+^$QL9P1"';^ 7NB73W0"]N5C^/\HLB!(73M2*WLB-7=EMA9&BU&_
M!6&T @:'^'9!F[5+R1UIKU;[ES+#I'>>:\W,@/C&& U3AP9K(5QXB&A']T@3
M)7]^[X9[KE%4ES*^%H]GR@K\L\$!PV?JS.B5YTXN,)T%M_F['8PNP']V)]2+
M<V!=WZ?PC_5@_,P[C;8M-Z7.JB8C)=)U]V@2B%V!V$8*8I4Y8C,>42P)L8HL
M:2#!=65%5=->(;M[=7Y(R;L+UP^P5]64:R<?B[^L>BBF'.6,>Q4 !8SB:*G-
M C0;8N)V^,UU+9;'H-ZS;5)_ ,#(V[F\ PI,[JRHT=@O_6NLYXZ2 5H%*,H=
M,$!'E=IEJ\,B&>  _+H2M>8WS_5]U)E#NQY>7'6$P'KNU@M0;XQX=XQV.<=+
M@3Z3@9U7).2%0U93\+4+4"U;@Z\E:8J" *P@^$2DM%Z1TC([Y5-6#2Z1)^I0
MSQBS&E+#FMB.[0<X(_"9$OIS2AT_V>Y&"+V="[U. 1HW).XW3EHPJ;L+A.UQ
MNN;MDR@UE8:DK3KM+;1Q/8&IR05HXQT#4P>YO')@6\TU]2$IGWOJ4\,S1TSI
M6/29CMTIUF$*C;,/QE8*2<YQB@)+7\[IN1T_2TI3EE1YQ<1LH6=J"D>UD,Q;
MX7!LZVU)7=4\J0ZZI2:.S26=>D Y@^&*.343/!3['_Y&J&!JH5^.,M^@%5%*
MDL0(&J$)A.0,$FF2WES1EOH0L@T"_H<"_R+J4@J'OZY);:WD<JD*)MMJXIWQ
M\^7NE*)3[CP)IVP?5G 1=26W$0E#P]?/?_I;!>.WK5?0^!48W!T&BRCM* Z#
MK0[._FA7$(.[=\"JD4&K4AJN)KKV&NM:AIX[B?2MZP@]6[2,6]>64BNBPB46
M<GW'="<4B;IED\JVU&:C[_:?9/M8!90<!1*+*'<I'HFZI.EMJ5D!Q?NQ7)U[
M2&HD:NI';$9V<A+Z;!^%+BG17BZB=".B).??T&B^H3F+UYH-J24+MZU^,%RG
M2!I%5&H4BL-$\VV<%;'_)-HN5$E-/))OANT0 )1%'[$> VV)F>V/,']Z>G=W
M5PN%<I2I@T81=1Z(#A^M2NK?.KT%=-P.+P$RJ^3#?ZCG6H8_>J.B3@\W;2"@
M?RC0+Z*F)#?TUYMHJMZ2E';)*K&"R;.:>&(LH/=(@?X4SZL]VSYB$?Z,7+/
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MQA)#5V">6/;%KC7=BZBE61 _V[N/<DM2M'VG4K)O[\&[F8(1D!&*J*PIDA'
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M6P3ZBXZW9H:]\.BK<8\]8[V3,;M;!-9W$Y 5B!>(WPCQ&7/ 12"^T(BM +H
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MLBK=6H:"#P&-:2U2E#D:E5+1V)+:.L9DU6JA\0!-SQ)52M?"0 >+[6( V*.
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M/%*.V$U-QFXX KP^O>QC_MDV6909;J5T;[(,B:^'WDT!RI_W+TO>$1)%U&\
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MA$!, $\[,5W3,M4>Y85<C@N%,J]A=>;21Z/)/?>O1B?8V1KUVH7[Q]@>CL^
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M&OYU!6'<Q6K[:C3"^]]_N[V^N_H0]P,&MP?]&A?F3<+A.G+ 4!&"0$JZ)U0
M:!7=H^:B]]USEX_P/DEB=.L?2%.)*4_D"P.'Q8Q073[[P B*1E'[9;X3#00$
M9LM9*Q"W<J5@[&0BC9[1AH.G@$1TD FE?_$$(T+]1"V1&>X:V/XX9J!OQQ9.
M%W 3ZB!^_\SL"95QH4,"PX,54LW5!,F3YT!W,POE<&P(QK9&G5U,T.,%VG#
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ML2!6L,1'&)>EIQO,'J'QXF?%!%;(0<DQQ0R1H&* C !+?W_&';CX:@657ZV
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MY&&0.P.V9\TWW0?R64A<!O)\&HRF":>L"[SPP?'N02IQ>+PW$9(_B0F(X\9
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M_46:29T^PGZ LXZ7?M3JM@/^0 ;?+RH212G-(@&9+%4?(?BXP;2"K%1=>5+
M*CP'F6OGR9!FDE-^;P:V=%,B'ROBZ%GR_4F^G83("@@#D:QW61/EZ(F(\>7H
MHG"L;.;LJTQR]/PD#J>Q/EG6HD[,2(+XNLN1^!+JD$#6/4NS%W%H'M"&5CA
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M:^=P\[$0'H]YI>>P"-&\R HOLBI%Y\7E=K5$K!@0B ZV>7PVYE9MI=U.!:G
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M3VHLGC?3)EYY[/HX:,%$MK8=J%Z(0Z[;H:),4Z3/@56+O2.28E",=)JV "D
M/1F,L%92._*R7='IBP \Q252;:B3*IEU34DAF'.BG27%:2CJ(FETRP1T.M#"
MF#1[SW_8H1CYAU0=:1)W1P<7S\)AVFR43%I[%+TVA^+ G!/B=[ZK.-8G22#T
M?6]H5?M9]6X^\-E\P12SW$P?Y0> #1C(DV)J^<)'!$4(3@".B5M")(#[$;D*
MUO<#B20!NB*DBCS&M]#CP7*DI/IP[D!<R]H6E(/PG>:0RM$7R*;Y2J6*PBL*
M7T;AK>44+G_3 #?3-!][R;()4E&N(D(G_-7[@/NB,Y ZLLQD#8-Q6X $41=H
M1[9T4I\J!J@88'4&:*<88(;T(U>C37E)+HE6Y:+%G('87UJ0%48XC\**MO5.
M*ZI#31 RAW86^[CAO@AI@E#]>O6O+ O-M,+K["H299Y!H(ID" 5@MHF]J]Z0
M][0DR^[/R'J(,^ *0=BHW+)4XP)E^R=O6YQ#1P=@%(R<.N90C$<*XYEGC&WN
M8W;^LUB^8%MMX8K%DV1H4_.:+(\7:UA/@56\(\=HHKAN7#,,7^B+YU(7#$S[
M1T>JZK90QHC6'H)7%,?]A.(%29*[@0CU4G">DKNPI@!,>,2 S@QE[:G[_-*H
ME>RDQF[Q=*1&,V3Z%/5PEH]E F71#<L3H>G IR9TPE";DDR*QI2(.V\*=^4U
MFFL>RQ@W48!<H&O1_+->^!DJ3"YE/QZ8TJ&H'%W<3!2AB293QWOF:,8"R=:T
MC\* ]7P) B"@._&3L*Q17CV(PU$0TNJ^V9,QE2 <)UUFY7P&J8Q*#6PAANU$
M:P?#<N*\U9#M=A*X))FO::15,@VO1A&R1.:67KY6M4Q8=5_5,KWF6J:]M$VP
M/?^:Y,<-5T;\D 3-@&)C*(!.06GZ-@FOM#[=$V3%4GVZN%71["1W??"SEP*-
M$UF!X,],'@QUF<%P+\Y<K+CFIE#:N*ZN9!?-C#H%D47HXFE[L:>W5GBZRB.5
M[1CN"!)[=IZ!J!_)\US$*V5ZB.?&*3F$D)J !YE!W!*.NM--/3_<>V7RFW9#
MRG*P#E,9Q#VLKGW/];#R1SM4S\V./RC A<Q&--A5'=@Q60.67H3J@#W="BX?
M'"AZ@$MU9*#SP>TGF6DIHT"WWY95 8DFSCD7-7IZJ$<EXR%0E?B[0W\+@.D3
MSP6W@R!ZT.^YHMC^E<P,?7\;W8?+/+#.T?(1R4%_D+ =OOU(\(\B:O8;MV!=
M']388$2A3^U-0;6=45N!!"#ZZLEELBUAH<$=-[M+!]>1@_M%IW+T<<7:B,)7
M+:>$!IT:I9DW4)4!*6$W#(EWYSC/AJ@CL& ='B)0B!CLQ/=J'?H0Y\DG[]/2
M5DV@[6)6KB<:+V#X3<_H%T!V>F(S><3H4V^#O#3JL@.I7?&(E08/QGH\)HEA
MCKEY,O?UGL->NU0Q, +?JEB\L]D5F$N2:1*7G,KS[$E<?X?4RVUA,##3$HZY
M"./:U&3=M6 YP=E?8C:D YX$!B[LAS12XK):SBI5NJAD_&?D<MCB9D]#3--D
MXW*Z;?:6TFVSK:HL[8]?M5,#((\3GV-1Y!?9;=)=E$QF?TR2F[<S)"4=A A2
MT#Q@@KB"G!/) *,2<75*0A(#EMGER'>J''DT>ZRC!^.3MBNB"UK"22#,+)7Z
MA8=DLAD8[0&X$RS5W5IN"G80PP+2:&I1B;_T A2;*?%&S)Z40.@3BFNH48XC
M/\$#$QQ0]2 <"K"O>$T2Z(NE3*H<VM3[3=/"I)9*M,XQ\1=,5J\YGO==Q=0H
MDUWTKDS0_R>>Q1V#A>9W*7"\N'> =+82E'-\B&^+/JZJOR5<+*8N(XM!-$7O
M0IVT<_!"%$2K%#-#SW%@+#*IKI(A167()5 /J0LJJ%Y7CO27,VTCD2.9<H+5
M9@3*>PIC&[E'X*V>$@&S]M%8V$?R*46LG0^"U+Y@<5)0Y+Y.2YE 9TJ9H[!3
M-7L?B;_Q&R6@$M0,+"91]\@B1-F58SL"4BRU.O"7NA<,&1GA,!5D2:$7%M_<
M@M;X"E-8VU*2$UW97&HM,Y?DP7.FK22%K5WL9%B'2!%&$T,D4A\98X'Q)%/J
MBEA0I3V^F!T8?8?AYO\O':!.8M#; *3"%C^>_WP*Q +*"E3[;/"AU>XTVLVY
M0]%21&\NK^[.V&DJ@DM>'V%07?Y^=GEW=7-Q=ILTL]W[H#/0]S8\[AZ"1(\<
M?C6*]_)$& MW:!5D[^9<2'[=A&]YK@*\1F^+CVW2>=JM>G<VG5M\)<]R^OAW
MYA(7VAQ::=O%+%Q<^Q^9*>'SIU#^P_W[5J,#TJU]#/]TNQ]^9;/9</=>&'J3
MC!PX+8-N;2I:E&"XO0?"3!'S][_?M9:?2*[%!ZD];;QT=F#6V&=BW(O5RUR^
MDXQ/9N1$5CMZD#O:?/$=G4U"7B!4NEV2)QL+E8*$55U6\+*"V[=/G:!48N_X
MI]UE6B,K48]A;!!) (</'ECTF9RDTB]^VD#(+-J\;3P[2X#];=&+VC^E11#9
M*UM^^>*:]V:[OQB1\#\Q5MXGV:OLEE,6<C#X80<UL6'RJZ\D!O,!\&+K\%SN
M\6?<XDL>7HT0X-M_Y(OP#)>4O3<-L">-5J\]5_:^J^U].6*J"%40:J>10:C-
M R/4=J=E='K=4I#IC@V)]6A_=TC)W**(]RM0/\N>O6]&SL' 7<+(<I-*P<GM
MCM%L=4K!R15I;HLT6VOKF!*19M-H-OO&4:-?"N(\ (=GAVH&3PL\E_)!35]F
MWH@::'6\<)@Z1P9L:V*?X&'3'XS.06AW&P;#_WTH ?\7'FB>F&BOB^(>\_P?
MGO_]PKWV/01?V ;/@V'9[\S#=^Z&X[>T^Q5QEX&X.XMUX)Z(^ZAOM-O[TF9K
M;7[E6^E*[PYA)YDMR2/&F3HT*; ^:>PQIK(5D=#=6-^!%%C7F#WJMX#]=Q0S
M*;9:K\<A>\-$W=M8SVU U-T._']S1_'J[1!U-O),7(8ZDS54KA2772FZ=,]F
MV419S]_%>@;XFTV\1\Q?RXXZSK6_9G_+.\')"HRK>-IU=._8PV^AA#2)29=B
M%K<PDJ\T$#F.5"1BI1A&W+)L,TNO>]S"SMUS;&$D&,.Y2Y$56FP>YE)TNHW,
MI<#2SE5A=39I3<"L*"ZV)=)-9U9RQJ>V%?EDX*4KBL;PS]3&#G6SH*8%."/S
M-'A%QLAQTXM2@QC&/HD!&WGMGPKJ^\@0G3A!\,O >J0&B'>>JE#[:KK1"/X;
M^=S/SBV<JU+=-3;")2:%GF4GA0Y.?Q]<GIS=LJM+=G)U>7<S.+DK<WKH/L<B
M,KD% 5!YC:>*%'T>MZN+9.^#D>K>:0G9<7LW8.]NX2>'LSO/"\=LX/( 1%9@
MF^SV.0CYY)VH*TPDF&1;[(\T'&.Q0:)XXJO@U0H0+1!A7"'?[DU'P;N%^KA?
MDE5EXTDSF)&+_\ ,/74CM@FLV3]J8]N"I?E%&<!](-7EEW4;8.HWZV"JXK4?
MY7\84(&#2 9I:ME'_K@H2OU*S6E1[@HHD&!9-OE1>;/)SV<%1SO!!<&4\MN[
MKV>7=^SBD@TN3QD(D,M;D"$75Y>W[(^+N]_8V?]\N[C[-Q.7GIW=5K)EP6HG
MJ& G8]LUV9<0(3*JQ<I8+/OCU9/+_6!L3Y'+JR5:MR"X(XN8,A'I;))?/-_+
MZ69X.<U.K=&KM1O_26HQLN7B_+><7X(\%8?8:DS$#D4,W07"-[9R>T6MW!XA
M.,]:N5++("1!%J\FM<LSOR9-FNZ?A=%@WT>A0!UPPQE?!9R;V8=3-5M.JZ!F
M-R-38"=[<!W--QS*?DO,K]?<Q[QV\R%I(UQK%=R7ID"3F-F7GY@7"P/54+@^
MMXAPS9Q9DK.B&=Y:O*)?^(/I"$2*A8NTI67_Q.T_*0RPWX5OO?MX-!_S_@DM
MR62=Y5CC,!*.9TI%WM+7-I!-LKA$WAGS29T-!%9P"%+2R'@% E--?1B<_TR.
M(5:,RR8IJI0U@!D&AFQ+ />(FEW+#B3W)2&#I F!!!>17 FD8D42@H1V-KMU
M>!)!$*V_U<)GB0F!WDEQ"H&R,J'=HDA"C$I2+Y,>*=-8\G7:R/8#62_[OQ'X
M0:*E:K&6W[/[A*2BP!,FL8,/>_-S3$_,'(V X@B9@>IT"(\4&X #07C^@^G:
M?\DV>@\^%U 8[W'G%?G?)?U[$@6A=\(5I>"S0T/O"GX$!^6!RQ>ZR5BL]' )
M.Y8X;^".(YM]-6T0!989\^@='XY=S_$>X)(3KSZCQ^BF>'"&J*(63Q*] 1EX
M-(\VA<BHU/I9-:JE*F5\N<,)4V*.10NPYTQ1>A'^'% 5MWROQN+:6AO93(S+
M.E]F[>H:(U=?Y)S?;*8*:+GW+?_;P"W']?G\TI\DL&]* PL*J;/3)%1[<O7[
MQ6EN%;^ #F"PT1:?()@#WN;S!^Q%B2$0VH='TU$[.G5,%SL8:#M+>VAQQWS&
M1AUCV&6]*?,#@I^X$I%F1%T]"$P=W7(!)9RP_F\>$/2_X)\Z^P;TX4B4X5FJ
MTCMP91'5WW.K^W%!?U*=&217X0S&W"&(EAG&KY=#!F>4:U< P^T*8/A0 (8-
ML=T&HH#;HT6G^QDL0$OQ[N-549"<=@I3#=X/@E?A865JH'L^!'%.37Y5#^W\
M=UT-0P]?=9QZ$^IH+PH3@3GRO4GF&PWVWOXP9U^D;9D8#O!.-20<Q-;,$Z+!
MS0NJ1$\7B.?V&K$@%)%<:1<'H?F=I^6B:HDH&Q!^L2V4TO__V$3C@93,V55Z
M<1.!3D]!/"[L.8YW"(B8FZ^?\I1ZKYG9@;?9J#6.]3]?WA_4C(#_W-FA +<
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M(M<+@R\R5"@*3I3[BU0.JZ%?6R1(4V>%#U);*;OY#]'B#!. #';A#NLX^6_
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M(;B4<5M1WUN@OL7!V5HFSEZUA=46OKPUMIM3^)U98TJN'J9!MB7,HI?GA2T
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M@)R@,T,%.2'A(*2N3@L5&:G-5(Y">Y,S'K\.*3W@])I !:>?5(]W4_9X3XR
MU<]%BV_JCK91J 2P6>17>%TS!9=XU,Z!2VS7&_VY\V0MA+I"Y\E#7)I.[M)T
MYI=&GBN\O,A.<<&;4842".59F (" P47 <^),:J<P-,D&%M3Q\3H,YZ[C3%@
M%<36NY@%6?!R0JOOF!VP*>P%I_C?/7>\IU_V&538+(OC=CCF5H2!Q&PNTW@U
M&,AUSP(].6\V6]U>HUL[/3[Y5.L,^I]JQ_W6IUJWTS_KGWUJ]YO-TYDD#QJN
M[4; P<!LPT;_J-'OGIS7^MW62:USVCJO'9\,CFN-\[.CD^[YIT;G[+0"4:E
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M@LO]T+01JA562! 8+*@4&SXWXW5][0ITD'1-P?5+5@;[H@"A"M&):PB?IT#
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MIEZ<MYG-OMA*-<:X9^/,A]3?X_BP['KP^:SVZ>9L\*_:X/SN[.87,"N>S.=
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MCWM%Z[56[(I.6[=:H! PYP_S="EF&\T9R!,RP"]@%QI!^A&;-ITQ_P<DB8Q
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MAT5! LC;I]#?*C($DLS V9)#/'&D?5IJ"?>@^!./@&-S(NXL-J!A12'=PMO
M/-JQC4ZOYP]]'K&ZHB,7^)W'QZY@=J[)[^YZZ#^Z>!F6S/85>4]<_F"AH0GG
MWMH!48!!!'\L34T)!9J09W=BI9^X\;I!@*ZM59KSN<!+$G+:Y9C#@DO65?]U
M5.M:+FFM]GP-=@*]"93PC$8.&@$6W'6<D6B@'7,J<;OJTK]\TYT<'H']I_D+
MX^\6&/8\EC@ 24]%)M%2RL7E^L51KC@4^H[WT=)I.EW+N5_RJ:_I3C^+VUDB
M@1B.%K6/XTW.LPD]Q9TA(./%8@?R#E4,R#4A[6((BY&21*K$9?KM+U4>I>#O
M2'&_)H3*6KD:N_<7K7*TH)' T1"0(E0ZDQL]HR<1N9:"L?HN#6YWY.G%H;DH
MB&:9P767PL$L\A1FG^*'R$Z=_BE>T @;&>KQDV(1#*.KB>-4'L,=\5G@\5O,
MGC$PG)C68&)TI',32/3-+\YT\"YC&4$;P?8/Y\U=5+"7XC^PF 2>17)%7N*)
MWCT\BHVW=F)B(2Y1<#1NL@ ]AWF,#V(D68QX^B_*@F-S\E15" -\C@Y-K.HR
M='@L4K>Y ?6"PQ?UW[C3-\QJQ*ZGJZC#6G(C%]L6TP[JVQUG59 497(W"/TY
M(-'$5$3I'FGGS_,\6UJ*IUV.<\>%:2Y)KK(;T3<7+T_8]4/_!Z-X2?FZYYB;
M6J,68_&(8Z!X+$E.-Y0!)DTQPTI"=#/]#+\'8F?=1#2MU)CWYH?.9@&LQ&F4
MMSJ-C6ICMK5J8P&A$J>0$!Q=8PH;GYLO:8TX0Y!SU(*[IJ5HEY^UV&HIFP$[
M(LD#0),(H%/LCBNUDW.<PV^U6E5KM.K!)GF"HT4Z-1V>XD*6J:@X;9)LB*A:
MLZ&U6W&.]71PBHL=;C*+S0!5UIJE^3M:ER,J(>BTUBPVQ52U58=MZ_PE8@(:
M&R)KC=AD>5YGDLV59E(AD8R59J6A5=HQ]<TW5)H+"A)DK#1;6J,TGZ63#N +
MCL;GHB];6GV189,XA?BS[7GI2V[#S*?_9*\ORROHR^6<GE#[?!41NA4TURLU
MK5)>E)BV)05>3<@YRE"!U^M-4.#S2B^E I\]&KOQ+#:LOZ^5%BGP!-;^+;1B
MT(^P(9".X];!A"*;H1O%$+G@DYI#Z!$3;IZ^8UG..[]4)E)C%Q[QAR-QJLNT
MP^JV^!CZ7N*,!&RYY[A(!\<V8J'XI1A+,TLFC[MI1&X"9W,,\(]T R<1?H8M
M0R_XO/'0IS(?Q(A/,37A"]%]SPF_<D5*!/_NY/QW[\4QQO ?=VH DV;Q$2/X
M[8VZW'L73-]S1F&_HI-8G\Q<D\%B><9JK<\UE#O-*_5>7U!][V?3F7+=3JJ4
M"4<J,=*Y:8-ZU[!_-H?H"C4]@F[;Z5HD%#H=ZH%7F%<$&(JB.( 85X@.[NP%
M.0%KV$,W/WXG?,B4H;1^TRV?!@[LZ8CK=" )G="^!^(""VF;'DOJ[X7[:L4%
M(9$C'Y.GA.,7?<+8NLM1+K(KT2R0'O8[:G GMTB1@V\-6&57)J )1OGLN>=_
M4[!3L'LV;5GC)01'$#!Q@@  =__S%("9<(=(\$!%R9B# 3"Z("HB;H8#!A;L
M^F)B*LC,4QH1%6;DZ2;,7P8DBW/8(N/>"K(\9&AC44N*T16CQQJ/&+#BO#V)
M#8>54H7IC3MJRYI<YR0%.Z@9QP"Y_H1I4WQOQKE2?L^#96FTTVPHU* X!-C'
M\]:F=(D8FXAGCL6N(5U>E\X<&\8_#J.& )87G#IU>R9HEWEP?)9&V&=N-!;0
MF,V;;2*"#&@T%?N4]S(RN><HZG9@[=/O,MF )]\SK"W%+WNY%4=OD6N[R#.Q
MQ]YKI=AC[VOL362:<M\4O86;E>DM1>6L/KOS$%])J=3&O]?-L9<+#:8415*4
M1K]B=R_S2=WNZ\O'2AU+?\I_/GTEL[+SQ?$\9Q@C,2/R=FTF6J2.MM<@S!2#
M3UC<<VF"_UHPF*(IYWK!/*=BX6#3.?I%^&$GOMPEC>#_?=JMRHF;XK3KY/>7
MI%.)<P%">1^V3)3>&KE2KY5BDWU@DW*1V&36N%X@_DHU&'JUE8OX"Z1_H_4A
M.Q/TY/P2Z\?Q;$7<.R6X\F.I&/C2/FP AT6 WD;;\U [.?]M44?5#],HX.IZ
MRYTGQ!#JZ0K'K1)."!(LURW*U-3:[?E085:$VAU;*):3+%=-55@L6Y:K5^8/
MY.?!<BEU1KXF<TYZ(DSC. @ML:SMO%&:[K*QA"3\: ;&8U!].T#JK2T/M7?$
MS3K!]9-KYS$V8ZH/*9VQSPR8[LXWQ8#[M^O(4(,\Q>0M."_H^15^9OJK-Q#'
M-4'!X)&/I+RBC^5/2M7L .GIBO NN8=T.OGL0=+XUKZ6%+YQW!63M_Y+7<<
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MY;Y^V/"&RV3E+Y2P_W;<G^0C_Q&H9]%7^NEHE$,'B;^VK!<2-UYP=]S_H%S
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M!1*_NT%&6A:M+&)1LB9WHE4EO1OO: I)J^5.1T+J6H3^USY>]PHB7/HMHOR
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MZ#_KH>5$1U; !_P;RQ$.('(] DWL@B4GW$+<^10&C1*ZK9>%9/WX\Q.YN>J
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M-#DP-#,T+FAT;5!+ 0(4 Q0    ( #.)?E9KD[G76@,  #D,   -
M      "  :D"  !E>%\T.3 T,S4N:'1M4$L! A0#%     @ ,XE^5L +S>)+
M!P  BR\   T              ( !+@8  &5X7S0Y,#0T,2YH=&U02P$"% ,4
M    "  SB7Y6D]]/R$L'  !X+@  #0              @ &D#0  97A?-#DP
M-#0R+FAT;5!+ 0(4 Q0    ( #.)?E:P$_A[A@0  $D4   -
M  "  1H5  !E>%\T.3 T-#,N:'1M4$L! A0#%     @ ,XE^5J00 UMS!
M'18   T              ( !RQD  &5X7S0Y,#0T-"YH=&U02P$"% ,4
M"  SB7Y6$5F@HU@#  !E"P  #0              @ %I'@  97A?-#DR-S0Q
M+FAT;5!+ 0(4 Q0    ( #.)?E8GA4(F>A@  '9H   -              "
M >PA  !E>%\T.3(W-#(N:'1M4$L! A0#%     @ ,XE^5LIJM/P+%0  A04!
M !$              ( !D3H  &UL<W,M,C R,C$R,S$N>'-D4$L! A0#%
M  @ ,XE^5FCG-?([#@  D-(  !4              ( !RT\  &UL<W,M,C R
M,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( #.)?E;O[C\BWU4  #&"!P 5
M          "  3E>  !M;'-S+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4
M"  SB7Y6K6F)HQMT  !D;@8 %0              @ %+M   ;6QS<RTR,#(R
M,3(S,5]L86(N>&UL4$L! A0#%     @ ,XE^5@&X.F$B60  @08( !4
M         ( !F2@! &UL<W,M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    (
M #.)?E9,^A,8,?@! "6M%P 4              "  >Z! 0!M;'-S,C R,C$R
@,S%?,3!K+FAT;5!+!08     #@ . &4#  !1>@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
